<SEC-DOCUMENT>0001493152-25-008044.txt : 20250224
<SEC-HEADER>0001493152-25-008044.hdr.sgml : 20250224
<ACCEPTANCE-DATETIME>20250224160531
ACCESSION NUMBER:		0001493152-25-008044
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		70
FILED AS OF DATE:		20250224
DATE AS OF CHANGE:		20250224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scienture Holdings, Inc.
		CENTRAL INDEX KEY:			0001382574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283591
		FILM NUMBER:		25656961

	BUSINESS ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558
		BUSINESS PHONE:		(800) 261 0281

	MAIL ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRxADE HEALTH, INC
		DATE OF NAME CHANGE:	20210602

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRXADE GROUP, INC.
		DATE OF NAME CHANGE:	20140207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCELLINK INTERNATIONAL INC.
		DATE OF NAME CHANGE:	20081230
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:SCNX="http://scienture.com/20240630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_SCNX_scienture.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240101_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DDocumentType_424B3 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityRegistrantName_Scienture Holdings, Inc. -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001382574 -->
<!-- Field: Set; Name: xdx; ID: xdx_071_XDX_forms%2D1a.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_063_MBbls_0_utr%2D%2DMBbls -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000004" name="dei:DocumentType">424B3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000005" name="dei:EntityRegistrantName">Scienture Holdings, Inc.</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001382574</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0024" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0051" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:DevelopmentAgreementLiability" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:TerminationFee" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:IncreaseDecreaseInDevelopmentAgreementLiability" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:ConversionOfNotesAndAccruedInterestIntoPreferredStock" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0377" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0379" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl0535" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl0537" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl0539" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl0541" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:OperatingLeaseInterestExpense" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="xdx2ixbrl0635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0672" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:DividendIncome" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0794" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0845" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0848" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0875" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="xdx2ixbrl0883" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl0886" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="xdx2ixbrl0887" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="xdx2ixbrl0888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0925" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0940" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0972" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:WarrantsIssuedInConnectionWithLongtermConvertibleDebt" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl0979" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0993" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="xdx2ixbrl0995" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl1049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl1124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl1156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl1158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="xdx2ixbrl1178" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="xdx2ixbrl1188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="xdx2ixbrl1202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl1226" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl1228" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="xdx2ixbrl1232" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember" id="xdx2ixbrl1298" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember" id="xdx2ixbrl1302" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember" id="xdx2ixbrl1306" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember" id="xdx2ixbrl1308" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember" id="xdx2ixbrl1310" name="us-gaap:WarrantsAndRightsOutstandingTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SCNX:OperatingLeaseInterestExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="xdx2ixbrl1376" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="scnx-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_DirectorMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SCNX:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_WarrantMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214093">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="MBbls">
      <xbrli:measure>utr:MBbls</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>SCNX:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
Pursuant to Rule 424(b)(3)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-283591</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCIENTURE
HOLDINGS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form424b3_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,300,000
SHARES OF COMMON STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale from time to time of up to 4,300,000 shares of common stock, par value $0.00001, of Scienture
Holdings, Inc. (f/k/a TRxADE HEALTH, INC.), a Delaware corporation (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;),
by Arena Finance Markets, LP (&#8220;Arena Finance&#8221;), Arena Special Opportunities Partners III, LP (&#8220;ASOP&#8221; and,
together with Arena Finance, the &#8220;Arena Investors&#8221;), and Arena Business Solutions Global SPC II, Ltd (&#8220;Arena Global&#8221;
and, together with the Arena Investors, the &#8220;Selling Stockholders&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the resale of up to 4,300,000 shares of common stock, comprised of (i) 3,925,000 ELOC Shares (as
defined below), (ii) 70,000 shares of common stock (the &#8220;Initial Commitment Fee Shares&#8221;) issued to Arena Global as a
commitment fee upon the execution of a purchase agreement dated November 25, 2024 (the &#8220;ELOC Purchase
Agreement&#8221;), (iii) up to 250,000 shares of common stock issuable to Arena Global as an additional commitment fee
pursuant to the ELOC Purchase Agreement (the &#8220;Additional Commitment Fee Shares&#8221; and, together with the Initial
Commitment Fee Shares, the &#8220;ELOC Commitment Fee Shares&#8221;), and (iv) 55,000 shares of common stock (the
&#8220;SPA Commitment Fee Shares&#8221;) issued to the Arena Investors as a commitment fee upon the execution of a securities
purchase agreement dated November 22, 2024 (the &#8220;Securities Purchase Agreement&#8221;). See &#8220;<i>The Arena Global Transactions&#8221;</i>
for a description of the terms and conditions of the ELOC Purchase Agreement and the Securities Purchase Agreement, including
the ELOC Shares, the ELOC Commitment Fee Shares, and the SPA Commitment Fee Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prices at which the Selling Stockholders may resell the shares offered hereby will be determined by the prevailing market price
for the shares or in negotiated transactions. We are not selling any securities under this prospectus and will not receive any of the
proceeds from the sale of shares of common stock by the Selling Stockholders. However, we may receive up to $50,000,000 in
aggregate gross proceeds under the ELOC Purchase Agreement and we have received approximately $3,000,000 of gross proceeds in connection
with the first closing under the Securities Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may sell the shares of common stock described in this prospectus in a number of different ways and at varying
prices. We provide more information about how the Selling Stockholders may sell their shares of common stock in the section
titled &#8220;<i>Plan of Distribution</i>&#8221; on page 77 of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Each
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling Stockholder is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) with respect to the
resale of their shares of common stock hereunder.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the expenses incurred in registering the securities covered by this prospectus, including legal and accounting fees. To the
extent the Selling Stockholders decide to sell their shares of common stock we will not control or determine the price
at which the shares are sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, together with additional information described under the heading &#8220;<i>Where You Can Find More Information</i>&#8221;
carefully before you invest in any of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;SCNX&#8221;. The last reported sale
price of our common stock on Nasdaq on February 21, 2025, was $2.7962 per share. We urge prospective purchasers of our
common stock to obtain current information about the market prices of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVESTING
IN OUR SECURITIES INVOLVES RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;<i>RISK
FACTORS</i>&#8221; BEGINNING ON PAGE 10  HEREIN, AS WELL AS OUR PERIODIC AND CURRENT REPORTS WHICH WE HAVE FILED WITH THE SECURITIES
AND EXCHANGE COMMISSION, WHICH ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS. YOU SHOULD READ THE ENTIRE PROSPECTUS CAREFULLY BEFORE
YOU MAKE YOUR INVESTMENT DECISION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEITHER
THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED
UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this Prospectus is February 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: #CCEEFF">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
    OFFERING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING
    STOCKHOLDERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF ELOC PURCHASE AGREEMENT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#xca_001">DESCRIPTION OF SECURITIES PURCHASE AGREEMENT</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bs_001">DESCRIPTION OF BUSINESS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">PLAN OF DISTRIBUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_002">DESCRIPTION OF CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_001">EXECUTIVE COMPENSATION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">82</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#sj_002">DIRECTOR COMPENSATION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">87</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bs_002">CHANGE IN AUDITOR</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">89</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_004">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_005">INFORMATION INCORPORATED BY REFERENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_006">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bss_003">INDEX TO FINANCIAL INFORMATION</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">F-1</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Scienture
Holdings, Inc. and its consolidated subsidiaries are referred to herein as &#8220;Scienture,&#8221; &#8220;the Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our,&#8221; unless the context indicates otherwise.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
pursuant to which the Selling Stockholders may, from time to time, offer and sell or otherwise dispose of the shares of our common
stock covered by this prospectus. We will not receive any proceeds from the sale by the Selling Stockholders of the shares
offered by them described in this prospectus. We may also file a prospectus supplement or post-effective amendment to the
registration statement of which this prospectus forms a part that may contain material information relating to this offering. The prospectus
supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there is any inconsistency
between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the
prospectus supplement or post-effective amendment, as applicable. The registration statement we filed with the SEC, of which this prospectus
forms a part, includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus,
any post-effective amendment, and any applicable prospectus supplement and the related exhibits filed with the SEC before making your
investment decision. The registration statement and the exhibits can be obtained from the SEC, as indicated under the section entitled
&#8220;<i>Where You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without
charge by following the instructions under &#8220;<i>Where You Can Find More Information</i>.&#8221; You should carefully read this prospectus
as well as additional information described under &#8220;<i>Information Incorporated By Reference</i>&#8221; before deciding to invest
in our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. Neither we nor the Selling Stockholders have authorized anyone
to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective
amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling
Stockholders take no responsibility for and can provide no assurance as to the reliability of any other information that others
may give you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the
information appearing in this prospectus, any post-effective amendment and any applicable prospectus supplement to this prospectus is
accurate only as of the date on its respective cover. Our business, financial condition, results of operations and prospects may have
changed since those dates. You should read carefully the entirety of this prospectus before making an investment decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the Selling Stockholders are making an offer to sell our common stock in any jurisdiction where the offer
or sale thereof is not permitted. The distribution of this prospectus and the offering of our common stock in certain jurisdictions may
be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus outside the United States.
This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy,
any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer
or solicitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled
&#8220;<i>Where You Can Find More Information</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="a_003"></span><b>THE
OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Offered by the Selling Stockholders</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 4,300,000 shares of common stock. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Outstanding Prior to this Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,990,582
    shares of common stock (as of February 21, 2025, and including (i) the 70,000 Initial Commitment Fee Shares, which have been
    issued to Arena Global, and (ii) the 55,000 SPA Commitment Fee Shares, which have been issued to the Arena Investors).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Outstanding After this Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,165,582
    shares of common stock, assuming the sale of all of the ELOC Shares and the issuance of 250,000 Additional Commitment Fee Shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
    of the Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Selling Stockholders and any of their pledgees, assignees and successors-in-interest will determine when and how they sell the shares
    offered in this prospectus and may, from time to time, sell any or all of their shares covered hereby on Nasdaq or any other stock
    exchange, market or trading facility on which the shares are traded or in privately negotiated transactions. These sales may be at
    fixed or negotiated prices. For more information, see &#8220;<i>Plan of Distribution</i>.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of Proceeds</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Selling Stockholders will receive all of the proceeds from the sale of the shares offered
                                            for sale by them under this prospectus. We will not receive proceeds from the sale of the
                                            shares by the Selling Stockholders.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may receive up to $50,000,000 in aggregate gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares
    of common stock to Arena Global that we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement
    after the date of this prospectus. We intend to use the proceeds from the sale of our shares of common stock to Arena Global for
    general corporate and working capital purposes. Our management will have broad discretion over the use of proceeds from the sale
    of our shares of common stock under the ELOC Purchase Agreement.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    more information, see &#8220;<i>Use of Proceeds</i>.&#8221;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. You should carefully read the section titled &#8220;<i>Risk Factors</i>&#8221;
    beginning on page 10 and the other information included in this prospectus for a discussion of factors you should consider carefully
    before deciding to invest in our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
    for the Common Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on Nasdaq under the symbol &#8220;SCNX&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock that are and will be outstanding immediately before and after this offering as shown above is based
on 8,990,582 shares of common stock outstanding as of February 21, 2025 and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">190,242
                                            shares of common stock issuable upon exercise of warrants (as of February 21, 2025);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,575,900
                                            shares of common stock issuable upon conversion of preferred stock (as February 21,
                                            2025); and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,930
                                            shares of common stock issuable upon exercise of options (as of February 21, 2025).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="a_004"></span><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Statement contains statements that constitute forward-looking statements which are subject to the safe-harbor provisions
of the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). Some of the statements in this Registration Statement constitute forward-looking statements because they relate to future
events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather
are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Our forward-looking
statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions
or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, the words &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; or the negative of these terms or other similar expressions, may identify forward-looking statements, but the absence
of these words does not mean that a statement is not forward-looking. These forward-looking statements are subject to known and unknown
risks, uncertainties and assumptions about the Company that may cause the Company&#8217;s actual results, levels of activity, performance
or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied
by such forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
performance or results could differ materially from those expressed in or suggested by the forward-looking statements. Important factors
that could cause such differences include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to our history of operating losses and that our operations may not become profitable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">claims
    relating to alleged violations of intellectual property rights of others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to manage our growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and licensing requirement risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    related to changes in the U.S. healthcare environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    associated with the operations of our more established competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to respond to general economic conditions, including financial market volatility and disruption, elevated levels of inflation,
    and declining economic conditions in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations relating to our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    growth strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actual number of shares we will issue or sell under the ELOC Purchase Agreement to Arena Global;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with the continued listing requirements of Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    relating to the liquidity and trading of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise financing in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand
    for our products and services may decline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">data
    security breaches, cyber-attacks or other network outages; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risks disclosed below under, and incorporated by reference in, &#8220;<i>Risk Factors</i>.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this Registration Statement are based on our current expectations and beliefs concerning future
developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we
have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or
other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not limited to, those factors described under the section titled &#8220;<i>Risk
Factors</i>.&#8221; Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect,
actual results may vary in material respects from those projected in these forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove
to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these
and other uncertainties, the inclusion of a projection or forward-looking statements in this Registration Statement should not be regarded
as a representation by us that our plans and objectives will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based the forward-looking statements included in this Registration Statement on information available to us on the date of this
Registration Statement, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation
to revise or update any forward-looking statements in this Registration Statement, whether as a result of new information, future events
or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we may file
in the future with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_002"></span>PROSPECTUS SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the
information that you should consider in making your investment decision. Before investing in our common stock, you should read the entire
prospectus carefully, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained
in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus. Prospective
purchasers of our securities should also carefully read the information incorporated by reference into this prospectus, including our
financial statements, and the exhibits to the registration statement of which this prospectus is a part.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience via an online pharmaceutical
marketplace. Our legacy operations are currently conducted through Integra Pharma Solutions, LLC (&#8220;IPS&#8221;), which is a licensed
pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS&#8217; customers span various healthcare markets
including government organizations, hospitals, clinics and independent pharmacies nationwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, we acquired a wholly-owned subsidiary, Scienture, LLC (f/k/a Scienture, Inc.) (&#8220;Scienture LLC&#8221;), which
is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
and cardiovascular diseases. Scienture LLC is developing a broad range of novel product candidates including new potential treatments
for hypertension, migraine, pain and thrombosis and other related disorders. The intellectual property application process was initiated
in November 2019 and the product development activities commenced in January 2020. Scienture LLC&#8217;s assets in development
are across therapeutics areas and indications and cater to different market segments. Scienture LLC&#8217;s mission is to identify,
develop and bring to market innovative technology-based products to address unmet medical needs. Its targeted portfolio consists of short
term and long-term opportunities with efficient development, regulatory, and go to market strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2024, we changed the legal name of the Company from &#8220;TRxADE HEALTH, Inc.&#8221; to &#8220;Scienture Holdings, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, we owned 100% of Softell Inc. (f/k/a Trxade Inc.), IPS, Bonum Health, LLC, Bonum Health Inc., and Scienture LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, we entered into an Assignment and Assumption of Membership Interests (the &#8220;IPS Assignment Agreement&#8221;) with
our wholly-owned subsidiary, Softell Inc. (f/k/a Trxade Inc.) (&#8220;Softell&#8221;), pursuant to which we transferred, and Softell
accepted, 100% of the membership interests of IPS. As a result, IPS became a wholly-owned subsidiary of Softell and Softell&#8217;s current
primary operations are conducted through IPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonum
Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The &#8220;Bonum Health Hub&#8221; was launched in
February 2020. However, we do not anticipate installations moving forward and we anticipate dissolving Bonum Health, Inc. and Bonum Health,
LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal business address is 6308 Benjamin Rd, Suite 708, Tampa, Florida 33634 and our telephone number is (800) 261-0281. We maintain
our corporate website at <i>https://scienture.com. </i>The reference to our website is intended to be an inactive textual reference only.
Information on our website does not constitute a part of, nor is it incorporated in any way, into this prospectus and should not be relied
upon in connection with making an investment decision. Our common stock is listed on Nasdaq under the symbol &#8220;SCNX&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status
as a Public Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are a &#8220;smaller
reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced
disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (1) the market value of our shares of common stock held by non-affiliates
exceeds $250 million as of the last business day of that year&#8217;s second fiscal quarter, or (2) our annual revenues exceeded $100
million during such completed fiscal year and the market value of our shares of common stock held by non-affiliates equals or exceeds
$700 million as of the last business day of that year&#8217;s second fiscal quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Arena Global Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ELOC
Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, we entered into the ELOC Purchase Agreement with Arena Global, pursuant to which we have the right, but not the obligation,
to direct Arena Global to purchase up to $50,000,000 in shares of our common stock (the &#8220;ELOC Shares&#8221;) upon satisfaction
of certain terms and conditions contained in the ELOC Purchase Agreement, which includes, but is not limited to, filing a registration
statement with the SEC and registering the resale of any shares sold to Arena Global. The term of the ELOC Purchase Agreement began on
the date of execution and ends on the earlier of (i) December 1, 2027, (ii) the date on which Arena Global shall have purchased the maximum
amount of ELOC Shares, or (iii) the effective date of any written notice of termination delivered pursuant to the terms of the ELOC Purchase
Agreement (the &#8220;Commitment Period&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Commitment Period, the Company may direct Arena Global to purchase ELOC Shares by delivering a notice (an &#8220;Advance Notice&#8221;)
to Arena Global. The Company shall, in its sole discretion, select the amount of ELOC Shares requested by the Company in each Advance
Notice. However, such amount may not exceed the Maximum Advance Amount, which is calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received by 8:30 a.m. Eastern Time, the lower of: (i) an amount equal
                                            to eighty percent (80%) of the average of the Daily Value Traded (as defined in the ELOC
                                            Purchase Agreement) of our common stock on the ten (10) trading days immediately preceding
                                            an Advance Notice, or (ii) $20,000,000;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 8:30 a.m. Eastern Time but prior to 10:30 a.m. Eastern
                                            Time, the lower of: (i) an amount equal to forty percent (40%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $10,000,000;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 10:30 a.m. Eastern Time, but prior to 12:30 p.m. Eastern
                                            Time, the lower of: (i) an amount equal to twenty percent (20%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $5,000,000; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 12:30 p.m. Eastern Time but prior to 2:30 p.m. Eastern
                                            Time, the lower of: (i) an amount equal to ten percent (10%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $2,500,000.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price to be paid by Arena Global for the ELOC Shares will be ninety-six percent (96%) of the VWAP (as defined in the ELOC Purchase
Agreement) of the Company&#8217;s common stock during the trading day commencing on the date of the Advance Notice, subject to adjustment
pursuant to the terms of the ELOC Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any given time of any sale by us to Arena Global, we may not sell, and Arena Global may not purchase, ELOC Shares that would result in
Arena Global owning more than 9.99% of our outstanding common stock upon such issuance (the &#8220;Beneficial Ownership Limitation&#8221;).
Additionally, the Company must obtain shareholder approval to issue an aggregate number of shares of common stock to Arena Global, under
the ELOC Purchase Agreement, in excess of 19.99% of the number of shares of common stock outstanding immediately prior to the execution
of the ELOC Purchase Agreement prior to delivering any Advance Notices. For purposes of the foregoing, and the Beneficial Ownership Limitation,
any additional shares issued pursuant to the terms of the Securities Purchase Agreement described below will be aggregated with
the ELOC Shares, ELOC Commitment Fee Shares, and SPA Commitment Fee Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for Arena Global&#8217;s execution and delivery of the ELOC Purchase Agreement, we agreed to issue to Arena Global, as
a commitment fee: (i) 70,000 Initial Commitment Fee Shares and (ii) in two separate tranches, a number of Additional Commitment Fee Shares
equal to (a) with respect to the first tranche, 500,000 divided by the simple average of the daily VWAP of our common stock during the
five (5) trading days immediately preceding the effectiveness (the &#8220;Effectiveness Date&#8221;) of the initial registration statement
on which the ELOC Commitment Fee Shares are registered (the &#8220;First Trance Price&#8221;) and (b) with respect to the second
tranche, 500,000 divided by the simple average of the daily VWAP of our common stock during the five (5) trading days immediately preceding
the two (2) month anniversary (the &#8220;Anniversary&#8221;) of the Effectiveness Date (the &#8220;Second Tranche Price&#8221;). The
Additional Commitment Fee Shares shall be subject to a true-up after each issuance pursuant to the terms of the ELOC Purchase Agreement.
We are registering up to 320,000 ELOC Commitment Fee Shares hereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ELOC Purchase Agreement we also agreed to, no later than ten (10) business days following the execution date, file with the SEC a
registration statement for the resale by Arena Global of the ELOC Shares and the ELOC Commitment Fee Shares, and to file one or
more additional registration statements if necessary. This registration statement on Form S-1 (&#8220;Registration Statement&#8221;)
is being filed in order to satisfy our obligations under the ELOC Purchase Agreement related to registering for resale the ELOC Shares
and the ELOC Commitment Fee Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Purchase Agreement contains customary representations, warranties, agreements and conditions to completing future sale transactions,
indemnification rights and obligations of the parties. Among other things, Arena Global represented to us, that it is an &#8220;accredited
investor&#8221; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). We will sell the securities in reliance
upon an exemption from registration contained in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities
Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2024, the Company entered into the Securities Purchase Agreement  with
the Arena Investors. Under the Securities Purchase Agreement, the Company will issue 10%
original issue discount secured convertible debentures (&#8220;Debentures&#8221;) in a principal amount of up to $12,222,222 million,
divided into up to three separate tranches that are each subject to certain closing conditions. The conversion price per share of each
Debenture is equal to 92.5% of the lowest daily VWAP (as defined in the Debentures) of the Company&#8217;s shares of common stock during
the five trading day period ending on the trading day immediately prior to delivery or deemed delivery of the applicable Conversion Notice
(as defined in the Debentures), subject to adjustments related to the trading price of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the first tranche was consummated on November 25, 2024 (the &#8220;First Closing&#8221;) and the Company issued to the Arena
Investors Debentures in an aggregate principal amount of $3,333,333 (the &#8220;First Closing Debentures&#8221;). The First Closing Debentures
were sold to the Arena Investors for a purchase price of $3,000,000, representing an original issue discount of ten percent (10%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Closing Debentures contain customary events of default. If an event of default occurs, until it is cured, the holder may increase
the interest rate applicable to the First Closing Debentures to two percent (2%) per annum and accelerate the full indebtedness under
the First Closing Debentures, in an amount equal to 125% of the outstanding principal amount and accrued and unpaid interest. Subject
to limited exceptions set forth in the First Closing Debentures, the First Closing Debentures prohibit the Company and, as applicable,
its subsidiaries from incurring any new indebtedness that is not subordinated to the Arena Investors and, as applicable, any subsidiary&#8217;s
obligations in respect of the First Closing Debentures until the First Closing Debentures are paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Arena Investors&#8217; consummation of the First Closing, concurrently with the First Closing, the Company issued
to each Arena Investor participating in the First Closing its pro rata portion of 55,000 shares of Company common stock. Furthermore,
as consideration for the Arena Investors&#8217; consummation of subsequent closings, the Company shall issue to the Arena Investors participating
in such closing a certain number of Company common stock as agreed upon among the Company and the Arena Investors participating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed, pursuant to a Security Agreement, dated November 25, 2024 (the &#8220;Security Agreement&#8221;), with the Arena Investors,
to grant the Arena Investors a security interest in all of its assets to secure the prompt payment, performance, and discharge in full
of all of the Company&#8217;s obligations under the Debentures. In addition, the Company&#8217;s wholly-owned subsidiary, Scienture
LLC, entered into a Guarantee Agreement, dated November 25, 2024 (the &#8220;Guarantee&#8221;), with the Arena Investors, pursuant to
which it agreed to guarantee the prompt payment, performance, and discharge in full of all of the Company&#8217;s obligations under the
Debentures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed, pursuant to a Registration Rights Agreement, dated November 25, 2024 (the &#8220;Registration Rights Agreement&#8221;),
with the Arena Investors to file with the SEC an initial registration statement within 45 days to register the maximum number of Registrable
Securities (as defined in the Registration Rights Agreement) in accordance with applicable SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Purchase Agreement, Debentures, Security Agreement, Guaranty Agreement, and Registration Rights Agreement contain customary
representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations
of the parties. Among other things, the Arena Investors represented to the Company, that they are each an &#8220;accredited investor&#8221;
(as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The Company issued, and will issue, the securities
in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">We
are subject to numerous risks, including risks that may prevent us from achieving our business objectives or that may adversely affect
our business, results of operations, financial condition, and/or cash flows. You should carefully consider the risks discussed in the
section titled &#8220;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk Factors</i></span>,&#8221; including
the following risks, before investing in our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    operate a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate its
    current business and predict its future success and viability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    executive officers lack experience with the clinical development of therapeutic products for FDA marketing approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need additional capital which may not be available when needed or on commercially acceptable terms, thereby casting substantial doubt
    on our ability to continue as a going concern. Raising additional capital may cause dilution to our stockholders, restrict our operations
    or require us to relinquish rights to our product candidates. To the extent outstanding loan conversion rights associated with our
    existing indebtedness are exercised, there will be dilution to our stockholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness
    and liabilities could limit the cash flow available for our operations, including under Scienture LLC&#8217;s outstanding secured
    convertible debt, expose us to risks that could adversely affect our business, financial condition, and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to the significant resources required to develop our product pipeline, and depending on our ability to access capital, we must prioritize
    the development of certain product candidates over others and we may fail to expend our limited resources on product candidates or
    indications that may have been more profitable or for which there is a greater likelihood of success.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business is highly dependent on the success of certain product candidates. If we are unable to successfully complete clinical development,
    obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our
    business will be materially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent upon our current management, who may have conflicts of interest. Our ability to develop product candidates and our
    future growth depends on attracting, hiring and retaining key personnel and recruiting additional qualified personnel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may seek to collaborate with third parties and may not be able to implement these collaborations on commercially acceptable terms,
    if at all. The success of certain of our product candidates may depend in significant part on the success of such collaborations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    third-party manufacturing partners may be unable to increase the scale of production or product yield of our product candidates,
    resulting in increased manufacturing costs and delays in commercialization of our products. Furthermore, changes in methods of manufacturing
    our product candidates could result in additional costs or delays.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    growth depends in part on the success of our strategic relationships with third parties. Some of these third parties may be located
    outside of the United States.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to lawsuits.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    successful development of Scienture LLC&#8217;s pharmaceutical products involves a lengthy and expensive process and is highly uncertain.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Legal and Regulatory Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject, directly or indirectly, to federal and state healthcare, fraud, abuse false claims, and other laws and regulations as
    well as health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable
    to comply, or have not fully complied, with such laws, we could face investigations and substantial penalties. Furthermore, it may
    be difficult and costly for us to comply with the extensive government regulations to which our business is subject.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay
    of any such approval would delay commercialization of our product candidates and adversely impact our business and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval for any of our product candidates, we will be subject to ongoing regulatory requirements, which
    may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and
    other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated
    problems with our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use certain regulatory pathways to seek regulatory approval of several of our product candidates. If the FDA concludes
    that our marketing applications no longer qualify for these regulatory pathways, then our applications may not be accepted by the
    FDA for review and approval of our products may be delayed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may seek priority review designation for our product candidates. We might not receive such designation, and even if we do, such designation
    may not lead to faster regulatory review or approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may seek orphan drug designation from the FDA for our product candidates. We may be unable to obtain such designation or, if obtained,
    to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    regulatory authorities approve generic versions of our products, or do not grant our products a sufficient period of market exclusivity
    before approving a generic version, our ability to generate revenue may be adversely affected.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain FDA approval for a product candidate in the United States, we may never obtain approval for or successfully commercialize
    that candidate outside of the United States, which would limit our ability to realize a product&#8217;s full market potential.</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we are able to commercialize any of our product candidates, the third-party payor coverage and reimbursement status of newly-approved
    products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit
    our ability to market those products and decrease our ability to generate revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are developing a drug-device combination product, which may result in additional regulatory risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    third party collaborators and service providers are, or may become, subject to a variety of stringent and evolving privacy and data
    security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy
    and data security. Any actual or perceived failure to comply with such obligations could expose us to significant fines or other
    penalties and otherwise harm our business and operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
    legislative reform measures may have a negative impact on our business and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
    funding for the FDA and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217;
    operations, could hinder such agencies&#8217; ability to hire and retain key leadership and other personnel, prevent new products
    and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal
    business functions on which the operation of our business may rely.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Technology and Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to protect our intellectual property and trade secret rights throughout the world. If our efforts to protect our
    intellectual property rights are inadequate, we may not be able to compete effectively in our market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on in-licensed intellectual property. If we fail to comply with our obligations under intellectual property licenses with
    third parties, we could lose license rights that are important to our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we or our licensors are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent
    protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our
    product candidates, and our ability to successfully commercialize our product candidates may be adversely affected. Furthermore,
    we do not intend to seek patent protection for one of our products, SCN-106.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
    and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
    imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    to patent law in the United States and in foreign jurisdictions could diminish the value of our patents in general, thereby impairing
    our ability to protect our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not obtain patent term extension for our current product candidates, our business may be materially harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may become involved in lawsuits to protect or enforce our intellectual property rights, which could be distracting, expensive, time
    consuming, and unsuccessful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims challenging the inventorship or ownership of our intellectual property or asserting that we violated intellectual
    property rights of others, the outcome of which would be uncertain. These claims could be extremely costly to defend, could require
    us to pay significant damages and limit our ability to operate, and could distract our personnel from normal responsibilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    use, or the use by our third party collaborators and service providers, of new and evolving technologies, such as artificial intelligence
    (&#8220;AI&#8221;) and machine learning (&#8220;ML&#8221;), may result in spending additional resources and present new risks and
    challenges that can impact our business, including by posing security and other risks to our sensitive data. As a result, we may
    be exposed to reputational harm, other adverse consequences, and liability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our trademarks and trade names are not adequately protected then we may not be able to build name recognition in our markets of interest
    and our business may be adversely affected.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to the Offering and Our Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is not possible to predict the actual number of shares we will issue to Arena Global.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
    who buy shares at different times will likely pay different prices.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    issuance of common stock to the Selling Stockholders may cause substantial dilution to our existing stockholders and the sale of
    such shares acquired by the Selling Stockholders could cause the price of our common stock to decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to comply with Nasdaq&#8217;s continued listing standards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock has in the past been a &#8220;penny stock&#8221; under SEC rules, and may be subject to the &#8220;penny stock&#8221;
    rules in the future. It may be more difficult to resell securities classified as &#8220;penny stock.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    exercise of outstanding warrants, options and other securities that are exercisable into shares of our common stock will be dilutive
    to our existing stockholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not historically paid or declared any dividends on our common stock and do not expect to pay or declare cash dividends in the
    future on a regular basis, if at all.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock price is likely to be highly volatile because of several factors, including a limited public float.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    may not be sufficient liquidity in the market for our securities in order for investors to sell their shares. The market price of
    our common stock may continue to be volatile.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
    may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares
    of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_005"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our securities involves a high degree of risk. Please see the risk factors under the heading &#8220;Risk Factors&#8221; in our Annual
Report on Form 10-K for the year ended December 31, 2023, on file with the SEC, and those risk factors identified in reports subsequently
filed with the SEC, including our Quarterly Reports on Form 10-Q, which are incorporated by reference into this prospectus. Before you
invest in our securities, you should carefully consider these risks as well as other information we include or incorporate by reference
into this prospectus. All of these risk factors are incorporated herein in their entirety. The risks and uncertainties we have described
are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial
may also affect our business operations. The occurrence of any of these risks might cause you to lose all or part of your investment
in the offered securities. Certain statements in this section, or which are incorporated by reference in this section, are forward-looking
statements. For more information, see &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Where You Can Find
More Information.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate its current
business and predict its future success and viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We hold a clinical-stage
biopharmaceutical company with a limited operating history. Scienture LLC was formed in 2019 and its operations to date have been limited
to organizing and staffing its company, business planning, raising capital, identifying and developing its product candidates for the
treatment of central nervous system (&#8220;CNS&#8221;) and cardiovascular (&#8220;CVS&#8221;) diseases, securing intellectual property
rights, and planning and undertaking preclinical studies and clinical trials. Scienture LLC has not yet demonstrated an ability to generate
revenues, obtain regulatory approvals, manufacture any product on a commercial scale or arrange for a third party to do so on its behalf
or conduct sales and marketing activities necessary for successful product commercialization. Scienture LLC&#8217;s limited operating
history as a company makes any assessment of its future success and viability subject to significant uncertainty. Scienture LLC will
encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and Scienture
has not yet demonstrated an ability to successfully overcome such risks and difficulties. If Scienture does not address these risks and
difficulties successfully, its business will suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The success of
our business depends primarily upon its ability to identify, develop, and commercialize product candidates, including our existing product
candidates: SCN-102, SCN-104, SCN-106, and SCN-107. We only have one product candidate, SCN-102, for which it has conducted pivotal clinical
studies to date, and we will be required to similarly perform pivotal clinical studies for the other products in its pipeline in order
to obtain regulatory approval for these earlier stage candidates. Our business depends heavily on its ability to obtain FDA approval
for SCN-102 and successfully launch this product candidate and do the same for the other products in its pipeline. We do not know whether
it will be able to develop any products of commercial value. We do not have any products approved for commercial sale and have not generated
any revenue from product sales to date. We will continue to incur significant research and development and other expenses related to
its preclinical and clinical development and ongoing operations. As a result, we are not profitable and has incurred losses in each period
since its inception. Net losses and negative cash flows have had, and likely will continue to have, an adverse effect on our financial
condition. Scienture LLC&#8217;s net losses totaled $3.7 million and $2.2 million for the years ended December 31, 2022 and December
31, 2023, respectively. Scienture LLC&#8217;s net losses totaled $4.4 million and $471 thousand for the six months ended June 30, 2023
and 2024, respectively. As of June 30, 2024, Scienture LLC has not yet generated revenues and had an accumulated deficit of $15.8 million.
We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our
research and development of, and seek regulatory approvals for, our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate
that our expenses will increase substantially if, and as, we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    its product candidates through clinical development; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for Scienture&#8217;s product candidates that successfully complete clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, quality control, medical, scientific and other technical personnel to support the clinical development of Scienture&#8217;s
    product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    an increase in headcount as Scienture expands its research and development organization and market development and pre-commercial
    planning activities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertake
    any pre-commercial or commercial activities to establish sales, marketing and distribution capabilities, including in relation to
    its product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to identify, acquire and develop additional product candidates, including through business development efforts to invest in or in-license
    other technologies or product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expands and protects its intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    milestone, royalty or other payments due under any future in-license or collaboration agreements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    milestone, royalty, interest or other payments due under any future financing or other arrangements with third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Biopharmaceutical
product development entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail
to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and
become commercially viable, and therefore any investment in us is highly speculative. Accordingly, you should consider our prospects,
factoring in the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially
clinical-stage biopharmaceutical companies such as us. Any predictions you make about our future success or viability may not be as accurate
as they would otherwise be if it had a longer operating history or a history of successfully developing and commercializing pharmaceutical
products. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving Scienture&#8217;s
business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Additionally,
our expenses could increase beyond our expectations if we are required by the FDA or other comparable regulatory authorities to perform
clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements
for or in completing its clinical trials or the development of any of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
of our executive officers lack experience with the clinical development of therapeutic products for FDA marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our primary executive
officers, including Suren Ajjarapu, Chairman of the Board, Chief Executive Officer, and Secretary, and Prashant Patel, President, Chief
Operating Officer, Interim Principal Financial/Accounting Officer and Director, lack experience in overseeing the clinical development
of therapeutic products for FDA marketing approval. While Scienture LLC&#8217;s executive officers have extensive experience in this
regard, the lack of such experience at the executive level of the Company presents a risk that the Company may not effectively oversee
the operations of Scienture LLC and Scienture LLC&#8217;s comply with applicable laws, rules and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need additional capital which may not be available when needed or on commercially acceptable terms, thereby casting substantial doubt
on our ability to continue as a going concern. Raising additional capital may cause dilution to our stockholders, restrict our operations
or require us to relinquish rights to our product candidates. To the extent outstanding loan conversion rights associated with our existing
indebtedness are exercised, there will be dilution to our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our historical
financial statements have been prepared under the assumption that we will continue as a going concern. As of June 30, 2024, the Company
had an accumulated deficit of $26.5 million. After the Company&#8217;s MMS disposition, the Company had $3.5 million in cash. The Company
received $7.5 million in May 2024 pertaining to the final payment of the MMS disposition. As of June 30, 2024, Scienture had $109,000
in cash and cash equivalents and $5,000 in money market securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Scienture LLC&#8217;s
activities of developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming,
expensive and uncertain process that takes years to complete. Moving forward, we expect our expenses to continue to increase in connection
with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, our product
candidates. Even if our current or future product candidates are approved for commercial sale, we anticipate incurring significant costs
associated with commercializing any approved product candidate. Because of the numerous risks and uncertainties associated with research
and development of product candidates, we are unable to predict the timing or amount of our working capital requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Until such time,
if ever, as we can generate substantial product revenue, we expect to finance our operations with existing cash, cash equivalents, short-term
investments, and any future equity or debt financings and upfront and milestone and royalty payments, if any, received under any future
licenses or collaborations. While the Company believes that its cash as of the date of this Registration Statement will be sufficient
to meet its funding requirements during the next 12 months, this belief may prove to be wrong as we could utilize available capital resources
sooner than we expect. We will eventually need to raise additional capital or secure debt funding to support on-going operations. This
may include raising additional financing on an opportunistic basis in the future. For example, we may seek to raise equity capital or
obtain additional capital in the near term due to favorable market conditions or strategic considerations even if we believe we have
sufficient funds for current or future operating plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Attempting to
secure additional financing may divert management from day-to-day activities, which may adversely affect our ability to develop product
candidates. Our future capital requirements will depend on many factors, including but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product
    candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of clinical trials required for regulatory approval of our current or future product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of any of our current or future product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount
    of any milestones, royalties or other payments due in connection with our acquisitions and licenses; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing clinical and commercial supplies of our current or future product candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
    and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual
    property rights; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our approach at identifying target patient populations and utilizing our approach to enrich our patient population
    in our clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such
    agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our
    product candidates for which we receive marketing approval; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    to attract, hire and retain skilled personnel; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party
    and government payors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of macroeconomic trends including inflation and rising interest rates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    any potential supply chain interruptions or delays; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or invests in business, products and technologies. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate
that the sources of capital available to us will be through the sale of equity and debt, which may not be available on favorable terms,
if at all, and may, if sold, cause significant dilution to existing stockholders. Our ability to raise additional funds will depend on
financial, economic, political and market conditions and other factors, over which we may have no or limited control. The issuance of
additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our shares to decline.
If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial
position, and liquidity. Furthermore, we could be forced to delay, limit, reduce or terminate product development programs, future commercialization
efforts or other operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On September 2023,
Scienture LLC entered into a Loan and Security Agreement dated September 8, 2023, by and between NV Finance LLC, a Nebraska Limited Liability
Company (&#8220;NVK&#8221;) and Scienture LLC (the &#8220;NVK Loan Agreement&#8221;) for a principal amount of $2,000,000. The loan is
due upon maturity, together with all unpaid interest expense, in September 2025. The outstanding balance under the NVK debt is convertible,
at NVK&#8217;s option at any time, into common stock. NVK is entitled to receive warrants to purchase shares of Scienture LLC&#8217;s
common stock. Scienture LLC entered into a Consent and Waiver on July 25, 2024 (the &#8220;NVK Consent and Waiver&#8221;), regarding
the NVK loan in connection with the business combination with Scienture Holdings. Under the NVK Consent and Waiver, the warrants previously
granted to NVK were converted into 5.25% warrants on a fully diluted basis, equaling 500,526 shares of outstanding common stock of Scienture
LLC and placed in escrow. Any such conversion by NVK will result in dilution to holders of the Company&#8217;s common stock. Conversely,
should NVK not exercise its conversion right prior to maturity of the loan, Scienture LLC would need to obtain additional financing to
fund its cash payment obligations thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we raise additional
capital through the sale of equity or convertible debt securities or we issue any equity or convertible debt securities in connection
with a collaboration agreement or other contractual arrangement, our stockholders&#8217; ownership interests also will be diluted, and
the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Debt financing,
if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring,
selling or licensing intellectual property rights or assets, which could adversely impact the ability to conduct our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we raise additional
funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have
to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses
on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at
an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating
results and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Market conditions
and changes in financial regulations and policies can impact the viability of financial institutions. In the event of failure of any
of the financial institutions where we maintain cash and cash equivalents, there can be no assurance that we would be able to access
uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business
and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to
predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse
effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">These matters,
when considered in the aggregate, raise substantial doubt about our ability to continue as a going concern for a reasonable period of
time, which is defined as within one year after the date that our condensed financial statements are issued. The financial herein do
not contain any adjustments to reflect the possible future effects on the classification of assets or the amounts and classification
of liabilities that might result from the outcome of this uncertainty. The doubt regarding our potential ability to continue as a going
concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue
as a going concern, our stockholders may lose some or all of their investment in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indebtedness
and liabilities could limit the cash flow available for our operations, including under Scienture LLC&#8217;s outstanding secured convertible
debt, expose us to risks that could adversely affect our business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023,
Scienture LLC incurred $2 million of indebtedness under a Loan and Security Agreement dated September 8, 2023, by and between NVK Finance
LLC, a Nebraska Limited Liability Company (&#8220;NVK&#8221;) and Scienture LLC (the &#8220;NVK Loan Agreement&#8221;) in connection
with the business combination of NVK with Scienture LLC. In the future, we may incur indebtedness to meet financing needs or otherwise
refinance existing indebtedness. Indebtedness could have significant negative consequences for our security holders and our business,
results of operations, and financial condition by, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Increasing vulnerability
to adverse economic and industry conditions;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limiting
    our ability to obtain additional financing;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requiring
    the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which would reduce the amount
    of cash available for other purposes;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limiting
    our flexibility to plan for, or react to, changes in our business; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placing
    us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Scienture LLC&#8217;s
obligations under the NVK loan agreement are secured by a first priority security interest in all of Scienture LLC&#8217;s assets, including
its intellectual property rights. Accordingly, Scienture LLC&#8217;s failure to perform its obligations under the NVK loan agreement
could result in NVK selling to foreclose on this collateral. Our business may not generate sufficient funds, and we may otherwise be
unable to maintain sufficient cash reserves to pay amounts due under any indebtedness incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to the significant resources required to develop our product pipeline, and depending on our ability to access capital, we must prioritize
the development of certain product candidates over others and we may fail to expend our limited resources on product candidates or indications
that may have been more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Scienture LLC&#8217;s
lead product candidate, SCN-102, for the treatment of hypertension, is currently under FDA review. Its other product candidates and programs
are at various stages of development, and Scienture LLC has not yet initiated clinical trials for these other candidates in our pipeline.
We seek to support Scienture LLC in rapidly advancing discovery and development of transformational medicines for patients suffering
from CNS and CVS diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Due to the significant
resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and
advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration,
management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development
of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding
the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for
CNS and CVS diseases, our business, financial condition and results of operations could be materially and adversely affected. As a result,
we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of
opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential
than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty
arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization
rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on the success of certain product candidates. If we are unable to successfully complete clinical development,
obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business
will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Scienture LLC
has not completed the development of any product candidates. Although Scienture LLC has initiated development for product candidates,
all of these candidates, other than SCN-102, remain in early-stage clinical or preclinical development. Our future success and ability
to generate revenue from Scienture LLC&#8217;s product candidates is dependent on our ability to successfully develop, obtain regulatory
approval for and commercialize one or more of our product candidates. Even if approved by the FDA, SCN-102 will require substantial additional
investment for commercialization, clinical development, regulatory review, and approval in one or more jurisdictions. If any of Scienture
LLC&#8217;s product candidates encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development
plans and business would be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may not have
the financial resources to continue development of Scienture LLC&#8217;s product candidates, particularly if Scienture LLC experience
any issues that delay or prevent regulatory approval of, or its ability to commercialize, product candidates, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
    LLC&#8217;s inability to demonstrate to the satisfaction of the FDA or other comparable regulatory authorities that our product candidates
    are safe and effective; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficiency
    of our financial and other resources to complete the necessary clinical trials and preclinical studies; </span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from Scienture LLC&#8217;s clinical trials, preclinical studies or the clinical trials of others for product
    candidates similar to Scienture LLC, leading to a decision or requirement to conduct additional clinical trials or preclinical studies
    or abandon a program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related
    adverse events experienced by subjects in Scienture LLC&#8217;s clinical trials, including unexpected toxicity results, or by individuals
    using drugs or therapeutic biologics similar to Scienture LLC&#8217;s product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug (&#8220;IND&#8221;) application or other regulatory submission to the FDA or other comparable
    regulatory authorities, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or
    a suspension or termination, or hold, of a clinical trial once commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA or other comparable regulatory authorities regarding the scope or design of Scienture LLC&#8217;s clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">better
    than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from Scienture
    LLC&#8217;s clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling subjects in Scienture LLC&#8217;s clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of subjects from Scienture LLC&#8217;s clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate
    supply or quality of product candidates or other materials necessary for the conduct of Scienture LLC&#8217;s clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
    than anticipated clinical trial or manufacturing costs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA or comparable regulatory authority inspection and review of Scienture LLC&#8217;s clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial protocol or otherwise
    meet their contractual obligations in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to Scienture LLC&#8217;s therapies in particular; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA or other comparable regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, clinical
trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country
does not guarantee regulatory approval in any other country. Scienture LLC may in the future conduct one or more of its clinical trials
with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted
outside the United States, acceptance of this data is subject to conditions imposed by the FDA, and there can be no assurance that the
FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct
outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could
delay or permanently halt our development of the applicable product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent upon our current management, who may have conflicts of interest. Our ability to develop product candidates and our future
growth depends on attracting, hiring and retaining key personnel and recruiting additional qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
upon the continued contributions of our key management and scientific personnel, many of whom have substantial experience with developing
therapies, identifying potential product candidates and building the technologies related to the clinical development of our product
candidates. However, some of officers and directors have duties and affiliations with other companies. Involvement of our officers and
directors in other businesses may present a conflict of interest regarding decisions they make for the Company or with respect to the
amount of time available for the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Given the specialized
nature of CNV and CVS diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue
developing product candidates, we will require personnel with medical, scientific, or technical qualifications specific to each program.
The loss of any of our officers or directors, in particular our current management team consisting of Shankar Hariharan, Narasimhan Mani,
Rahul Surana, Suren Ajjarapu, or Prashant Patel, could have a materially adverse effect upon our business and future prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company holds,
on behalf of and for the benefit of Mr. Ajjarapu, a personal disability insurance policy providing for a $1,500,000 lump sum benefit,
payable to Mr. Ajjarapu, in the event of Mr. Ajjarapu&#8217;s disability. The premiums on such policy will be paid by the Company for
so long as Mr. Ajjarapu is employed by the Company. The Company also holds a $4,000,000 key-man life insurance policy on the life of
Mr. Ajjarapu, and a $1,500,000 lump sum disability insurance policy on Mr. Ajjarapu, providing for the Company as beneficiary of such
policies. The Company does not hold key-man life insurance policies for any other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Despite our efforts
to retain valuable employees, members of our team may terminate employment on short notice. The competition for qualified personnel in
the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and
motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities,
public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future,
it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition,
our clinical operations and research and development programs depend on our ability to attract and retain highly skilled scientists,
data scientists, and engineers, particularly in New York, New Jersey, Massachusetts and Pennsylvania. There is powerful competition for
skilled personnel in these geographical markets, and we may experience, difficulty in hiring and retaining employees with appropriate
qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources
than we do. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees
have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates
and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived
benefits of stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel
or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may seek to collaborate with third parties and may not be able to implement these collaborations on commercially acceptable terms, if
at all. The success of certain of our product candidates may depend in significant part on the success of such collaborations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We plan to opportunistically
pursue strategic partnerships if we believe that these partnerships can accelerate the development or maximize the market potential of
our product candidates. Likely collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. In addition, if we are able to obtain regulatory approval for product candidates from foreign
regulatory authorities, we may enter into partnerships or collaborations with international biotechnology or pharmaceutical companies
for the commercialization of such product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We face significant
competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a partnership or collaboration will depend,
among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed
partnerships or collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the
potential differentiation of our product candidates from competing product candidates, design or results of clinical trials, the likelihood
of approval by the FDA or other comparable regulatory authorities and the regulatory pathway for any such approval, the potential market
for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing
products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available
for partnership or collaboration and whether such a partnership or collaboration could be more attractive than the one with the Company
for our product candidate. If we elect to increase expenditures to fund development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds,
we may not be able to further develop product candidates or bring them to market and generate product revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Partnerships and
collaborations are each complex and time-consuming to negotiate and document. Further, business combinations among large pharmaceutical
companies could result in a reduced number of potential future collaborators. Any partnership or collaboration agreement that we enter
into in the future may contain restrictions on our ability to enter into potential partnerships or collaborations or to otherwise develop
specified product candidates. We may not be able to negotiate partnerships or collaborations on a timely basis, on acceptable terms,
or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate,
reduce or delay development programs, delay potential commercialization or reduce the scope of any sales or marketing activities, or
increase expenditures and undertake development or commercialization activities at our own expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may have limited
control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product
candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#8217; abilities to successfully
perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research
or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed
upon terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Collaborations
involving our product candidates pose a number of risks, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not perform their obligations as expected; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization
    programs, based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors,
    such as an acquisition, which divert resources or create competing priorities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing
    and distribution of such product or products; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual property rights, contract
    interpretation, or the preferred course of development might cause delays or termination of the research, development or commercialization
    of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation
    or arbitration, any of which would be time-consuming and expensive; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
    may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
    of the applicable product candidates. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future
collaborator is involved in a business combination, we could decide to delay, diminish or terminate the development or commercialization
of any licensed product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have relied
upon and plan to continue to rely on third parties, such as Contract Research Organizations (&#8220;CROs&#8221;), clinical data management
organizations, medical institutions and clinical investigators, to conduct our clinical trials and expect to rely on these third parties
to conduct clinical trials of any other product candidate that we develop. Our ability to complete clinical trials in a timely fashion
depends on a number of key factors. These factors include protocol design, regulatory and Institutional Review Board approval, patient
enrollment rates and compliance with GCPs. Generally, we rely on our third-party partners to accurately report their results. Our reliance
on third parties for clinical development activities may impact or limit our control over the timing, conduct, expense and quality of
our clinical trials. Moreover, the FDA requires that we to comply with GCPs for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial
participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators,
clinical trial sites and Institutional Review Boards. For certain commercial prescription drug products, manufacturers and other parties
involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product
tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products
that are otherwise unfit for distribution in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We remain responsible
for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific
standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and
scientific standards can result in rejection of our clinical trial data or other sanctions. If we or our third-party clinical trial providers
or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval
of a product candidate may be delayed or be unsuccessful. Additionally, if we or our third-party contractors fail to comply with applicable
GCPs for any reason, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform
additional clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain
that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register certain
clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the
third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements
with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs.
These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting
clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs.
If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines
or conduct its clinical trials in accordance with regulatory requirements or its stated protocols, we may not be able to obtain, or may
be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in
our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects
for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could
be delayed, impaired or foreclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on
other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors
could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing
additional losses and depriving us of potential product revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we
rely on wholesalers and attempt to structure our agreements with such wholesalers to ensure that we are appropriately and predictably
compensated for the services we provide. We cannot control the frequency or magnitude of pharmaceutical price changes. We might be unable
to renew agreements with wholesalers in a timely and favorable manner. These risks might have a materially adverse impact on our business
operations and our financial positions or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any of the third-party
organizations we utilize may terminate our engagements with us under certain circumstances. The replacement of an existing CRO or other
third party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and
commercialize our product candidates. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms.
In addition, even if there are suitable replacements for one or more of these service providers, there is a natural transition period
when a new service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected
clinical development timelines and harm our business, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
third-party manufacturing partners may be unable to increase the scale of production or product yield of our product candidates, resulting
in increased manufacturing costs and delays in commercialization of our products. Furthermore, changes in methods of manufacturing our
product candidates could result in additional costs or delays.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In order to produce
sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates,
our third-party manufacturers will be required to increase production and optimize manufacturing processes while maintaining the quality
of our product candidates. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers
are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if such third party
manufacturers are unable to produce increased amounts of our product candidates while maintaining the same quality, then we may not be
able to meet the demands of clinical trials or market demands. This could decrease our ability to generate profits and have a material
adverse impact on our business and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
growth depends in part on the success of our strategic relationships with third parties. Some of these third parties may be located outside
of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In order to grow
our business, we anticipate that we will need to continue to depend on our relationships with third parties, including our technology
providers. Identifying partners, and negotiating and documenting relationships with them, requires significant time and resources. Our
competitors may be effective in providing incentives to third parties to favor their products or services, or utilization of, our products
and services. In addition, acquisitions of our partners by our competitors could result in a decrease in the number of our current and
potential customers. If we are unsuccessful in establishing or maintaining our relationships with third parties, our ability to compete
in the marketplace or to grow our revenue could be impaired and our results of operations may suffer. Even if we are successful, we cannot
assure you that these relationships will result in increased customer use of our products or increased revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We do not own
or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the
resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of its product candidates to third parties,
including in jurisdictions outside of the United States such as China. As such, we currently rely on third-party manufacturers to provide
all of the API and the final drug product formulation of all of our product candidates that are being used in our clinical trials and
preclinical studies. If we were to need an alternate manufacturer, we would incur added costs and delays in identifying and qualifying
any such replacement. In addition, we typically order raw materials, API and drug product and services on a purchase order basis and
do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. We may not be able to
timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have
a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved.
We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable
terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and the costs of manufacturing
could be prohibitive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Many of the third-party
manufacturers we rely on have only recently begun working with us and have limited or no experience manufacturing our API and final drug
products. If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications,
it may limit supply of our product candidates and could delay our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are
able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional
risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third parties for manufacturing
    process development, regulatory compliance and quality assurance; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise
    do not satisfactorily perform according to the terms of the agreement between parties; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on supply availability resulting from capacity and scheduling constraints of third parties; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of the third-party manufacturer to produce materials with acceptable quality on a larger scale;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of manufacturing agreements by third parties because of factors beyond our control; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or non-renewal of the manufacturing agreements by the third party, at a time that is costly or inconvenient
    to us; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible misappropriation of our proprietary information, including our trade secrets and know-how.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we do not maintain
its key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which
could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers,
we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay
before new facilities could be qualified and registered with the FDA and other comparable regulatory authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Additionally,
if any third-party manufacturer with whom we contract fail to perform its obligations, we may be forced to manufacture the materials
ourself, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either
scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical
skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty,
or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may
be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will
be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable
regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will
produce its product candidate according to the specifications previously submitted to the FDA or other comparable regulatory authorities.
We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical
trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop
product candidates or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess
technology related to the manufacture of our product candidates that such third party owns independently. This would increase our reliance
on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third
party manufacture our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If any of our
product candidates are approved by any regulatory agency, we intend to utilize arrangements with third-party contract manufacturers for
the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing
facilities as there are a limited number of contract manufacturers operating under cGMPs that are capable of manufacturing our product
candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay
commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Some of our manufacturers
are located outside of the United States, including in China. There is currently significant uncertainty about the future relationship
between the United States and various other countries, including China, with respect to trade policies, treaties, government regulations
and tariffs. Increased tariffs or pending legislation that would impose federal contracting or federal funding limitations on parties
directly using or connected to those using the services or equipment of certain foreign entities with known or alleged associations with
foreign adversaries could potentially disrupt our existing supply chains and impose additional costs on our business. In particular,
certain Chinese biotechnology companies and commercial manufacturing organizations may become subject to trade restrictions, sanctions,
and other regulatory requirements by the U.S. government, which could restrict or even prohibit our ability to work with such entities,
thereby potentially disrupting our supplies and manufacturing. Additionally, it is possible further tariffs may be imposed that could
affect imports of any Active Pharmaceutical Ingredients (&#8220;APIs&#8221;) used in our product candidates in the future, or our business
may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials
used in its product candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding
how the U.S. or foreign governments will act with respect to tariffs, international trade agreements and policies, further governmental
action related to tariffs, additional taxes, contracting matters, regulatory changes or other retaliatory trade measures in the future
could occur with a corresponding detrimental impact on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our failure, or
the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including
clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of
product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product
candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA. We
do not control the manufacturing process of, and is completely dependent on, its contract manufacturing partners for compliance with
cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or other comparable regulatory authorities, we may not be able to secure and/or maintain regulatory approval
for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers
to maintain adequate quality control, quality assurance and qualified personnel. If the FDA finds deficiencies or a comparable foreign
regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval
in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our approved product candidates. Contract manufacturers may face manufacturing or quality control problems
causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with
the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign regulatory requirements
could adversely affect our clinical research activities and our ability to our its product candidates and market our products, if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The FDA or other
comparable regulatory authorities require manufacturers to register manufacturing facilities, and also inspect these facilities to confirm
compliance with cGMPs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Contract manufacturers
may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor
may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA
and other comparable regulatory requirements could adversely affect our clinical research activities and our ability to develop our product
candidates and market our products following approval, if obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, should
we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would need to maintain
licenses to those APIs from those third parties. If we are unable to gain or continue to access rights to such APIs prior to conducting
preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs
by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product
candidates. If we are unable to gain or maintain continued access rights to the desired APIs on commercially reasonable terms or develop
suitable alternate APIs, we may not be able to commercialize product candidates from these programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As product candidates
proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that
various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation,
are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these
intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned
clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also
require additional testing, FDA notification or FDA approval. This could delay or prevent completion of clinical trials, require conducting
bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of
our product candidates and jeopardize our ability to commence sales and generate revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to lawsuits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, we may be subject to legal proceedings and claims in the ordinary course of business. Such claims, even if lacking merit,
could result in the expenditure of significant financial and managerial resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2022 and April 2023, Scienture LLC entered into exclusive license and commercial agreements with Kesin Pharma Corporation (&#8220;Kesin&#8221;),
a related party, pursuant to which Scienture LLC granted the exclusive license rights to commercialize two of its potential products,
SCN-102 and SCN-104, to Kesin for use in the United States. In March 2024, Scienture LLC and Kesin agreement to terminate those agreements
and agreed that Scienture LLC would pay Kesin a total gross amount of $1.3 million upon commercialization of either SCN-102 or SCN-104
via a royalty arrangement. This agreement also requires that if the full $1.3 million has not been repaid within two years of the earlier
of i) commercial launch of a product or ii) 120 days after FDA approval of a product, then interest will accrue prospectively at a rate
of 8% annually on the unpaid balance. In August 2024, Kesin demanded immediate payment of the full amount under this agreement, alleging
it is payable in connection with the consummation Scienture LLC&#8217;s business combination with the Company. We have disputed that
the amount is now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution
will be obtained. If Kesin brings a legal action, we will vigorously defend it. Any litigation arising from this matter could be costly
and may divert management&#8217;s attention from the day-to-day operations of our business. We would have to obtain financing to fund
any amounts payable under this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful development of Scienture LLC&#8217;s pharmaceutical products involves a lengthy and expensive process and is highly uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Successful development
of Scienture LLC&#8217;s pharmaceutical products involves a lengthy and expensive process, is highly uncertain, and is dependent on numerous
factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to
reach the market for several reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial results may show the product candidates to be less effective than expected; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things, may be caused by
    patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost
    to follow-up, length of time to achieve trial endpoints, additional time requirements for data analysis or New Drug Application (&#8220;NDA&#8221;)
    or similar foreign application preparation, discussions with the FDA or other comparable regulatory authority, FDA or other comparable
    regulatory request for additional preclinical or clinical data (such as long-term toxicology studies) or unexpected safety or manufacturing
    issues; </span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    study results may show the product candidate to be less effective than desired or to have harmful side effects; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary post-marketing approval requirements; or </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proprietary rights of others and their competing products and technologies may prevent our product candidates from being commercialized.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the
length of time necessary to complete clinical trials and submit an application for marketing approval for a final decision by a regulatory
authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult
to predict.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if a product
is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling
or require expensive and time-consuming clinical trials and/or reporting as conditions of approval. Regulators of other countries and
jurisdictions have their own procedures for the approval of product candidates with which we must comply prior to marketing in those
countries or jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are
successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability
of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs
and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be
affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require
us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement,
which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement
for our products once approved, market acceptance and commercial success would be reduced. Even if we are able to obtain coverage and
adequate reimbursement for approved products, there may be features or characteristics of our products, such as dose preparation requirements,
that prevent our products from achieving market acceptance by the healthcare or patient communities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if
any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding the submission
of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our
third-party providers comply) with current Good Manufacturing Practices (&#8220;cGMPs&#8221;) and Good Clinical Practices (&#8220;GCPs&#8221;)
for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third
party might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency.
Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could
adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Legal and Regulatory Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject, directly or indirectly, to federal and state healthcare, fraud, abuse false claims, and other laws and regulations as well
as health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply,
or have not fully complied, with such laws, we could face investigations and substantial penalties. Furthermore, it may be difficult
and costly for us to comply with the extensive government regulations to which our business is subject.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our operations
are subject to extensive regulation by the U.S. federal and state governments. Healthcare providers and third-party payors in the United
States and elsewhere play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our operations and our current and future arrangements with healthcare professionals, principal investigators, consultants,
customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including,
without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred
to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well
as our proposed sales and marketing programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject
to health information privacy and security laws by the federal government, the states and other jurisdictions in which we may conduct
our business. In particular, we may be subject to regulations promulgated pursuant to the Health Insurance Portability and Accountability
Act of 1996 (&#8220;HIPAA&#8221;), which establishes privacy and security standards that limit the use and disclosure of individually
identifiable health information, known as &#8220;protected health information,&#8221; and requires the implementation of administrative,
physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity
and availability of electronic protected health information. We are directly subject to certain provisions of the regulations as a &#8220;Business
Associate&#8221; through our relationships with customers. We are also directly subject to the HIPAA privacy and security regulations
as a &#8220;Covered Entity&#8221; with respect to our operations as a healthcare clearinghouse, specialty pharmacy and medical surgical
supply business. If we are unable to properly protect the privacy and security of protected health information entrusted to us, we could
be found to have breached our contracts with our customers. Further, if we fail to comply with applicable HIPAA privacy and security
standards, we could face civil and criminal penalties. Although we have implemented and continue to maintain policies and processes to
assist us in complying with these regulations and our contractual obligations, we cannot provide assurances regarding how these regulations
will be interpreted, enforced or applied by the government and regulators to our operations. In addition to the risks associated with
enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the
federal and state level might also require us to make costly system purchases /or modifications from time to time. For more information,
see &#8220;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Scienture&#8217;s Business&#8211;Government Regulation&#8211;Other
Healthcare Laws.</i></span>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We also may be
subject to extensive, and frequently changing, local, state and federal laws and regulations relating to healthcare fraud, waste and
abuse. Local, state and federal governments continue to strengthen their position and scrutiny over practices involving fraud, waste
and abuse affecting Medicare, Medicaid and other government healthcare programs. Many of the regulations applicable to us, including
those relating to marketing incentives, are vague or indefinite and have not been interpreted by the courts. The regulations may be interpreted
or applied by a prosecutorial, regulatory, or judicial authority in a manner that could require us to make changes in our operations.
If we fail to comply with applicable laws and regulations, we could become liable for damages and suffer civil and criminal penalties,
including the loss of licenses or our ability to participate in Medicare, Medicaid and other federal and state healthcare programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we
may be subject to the operating and security standards of the Drug Enforcement Administration, the FDA, various state boards of pharmacy,
state health departments, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), the Centers for Medicare &amp; Medicaid
Services (&#8220;CMS&#8221;), and other comparable agencies. We are also subject to certain state laws relating to price gouging. Although
we have enhanced our procedures to ensure compliance, a regulatory agency or tribunal may conclude that our operations are not compliant
with applicable laws and regulations. In addition, we may be unable to maintain or renew existing permits, licenses or any other regulatory
approvals or obtain without significant delay, future permits, licenses or other approvals needed for the operation of our businesses.
Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses
could lead to litigation and have a material adverse impact on our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
of the breadth of these laws and the limited statutory exceptions and regulatory safe harbors available, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us
for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert
our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain
robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases
the possibility that a healthcare company may run afoul of one or more of the requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be
subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation
in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment
or restructuring of our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay
of any such approval would delay commercialization of our product candidates and adversely impact our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have submitted
an NDA to the FDA for our lead candidate, SCN-102. However, we have not yet received approval of this NDA and have not prepared or submitted
an NDA or submitted similar filings to comparable foreign regulatory authorities for any other product candidates. An NDA or other similar
regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting
information to establish that the product candidate is safe, effective, pure and potent for each desired indication. The NDA or other
similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The research,
testing, manufacturing, labeling, approval, sale, marketing and distribution of pharmaceutical products are subject to extensive regulation
by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country.
We are not permitted to market any product candidate in the United States or in any foreign countries until we receive the requisite
approval from the applicable regulatory authorities of such jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The FDA or any
foreign regulatory bodies can delay, limit or deny approval of a product candidate for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that the product candidate is safe
    and effective for the requested indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement with our trial protocol or the interpretation of data
    from preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate that the clinical and other benefits of a product candidate outweigh any safety or other perceived risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s or the applicable foreign regulatory agency&#8217;s requirement for additional preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s or the applicable foreign regulatory agency&#8217;s non-approval of the formulation, labeling or specifications of a
    product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s or the applicable foreign regulatory agency&#8217;s failure to approve our manufacturing processes and facilities or
    the facilities of third-party manufacturers upon which we rely; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in
    a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Of the large number
of pharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#8217; approval
processes and are commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if we eventually
complete clinical testing and receive approval from the FDA or applicable foreign agencies for our product candidates, the FDA or the
applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may
be required after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited
indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not
approve it with the labeling that we believe is necessary or desirable for the successful commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any delay in obtaining,
or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially
adversely impact our business and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for any of our product candidates, we will be subject to ongoing regulatory requirements, which may
result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other
restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems
with our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If any of our
product candidates are approved by the FDA or a comparable foreign regulatory authority, they will be subject to extensive and ongoing
regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of
post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements
in the United States and requirements of comparable foreign regulatory authorities. These requirements include submissions of safety
and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs
and GMPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may
also be subject to limitations on the approved indicated uses, including the duration of use, for which the product may be marketed or
to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials,
and surveillance to monitor the safety and efficacy of the product. The FDA may also require a Risk Evaluation and Mitigation Strategy
in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers
and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements,
including ensuring that quality control and manufacturing procedures conform to cGMP regulations and implementing tracking and tracing
requirements for certain prescription pharmaceutical products. As such, we and our contract manufacturers will be subject to continual
review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly,
we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing,
production, and quality control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We will have to
comply with requirements concerning advertising and promotion for our product candidates. Promotional communications with respect to
prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s
approved label. As such, we may not promote any of our products for indications or uses for which they do not have approval. However,
companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling.
We also must submit new or supplemental applications and obtain approval for certain changes to the product labeling or manufacturing
processes for our products, if approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we discover
previously unknown problems with any of our product candidates, such as adverse events of unanticipated severity or frequency, or problems
with the facility where they manufactured, or if the FDA disagrees with the promotion, marketing or labeling of our products, the FDA
may impose restrictions on us, including requiring withdrawal from the market. If we fail to comply with applicable regulatory requirements,
the FDA and other regulatory authorities may, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters or other regulatory enforcement action;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    injunctions, fines or civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    revisions to the labeling, including limitations on approved uses or the addition of additional warnings, contraindications or other
    safety information, including boxed warnings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    a Risk Evaluation and Mitigation Strategy, which may include distribution or use restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    the conduct of an additional post-market clinical trial or trials to assess the safety of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including closing our contract manufacturers&#8217; facilities where regulatory inspections identify
    observations of noncompliance requiring remediation; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing of the product, require a product recall, seizure or detention, or refuse to permit the import or export of the product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any government
action or investigation of alleged violations of law could require us to expend significant time and resources in response, and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability
to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn,
our operating results will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the
policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent,
limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative or executive action, either in the United States or abroad. In addition, if
we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to use certain regulatory pathways to seek regulatory approval of several of our product candidates. If the FDA concludes that
our marketing applications no longer qualify for these regulatory pathways, then our applications may not be accepted by the FDA for
review and approval of our products may be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek
FDA approval for certain product candidates through the Section 505(b)(2) regulatory pathway. Section 505(b)(2) of the Federal Food,
Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) was enacted as part of the Drug Price Competition and Patent Term Restoration Act of
1984, (the &#8220;Hatch-Waxman Amendments&#8221;), and permits the submission of an NDA where at least some of the information required
for approval comes from preclinical studies or clinical trials not conducted by or for the applicant and for which the applicant has
not obtained a right of reference. The FDA interprets Section 505(b)(2) of the FDCA to permit the applicant to rely upon the FDA&#8217;s
previous findings of safety and efficacy for an approved product. The FDA requires submission of information needed to support any changes
to a previously approved drug, such as published data or new studies conducted by the applicant or clinical trials demonstrating safety
and efficacy. The FDA could require additional information to sufficiently demonstrate safety and efficacy to support approval. If the
FDA later determines our applications for any of our product candidates do not meet the requirements of Section 505(b)(2), or that additional
information is needed to support a marketing application for such candidates we are planning to develop under the Section 505(b)(2) pathway,
we could experience delays in submitting a marketing application or in obtaining marketing approval. Moreover, even if we obtain approval
for our product candidates under the Section 505(b)(2) regulatory pathway, the approval may be subject to limitations on the indicated
uses for which they may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing
and surveillance to monitor the safety or efficacy of the products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may seek priority review designation for our product candidates. We might not receive such designation, and even if we do, such designation
may not lead to faster regulatory review or approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA determines
that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement
in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that
the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority
review for one or more of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review
status, so even if we believe a product candidate for such designation or status, the FDA may decide not to grant it. Moreover, a priority
review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage
with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval
within the six-month review cycle or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may seek orphan drug designation from the FDA for our product candidates. We may be unable to obtain such designation or, if obtained,
to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may seek orphan
drug designation for certain of our product candidates, but we may not be able to obtain such designation or maintain the benefits associated
with orphan drug designation (if obtained), including the potential for non-patent market exclusivity. Under the Orphan Drug Act, the
FDA may designate a drug or biologic as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally
defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or
more in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales
in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for
grant funding towards clinical trial costs, tax advantages and user-fee waivers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Generally, if
a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application
for the same product and indication for that time period, except in limited circumstances. Any competitor developing the same product
in the same indication with orphan drug designation may block our ability to obtain orphan drug exclusivity in the future if the competitor
receives marketing approval before we do. The applicable exclusivity period is seven years in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain
orphan drug exclusivity, that exclusivity may not effectively protect our product from competition because different products can be
approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same
condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes
a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved
for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights
in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer
is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another
product with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan
drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in
the regulatory review or approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
regulatory authorities approve generic versions of our products, or do not grant our products a sufficient period of market exclusivity
before approving a generic version, our ability to generate revenue may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Once an NDA is
approved, including under the 505(b)(2) pathway, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s
publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Manufacturers
may seek approval of generic versions of reference listed drugs through submission of Abbreviated New Drug Applications and may obtain
therapeutical equivalence evaluations for 505(b)(2) pathway drugs under the Food and Drug Omnibus Reform Act&#8217;s expanded authorities,
in the United States. In support of an Abbreviated New Drug Application, a generic manufacturer need not conduct clinical trials to assess
safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength,
route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent
to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly
less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer
them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product
or reference listed drug is typically lost to the generic product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Generic drug manufacturers
may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if any of our products is
approved, even if we still have patent protection. In particular, competition that our lead candidate, SCN-102, could face from generic
versions could materially and adversely affect our future revenue, profitability, and cash flows and substantially limit our ability
to obtain a return on the investments we have made in SCN-102.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain FDA approval for a product candidate in the United States, we may never obtain approval for or successfully commercialize
that candidate outside of the United States, which would limit our ability to realize a product&#8217;s full market potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In order to market
a candidate outside of the United States, we must obtain marketing authorizations and comply with numerous and varying regulatory requirements
of other countries regarding quality, safety and efficacy. Clinical trials conducted in one country may not be accepted by foreign regulatory
authorities, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical
trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or
prevent the introduction of our product candidates in those countries. We do not have experience in obtaining regulatory approval in
international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required
approvals, or if regulatory approval in international markets is delayed, our target market for our product candidates will be reduced
and we would not be able to realize the full market potential of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to commercialize any of our product candidates, the third-party payor coverage and reimbursement status of newly-approved
products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our
ability to market those products and decrease our ability to generate revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health
insurers and other third-party payors in the United States are essential for most patients to be able to afford treatments such as our
products or product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for drug treatments
by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize
our products, and potentially attract additional collaboration partners to invest in the development of our product candidates. We cannot
be sure that adequate coverage and reimbursement in the United States, the EU or elsewhere will be available for our products or any
products that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more
information, see &#8220;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Scienture&#8217;s Business&#8211;Government
Regulation&#8211; Pharmaceutical Coverage, Pricing, and Reimbursement</i></span>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party
payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining
the extent to which new drugs, biologics and medical devices will be covered. The Medicare and Medicaid programs increasingly are used
as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs, biologics
and medical devices. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement
for our products or product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover
or provide adequate payment for our products or product candidates. We expect to experience pricing pressures in connection with the
sale of our products and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs,
medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are developing a drug-device combination product, which may result in additional regulatory risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our SCN-104 injection
pen will be regulated as a drug-device combination product. We currently plan to develop this product as a combination of a small molecule
drug product administered using a disposable, multiple fixed dose injection pen. There may be additional regulatory risks for drug-device
combination products. We may experience delays in obtaining regulatory approval of SN-104 given the increased complexity of the review
process when approval of the product and a delivery device is sought under a single marketing application. In the United States, each
component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug,
biologic or device. The delivery device will be subject to FDA design control device requirements which comprise among other things,
design verification, design validation (including human factors testing), and testing to assess performance, cleaning, and robustness.
Delays in or failure of the studies conducted by us, or failure of us, our collaborators, if any, or our third-party providers or suppliers
to maintain compliance with regulatory requirements could result in increased development costs, delays in or failure to obtain regulatory
approval, and associated delays in SCN-104 reaching the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
third party collaborators and service providers are, or may become, subject to a variety of stringent and evolving privacy and data security
laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data
security. Any actual or perceived failure to comply with such obligations could expose us to significant fines or other penalties and
otherwise harm our business and operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary
course of our business, we and the third parties upon which we rely (such as our third party CROs and other contractors and consultants)
collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share
personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property,
sensitive third-party data, business plans, transactions, financial information and data we collect about trial participants in connection
with clinical trials. Our data processing activities subject us to numerous evolving privacy and data security obligations, such as various
laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other
obligations relating to privacy and data security.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The legislative
and regulatory framework for the processing of personal data worldwide is rapidly evolving and is likely to remain uncertain for the
foreseeable future. In the United States, numerous federal, state and local laws and regulations, including federal health information
privacy laws, state information security and data breach notification laws, federal and state consumer protection laws (e.g., Section
5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws) govern the processing of health-related and other
personal data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">At the state level,
numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut and Utah&#8212;have enacted comprehensive privacy laws
that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording individuals
certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and
local levels, and we expect more states to pass similar laws in the future. While these states exempt some data processed in the context
of clinical trials, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us
and the third parties upon whom we rely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Additionally,
we may be subject to new laws governing the privacy of consumer health data. For example, Washington&#8217;s My Health My Data Act broadly
defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent
consent requirements and grants consumers certain rights with respect to their health data, including to request deletion of their information.
Connecticut and Nevada have also passed similar laws regulating consumer health data. These various privacy and data security laws may
impact our business activities, including our identification of research subjects, relationships with business partners and ultimately
the marketing and distribution of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United
States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For example, the European
Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the United Kingdom&#8217;s GDPR (collectively, &#8220;GDPR&#8221;)
impose strict requirements for processing personal data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">GDPR establishes
stringent requirements regarding the processing of personal data, including (i) strict requirements relating to processing of sensitive
data (such as health data), ensuring there is a legal basis or condition to justify the processing of personal data, where required,
(ii) strict requirements relating to obtaining consent of individuals, (iii) expanded disclosures about how personal data is to be used,
(iv) limitations on retention of information, (v) implementing safeguards to protect the security and confidentiality of personal data,
where required, (vi) providing notification of data breaches, (v) maintaining records of processing activities, and (vii) documenting
data protection impact assessments where there is high risk processing and taking certain measures when engaging third-party processors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Under GDPR, companies
may face temporary or definitive bans on data processing and other corrective activities, fines, and private litigation related to processing
of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.
Non-compliance could also result in a material adverse effect on our business, financial position and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we
may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization
requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized
or limiting the transfer of personal data to other countries. In particular, the European Economic Area (&#8220;EEA&#8221;) and the United
Kingdom (&#8220;UK&#8221;) have significantly restricted the transfer of personal data to the United States and other countries whose
privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization
and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from
the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International
Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to
relevant U.S.-based organizations who self-certify compliance and participate in the framework), these mechanisms are subject to legal
challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United
States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States,
or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the
interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other
jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the
inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring
of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other
jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities
activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal
data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition to
privacy and data security laws, we are contractually subject to industry standards adopted by industry groups and may become subject
to such obligations in the future. We are also bound by other contractual obligations related to privacy and data security, and our efforts
to comply with such obligations may not be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may publish
privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles,
regarding privacy and data security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive,
unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse
consequences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Obligations related
to privacy and data security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent,
and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be
inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources
and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that
process personal data on our behalf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may at times
fail (or be perceived to have failed) in our efforts to comply with our privacy and data security obligations. Moreover, despite our
efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business
operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable privacy
and data security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g.,
investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration
demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal
data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including
class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis,
and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any
of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to:
loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process
personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and
resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain approval
of any of our product candidates and we are found to have improperly promoted off-label uses of such products, we may become subject
to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription
products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved
product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory agencies as reflected
in the product&#8217;s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant
liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label
use and has enjoined several companies from engaging in off-label promotion. The government has also imposed consent decrees, corporate
integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully
manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially
adversely affect our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative reform measures may have a negative impact on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. For
more information, see &#8220;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Scienture&#8217;s Business&#8211;
Other Regulatory Requirements&#8211;Healthcare Reform</i></span>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In 2010,
the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly
impacts the U.S. pharmaceutical industry.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">There are continued
efforts to challenge the ACA. There are also efforts to broaden healthcare coverage. U.S. lawmakers also have explored proposals to reduce
drug prices, including requiring price transparency and drug importation measures. These proposals might result in significant changes
in the pharmaceutical value chain as manufacturers, PBM, managed care organizations and other industry stakeholders look to implement
new transactional flows and adapt their business models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Provincial governments
in Canada that provide partial funding for the purchase of pharmaceuticals and independently regulate the sale and reimbursement of drugs
have sought to reduce the costs of publicly funded health programs. For example, provincial governments have taken steps to reduce consumer
prices for generic pharmaceuticals and, in some provinces, change professional allowances paid to pharmacists by generic manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Many European
governments provide or subsidize healthcare to consumers and regulate pharmaceutical prices, patient eligibility and reimbursement levels
in order to control government healthcare system costs. Some European governments have implemented or are considering austerity measures
to reduce healthcare spending. These measures exert pressure on the pricing and reimbursement timelines for pharmaceuticals and may cause
our customers to purchase fewer of our products and services or influence us to reduce prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain
or reduce costs of healthcare may adversely affect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    demand for any of our product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to set a price that we believe is fair for any of our product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate revenues and achieve or maintain profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of taxes that we are required to pay; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of capital.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
and biologic products. In addition, there has been increasing legislative and enforcement interest in the United States with respect
to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be
changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased
scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare reform measures
that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we
receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being
able to generate revenue, attain profitability, or commercialize our drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inadequate
funding for the FDA and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217;
operations, could hinder such agencies&#8217; ability to hire and retain key leadership and other personnel, prevent new products and
services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business
functions on which the operation of our business may rely.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The ability of
the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability
to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times
at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary
for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.
In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund
research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at
the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government
agencies, which would adversely affect our business. For example, over the last several years the United States government has shut down
several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future
government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize
and continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Technology and Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property and trade secret rights throughout the world. If our efforts to protect our intellectual
property rights are inadequate, we may not be able to compete effectively in our market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may not be
able to pursue patent coverage of our product candidates in certain countries outside of the United States. Filing, prosecuting and defending
patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights
in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. The breadth
and strength of our or our licensors&#8217; patents issued in foreign jurisdictions or regions may not be the same as the corresponding
patents issued in the United States. Consequently, we may not be able to prevent third parties from practicing our or our licensors&#8217;
inventions in all countries outside the United States, or from selling or importing products made using our or our licensors&#8217; inventions
in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained
patent protection to develop their own products and further, may export otherwise infringing products to certain territories where we
have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition to
seeking patents for some of our product candidates, we also rely on trade secrets, including unpatented know-how, technology, and other
proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure
and confidentiality agreements with parties who have access to them, such as employees, corporate collaborators, outside scientific collaborators,
contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment
agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome
is unpredictable. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may
not be able to establish or maintain a competitive advantage in the market, which could materially adversely affect our business, operating
results and financial condition. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur
substantial costs. These lawsuits may consume our time and other resources even if successful. In addition, some courts inside and outside
the United States are less willing or unwilling to protect trade secrets. As a result, we may encounter significant problems in protecting
and defending our intellectual property both in the United States and abroad. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would
be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Many companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual
property protections, particularly those relating to biotechnology and biopharmaceutical products. This difficulty with enforcing patents
could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products otherwise
generally in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk
of being invalidated or interpreted narrowly, put our or our licensors&#8217; patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded,
if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may
be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on in-licensed intellectual property. If we fail to comply with our obligations under intellectual property licenses with third
parties, we could lose license rights that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Scienture LLC
is a party to a Feasibility Study and Animal Trial Material Manufacturing Agreement with Innocore Technologies, B.V. (&#8220;Innocore&#8221;),
as amended on December 2, 2022 (the &#8220;Innocore License&#8221;), an exclusive and royalty-bearing intellectual property license agreement.
In connection with our efforts to expand our pipeline of product candidates, we expect to enter into additional license agreements in
the future. We expect that any future license agreements we may enter into may impose various diligence, milestone payment, royalty,
insurance, and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate the
relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property,
or to pursue other remedies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may not be
able to obtain licenses at a reasonable cost or on reasonable terms, or at all. Furthermore, if we lose intellectual property rights
licensed under existing agreements or fail to obtain future licenses, we may be required to expend considerable time and resources to
develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected proprietary
technologies and product candidates, which could harm our business significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our licensors are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection
obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our product candidates,
and our ability to successfully commercialize our product candidates may be adversely affected. Furthermore, we do not intend to seek
patent protection for one of our products, SCN-106.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product
candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment
that are important to our business. If we or our licensors does not adequately protect our or our licensors&#8217; intellectual property
rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to
achieve profitability. We and our licensors seek to protect our proprietary position by filing patent applications in the United States
and abroad related to our product candidates that are important to our business. We may in the future also license or purchase patent
applications filed by others. If we or our licensors are unable to secure or maintain patent protection with respect to our product candidates
and any proprietary product candidates and technology we develop, our business, financial condition, results of operations, and prospects
could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If the scope of
the patent protection we or our licensors obtain is not sufficiently broad, we may not be able to prevent others from developing and
commercializing products and technology similar or identical to our product candidates or otherwise maintain a competitive advantage.
The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some
cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances
that any of our or our licensors&#8217; patents have, or that any of our or our licensors&#8217; pending patent applications that mature
into issued patents will include, claims with a scope sufficient to protect our product candidates or otherwise provide any competitive
advantage. In addition, to the extent that we license intellectual property, we cannot make assurances that those licenses will remain
in force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if our owned
and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The scope of the invention claimed
in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance.
Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether any
of our product candidates will be protectable or remain protected by valid and enforceable patent rights. Our competitors or other third
parties may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing
manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The patent prosecution
process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications
at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is
also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain
patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent
applications, or to maintain the patents, covering product candidates that we license from third parties and are reliant on our licensors.
Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best
interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed
may be reduced or eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, patents
have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available; however, the life of a patent, and the protection it affords, is limited. Publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases, at all. Therefore, we cannot be certain that we or our licensors were the
first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were
the first to file for patent protection of such inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The patent position
of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in
recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial value of
our and our licensors&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications
may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing
competitive products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of
a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and licensed patents may be challenged
in the courts or patent offices in the United States and abroad. There may be prior art of which we are not aware that may affect the
validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects
the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a
claim. We or our licensors may in the future, become subject to a third-party pre-issuance submission of prior art, opposition, derivation,
revocation, re-examination, post-grant and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>inter partes
</i></span>review, or interference proceeding and other similar proceedings challenging our patent rights or the patent rights of others
in the USPTO or other foreign patent office. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims
being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar
or identical products, or limit the duration of the patent protection of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, given
the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we
rely on certain of our licensors to prosecute patent applications and maintain patents and otherwise protect the intellectual property
we license from them and may continue to do so in the future. We have limited control over these activities or any other intellectual
property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these
licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents
and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding
against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to
us. It is possible that any licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted
them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, some
of our owned and in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain
an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be
able to license their rights to other third parties, including our competitors, and our competitors could market competing products and
technology. In addition, we or our licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order
to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing
could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding
the importance of obtaining and maintaining patent protection for our products, we are not pursuing, and do not intend in the future
to pursue, patent protection for one of our products, SCN-106. SCN-106 is a potential biosimilar product. Developing and commercializing
a biosimilar product is time consuming, costly, and subject to numerous factors that may delay or prevent such development and commercialization.
The biosimilar markets in which we compete are undergoing and are expected to continue to undergo, rapid and significant change. We expect
competition to intensify as technology advances and consolidation continues. New developments by other manufacturers and distributors
could render our products uncompetitive or obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are
able to obtain regulatory approvals for SCN-106, the commercial success of SCN-106 is dependent upon market acceptance. Levels of market
acceptance for our product could be affected by several factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">a. the availability
of alternative products from our competitors;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">b. the prices
of our products relative to those of our competitors;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">c. the timing
of our market entry;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">d. the ability
to market our products effectively at the institutional level;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">e. the perception
of patients and the healthcare community, including third-party payers, regarding the safety, efficacy and benefits of our drug products
compared to those of competing products; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">f. the acceptance
of our products by government and private formularies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Some of these
factors will not be in our control, and SCN-106 may not achieve expected levels of market acceptance. Many of our competitors in the
biosimilar space have longer operating histories and greater financial, research and development, marketing, and other resources than
we do. Consequently, some of our competitors may be able to develop biosimilar products and/or processes competitive with, or superior
to, our products and/or processes and can enter the market prior to or after we launch the product. Furthermore, we may not be able to
offer customers payment and other commercial terms as favorable as those offered by our competitors. Such actions have the potential
to significantly reduce the potential market share and profitability of SCN-106.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain
that an allowed patent application will become an issued patent because there may be events that cause withdrawal of the allowance of
a patent application. For example, after a patent application has been allowed, but prior to being issued, material that could be relevant
to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO
to review the application in view of the new material. We cannot be certain that the USPTO will issue the application in view of the
new material. Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign countries may require the payment
of maintenance fees or patent annuities during the lifetime of a patent application and/or any subsequent patent that issues from the
application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations
in which noncompliance can result in abandonment or lapse of the patent or patent application. Such noncompliance can result in partial
or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent
or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment
of fees and failure to properly legalize and submit formal documents. Such an event could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issued
patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we or one of
our licensing partners initiates legal proceedings against a third party to enforce a patent covering our product candidates, the defendant
could counterclaim that the patent covering our product candidates, as applicable, is invalid and/or unenforceable. In patent litigation
in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are various grounds
upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative
bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>inter
partes</i></span> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such
proceedings could result in revocation or amendment to our or our licensors&#8217; patents in such a way that they no longer cover our
product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity
question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, our licensors and
the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability,
or if we are otherwise unable to adequately protect our or our licensors&#8217; rights, we would lose at least part, and perhaps all,
of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business
and our ability to commercialize or license our technology and product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to patent law in the United States and in foreign jurisdictions could diminish the value of our patents in general, thereby impairing
our ability to protect our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As is the case
with other biotechnology and biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology and biopharmaceutical industry involves both technological and legal complexity,
and is therefore costly, time-consuming and inherently uncertain. Patent reform legislation in the U.S. and other countries could increase
those uncertainties and costs. Passed in 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) made a number
of significant changes to U.S. patent law, including provisions affecting the way patent applications are prosecuted, redefining prior
art and providing more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith
Act transformed the U.S. patent system into a &#8220;first-to-file&#8221; system, effective on March 16, 2013 and has impacted our business
by making it more difficult to obtain patent protection for our inventions and increasing the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recent
U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of
patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending
on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable
ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our or our licensors&#8217; existing patents
and patents that we or our licensors might obtain in the future. We cannot predict how future decisions by the courts, Congress or the
USPTO may impact the value of our or our licensors&#8217; patents. Similarly, any adverse changes in the patent laws of other jurisdictions
could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in
other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension for our current product candidates, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon
the timing, duration and specifics of any FDA marketing approval of our current product candidates, one or more of our or our licensors&#8217;
U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit
a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term
extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent
may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended.
However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory
review process, failing to apply for a patent extension within applicable deadlines, failing to apply prior to expiration of relevant
patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection
afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than
we believe we are entitled to, our competitors may obtain approval of competing products sooner than we would expect, and our business,
financial condition, results of operations, and prospects could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our intellectual property rights, which could be distracting, expensive, time consuming,
and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may
infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement
claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that our patents or
our licensors&#8217; patents are invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on
the grounds that the patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or
more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.
Defense against these assertions, non-infringement, invalidity or unenforceability regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement,
obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require
substantial time and monetary expenditure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Post-grant proceedings
provoked by third parties or brought by the USPTO may be brought to determine the validity or priority of inventions with respect to
our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights
and could require us to cease using the related technology or require us to obtain license rights from the prevailing party. Our business
could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or post-grant proceedings
may result in a decision adverse to our interests and, even if successful, may result in substantial costs and distract our management,
employees, and contractors. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential
information, particularly in countries where the laws may not protect those rights as fully as those within the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. In addition, our licensors may have rights
to file and prosecute such claims, and we are reliant on them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims challenging the inventorship or ownership of our intellectual property or asserting that we violated intellectual
property rights of others, the outcome of which would be uncertain. These claims could be extremely costly to defend, could require us
to pay significant damages and limit our ability to operate, and could distract our personnel from normal responsibilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial
success depends upon our ability and the ability of our collaborators to commercialize, develop, manufacture, market, and sell our product
candidates without infringing the proprietary rights of third parties. We have yet to conduct comprehensive freedom to operate searches
to determine whether we would infringe patents issued to third parties. We may become party to, or threatened with, future adversarial
proceedings or litigation regarding intellectual property rights with respect to our product candidates, including interference proceedings
before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in
the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license
from such third party to continue developing and marketing its product candidates. However, we may not be able to obtain any required
license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving
our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing
the infringing product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing
our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we
have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If a third party
alleges that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
    and other intellectual property misappropriation which, regardless of merit, may be expensive and time-consuming to litigate and
    may divert management&#8217;s attention from our core business; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    damages for infringement or misappropriation, which we may have to pay if a court decides that the product or technology at issue
    infringes on or violates the third-party&#8217;s rights, and, if the court finds we have willfully infringed intellectual property
    rights, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    injunction prohibiting us from manufacturing, marketing or selling our product candidates, or from using our proprietary technologies,
    unless the third party agrees to license its patent rights to us; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant
    cross-licenses to intellectual property rights protecting our product candidates; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be forced to try to redesign our product candidates or processes so they do not infringe third-party intellectual property rights,
    an undertaking which may not be possible or which may require substantial monetary expenditures and time. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Some of our competitors
may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect
on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business,
results of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Third parties
may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy
a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of
proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of
manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications can take many years
to issue. There may be currently pending patent applications which may later result in issued patents that may be infringed by our product
candidates. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted,
or not infringed by its activities. If any third-party patents, held now or obtained in the future by a third party, were found by a
court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed
during the manufacturing process, or any final product or methods use of the product, the holders of any such patents may be able to
block our ability to commercialize the product unless we obtained a license under the applicable patents, or until such patents expire
or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent
jurisdiction to cover any aspect of our formulations, any combination therapies or patient selection methods, the holders of any such
patent may be able to block our ability to develop and commercialize the product unless we have obtained a license or until such patent
expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially
reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms,
or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our
business. Even if we obtain a license, such license may be non-exclusive, thereby giving our competitors access to the same technologies
licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications are threatened,
it could dissuade companies from collaborating with us to license, develop or commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Parties making
claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or
more licenses from third parties, pay royalties or redesign its infringing product candidates, which may be impossible or require substantial
time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available
on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third
parties to advance its research or allow commercialization of its product candidates. We may fail to obtain any of these licenses at
a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize its product
candidates, which could harm our business significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter
into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements
generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However,
these agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances
where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can
also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in
or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we are unsuccessful, we could
lose valuable rights in intellectual property that we regard as our own.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This is especially
relevant as some of our employees and contractors may have been previously employed at, or may have previously provided or may be currently
providing consulting services to, universities or other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. We could in the future be subject to claims that we or our employees and contractors have inadvertently or otherwise used
or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that
our employees and contractors do not use the proprietary information or know how of others in their work for us, we may be subject to
claims that we caused an employee or contractor to breach the terms of his or her non-competition or non-solicitation agreement, or that
we or our employees or contractors have, inadvertently or otherwise, used or disclosed intellectual property, including trade secrets
or other proprietary information, of a former employer or competitor. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors&#8217; European
patents and patent applications could be challenged in the recently created Unified Patent Court (&#8220;UPC&#8221;) for the European
Union. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements
are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of
the UPC. We cannot be certain that our or our licensors&#8217; European patents and patent applications will avoid falling under the
jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable
in numerous European countries. A successful invalidity challenge to a European patent under the UPC would result in loss of patent protection
in those European countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection
in numerous European countries, rather than in each validated European country separately as such patents always have been adjudicated.
Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology
and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
use, or the use by our third party collaborators and service providers, of new and evolving technologies, such as artificial intelligence
(&#8220;AI&#8221;) and machine learning (&#8220;ML&#8221;), may result in spending additional resources and present new risks and challenges
that can impact our business, including by posing security and other risks to our sensitive data. As a result, we may be exposed to reputational
harm, other adverse consequences, and liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The use of new
and evolving technologies, such as AI/ML, in our operations, and the operations of third parties upon which we rely presents new risks
and challenges that could negatively impact our business. The use of certain AI/ML technologies can give rise to intellectual property
risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, several jurisdictions
around the globe, including Europe and certain U.S. states, have proposed, enacted, or are considering, laws governing the development
and use of AI/ML, such as the European Union&#8217;s AI Act. We expect other jurisdictions will adopt similar laws. Additionally, certain
privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which
may be incompatible with our use of AI/ML. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory
fines or penalties, require us to change our business practices, retrain our AI/ML, or prevent or limit our use of AI/ML. For example,
the Federal Trade Commission has required other companies to turn over (or disgorge) valuable insights or trainings generated through
the use of AI/ML where they allege the company has violated privacy and consumer protection laws. If we cannot use AI/ML or our use is
restricted, our business may be less efficient, or we may be at a competitive disadvantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The rapid evolution
of AI/ML will require the application of significant resources to design, develop, test and maintain our products and services to help
ensure that AI/ML is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize
any real or perceived unintended harmful impacts. Our vendors may in turn incorporate AI/ML tools into their own offerings, and the providers
of these AI/ML tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and
data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI/ML, to engage in
illegal activities involving the theft and misuse of sensitive data. Any of these effects could damage our reputation, result in the
loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our trademarks and trade names are not
adequately protected then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our trademarks or trade names may be challenged, infringed, circumvented
or declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may
receive so called &#8220;Office Actions&#8221; from the USPTO objecting to the registration of our trademark. Although we would be given
an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable
agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek
the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks
may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not
be able to compete effectively and our business may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering and Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is not possible to predict the actual number of shares we will issue to Arena Global.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of the ELOC Shares will be ninety six percent (96%) of the VWAP (as defined in the ELOC Purchase Agreement) of the Company&#8217;s
common stock during the trading day commencing on the date of the Advance Notice, subject to adjustment pursuant to the terms of the
ELOC Purchase Agreement. Accordingly, the number of ELOC Shares issuable pursuant to the ELOC Purchase Agreement cannot be determined
at this time and may change over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investors
who buy shares at different times will likely pay different prices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different levels of dilution
and different outcomes in their investment results. The Selling Stockholders may sell such shares at different times and at different
prices. Investors may experience a decline in the value of the shares they purchase from the Selling Stockholders in this offering
as a result of sales made by us in future transactions to the Selling Stockholders at prices lower than the prices they paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
issuance of common stock to the Selling Stockholders may cause substantial dilution to our existing stockholders and the sale
of such shares acquired by the Selling Stockholders could cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering for resale by the Selling Stockholders up to 4,300,000 shares of common stock, comprised of (i) 3,925,000
ELOC Shares, (ii) 70,000 Initial Commitment Fee Shares, (iii) up to 250,000 Additional Commitment Fee Shares, and (iv)
55,000 SPA Commitment Fee Shares. The number of shares of our common stock ultimately offered for resale by the Selling Stockholders
under this prospectus is dependent upon the number of ELOC Shares issued. Depending on a variety of factors, including market liquidity
of our common stock, the issuance of shares to the Selling Stockholders may cause the trading price of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to comply with Nasdaq&#8217;s continued listing standards.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that we will be able to maintain our listing on Nasdaq for any period of time by perpetually satisfying Nasdaq&#8217;s
continued listing requirements. Our failure to continue to meet these requirements may result in our securities being delisted from Nasdaq.
At times, including during our 2023 and 2024 fiscal years, we have received deficiency notices from Nasdaq regarding our
inability to comply with various of the continued listing rules (including stockholders&#8217; equity requirements, publicly held share
requirements, and timely filing requirements). For example, the Company received a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">written
notice from the Listing Qualifications department of Nasdaq on January 3, 2025, indicating that the Company (i) was not in compliance
with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Company&#8217;s
2023 fiscal year end and (ii) has until February 18, 2025, to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the
Company may receive until as late as June 30, 2025, to regain compliance.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past we have taken steps to attempt to regain compliance with these listing rules. Most recently, the Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has begun
the process of scheduling its annual meeting of stockholders and preparing a proxy statement for such meeting with the SEC so that the
Company can hold the meeting as soon as practicable in order to regain compliance with Nasdaq Listing Rule 5620(a). While <span>the
Company believes it will be able to timely regain compliance with Nasdaq&#8217;s continued listing requirements, there can be no assurance
that the Company will be able to regain compliance with&#160;</span>Nasdaq Listing Rule 5620(a)&#160;<span>or
will otherwise be able to maintain compliance with other Nasdaq listing criteria.</span></span> If our common stock were to be delisted
from Nasdaq, it would likely reduce the liquidity of our common stock, and, among other things, may decrease the attractiveness of our
common stock to the investment community, and make it more difficult for us to issue equity securities for capital raising purposes or
for acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock has in the past been a &#8220;penny stock&#8221; under SEC rules, and may be subject to the &#8220;penny stock&#8221; rules
in the future. It may be more difficult to resell securities classified as &#8220;penny stock.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past (including immediately prior to our common stock being listed on Nasdaq in February 2020), our common stock was a &#8220;penny
stock&#8221; under applicable SEC rules (generally defined as non-exchange traded stock with a per-share price below $5.00). While our
common stock is not now considered a &#8220;penny stock&#8221; because it is listed on Nasdaq, if we are unable to maintain that listing,
unless we maintain a per-share price above $5.00, our common stock will become &#8220;penny stock.&#8221; These rules impose additional
sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify
as &#8220;established customers&#8221; or &#8220;accredited investors.&#8221; For example, broker-dealers must determine the appropriateness
for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior to a transaction in a penny stock
not otherwise exempt from the rules, a standardized risk disclosure document that provides information about penny stocks and the risks
in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock,
disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly account statements showing the
market value of each penny stock held in the customer&#8217;s account, provide a special written determination that the penny stock is
a suitable investment for the purchaser, and receive the purchaser&#8217;s written agreement to the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
remedies available to an investor in &#8220;penny stocks&#8221; may include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 31.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a &#8220;penny stock&#8221; is sold to the investor in violation of the requirements listed above, or other federal or states securities
    laws, the investor may be able to cancel the purchase and receive a refund of the investment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    a &#8220;penny stock&#8221; is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and firms
    that committed the fraud for damages.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes
subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers
from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirements
may restrict the ability of broker-dealers to sell our common stock and may affect your ability to resell our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not invest
in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the increased financial
risk generally associated with these investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance at what time, if
ever, our common stock may be classified as a &#8220;penny stock&#8221; in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
exercise of outstanding warrants, options and other securities that are exercisable into shares of our common stock will be dilutive
to our existing stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Registration Statement, we had outstanding various warrants, stock options and other securities that are exercisable
into shares of our common stock. For the life of the options and warrants, the holders have the opportunity to profit from a rise in
the market price of our common stock without assuming the risk of ownership. The issuance of shares upon the exercise of outstanding
securities will also dilute the ownership interests of our existing stockholders. The availability of these shares for public resale,
as well as any actual resales of these shares, could adversely affect the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict the size of future issuances of our common stock pursuant to the exercise of outstanding options or warrants, or the effect,
if any, that future issuances and sales of shares of our common stock may have on the market price of our common stock. Sales or distributions
of substantial amounts of our common stock (including shares issued in connection with an acquisition), or the perception that such sales
could occur, may cause the market price of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not historically paid or declared any dividends on our common stock and do not expect to pay or declare cash dividends in the future
on a regular basis, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we declared special cash dividends in the first and third quarters of 2024, those dividends were declared as the result of a sale various
business assets and not paid from cash generated in our operations. The Company has not historically paid or declared any dividends on
our common stock or preferred stock. Any future dividends on common stock will be declared at the discretion of our board of directors
and will depend, among other things, on our earnings, our financial requirements for future operations and growth, and other facts as
we may then deem appropriate. As such, the return on your investment, if any, has historically been dependent solely on an increase,
if any, in the market value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock price is likely to be highly volatile because of several factors, including a limited public float.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock has been volatile in the past and the market price of our common stock is likely to be highly volatile
in the future. You may not be able to resell shares of our common stock following periods of volatility because of the market&#8217;s
adverse reaction to volatility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
factors that could cause such volatility may include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    absence of securities analysts covering us and distributing research and recommendations about us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have a low trading volume for a number of reasons, including that a large portion of our stock is closely held;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    stock market fluctuations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    concerning our business or those of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or perceived limitations on our ability to raise capital when we require it, and to raise such capital on favorable terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in market valuations of other similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    sales of common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departure
    of key personnel or failure to hire key personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could have a significant and adverse impact on the market price of our common stock. In addition, the stock market in
general has at times experienced extreme volatility and rapid decline that has often been unrelated or disproportionate to the operating
performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock, regardless
of our actual operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may not be sufficient liquidity in the market for our securities in order for investors to sell their shares. The market price of our
common stock may continue to be volatile</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock will likely continue to be highly volatile. Some of the factors that may materially affect the market
price of our common stock are beyond our control, such as conditions or trends in the industry in which we operate or sales of our common
stock. This situation is attributable to a number of factors, including the fact that we are a small company which is relatively unknown
to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume,
and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company
such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared
to a mature issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse
effect on share price. It is possible that a broader or more active public trading market for our common stock will not develop or be
sustained, or that trading levels will not continue. These factors may materially adversely affect the market price of our common stock,
regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This
volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating
performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares
of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that
the non-cash consideration will consist of restricted shares of our common stock or where shares are to be issued to our officers, directors
and applicable consultants. Our board of directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules
and regulations (which generally require shareholder approval for any transactions which would result in the issuance of more than 20%
of our then outstanding shares of common stock or voting rights representing over 20% of our then outstanding shares of stock), to issue
all or part of the authorized but unissued shares of common stock. In addition, we may attempt to raise capital by selling shares of
our common stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders,
which may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing
management&#8217;s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting
existing management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_006"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders will receive all of the proceeds of the sale of shares of common stock offered from time to time pursuant
to this prospectus. Accordingly, we will not receive any proceeds from the sale of shares of common stock that may be sold from time
to time pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to $50,000,000 in aggregate gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares of
common stock to Arena Global that we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement
after the date of this prospectus. We intend to use the proceeds from the sale of our shares of common stock to Arena Global for
general corporate and working capital purposes. Our management will have broad discretion over the use of proceeds from the sale of our
shares of common stock under the ELOC Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
specifically, we intend to use the net proceeds from the sale of our shares of common stock under the ELOC Purchase Agreement to fund
(i) continued research and development, clinical development, and regulatory approvals of our products; (ii) costs associated with seeking
and maintaining intellectual property protections of our products; (iii) our commercial operations, including building out a sales and
marketing infrastructure through contract partners and service providers; (iv) the expansion of our product portfolio through strategic
third party in-licensing and synergistic acquisitions of product assets that can leverage our commercial infrastructure; (v) the strategic
expansion of our leadership team through recruitment of experienced team members; and (vi) to pay down certain outstanding debt obligations
and settle payments coming due. These intended uses are summarized in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Function</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Product</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">G&amp;A</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,908,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,236,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,478,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,622,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">R&amp;D/Clinical/ Regulatory</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,690,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,178,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,593,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23,461,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-102<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">405,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">838,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">838,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,081,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-104<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,895,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">405,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,550,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-106<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">890,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,090,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-107<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercial<sup>(5)</sup></b></span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,318,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,518,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,718,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,554,885</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual Property<sup>(6)</sup></b></span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">330,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Development<sup>(7)</sup></b></span></td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,800,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">One Time Convertible Debt Payment</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,865,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,865,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">One Time Settlement</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">985,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">15,346,695</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">13,932,295</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">20,639,695</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">49,918,685</td><td style="padding-bottom: 6px; font-weight: bold; text-align: left"><sup>(8)</sup></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Company anticipates using a portion of the net proceeds to fund NDA approval and the launch of SCN-102.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The Company anticipates using a portion of the net proceeds to fund NDA filing costs associated with SCN-104 as well as to conduct
a planned Phase 1 single dose study in healthy adults in 2025, following submission of an IND, if the IND is cleared by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The Company anticipates using a portion of the net proceeds to fund process development, optimization, clinical trials, BLA
approval and the launch of SCN-106.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
The Company anticipates using a portion of the net proceeds to fund the scale-up of, and preclinical activities associated with, SCN-107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
The Company anticipates using a portion of the net proceeds to improve and implement its commercial infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
The Company anticipates using a portion of the net proceeds to pay for certain expenses associated with obtaining and maintaining patent
protection for its product portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
The Company anticipates using a portion of the net proceeds to fund business development activities, such as in-licensing and
commercialization of yet to be identified third-party assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(8) The Company does not anticipate that it
will require a material amount of other funds necessary to accomplish the specified purposes for which the proceeds are to be used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expected use of net proceeds from the sale of our shares of common stock under the ELOC Purchase Agreement represents our current intentions
based upon our present plans and business condition. We reserve the right to change the foregoing use of proceeds, should our management
believe it to be in the best interest of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we cannot currently allocate specific percentages of the net proceeds that we may use for the purposes
specified above, and we cannot predict with certainty all of the particular uses for the net proceeds to be received pursuant to the
ELOC Purchase Agreement, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual
expenditures will depend upon numerous factors, including our sales and marketing efforts, demand for our products, our operating costs
and the other factors described under and incorporated by reference in &#8220;<i>Risk Factors</i>&#8221; in this prospectus. Accordingly,
our management will have flexibility in applying the net proceeds from the sale of our shares of common stock under the ELOC Purchase
Agreement. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions
on how to use the proceeds. In the event we do not obtain the entire amount pursuant to the ELOC Purchase Agreement, we may attempt to
obtain additional funds through other offerings of our securities or by borrowing funds.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_007"></span>SELLING
STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders listed in the table below may from time to time offer and sell any or all of the shares set forth below pursuant
to this prospectus. When we refer to the Selling Stockholders in this prospectus, we refer to each entity listed in the
table below, and the pledgees, donees, transferees, assignees, successors and other permitted transferees that hold any of the Selling
Stockholders&#8217; interest in the shares after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information provided by or on behalf of the Selling Stockholders concerning the shares that
may be offered from time to time by the Selling Stockholders pursuant to this prospectus. The Selling Stockholders identified
below may have sold, transferred or otherwise disposed of all or a portion of their shares or other Company securities after the date
on which they provided us with information regarding such securities. Moreover, the shares identified below include only the shares being
registered for resale and may not incorporate all shares of common stock or other securities of the Company deemed to be beneficially
held by the Selling Stockholders. Any changed or new information given to us by the Selling Stockholders, including regarding
the identity of, and the securities held by, the Selling Stockholders, will be set forth in a prospectus supplement or amendments
to the registration statement of which this prospectus is a part, if and when necessary. The Selling Stockholders may sell all,
some or none of the shares in this offering. See &#8220;<i>Plan of Distribution</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described below or elsewhere in this prospectus, the Selling Stockholders do not have any material relationship with
us or any of our predecessors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock beneficially owned by each Selling Stockholder is determined under rules promulgated by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and address of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling Stockholder</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                                                               of Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned Prior to</b></span></p>
                                                                                                        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>the Offering </b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Number</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
                                                                               Shares to be</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sold Pursuant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to this Prospectus</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></p>
                                                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned After</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offering
                                            (1)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Percent of Shares</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Owned After</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Offering (1)</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Arena Finance Markets, LP (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">44,703</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">44,703</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="margin: 0">Arena Special Opportunities Partners III, LP (3)</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">10,297</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">10,297</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">&#8212;</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Arena Business Solutions Global SPC II, Ltd (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,193</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,245,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    that the Selling Stockholders will sell all of the shares offered by them under this prospectus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    principal business address for Arena Finance is 405 Lexington Ave, 59th Floor, New York, NY 10174. Dan Zwirn has voting and dispositive power over the shares owned by Arena
    Finance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    principal business address for ASOP is 405 Lexington Ave, 59th Floor, New York, NY 10174. Dan Zwirn has voting and dispositive power over the shares owned by ASOP.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    principal business address for Arena Global is 405 Lexington Ave, 59th Floor, New York, NY 10174. Dan Zwirn has voting and dispositive
    power over the shares owned by Arena Global.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
                                            shares owned (i) assumes the issuance of all shares of common stock under the ELOC Purchase
                                            Agreement and (ii) gives effect to the 9.99% Beneficial Ownership Limitation.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_008"></span>DESCRIPTION
OF eloc PURCHASE AGREEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 25, 2024, we entered into the ELOC Purchase Agreement with Arena Global, pursuant to which we have the right, but not
the obligation, to direct Arena Global to purchase up to $50,000,000 in ELOC Shares upon satisfaction of certain terms and conditions
contained in the ELOC Purchase Agreement. Such sales of our common stock, if any, will be subject to certain limitations, and may occur
from time to time at our sole discretion over the approximately 36-month period commencing on the date of execution of the ELOC Purchase
Agreement, provided that the registration statement of which this prospectus forms a part, and any other registration statement the Company
may file from time to time covering the resale by Arena Global of ELOC Shares or Commitment Fee Shares, is declared effective by the
SEC and remains effective, and the other conditions set forth in the ELOC Purchase Agreement are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arena
Global has no right to require any sales by us, but Arena Global is obligated to make purchases at our direction subject to certain conditions.
There is no upper limit on the price per share that Arena Global could be obligated to pay for ELOC Shares under the ELOC Purchase Agreement.
Actual sales of ELOC Shares to Arena Global from time to time will depend on a variety of factors, including, among others, market conditions,
the trading price of our common stock and determinations by us as to the appropriate sources of funding for us and our operations. The
net proceeds that we may receive under the ELOC Purchase Agreement, if any, cannot be determined at this time, since it will depend on
the frequency and prices at which we sell ELOC Shares to Arena Global, our ability to meet the conditions of the ELOC Purchase Agreement,
and the other limitations, terms and conditions of the ELOC Purchase Agreement and any impacts of the Beneficial Ownership Limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchase
of ELOC Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the ELOC Purchase Agreement, after the satisfaction of certain conditions, we have the right to present Arena Global with an Advance
Notice directing it to purchase any amount of ELOC Shares, up to the Maximum Advance Amount, which is calculated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received by 8:30 a.m. Eastern Time, the lower of: (i) an amount equal
                                            to eighty percent (80%) of the average of the Daily Value Traded (as defined in the ELOC
                                            Purchase Agreement) of our common stock on the ten (10) trading days immediately preceding
                                            an Advance Notice, or (ii) $20,000,000;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 8:30 a.m. Eastern Time but prior to 10:30 a.m. Eastern
                                            Time, the lower of: (i) an amount equal to forty percent (40%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $10,000,000;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 10:30 a.m. Eastern Time, but prior to 12:30 p.m. Eastern
                                            Time, the lower of: (i) an amount equal to twenty percent (20%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $5,000,000; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the Advance Notice is received after 12:30 p.m. Eastern Time but prior to 2:30 p.m. Eastern
                                            Time, the lower of: (i) an amount equal to ten percent (10%) of the average of the Daily
                                            Value Traded of our common stock on the ten (10) trading days immediately preceding an Advance
                                            Notice, or (ii) $2,500,000.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price to be paid by Arena Global for the ELOC Shares will be ninety-six percent (96%) of the VWAP (as defined in the ELOC Purchase
Agreement) of the Company&#8217;s common stock during the trading day commencing on the date of the Advance Notice, subject to adjustment
pursuant to the terms of the ELOC Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consideration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for Arena Global&#8217;s execution and delivery of the ELOC Purchase Agreement, we agreed to issue to Arena Global, as
a commitment fee: (i) 70,000 Initial Commitment Fee Shares and (ii) in two separate tranches, a number of Additional Commitment Fee Shares
equal to (a) the First Trance Price and (b) the Second Trance Price. The Additional Commitment Fee Shares shall be subject to a true-up
after each issuance pursuant to the terms of the ELOC Purchase Agreement. In connection with the true-up, we will issue to Arena Global
a number of additional shares of our common stock, if any, having an aggregate dollar value equal to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to the first tranche, 500,000 based on the lower of (A) the First Tranche Price and
                                            (B) the lower of (x) the simple average of the three (3) lowest daily intraday trade prices
                                            over the twenty (20) trading days after (and not including) the Effectiveness Date and (y)
                                            the closing price on the twentieth (20th) trading day after the Effectiveness Date; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            respect to the second tranche, 500,000 based on the lower of (A) the Second Tranche Price
                                            and (B) the lower of (x) the simple average of the three (3) lowest daily intraday trade
                                            prices over the twenty (20) trading days after (and not including) the Anniversary and (y)
                                            the closing price on the twentieth (20th) trading day after the Anniversary<span style="text-transform: uppercase">.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>C</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">onditions
to Delivery of Advance Notices</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to deliver Advance Notices under the ELOC Purchase Agreement is subject to the satisfaction of certain conditions, including,
among other things, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            representations and warranties of the Company under the ELOC Purchase Agreement being true
                                            and correct in all material respects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of that the registration statement of which this prospectus forms a part, and
                                            any other registration statement the Company may file from time to time covering the resale
                                            by Arena Global of ELOC Shares or ELOC Commitment Fee Shares;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having filed with the SEC all reports, notices and other documents required under
                                            the Exchange Act and applicable SEC regulations during the six-month period immediately preceding
                                            the delivery of the Advance Notice;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having obtained all permits and qualifications required by any applicable state for
                                            the offer and sale of all the ELOC Shares issuable pursuant to the Advance Notice, or having
                                            the availability of exemptions therefrom;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            continuing Material Outside Event or Material Adverse Effect (each as defined in the ELOC
                                            Purchase Agreement) having occurred;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having performed, satisfied and complied in all material respects with all covenants,
                                            agreements and conditions required by the ELOC Purchase Agreement to be performed, satisfied
                                            or complied with by the Company at or prior the delivery of the Advance Notice, including,
                                            without limitation, the delivery of all ELOC Shares issuable pursuant to all previously delivered
                                            Advance Notices and the issuance of all ELOC Commitment Fee Shares previously required
                                            to be issued;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            statute, rule, regulation, executive order, decree, ruling or injunction having been enacted,
                                            entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction
                                            that prohibits or directly, materially and adversely affects any of the transactions contemplated
                                            by the ELOC Purchase Agreement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company&#8217;s shares of common stock, including all of the ELOC Shares issuable pursuant
                                            to the Advance Notice, being quoted for trading on Nasdaq;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company shall not have received any written notice that is then still pending threatening
                                            the continued quotation of the common stock on Nasdaq;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having a sufficient number of authorized but unissued, and otherwise unreserved,
                                            shares of common shares available for the issuance of all of the ELOC Shares issuable pursuant
                                            to the Advance Notice;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            representations contained in the Advance Notice being true and correct in all material respects
                                            as of the date of delivery of the Advance Notice;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                            with respect to the first Advance Notice, the Pricing Period (as defined in the ELOC Purchase
                                            Agreement) for all prior Advance Notices having been completed; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company having obtained shareholder approval to issue an aggregate number of shares of common
                                            stock to Arena Global, under the ELOC Purchase Agreement, in excess of 19.99% of the number
                                            of shares of common stock outstanding immediately prior to the execution of the ELOC Purchase
                                            Agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Sales</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any given time of any sale by us to Arena Global, we may not sell, and Arena Global may not purchase, ELOC Shares that would result in
Arena Global owning more than the 9.99% Beneficial Ownership Limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Short Selling or Hedging by Arena Global</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arena
Global has agreed that, during the term of the ELOC Purchase Agreement, neither Arena Global nor any of its affiliates will engage in
any short sales or hedging transactions with respect to our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
of the ELOC Purchase Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated as provided in the ELOC Purchase Agreement, the ELOC Purchase Agreement will terminate automatically on the earliest
to occur of: (i) December 1, 2027, (ii) the date on which Arena Global shall have purchased the maximum amount of ELOC Shares, or (iii)
the effective date of any written notice of termination delivered pursuant to the terms of the ELOC Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Variable Rate Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the ELOC Purchase Agreement, from the date of the ELOC Purchase Agreement until the earlier of (i) the date that Arena Global has
purchased $20,000,000 in ELOC Shares, (ii) twelve (12) months after the Effectiveness Date, or (iii) three (3) months after the termination
of the ELOC Purchase Agreement, pursuant to its terms, the Company is prohibited from effecting or entering into an agreement to effect
any issuance of our common stock or common stock equivalents involving a Variable Rate Transaction (as defined in the ELOC Purchase Agreement),
other than in connection with an Exempt Issuance (as defined in the ELOC Purchase Agreement) or with the prior written consent of Arena
Global.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilutive Effect</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares of common stock registered in this offering which have been or may be issued or sold by us to Arena Global under the ELOC Purchase
Agreement are expected to be freely tradable. It is anticipated that the shares of common stock registered in this offering will be sold
over a period starting on the date that the registration statement of which this prospectus is a part is declared effective and ending
on December 1, 2027. The sale by Arena Global of a significant amount of common stock registered in this offering could cause the market
price of our common stock to decline and to be highly volatile. Sales of ELOC Shares to Arena Global, if any, will depend upon market
conditions and other factors to be determined by us. We may ultimately decide to sell to Arena Global all, some or none of the ELOC Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
may resell all, some or none of the shares of common stock held by it at any time, or from time to time, in its discretion. Therefore,
sales to Arena Global by us under the ELOC Purchase Agreement may result in substantial dilution to the interests of other holders of
common stock. In addition, if we sell a substantial number of ELOC Shares to Arena Global, or if investors expect that we will do so,
the actual sales of ELOC Shares or the mere existence of our arrangement with Arena Global may make it more difficult for us to sell
securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control
the timing and amount of any sales to Arena Global and we are not obligated to submit any Advance Notices under the ELOC Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following
table sets forth the amount of gross proceeds we would receive from Arena Global from the sale of ELOC Shares to Arena Global under the
ELOC Purchase Agreement at varying purchase prices, without giving effect to the Beneficial Ownership Limitation, for illustrative purposes
only. The Beneficial Ownership Limitation may not be increased above 9.99% of our then outstanding common stock.<b>&#160;</b>Furthermore,
as noted above, we are not obligated to submit any Advance Notices under the ELOC Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assumed
    Average<br/>
    Purchase<br/>
    Price Per Share (1)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Registered<br/>
    Common Shares to be<br/>
    Issued if Full Purchase,<br/>
    Without Giving Effect to the<br/>
    Beneficial Ownership Limitation (2)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of Outstanding<br/>
                                            Common Stock After Giving<br/>
                                            Effect to the Issuance to<br/>
                                            Arena Global, Without<br/>
                                            Giving Effect to the Beneficial </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership
    Limitation (3)</b></span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proceeds
    from the Sale of<br/>
    Common Stock to Arena<br/>
    Global Under the ELOC<br/>
    Purchase Agreement(4)</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.00</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,333,333</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 21%; text-align: right"><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.8</span></p></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000,000</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.00</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,142,857</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.0</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4112</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,746,545</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.6</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.00</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,250,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.50</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,882,353</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the avoidance of any doubt, this price reflects the purchase
    price after calculation (i.e. after discounts to the market price of our shares) in accordance with the terms of the ELOC Purchase
    Agreement.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the number of ELOC Shares that could potentially be issued
    to Arena Global during the Commitment Period, in the aggregate, based on the applicable assumed purchase price per share, without
    giving effect to the Beneficial Ownership Limitation. </span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The denominator is based on 8,730,366 shares of our common stock
    outstanding as of December 3, 2024, adjusted to include the issuance of the number of shares of common stock set forth in
    the adjacent column which we would have issued to Arena Global based on the applicable assumed purchase price per share.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company did not receive any proceeds from the issuance of the
    ELOC Commitment Fee Shares to Arena Global.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents the last reported sales price of our common stock on
    December 2, 2024, as reported by Nasdaq, less a four percent (4%) discount.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ELOC Shares and ELOC Commitment Fee Shares were, and will be, offered and sold to Arena Global in reliance upon the exemption
from registration provided by Section 4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summary of the ELOC Purchase Agreement is qualified in its entirety by reference to the full text of the ELOC Purchase Agreement,
which is incorporated by reference as an exhibit to the registration statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b><span id="xca_001"></span>DESCRIPTION
OF SECURITIES PURCHASE AGREEMENT </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">On
November 22, 2024, the Company entered into the Securities Purchase Agreement with the Arena Investors. Under the Securities Purchase
Agreement, the Company will issue Debentures in a principal amount of up to $12,222,222 million, divided into up to three separate tranches
that are each subject to certain closing conditions. The conversion price per share of each Debenture is equal to 92.5% of the lowest
daily VWAP (as defined in the Debentures) of the Company&#8217;s shares of common stock during the five trading day period ending on
the trading day immediately prior to delivery or deemed delivery of the applicable Conversion Notice (as defined in the Debentures),
subject to adjustments related to the trading price of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
First Closing was consummated on November 25, 2024 and the Company issued to the Arena Investors the First Closing Debentures in an aggregate
principal amount of $3,333,333. The First Closing Debentures were sold to the Arena Investors for a purchase price of $3,000,000, representing
an original issue discount of ten percent (10%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
First Closing Debentures contain customary events of default. If an event of default occurs, until it is cured, the holder may increase
the interest rate applicable to the First Closing Debentures to two percent (2%) per annum and accelerate the full indebtedness under
the First Closing Debentures, in an amount equal to 125% of the outstanding principal amount and accrued and unpaid interest. Subject
to limited exceptions set forth in the First Closing Debentures, the First Closing Debentures prohibit the Company and, as applicable,
its subsidiaries from incurring any new indebtedness that is not subordinated to the Arena Investors and, as applicable, any subsidiary&#8217;s
obligations in respect of the First Closing Debentures until the First Closing Debentures are paid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As
consideration for the Arena Investors&#8217; consummation of the First Closing, concurrently with the First Closing, the Company issued
to each Arena Investor participating in the First Closing its pro rata portion of the 55,000 SPA Commitment Fee Shares. Furthermore,
as consideration for the Arena Investors&#8217; consummation of subsequent closings, the Company shall issue to the Arena Investors participating
in such closing a certain number of Company common stock as agreed upon among the Company and the Arena Investors participating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
Company agreed, pursuant to the Security Agreement, to grant the Arena Investors a security interest in all of its assets to secure the
prompt payment, performance, and discharge in full of all of the Company&#8217;s obligations under the Debentures. In addition, the Company&#8217;s
wholly-owned subsidiary, Scienture LLC, entered into the Guarantee Agreement, pursuant to which it agreed to guarantee the prompt payment,
performance, and discharge in full of all of the Company&#8217;s obligations under the Debentures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
Company also agreed, pursuant to the Registration Rights Agreement, to file with the SEC an initial registration statement within 45
days to register the maximum number of Registrable Securities (as defined in the Registration Rights Agreement) in accordance with applicable
SEC rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
Securities Purchase Agreement, Debentures, Security Agreement, Guaranty Agreement, and Registration Rights Agreement contain customary
representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations
of the parties. Among other things, the Arena Investors represented to the Company, that they are each an &#8220;accredited investor&#8221;
(as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The Company issued, and will issue, the securities
in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="bs_001"></span>DESCRIPTION
OF BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
and Organizational History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background
of XCEL</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Delaware on July 15, 2005, as &#8220;Bluebird Exploration Company&#8221; (&#8220;Bluebird&#8221;). Bluebird was
originally formed to engage in the exploitation of mineral properties. In December 2008, Bluebird changed its name to &#8220;Xcellink
International, Inc.&#8221; (&#8220;XCEL&#8221;), and subsequently announced that its business plan was being expanded to include the
development and marketing of platform-independent customer-centric payment systems and methodologies. XCEL was unable to raise the funds
necessary to implement its business strategy, and never generated any revenue. On January 9, 2014, Trxade Group, Inc., a then privately
held Nevada corporation, merged with and into XCEL, and XCEL changed its name to &#8220;Trxade Group, Inc.&#8221; On June 1, 2021, the
Company changed its name from &#8220;Trxade Group, Inc&#8221; to &#8220;TRxADE HEALTH, Inc.&#8221; On September 20, 2024, the Company
changed its name from &#8220;TRxADE HEALTH, Inc.&#8221; to &#8220;Scienture Holdings, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Background
of Trxade</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PharmaCycle
LLC, a Nevada limited liability company (&#8220;PharmaCycle&#8221;), was formed in August 2010 by Prashant Patel, our President, Chief
Operating Officer, and Interim, to serve as a web-based market platform designed to enable trading among healthcare buyers and sellers
of pharmaceuticals, accessories and services. In January 2013, PharmaCycle converted into a Florida corporation and changed its name
to Trxade, Inc. (&#8220;Trxade Florida&#8221;). In May 2013, Trxade Florida created a new wholly-owned subsidiary, Trxade Group, Inc.,
a Nevada corporation (&#8220;Trxade Nevada&#8221;). Trxade Nevada acquired Trxade Florida pursuant to a reverse triangular merger, resulting
in Trxade Florida becoming a wholly-owned subsidiary of Trxade Nevada (the &#8220;Nevada-Florida Merger&#8221;). The sole purpose of
the Nevada-Florida Merger was to provide for a holding company to own Trxade Florida, the operating company. Immediately following the
Nevada-Florida Merger, Messrs. Ajjarapu and Patel collectively owned 99% of Trxade Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Merger with Trxade</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 26, 2008, Mark Fingarson, the former President, sole Director and controlling shareholder of XCEL, sold 80,000,000 shares of
XCEL (prior to the Merger Reverse Split and Reverse Stock Splits (each discussed and defined below)). On November 22, 2013, Trxade Nevada
acquired Mr. McIntyre&#8217;s controlling interest of 80,000,000 shares in XCEL pursuant to a Purchase and Sale Agreement dated November
7, 2013. At the time of the sale, XCEL had 104,160,000 shares of common stock issued and outstanding, including the 80,000,000 shares
of stock acquired by Trxade Nevada (prior to the Merger Reverse Split and Reverse Stock Split(s) (each discussed and defined below)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 16, 2013, Trxade Nevada and XCEL entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) providing for
the merger (the &#8220;Merger&#8221;) of Trxade Nevada with and into XCEL, with XCEL continuing as the surviving corporation. The Merger
closed on January 8, 2014. Under the terms of the Merger Agreement, we amended our certificate of incorporation and changed our name
to &#8220;Trxade Group, Inc.,&#8221; and changed our trading symbol to &#8220;TRXD&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recapitalization
of Common Stock by a Reverse Split and Increase of Authorized Shares of Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also reversed our issued and outstanding stock at the ratio of one for one thousand (1:1,000) shares effective upon the closing of the
Merger (the &#8220;Merger Reverse Split&#8221;). In connection with the Merger Reverse Split, 104,160,000 outstanding shares of our common
stock, including the 80,000,000 shares held by Trxade Nevada, were exchanged for 104,160 post-Merger Reverse Split shares of common stock.
As a result of the Merger, Trxade Nevada stockholders holding 28,800,000 shares of common stock and 670,000 shares of Series A Preferred
Stock converted their shares on a one-to-one basis into 28,800,000 shares of our common stock and 670,000 shares of our Series A Preferred
Stock, for an aggregate total of 29,470,000 shares. Further, 100,000 shares of our common stock (on a post-Reverse Split basis and considering
the Reverse Stock Split(s) (discussed below)) were issued following the Merger in connection with the conversion of our promissory notes.
The 80,000,000 pre-Merger shares held by Trxade Nevada, which amounted to 13,334 shares (on a post-Reverse Split basis and taking into
account the Reverse Stock Split(s)), reverted to treasury stock of the Company. Except as otherwise disclosed, the share amounts in the
paragraph above have not been adjusted for the Merger Reverse Split or the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February
2020 Reverse Stock Split and NASDAQ Capital Market Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2020, the Company effected a 1-for-6 reverse stock split of the then outstanding common stock in order to allow us to meet the
initial listing criteria of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock was approved for listing on Nasdaq under the symbol &#8220;MEDS&#8221;, on February 13, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
2023 Reverse Stock Split.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023 the Company effected a 1-for-15 reverse stock split of its issued and outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own 100% of Scienture LLC, Softell Inc. (f/k/a Trxade, Inc.), IPS, Bonum Health, Inc., and Bonum Health. During the year ended
December 31, 2023, and a portion of the quarter ended March 31, 2024, Softell, operated a web-based market platform that enables commerce
among healthcare buyers and sellers of pharmaceuticals, accessories and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS and cardiovascular CVS diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPS
is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS customers include all healthcare
markets including government organizations, hospitals, clinics and independent pharmacies nationwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonum
Health was formed to hold certain telehealth assets acquired in October 2019. The &#8220;Bonum Health Hub&#8221; was launched in February
2020; however, the Company does not anticipate installations moving forward. We currently anticipate dissolving Bonum Health, Inc. and
Bonum Health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2024, the Company and Softell Inc. (f/k/a Trxade, Inc.) (&#8220;Softell&#8221;) entered into an Assignment and Assumption
of Membership Interests (the &#8220;IPS Assignment Agreement&#8221;), pursuant to which the Company transferred, and Softell accepted,
100% of the membership interests of IPS. As a result, IPS is now a wholly-owned subsidiary of Softell. During the year ended December
31, 2023 and a portion of the quarter ended March 31, 2024, Softell, operated a web-based market platform that enabled commerce among
healthcare buyers and sellers of pharmaceuticals, accessories and services. Softell&#8217;s current primary operations are conducted
through IPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Superlatus
Merger</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the &#8220;Superlatus Merger Agreement&#8221;)
with Superlatus and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superlatus
is a diversified food technology company with distribution capabilities and systems to optimize food security and population health via
innovative Consumer Packaged Goods (&#8220;CPG&#8221;) products, agritech, foodtech, plant-based proteins and alt-protein and includes
wholly-owned subsidiary, Sapientia, Inc. (&#8220;Sapientia&#8221;), a food tech business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2023, the Company completed its acquisition of Superlatus in accordance with the terms and conditions of the Superlatus Merger
Agreement (the &#8220;Superlatus Merger&#8221;), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub
with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the Superlatus Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Superlatus Merger Agreement, at the closing of the Superlatus Merger (the &#8220;Closing&#8221;), shareholders of Superlatus
received an aggregate of 136,441 shares of the Company&#8217;s common stock and 306,855 shares of the Company&#8217;s Series B Preferred
Stock, par value $0.00001 per share (the &#8220;Series B Preferred Stock&#8221;), convertible into 100 shares of the Company&#8217;s
common stock. At Closing, the value of the Company&#8217;s common stock was $7.30 per share, resulting in a total value of $225,000,169.
Upon consummation of the Superlatus Merger, the Company continued to trade under the former ticker symbol &#8220;MEDS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
all of the closing conditions of the Superlatus Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the
Amended and Restated Agreement and Plan of Merger (the &#8220;Superlatus Amendment&#8221;) on January 8, 2024. Under the terms of the
Superlatus Amendment, the merger consideration to the shareholders of Superlatus was adjusted to the aggregate of 136,441 shares of the
Company&#8217;s common stock and 15,759 shares of the Company&#8217;s Series B Preferred Stock, resulting in a total value of $12,500,089.
Additionally, the shareholders of Superlatus agreed to surrender back to the Company 291,096 shares of the Company&#8217;s Series B Preferred
Stock. As described below, the Company divested of its interest in Superlatus in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scienture
Merger</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, the Company entered into and closed an Agreement and Plan of Merger (the &#8220;Scienture Merger Agreement&#8221;) with
MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;Merger Sub I&#8221;), MEDS Merger
Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221; and, together
with Merger Sub I, the &#8220;Merger Subs&#8221;), and Scienture LLC. Pursuant to the Scienture Merger Agreement, (i) Merger Sub I merged
with and into Scienture LLC (the &#8220;First Merger&#8221;), with Scienture LLC continuing as the surviving entity and a wholly owned
subsidiary of the Company, and (ii) Scienture LLC merged with and into Merger Sub II (the &#8220;Second Merger&#8221; and, together with
the First Merger and all other related transactions, the &#8220;Scienture Merger&#8221;), with Merger Sub II continuing as the surviving
entity. In connection with the transactions, the Company changed its name to &#8220;Scienture Holdings, Inc.&#8221; and Merger Sub II,
as the surviving entity of the Second Merger, changed its name to &#8220;Scienture, LLC&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Scienture Merger, at the effective time of the First Merger (the &#8220;Effective Time&#8221;), the shares of Scienture
LLC common stock issued and outstanding immediately prior to the Effective Time were converted into the right to receive, in the aggregate,
(i) 291,536 shares of the Company&#8217;s common stock and (ii) 6,826,753 shares of the Company&#8217;s Series X Non-Voting Convertible
Preferred Stock (the &#8220;Series X Preferred Stock&#8221;), each share of which is convertible into one share of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dispositions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>SOSRx,
LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SOSRx,
LLC (&#8220;SOSRx&#8221;) was formed on February 15, 2022. The Company entered into a relationship with Exchange Health, LLC (&#8220;Exchange
Health&#8221;), a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals.
SOSRx, a Delaware limited liability company, was formed, which was owned 51% by the Company and 49% by Exchange Health. SOSRx did not
generate material revenue and in February of 2023, the Company voluntarily withdrew from the joint venture agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Community
Specialty Pharmacy, LLC and Alliance Pharma Solutions, LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests
of the Company&#8217;s former subsidiaries, Community Specialty Pharmacy, LLC (&#8220;CSP&#8221;) and Alliance Pharma Solutions, LLC
(&#8220;APS&#8221; d.b.a DelivMeds). The Company also agreed to enter into a Master Service Agreement to operate the businesses prior
to closing. The transactions contemplated by the Membership Interest Purchase Agreements closed on August 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Softell
Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2024, the Company, together with Softell, and Micro Merchant Systems, Inc. (&#8220;MMS&#8221;) entered into an asset purchase
agreement (the &#8220;MMS APA&#8221;) under which MMS agreed to purchase for cash substantially all of the assets of Softell. On February
16, 2024, the parties consummated the closing of the transactions contemplated by the MMS APA. Softell operated a web-based market platform
designed to enable trading among healthcare buyers and sellers of pharmaceuticals, accessories and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Superlatus
Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2024, the Company entered in a Stock Purchase Agreement (&#8220;Superlatus SPA&#8221;) with Superlatus Foods Inc. (the &#8220;Buyer&#8221;).
Pursuant to the Superlatus SPA, the Company sold all of the issued and outstanding stock of Superlatus to the Buyer. The $1.00 purchase
price for the Stock was delivered to the Company at the closing, which occurred simultaneously with the execution of the Superlatus SPA.
As a result of the transaction Superlatus is no longer a subsidiary of the Company, and the rights and assets of Superlatus together
with various liabilities and obligations that were specific to Superlatus became rights and obligations of the Buyer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Historical
Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience via an online pharmaceutical
marketplace. Our current primary operations are conducted through our wholly-owned subsidiary, IPS, which is a licensed pharmaceutical
wholesaler and sells brand, generic and non-drug products to customers. IPS customers include all healthcare markets including government
organizations, hospitals, clinics and independent pharmacies nationwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
began operations as Trxade Group, Inc., a Nevada corporation (&#8220;Trxade Nevada&#8221;) in August of 2010 and spent over two years
creating and enhancing our web-based services. The Company changed its name on June 1, 2021, from &#8220;Trxade Group, Inc&#8221; to
&#8220;TRxADE HEALTH, Inc.&#8221; Our services provided pricing transparency, purchasing capabilities and other value-added services
on a single platform focused on serving the nation&#8217;s approximately 19,397 independent pharmacies with annual purchasing power of
$67.1 billion (according to the National Community of Pharmacists Association&#8217;s 2021 Digest). Our national wholesale supply partners
and manufacturers were able to fulfill orders on our platform in real-time and provide pharmacies and wholesale suppliers with cost-saving
payment terms and next-day delivery capabilities in unrestrictive states. We have expanded significantly since 2015 and served approximately
14,400+ registered members on our sales platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trxade.com
</i>previously operated the Company&#8217;s web-based pharmaceutical marketplace engaged in promoting and enabling commerce among independent
pharmacies, small chains, hospitals, clinics, and alternate dispensing sites with large pharmaceutical suppliers nationally. That marketplace
had over 60 national and regional pharmaceutical suppliers providing over 120,000 branded and generic drugs, including over-the-counter
drugs (OTCs), and drugs available for purchase by pharmacists. We served approximately 14,400+ registered members, providing access to
Trxade&#8217;s proprietary pharmaceutical database and data analytics regarding medication pricing. We generated revenue from these services
by charging a transaction fee to the seller of the products for sales conducted via the Trxade platform. The buyers did not bear the
cost of transaction fees for the purchases that they made, nor did they pay a fee to join or register with our platform. In February
2024 we divested substantially all of our assets related to our web-based pharmaceutical marketplace previously operated through Softell.
Substantially all of our revenues during Fiscal 2023, Fiscal 2022, and Fiscal 2021 were from platform revenue generated on <i>www.rx.trxade.com</i>,
product sales through IPS, and prescription sales through Community Specialty Pharmacy, LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously had a number of products and services focused on the US market in operation and business assets, which are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Integra
Pharma Solutions, LLC. </i>IPS is intended to serve as our logistics company for pharmaceutical distribution. We currently distribute
through our manufacturer and strategic distribution partners prescription medication, medical devices and over the counter medication
to over 1,600 pharmacies and medical clinics across 38 states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trxade
Prime.</i> Trxade Prime previously allowed pharmacy members on the Trxade platform to process, consolidate and ship purchase orders that
were placed directly with Trxade suppliers via Trxade Prime. This service was provided at no cost, with the goal of offering a single
tool with one low order minimum, one invoice, one package and one delivery from multiple quality wholesalers and distributors. Revenue
had been generated from this service through our IPS subsidiary, which provided the consolidation of the orders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonum
Health Application. </i>The &#8220;Bonum Health app,&#8221; previously provided an overall healthcare experience comparable to a primary
care practitioner, and an online portal as a personal electronic medical record and scheduling system was available on a subscription
basis, primarily as a stand-alone telehealth software application that could be licensed on a business-to-business (B2B) model to clients
as an employment health benefit for the clients&#8217; employees. Revenue was generated from this service through our Bonum Health subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonum+
Business to Business (B2B).</i> Bonum+ previously bundled telehealth, a COVID-19 risk assessment tool and a Personal Protective Equipment
(PPE) purchasing tool, through a secure mobile dashboard for corporate clients. The B2B platform eased pressure on employees who were
required to report any relevant health issues daily, centralizing communication and contact tracing to deliver risk scores. This allowed
employers to monitor employee COVID-19 risk profiles and streamlined the ordering of new PPE as needed. An integrated artificial intelligence
(AI) tool offered health recommendations and connects employees with board certified physicians, as needed. No revenue was generated
from this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SOSRx,
LLC.</i> On February 15, 2022, the Company entered into a relationship with Exchange Health, LLC (&#8220;Exchange Health&#8221;), a technology
company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals. SOSRx, LLC (&#8220;SOSRx&#8221;)
was formed, which was owned 51% by the Company and 49% by Exchange Health. SOSRx did not generate material revenue and in February of
2023, the Company voluntarily withdrew from the joint venture agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Superlatus.
</i>As of December 31, 2023, Superlatus was a wholly owned subsidiary of the Company as a result of a merger transaction that closed
in July 2023. Superlatus is a diversified food technology company with distribution capabilities and systems to optimize food security
and population health via innovative Consumer Packaged Goods products, agritech, foodtech, plant-based proteins and alt-protein and includes
wholly-owned subsidiary, Sapientia, Inc., a food tech business. Subsequent to December 31, 2023, the Company divested its entire interest
in Superlatus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current
Business &#8211; Scienture LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture LLC was originally incorporated in Delaware and commenced operations in 2019. In connection with our acquisition in July 2024,
Scienture became a wholly owned subsidiary of the Company. Scienture&#8217;s principal executive offices are located in Commack, New York.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS and CVS
diseases. Scienture LLC is developing a broad range of novel product candidates including new potential treatments for hypertension,
migraine, pain and thrombosis and other related disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Scienture
LLC&#8217;s Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s mission is to improve the lives of patients suffering from CNS and CVS diseases. Scienture LLC&#8217;s vision is to be a
leader in the industry by developing and commercializing new medicines for the treatment of CNS and CVS diseases. Key elements of
Scienture LLC&#8217;s strategy to achieve this vision include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advance
    product candidates through clinical studies and toward commercialization.</i> Scienture LLC is in various stages of clinical
    development for the product candidates in its pipeline, and it intends to move these programs efficiently toward being commercially
    available to patients, subject to approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). Scienture LLC is
    working to obtain regulatory approval of its first product candidate, SCN-102.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Drive
    growth and profitability.</i> Using dedicated sales and marketing resources in the U.S., which Scienture LLC is in the process of
    building, Scienture LLC will seek to drive the revenue growth of its product candidates approved for marketing by the
    FDA.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Continue
    to grow pipeline.</i> Scienture LLC will continue to evaluate and seek to develop additional product candidates that it believes
    have significant commercial potential through Scienture&#8217;s internal research and development efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Target
    strategic business development opportunities.</i> Scienture LLC is exploring a broad range of strategic opportunities. This may
    include in-licensing products and entering into co-promotion and co-development partnerships for Scienture&#8217;s product
    candidates, although no agreements have been reached.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development and Product Portfolio</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is committed to the development of innovative product candidates in the CNS and CVS therapeutic areas. The process by which Scienture
LLC intends to bring its product candidates to market and the anticipated launch dates of its product candidates is depicted in the following
table. The progress of the Company&#8217;s products through this process is represented by checkmarks in the table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form424b3_002.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture <span>LLC </span>
does not have any product candidates approved for sale and has not generated any revenue from product sales. Scienture <span style="background-color: white">LLC </span>
will not generate revenue from product sales unless and until it successfully obtains regulatory approval for its product
candidates. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture LLC is engaged in a
variety of research and development efforts including development of a pipeline of novel product candidates for the treatment of
various disease conditions. Scienture LLC has devoted and will continue to devote significant resources to research and development
activities, and expects to incur significant expenses as Scienture LLC continues advancing its product candidates towards FDA
approval and expanding product indications for approved products and its intellectual property portfolio. Scienture LLC&#8217;s
expectations regarding its research and development programs are subject to risks, including the risk that Scienture LLC&#8217;s
financial condition and results of operations for fiscal year 2024 and beyond may be materially and adversely affected by delays and
failures in the completion of clinical development of its product candidates, which could increase its costs or delay or limit our
ability to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SCN-102
(ARBLI<sup>TM</sup> - Losartan Oral Suspension)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-102
is an oral liquid formulation of losartan potassium in development under the 505(b)(2) pathway, for (i) treatment of hypertension, to
lower blood pressure in adults and children greater than 6 years old, (ii) reduction of the risk of stroke in patients with hypertension
and left ventricular hypertrophy, and (iii) treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients
with type 2 diabetes and a history of hypertension. Currently, there are no FDA-approved liquid formulations of losartan potassium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase I PK study has shown that SCN-102 has close comparability to the immediate-release tablet as depicted in the data below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="33" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary of Statistical Results
    for Losartan Potassium Oral Liquid 10 mg/ml (T) versus Losartan Potassium Immediate Release Tablets 100 mg (R) &#8211; For Losartan</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Geometric Means of treatment:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PK Parameter</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">N</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Test (T)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reference (R)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ratio (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intra-subject %CV</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">90% CI of Ratio</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SABE Result &#8211; Bound</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SABE SWR</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Log
    C<sub>max</sub> (ng/ml)</b></span></td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">44</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">1317.6955</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">974.6741</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">135.19</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">39.6</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.19
                                            &#8211; 149.58</span></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">0.070</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">0.3361</td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LogAUC<sub>0-t
    </sub>(ng.hr/ml)</b></span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">44</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1590.6271</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1581.0602</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100.61</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">13.2</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.25
                                            &#8211; 104.08</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-0.014</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.1576</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LogAUC<sub>0-inf
    </sub>(ng.hr/ml)</b></span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">44</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1615.4717</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1605.3052</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100.63</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">13.0</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.34
                                            &#8211; 104.03</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-0.014</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.1549</td><td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="33" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary of Statistical Results
    for Losartan Potassium Oral Liquid 10 mg/ml (T) versus Losartan Potassium Immediate Release Tablets 100 mg (R) &#8211; For Carboxylic
    Acid Metabolite</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Geometric Means of treatment:</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PK Parameter</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">N</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Test (T)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reference (R)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ratio (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intra-subject %CV</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">90% CI of Ratio</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SABE Result &#8211; Bound</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SABE SWR</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Log
    C<sub>max</sub> (ng/ml)</b></span></td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">44</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">1160.0978</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">1056.3253</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">109.82</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">25.5</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102.91
                                            &#8211; 117.20</span></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">-0.028</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 5%; text-align: center">0.2828</td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LogAUC<sub>0-t
    </sub>(ng.hr/ml)</b></span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">44</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6775.8841</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6726.8952</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100.73</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10.3</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.11
                                            &#8211; 103.42</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-0.006</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.1099</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LogAUC<sub>0-inf
    </sub>(ng.hr/ml)</b></span></td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">44</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6872.6739</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">6823.3736</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100.72</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10.2</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.13
                                            &#8211; 103.39</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-0.006</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">0.1071</td><td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the Phase I PK study showed that SCN-102 was comparable to immediate release tablets based on the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    overall exposure for the Carboxylic Acid metabolite (EXP-3174) meet the confidence interval 80-125% range.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    overall exposure for Losartan were within the 90% confidence interval.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Cmax for Losartan analyte, a pro-drug, for SCN-102 was slightly higher than the immediate release tablets (122.19 - 149.58%). This
    is due to the fact that the SCN-102 (oral liquid) and the reference product are two different dosage forms. SCN-102 is an oral liquid
    formulation and therefore it is expected to have an earlier Cmax than the immediate release tablet. Based on the discussion above,
    we believe that the impact of this Cmax difference will be minimal.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    data obtained in the study is similar to the PK study data for the immediate release tablet.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, SCN-102 would be the first FDA approved oral liquid formulation of losartan on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC submitted an IND application to the FDA in September 2022. Multiple human pharmacokinetics studies were performed, showing
close comparability with the oral solid dosage form. In October 2023, Scienture LLC submitted an NDA for losartan potassium oral suspension
to the FDA. In December 2023, the FDA accepted the NDA for review and assigned a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;)
target action date of August 19, 2024. Despite responding during the FDA&#8217;s review to information requests related to chemistry,
manufacturing, and controls (&#8220;CMC&#8221;), pharmacovigilance, clinical, microbiology and labeling, the FDA issued a Complete Response
Letter to Scienture LLC focused on the CMC information submitted. Scienture LLC prepared the requested information and resubmitted the NDA to the FDA on September 17, 2024. In October
2024, the FDA accepted the resubmitted NDA for review and assigned a PDUFA target action date of March 17, 2025. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SCN-104
(Multi-dose Dihydroergotamine Mesylate (&#8220;DHE&#8221;) injection pen)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SCN-104 injection pen is a disposable, multiple fixed dose, single entity combination product comprised of a small molecule drug, SCN-104,
which is administered using a customized injection pen. SCN-104 is a drug product containing DHE as the active ingredient. The mechanism
of action of SCN-104 is mediated through DHE and is exactly the same as that of DHE. DHE is available in the market as a single dose
nasal spray, which has a high degree of variability in clinical outcomes. DHE is also available in the market as single dose ampoules
for injection, however, We believe that the process of dose withdrawal from the ampoule followed by self-injection at
the time of intense need is cumbersome and difficult for the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> that the SCN-104 multi-dose self-injection
pen is easy to use and provides enhanced patient convenience. Furthermore, we believe that the SCN-104 injection pen provides
for consistent and accurate delivery of every dose which results in better exposure compared to the nasal spray formulation. The SCN-104
injection pen is being developed via the 505(b)(2) regulatory pathway. The SCN-104 injection pen is in development for the acute treatment
of migraine headaches with or without aura and the acute treatment of cluster headache episodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
shown in third party studies of DHE, SCN-104&#8217;s mechanism of action for its antimigraine effect is due to its potential action as
an agonist at the serotonin 5-HT1D receptors. SCN-104 is intended for subcutaneous administration. SCN-104 is also intended for acute
use and is not intended for chronic administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has conducted two preclinical studies of
SCN-104 and the SCN-104 injection pen: (i) a 30-day repeated dose toxicity study of dimethyl sulfoxide and caffeine following thrice
daily, 3 times per week subcutaneous administration in Sprague-Dawley rats and (ii) a 30-day repeated dose toxicity study of
dimethyl sulfoxide and caffeine following thrice daily, 3 times per week subcutaneous administration in G&#246;ttingen minipigs. The
objective of each study was to evaluate the safety and tolerability of the test items with and without DHE to the subject animals,
providing information on important potential toxic effects, target organs, progressive toxic effects, characterization of a possible
dose-response relationship, and an estimate the No-Observed-Adverse-Effect Level (the &#8220;NOAEL&#8221;). Both studies were
designed for the qualification of the excipients. The animals treated either with DHE + DMSO + caffeine or DMSO + Caffeine
formulations did not reveal any changes attributable to treatment at the end of the treatment/recovery periods. As such, both
studies support a conclusion that SCN-102 is considered to have no toxicological significance across the following attributes
&#8211; Hematology, Coagulation Parameters, Clinical Chemistry and Urinalysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">believes the SCN-104 injection pen may
offer a significant improvement, in terms of usability and patient acceptability, to the current standard of care in the market
(ampoules for injection). The intended pen delivery system was designed with patients in mind to carry multiple doses, have a lower
volume of injection, and utilize shielded needles to avoid unnecessary exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture LLC
has had initial discussions with the FDA to align on a path forward for this development program. As a result of these discussions,
Scienture LLC learned that its proposed plan for manufacturing NDA registration batches and that the reference product and
dose selection of the reference product that Scienture LLC selected for a comparative regulatory study are acceptable. Scienture
LLC also received guidance from the FDA on nonclinical safety studies and stability testing. The formulation has been scaled up
to enable future commercial scale production and the pen has been optimized for commercial use. As shown below, several
pharmacokinetics studies have shown comparability between SCN-104 and the currently available marketed injection product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form424b3_003.jpg" alt="" style="width: 650px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form424b3_004.jpg" alt="" style="width: 650px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form424b3_005.jpg" alt="" style="width: 650px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is initiating manufacturing activities and planning to conduct bioequivalence studies. Scienture LLC plans to initiate
a Phase 1 single dose study in healthy adults in 2025, following submission of an IND, if the IND is cleared by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SCN-106
(Potential Biosimilar)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is developing a potential biosimilar, SCN-106, based on Cathflo Activase, a reference product that is a thrombolytic agent
that binds to fibrin in clots and converts entrapped plasminogen to plasmin. SCN-106 is a sterile, purified glycoprotein that is synthesized
using the complementary DNA for natural human tPA obtained from a Chinese hamster ovary cell-line.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC is working with Anthem Biosciences Pvt, Ltd. (&#8220;Anthem&#8221;) to develop a biosimilar product that utilizes the
same mechanism(s) of action for the proposed condition of use, and has the same route of administration, dosage form, and strength as
the reference product. In this regard, Scienture LLC entered into a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master
Services Agreement with Anthem on October 29, 2024 (the &#8220;Anthem Agreement&#8221;). The following is a summary of the Anthem Agreement,
which is qualified in its entirety by the full text&#160;of the Anthem Agreement, previously filed as Exhibit 10.25 to the Registration
Statement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Under the Anthem
Agreement, Anthem has agreed to diligently complete the services associated with SCN-106 as included in work orders to be attached to
the Anthem Agreement. In performing these services, Anthem has agreed to strictly comply with the specifications in the Anthem Agreement,
the work order, standard operating procedures approved in writing by Scienture LLC, and relevant professional standards, and any regulatory
authority requirements, including current Good Laboratory Practices (&#8220;GLPs&#8221;) and current Good Manufacturing Practices (&#8220;GMPs&#8221;)
promulgated by the FDA, and any other applicable laws, rules, and regulations. In carrying-out its services, Anthem will only allow those
employees and personnel under Anthem&#8217;s direct control to perform such services and will obtain the Scienture LLC&#8217;s consent
prior to delegating or subcontracting any portion of the services. Anthem is required to provide prompt written reports to Scienture
LLC the status of the services provided by Anthem under the Anthem Agreement and any work order. Under the Anthem Agreement, Scienture
LLC is responsible for paying Anthem the amounts designated on any attached work order. These amounts are to be paid on the schedule
stated on the work order and Anthem is responsible for invoicing Scienture LLC for such amounts. Undisputed late payments incur interest
at the rate of 18% per annum payable until the date of actual payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any project or
work order in effect under the Anthem Agreement may be terminated by Scienture LLC without cause upon thirty (30) days&#8217; prior notice
to Anthem. Anthem may terminate the Anthem Agreement without cause upon thirty (30) days&#8217; prior notice to Scienture LLC. However,
Anthem is responsible for delivering all services and deliverables under the Anthem Agreement then required to be performed by Anthem
under a work order prior to any such termination. Either party may terminate the Anthem Agreement upon the breach of the Anthem Agreement
by the other party if the breach remains uncured for a period of thirty (30) days. In the event that performance by Anthem or Scienture
LLC under the Anthem Agreement is delayed due to an event beyond the control of Anthem or Scienture LLC for a period of ninety (90) days,
then the other party can terminate the Anthem Agreement upon written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">With respect to
projects to be performed by Anthem under the Anthem Agreement, any and all materials relating to such projects are the property of Scienture
LLC, and are to be protected as such by Anthem. Furthermore, Anthem has agreed to irrevocably assign to Scienture LLC all right, title,
and interest in and to any &#8220;Program Technology&#8221; (as defined in the Anthem Agreement) and to make any assignments necessary
to ensure that Scienture LLC has such ownership interest. The Anthem Agreement also contains customary confidentiality obligations, representations
and warranties, indemnification provisions, and anti-assignment provisions. The Anthem Agreement may only be amended upon the written
consent of both parties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CMC development program is focused on establishing the analytical similarity of SCN-106 to the reference product. Multiple clones of
CHO cells have been produced to synthesize lots of SCN-106 which were screened for similarity to the reference product for several key
biochemical quality attributes as well as overall protein yield and finalization of a lead clone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC completed a Biosimilar Initial Advisory meeting with the FDA in June 2023 to discuss the CMC, non-clinical, and clinical studies
required for regulatory approval. As a result of this meeting, Scienture LLC learned that its analytical strategy for initiating
analytical similarity studies between SCN-106 and a proposed biosimilar product is acceptable. Scienture LLC also learned that
SCN-106 is suitable for further development and received guidance from the FDA on a comparable clinical study needed to demonstrate biosimilarity
of SCN-106 and the reference product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SCN-107
(Bupivacaine Long-Acting Injection)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">SCN-107
is a long-acting injection suspension formulation of a non-opioid analgesic that is indicated for postsurgical local and regional analgesia.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture LLC&#8217;s long-acting formulation,
SCN-107, is a novel microsphere-based formulation of bupivacaine that comprises the drug in polymer-based microspheres and is intended
to provide pain management over a period of 5-7 days. The product candidate is designed to potentially provide longer term post-surgical
pain relief compared to the currently available products in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on initial discussions with FDA regarding this program, Scienture LLC believes this product candidate would require at least one
Phase 3 clinical trial to support submission of a marketing application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipates submitting an IND and, if
cleared by the FDA, initiating a Phase 1 single dose study in healthy adults in 2025 to conduct an initial assessment of safety and
tolerability of SCN-107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Sales
and Marketing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intends to market Scienture LLC<span style="background-color: white">&#8217;s
</span> products through its own sales forces in the U.S. and seek strategic collaborations with other pharmaceutical companies to
commercialize its products outside of the U.S. The Company is in the process of building a commercial sales and marketing operation
in the U.S., through a partnership with a Contract Sales Organization, to support sales of Scienture LLC&#8217;s products<span style="background-color: white">.
Once </span>approved<span style="background-color: white">, this </span>sales and marketing organization will include a combination of
field teams, virtual sales representatives and omnichannel marketing to effectively reach Health Care Providers (<span style="background-color: white">&#8220;</span>HCPs<span style="background-color: white">&#8221;</span>)
and offer patient education. The Company&#8217;s promotional efforts are expected to further include developing a market access
strategy to obtain commercial and government payor coverage for its products. In addition, the Company intends to partner with
a third-party logistics provider (<span style="background-color: white">&#8220;</span>3PL<span style="background-color: white">&#8221;</span>)
and have internal sales operations and analytics teams to provide state-of-the-art distribution capabilities to wholesalers, pharmacies,
institutional buying groups and hospitals. The Company <span>believes its commercial operations
infrastructure, once established, will enable it to effectively target healthcare providers to support and grow its products subsequent
to market entry.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Customers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of Scienture LLC&#8217;s product sales, if its products are approved by the FDA, are expected to be to pharmaceutical
wholesalers, specialty pharmacies, and distributors who, in turn, would sell such products to pharmacies, hospitals, long term care institutions
and other customers, potentially including federal and state entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Market
and Competition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">is </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaged
in segments of the pharmaceutical industry that are highly competitive and rapidly changing. Many large pharmaceutical and biotechnology
companies, academic institutions, governmental agencies, and other public and private research organizations are commercializing or pursuing
the development of products utilizing the same molecules or compounds or for the same indications that the Company is currently
pursuing or may target in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hypertension</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypertension
(high blood pressure) is a CVS condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the
Centers for Disease Control, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension
is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk
factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood
pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol.
Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings
on both days is &#8805;140 mmHg and/or the diastolic blood pressure readings on both days is &#8805; 90 mmHg.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
hypertension market has increased with the commercial launch of several branded products in recent years, as well as the launch of generic
versions of branded drugs, such as Prinvil, Lotensin, Cozaar, Cardizem, Apresoline, Nitrostat and Toprol-XL. Treatment options for hypertension
in the U.S. market can be broadly classified across the following product classes, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin
II receptor blockers (ARBs), Beta-Blockers, Diuretics and Calcium Channel Blockers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> product candidate SCN-102, ARBLI<sup>TM
</sup>(Losartan Oral Suspension 10mg/mL), is a ready to use oral suspension of losartan for increased patient convenience and ease of
dosing. Losartan is classified as an ARB for treating hypertension and is one of the highest prescribed molecules for this indication.
Current products in the market containing losartan are available only as oral solids, which can be further compounded to a liquid formulation.
Scienture LLC believes that ARBLI<sup>TM</sup>, if approved by the FDA, would be the first liquid formulation of losartan on the market
that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Migraine</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Migraine
is a painful, complex neurological disorder consisting of recurring painful attacks that can significantly impact quality of life. Migraine
headaches are often characterized by throbbing pain, extreme sensitivity to light or sound, and potentially nausea and vomiting. The
World Health Organization categorizes migraine as one of the most disabling medical illnesses worldwide. The American Research Foundation
categorizes migraine as the third most prevalent illness in the world, and nearly 1 in 4 U.S. households includes someone with migraines.
Migraine is estimated to affect over 39 million individuals in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
products in the market that are available to treat migraine headaches, include CGRP antagonists (calcitonin gene related peptide), which
is a class of products first introduced in 2018 (Nurtec, Ubrelvy), Botox, branded and generic versions of triptans (Imitrex, Maxalt,
Relpax), and ergot alkaloids (Ergotamine and Dihydroergotamine (DHE)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> product candidate, SCN-104, is supplied
in a multi-dose pen-based delivery system for self-injection and increased patient convenience. The product candidate is in development
for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Thrombotically
Occluded Catheter (CVAD) Management</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catheters,
which are a type of a Central Venous Access Device (&#8220;CVAD&#8221;), are employed to deliver life-sustaining therapies. They can
be used for short-term or long-term infusion of antibiotics, parenteral nutrition, chemotherapy, blood and blood products in patients
with limited peripheral access. More than 7 million CVADs are inserted each year in patients in the United States. Occlusion of catheters
while in use can complicate patient care by interrupting the administration of medications and solutions, delaying or disrupting therapies
and leading to additional procedures such as catheter replacement. Occlusion is the most common noninfectious complication in the long-term
use of CVADs and may occur soon after insertion of a device or develop at any time. About 58% of catheter occlusions are thrombotic,
resulting from the formation of a thrombus within, surrounding, or at the tip of the catheter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> product candidate, SCN-106, is a thrombolytic
agent currently in development. Scienture LLC plans to develop SCN-106 through the FDA&#8217;s 351(k) pathway for biosimilars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Postoperative
Pain</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-surgery
pain, also known as postoperative pain, is pain that a patient experiences after a surgical procedure. Pain can be caused by a number
of factors, including: the type of procedure, the size of the operation, and medications used during surgery. Chronic pain can negatively
impact a patient&#8217;s rehabilitation, quality of life, and the results of the procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
drug product treatments available in the market for treating postoperative pain include IV and oral opioids, injectable local anesthetics,
and steroidal and non-steroidal analgesics. Marketed products include branded and generic versions of Celebrex, Ketalar, Exparel, Lyrica,
Neurontin and Astromorph.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> product candidate, SCN-107, is a microsphere
based long-acting injection of Bupivacaine, a local anesthetic, in development for postsurgical analgesia. SCN-107 is designed to be
a non-opioid treatment regimen with rapid onset of action and analgesia that is intended to provide coverage over a period of 5-7 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">currently depends on third-party commercial
manufacturing organizations (&#8220;CMOs&#8221;) for all manufacturing operations, including the production of raw materials, finished
dosage form product, and product packaging for both its planned commercial scale manufacturer and the products used in its preclinical
and clinical research. Scienture LLC does not own or operate manufacturing facilities for the production of any of its product
candidates nor does Scienture LLC has plans to develop its own manufacturing operations in the foreseeable future to support clinical
trials or commercial production. Scienture LLC currently employs internal resources to manage its manufacturing contractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is in discussion with CMOs headquartered in
North America, Europe and Asia for its pipeline product candidates. These CMOs offer a comprehensive range of commercial contract
manufacturing and packaging services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Scienture LLC fails to produce its products and product candidates in the volumes that Scienture LLC requires on a timely
basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, Scienture LLC may face delays
in the development and commercialization of its products and product candidates or be required to withdraw its products from the market<b>&#8239;</b><span style="background-color: white">for
risks associated with manufacturing and supply of its products and product candidates.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2020, Scienture LLC entered into Feasibility Study and Animal Trial Material Manufacturing Agreement with Innocore Technologies,
B.V. (&#8220;Innocore&#8221;), as amended on December 2, 2022 (the &#8220;Innocore License&#8221;), for certain intellectual property
rights. Under the Innocore License, Innocore granted Scienture LLC a worldwide exclusive, milestone, royalty-bearing and sublicensable
license to certain patent rights for the research and development of SCN-107 in postsurgical local and regional analgesia. Pursuant to
the Innocore License, Scienture LLC is required to make low single-digit percentage royalty payments based on annual net sales
of licensed products for the first three years of sales on a country-by-country basis, subject to a low single digit increase as of the
fourth year of sales on a country-by-country basis. Scienture LLC is required to remunerate Innocore for the development of the
licensed product, subject to a limit of $0.4 million for certain safety and toxicity studies which will be deducted from certain development
and regulatory milestones as described below. Scienture LLC is required to make development and regulatory milestone payments
up to &#8364;2.7 million in the aggregate, commercial sale milestone payments of up to &#8364;18.875 million in the aggregate, and maintenance
fees of &#8364;0.25 million annually, subsequent to the first regulatory filing, until the date that Scienture LLC begins making
royalty payments based on annual net sales, up to &#8364;0.5 million of which may be credited toward the regulatory milestone payments.
As of October 25, 2024, Scienture LLC had made aggregate payments to Innocore of $1,021,089.37 in connection with the Innocore License.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Innocore License is terminable by either Scienture LLC or Innocore on thirty (30) days&#8217; prior written notice if the terminating
party determines in good faith, that it is technically or legally not feasible, or commercially not viable to jointly develop a formulation
which meets the specifications described in the Innocore License. The Innocore License can also be terminated for any material breach
of the Innocore License that remains uncured after thirty (30) days and if either party files for insolvency under any applicable foreign,
federal or state law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Intellectual
Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continues to build its intellectual property
portfolio to provide protection for its technologies, products, and product candidates. Scienture LLC seeks patent protection, where
appropriate, both in the U.S. and internationally for products and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> intended objective is to protect
its innovations and proprietary products by, among other things, filing patent applications in the U.S. and abroad, including Europe,
Canada, and other countries when appropriate. The Company also relies on trade secrets, know-how, proprietary knowledge, continuing
technological innovation, and in-licensing opportunities to develop and maintain its proprietary position. The Company cannot
be sure that patents will be granted with respect to its pending patent applications or with respect to any patent applications filed
by it in the future, nor can the Company be sure that any of its existing patents or any patents that may be granted to it in
the future will be commercially useful in protecting its technology or its products. The Company cannot be sure that any patents,
if granted, will sustain a legal challenge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patent
Portfolio</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">SCN-102</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-102
will soon have two orange book listable formulation composition and method of use patents in the U.S. One of them is already issued (Patent
#: 11,890,273, Issue Date: February 6, 2024, titled &#8220;LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE&#8221;, Expiration Date: October
7, 2041) and the other patent application is allowed, with the issue fee paid on July 24, 2024 (Appl. No. 18/421,405; Filing Date: January
24, 2024, titled &#8220;LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE&#8221;). A third application is pending (Appl. No. 18/061,819;
Filing Date: December 5, 2022; Expiration: on or after October 7, 2041).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">SCN-104</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-104
has a formulation composition and method of use application pending in the U.S. (Appl. No. 17/757,924; Filing Date: June 23, 2022; Expiration Date: June 15, 2035).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">SCN-106</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-106
is a potential biosimilar and considered by the Company to be part of its product development portfolio, however the Company is not pursuing
patent protection for this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">SCN-107</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCN-107
has a formulation composition and method of use application pending in the U.S. (Appl. No. 17/996,995; Filing Date: October 24, 2022; Expiration Date: on or after April 22, 2041).
Applications in Canada and Europe are currently pending. As described above, the Company licenses certain patent rights from Innocore
for the research and development of SCN-107.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Collaborations
and Licensing Arrangements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC entered into exclusive license and commercial agreements on August 28, 2022 and April 24, 2023, with Kesin, a related party, pursuant
to which Scienture LLC granted the exclusive license rights to commercialize SCN-102 and SCN-104, respectively to Kesin for use
in the United States of America (together, the &#8220;Kesin Agreement&#8221;). In consideration of the rights granted, Scienture LLC
received milestone payments and reimbursement of costs actually incurred related to SCN-102 and SCN-104.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2024, the parties terminated the Kesin Agreement by entering a Confidential Termination Agreement (the &#8220;Kesin Termination
Agreement&#8221;), and the parties agreed that Scienture LLC would pay Kesin a total gross amount of $1.285 million upon commercialization
of either SCN-102 or SCN-104 via a royalty arrangement. The Kesin Termination Agreement also requires that if the full $1.285 million
has not been repaid within two years of the earlier of (i) commercial launch of a product or (ii) 120 days after FDA approval of a product,
then interest will accrue prospectively at a rate of 8% annually on the unpaid balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable
in connection with the consummation Scienture LLC&#8217;s business combination with the Company. Scienture LLC has disputed
that the amount is now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution
will be obtained. If Kesin brings a legal action, Scienture LLC will vigorously defend it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Government
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Drug Development Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (the
&#8220;FDCA&#8221;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting,
sampling, and import and export of pharmaceutical products. The Company, along with third-party contractors, will be required
to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries
in which Scienture LLC wishes to conduct studies or seek approval of its product candidates. Failure to comply with applicable United
States requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending
applications, withdrawal of an approval, warning or untitled letters, clinical holds, product recalls or withdrawals from the market,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement of profits, civil penalties, and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is required before any new unapproved product or a product with certain changes to a previously approved product, including
a new use of a previously approved drug, can be marketed in the United States. The steps required to be completed by the FDA before a
drug may be marketed in the United States generally include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests, animal studies, and formulation studies performed in accordance with the FDA&#8217;s GLP regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin and
    must be updated annually or when significant changes are made;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the clinical trial
    is commenced;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCPs requirements and
    other clinical-trial related regulations to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    and submission to the FDA of an NDA or biologics license application (&#8220;BLA&#8221;), after completion of all pivotal clinical
    trials, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture
    and quality controls for the product candidate and proposed labeling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA Advisory Committee review, if applicable;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed drug is produced to
    assess compliance with current GMP regulations and of selected clinical trial
    sites to assess compliance with GCPs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA or BLA to permit commercial marketing of the product for particular indications for use in the United
    States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfaction
of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the
type, complexity, and novelty of the product or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preclinical
and Clinical Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product candidate. The conduct of the preclinical tests must comply with federal regulations
and requirements, including GLP. The results of preclinical testing are submitted to the FDA as part of an IND application along with
other information, including information about the product candidate, chemistry, manufacturing and controls, any available human data
or literature to support the use of the product candidate and a proposed clinical trial protocol. Long term preclinical tests, such as
animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND application must become effective before human clinical trials may begin. The IND application automatically becomes effective 30
days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions relating to one or more
proposed clinical trials and places the clinical trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns or questions before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate
at any time before or during clinical trials due to safety concerns, non-compliance or other issues affecting the integrity of the trial.
Accordingly, submission of an IND application may or may not result in the FDA allowing clinical trials to commence and, once begun,
issues may arise that could cause the trial to be suspended or terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational drug product to human subjects under the supervision of a qualified investigator.
Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCP, an international standard
meant to protect the rights and health of clinical research participants and to define the roles of clinical trial sponsors, administrators,
and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety,
and the effectiveness criteria to be evaluated. Each protocol involving testing on United States patients and subsequent protocol amendments
must be submitted to the FDA as part of the IND. Furthermore, an independent IRB or ethics committee for each site proposing to conduct
the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins
at that site, and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants
and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in
relation to anticipated benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objects. The FDA may order the temporary,
or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial is not
being conducted in accordance with FDA requirements. Further, an IRB may also require the clinical trial at the site to be halted, either
temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Some trials also
include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring
board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain
data from the study and may recommend a clinical trial to be halted if it determines that there is an unacceptable safety risk for subjects
or other grounds, such as futility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, but the phases may overlap
or be combined. In Phase 1 clinical trials, the investigational product is typically introduced into a limited population of healthy
human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, pharmacokinetics
and pharmacological actions of the investigational product, to identify side effects associated with increasing doses, and, if possible,
to gain early evidence on effectiveness. Phase 2 clinical trials usually involve administering the investigational product to a limited
patient population with the specified disease or condition to evaluate the preliminarily efficacy, dosage tolerance, and optimum dosage,
and to identify possible adverse effects and safety risks. Phase 3 clinical trials are typically undertaken in a larger number of patients,
typically at geographically dispersed clinical trial sites, to provide substantial evidence of clinical efficacy and to further test
for safety in an expanded and diverse patient population. These clinical trials are intended to permit the FDA to evaluate the overall
benefit-risk relationship of the investigational product and to provide adequate information for the labeling of the product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
reviewing an NDA or BLA, the FDA will consider all information submitted in the application, including the results of all clinical trials
conducted. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved
to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA or BLA. These
trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document
clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to
conducting Phase 4 clinical trials could result in the withdrawal of approval for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics
of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with current
GMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among
other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical
data, and clinical study investigators. Progress reports detailing the results of the clinical trials, among other information, must
be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious
and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the product candidate,
findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in
the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NDA
and BLA Submission and Review</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing in accordance with all applicable regulatory requirements, an NDA or BLA application
which includes, among other information, the results of product development, preclinical studies and clinical trials is submitted to
the FDA. FDA approval of the application is required before marketing of the product may begin in the United States. The application
must include, among other things, the results of all trials and preclinical testing, and other testing and a compilation of data relating
to the product&#8217;s pharmacology, chemistry, manufacture, controls and proposed labeling. The cost of preparing and submitting an
NDA or BLA is substantial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA or BLA to either issue a Refuse to File Letter or accept the NDA or BLA for filing, indicating
that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. The FDA has agreed to certain performance goals in the review of NDAs and BLAs. Under applications subject to the performance
goals of the PDUFA, the FDA has a goal of responding to standard review NDAs and BLAs within ten months after it accepts the application
for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing, but this
timeframe can be extended, such as by the submission of major amendments by applicants during the review period. The FDA reviews an application
to determine, among other things, whether the product is safe and effective and the facility in which it is manufactured, processed,
packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory
committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation, and a recommendation as to
whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows
such recommendations. Before approving an application, the FDA will typically inspect one or more clinical sites to assure compliance
with GCPs. Additionally, the FDA will inspect the facility or the facilities at which the proposed product is manufactured. If the FDA
determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies
in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the application and conducts inspections of the manufacturing facilities where the investigational product and/or its
drug substance will be produced, it issues either an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with approved prescribing information for specific indications. A Complete Response Letter indicates that the review
cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally outlines the
deficiencies in the submission, except that where the FDA determines that the data supporting the application are inadequate to support
approval, the FDA may issue the Complete Response Letter without first conducting required inspections or reviewing proposed labeling.
In issuing the Complete Response Letter, the FDA may require substantial additional clinical data and/or other significant, expensive,
and time-consuming requirements related to clinical trials, preclinical studies and/or manufacturing. If a Complete Response Letter is
issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, withdraw the application
or request a hearing. The FDA has committed to reviewing resubmissions of the NDA or BLA addressing such deficiencies in two or six months
depending on the type of information included. Even if such data are submitted, however, the FDA may ultimately decide that the NDA or
BLA does not satisfy the criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for a particular indication(s) and may include limitations
on the indicated use(s) for which such product may be marketed. Further, the FDA may require that certain contraindications, warnings
or precautions be included in the product labeling or may condition the approval of the application on other changes to the proposed
labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and
surveillance to monitor the effects of approved products. As a condition of NDA or BLA approval, the FDA may require a risk evaluation
and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include
medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can
include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The requirement for REMS can materially affect the potential market and profitability
of the product. Moreover, product approval may also be conditioned on substantial post-approval testing, such as Phase 4 post-market
studies, and surveillance to monitor the product&#8217;s safety or efficacy, and the FDA may limit further marketing of the product based
on the results of these post-approval studies. Once granted, product approvals may be withdrawn if compliance with regulatory standards
is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes
or facilities, require submission and FDA approval of a new NDA or BLA, or NDA or BLA supplement before the change can be implemented.
An NDA or BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA
uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs. As with new NDAs and
BLAs, the review process is often significantly extended by requests for additional information or clarification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>505(b)(2)
NDA Approval Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
505(b)(2) of the FDCA provides an alternate regulatory pathway for the FDA to approve a new product and permits reliance for such approval
on published literature or an FDA finding of safety and effectiveness for a previously approved drug product. Specifically, section 505(b)(2)
permits the filing of an NDA where one or more of the investigations relied upon by the applicant for approval were not conducted by
or for the applicant and for which the applicant has not obtained a right of reference. Typically, 505(b)(2) applicants must perform
additional trials to support the change from the previously approved drug and to further demonstrate the new product&#8217;s safety and
effectiveness. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced
product has been approved, as well as for any new indication sought by the section 505(b)(2) applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation
of Combination Products in the United States</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
products may be comprised of components, such as drug components and device components, that would normally be regulated under different
types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically,
under regulations issued by the FDA, a combination product may be:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced
    as a single entity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">two
    or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and
    biological products, or biological and drug products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    drug, or device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended
    for use only with an approved individually specified drug, or device, or biological product where both are required to achieve the
    intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need
    to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in
    dose; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    investigational drug, or device, or biological product packaged separately that according to its proposed labeling is for use only
    with another individually specified investigational drug, device, or biological product where both are required to achieve the intended
    use, indication, or effect.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for
review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one
FDA component for combination products, although it does not preclude consultations by the lead center with other components of FDA.
The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product.
Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible
for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an
Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review
process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible
for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that
has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
combination product with a drug primary mode of action generally would be reviewed and approved pursuant to the drug approval processes
under the FDCA. In reviewing the NDA application for such a product, however, FDA reviewers in the drug center could consult with their
counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding
safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to current GMP
requirements applicable to both drugs and devices, including the Quality System regulations applicable to medical devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Approval
Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an NDA or BLA is approved, a product will be subject to pervasive and continuing regulation by the FDA including, among other things,
requirements relating to current GMPs, quality controls, record-keeping, reporting of adverse experiences, periodic reporting, product
sampling and distribution, and advertising and promotion of the product. For instance, the FDA closely regulates the post-approval marketing
and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored
scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved
indications and in accordance with the provisions of the approved labeling. Failure to comply with these requirements can result in adverse
publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available
products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Scienture LLC and approved
by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment
for many patients in varied circumstances. The FDA does not regulate the practice of medicine by physicians or their choice of treatments.
The FDA does, however, regulate manufacturer&#8217;s communications on the subject of off-label use of their products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to current GMPs after approval.
Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies,
and are subject to periodic unannounced inspections by the FDA, and certain state agencies for compliance with current GMPs, which impose
certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. Changes
to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval
before being implemented. FDA regulations also require investigation and correction of any deviations from current GMPs and impose reporting
requirements upon Scienture LLC and any third-party manufacturers that Scienture LLC may decide to use. NDA or BLA holders
using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in
certain circumstances, qualified suppliers to these firms. Drug manufacturers and other parties involved in the drug supply chain for
prescription drug products must also comply with product tracking and tracing requirements and notify the FDA of counterfeit, diverted,
stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. The discovery
of violative conditions, including failure to conform to current GMPs, could result in enforcement actions that interrupt the operation
of any such facilities or the ability to distribute products manufactured, processed or tested by them. Accordingly, manufacturers must
continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with current GMPs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards or is not maintained,
if problems occur following initial marketing, or if previously unrecognized problems are subsequently discovered. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes,
or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition
of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
    approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
    decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
    modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>


<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other
    safety information about the product; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Patent Term Restoration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of the potential FDA approval of Scienture LLC&#8217;s product candidates, some of its
U.S. patents may be eligible for limited patent term extension. The Hatch-Waxman Amendments permit a patent restoration term, often referred
to as patent term extension, of up to five years as compensation for patent term lost during product development and the FDA regulatory
review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s
approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission
date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to
an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the
patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves or denies the application for any patent
term extension or restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Marketing Exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications, including 505(b)(2)
applications. The FDA provides three years of marketing exclusivity for an NDA (including a 505(b)(2) application), or supplement to
an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant
are deemed by the FDA to be essential to the approval of the application. Three-year exclusivity is typically awarded to innovative changes
to a previously-approved drug product, such as new indications, dosage forms or strengths. This three-year exclusivity covers only the
modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from
approving applications for drugs that do not have the innovative change, such as generic copies of the original, unmodified drug product.
Three-year exclusivity blocks approval of 505(b)(2) applications and Abbreviated New Drug Applications (&#8220;ANDAs&#8221;), but will
not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain
a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety
and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain
circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if
granted, adds six months to existing exclusivity periods, including exclusivity attaching to certain patent certifications. This six-month
exclusivity, which runs from the end of other exclusivity protection and patent terms, may be granted based on the voluntary completion
of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric
exclusivity is granted there is not less than nine months of term remaining.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Biosimilars
and Exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ACA, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the
&#8220;BPCIA&#8221;). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars.
A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; The FDA has
issued multiple guidance documents outlining an approach to review and approval of biosimilars. Under the BPCIA, a manufacturer may submit
an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously
approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that
there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity
and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar
product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times)
that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks
or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of
the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved.
Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version
of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity
periods for biosimilars approved as interchangeable products. Since the passage of the BPCIA, many states have passed laws or amendments
to laws, including laws governing pharmacy practices, which are state regulated, to regulate the use of biosimilars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition&#8212;generally
a disease or condition with either a patient population that affects fewer than 200,000 individuals in the United States or a patient
population greater than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and
making available the drug will be recovered from sales of the drug in the United States. Orphan drug designation must be requested before
submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the product and its potential orphan
use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation
is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year
exclusivity period, the FDA may not approve any other applications to market the same product for the same disease, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder
of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet
the needs of the patients with the disease or condition for which the product was designated. Orphan drug exclusivity does not prevent
the FDA from approving a different product for the same disease or condition, or the same product for a different disease or condition.
Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user
fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which
it received orphan drug designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA
later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities
of the product to meet the needs of patients with the rare disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fast
Track Designation and Breakthrough Therapy Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or
life-threatening disease or condition which demonstrate the potential to address unmet medical needs for the condition, and accordingly,
the FDA has established the fast track designation and breakthrough therapy designation programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition
and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination
of the product and the specific indication for which it is being studied. Under the fast track program, the sponsor of a drug candidate
may request that the FDA designate the candidate for a specific indication as a fast track product concurrent with, or after, the filing
of the IND for the candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60 days of
receipt of the sponsor&#8217;s request. Fast track designation provides increased opportunities for sponsor interactions with the FDA
during preclinical and clinical development, in addition to the potential for rolling review of sections of the applicant&#8217;s NDA
or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule
for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal
for reviewing an application does not begin until the last section of the application is submitted. Additionally, the fast track designation
may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if
the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough
therapy designation comes with all of the benefits of fast track designation. The FDA may take other actions appropriate to expedite
the development and review of the product candidate, including intensive guidance on an efficient product development program beginning
as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced
review staff in a cross-disciplinary review, where appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Priority
Review</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product is eligible for priority review if it has the potential to provide a significant improvement in safety or effectiveness in the
treatment, diagnosis or prevention of a serious disease or condition. A priority review means that the goal for the FDA to review an
application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement,
these six-and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new
molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission.
Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pediatric
Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act (the &#8220;PREA&#8221;), NDAs and BLAs, or supplements to NDAs and BLAs, must contain data to assess
the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and
administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers,
or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for
which orphan designation has been granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disclosure
of Clinical Trial Information</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of FDA-regulated products, including drugs and combination products, are required to register and disclose certain
clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators,
and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the
results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding
the progress of development programs. Disclosure of the results of these trials can be delayed until the new product or new indication
being studied has been approved. Failure to timely register a covered clinical study or to submit study results as provided for in the
law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal
government. The Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both the National
Institutes of Health and the FDA have signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant
clinical trial sponsors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: transparent"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Other
Regulatory Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Health
Care Laws</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through
which Scienture LLC <span style="background-color: white">researches, as well as sell, market and distribute any products for which
</span>Scienture LLC obtains marketing authorization. Such laws include, without limitation, state and federal anti-kickback,
fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value
made to physicians and other healthcare providers. If Scienture LLC&#8217;s <span style="background-color: white">operations are
found to be in violation of any of such laws or any other governmental regulations that apply, </span>the Company may be subject
to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment
or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare
programs and responsible individuals may be subject to imprisonment. The Company may be subject to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility,
    item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and
    Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent
    to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation,
    plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the
    government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
    a false or fraudulent claim for purposes of the federal False Claims Act or federal civil monetary penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, which impose
    criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other
    things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent;
    knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation
    to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing
    an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when
    they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent
    claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on
    behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes
    that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
    program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by,
    or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly
    and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious,
    or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services
    relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
    of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective
    implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered
    healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors
    or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure
    of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable
    health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
    directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions
    in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil
    actions. In addition, there&#8239;may be additional federal, state and non-U.S. laws which govern the privacy and security of health
    and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have
    the same effect, thus complicating compliance efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    U.S. federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine
    Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies
    for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the
    CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists,
    optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as
    ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such
    reported prices may be used in the calculation of reimbursement and/or discounts on approved products; <span style="background-color: white">and</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
    consumers<span style="background-color: white">.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company is subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among
others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the
federal Anti-Kickback Statute and False Claims Act, and may apply to the Company&#8217;s business practices, including, but not
limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the
April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research
and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions
or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical
sales representatives. There are ambiguities as to what is required to comply with these state requirements and if the Company
fails to comply with an applicable state law requirement the Company could be subject to penalties. State and foreign laws, including
for example the European Union General Data Protection Regulation, which became effective in May 2018, also govern the privacy and security
of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by
HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and
if the Company fails to comply with an applicable state law requirement the Company could be subject to penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform.
Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare
providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that the Company&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare
laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that the Company&#8217;s
business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If the Company&#8217;s operations are found to be in violation of any of the
laws described above or any other governmental laws and regulations that may apply to us, the Company  may be subject to significant
penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in
federal and state healthcare programs, individual imprisonment, reputational harm,&#8239; and the curtailment or restructuring of the
Company&#8217;s operations, as well as additional reporting obligations and oversight if the Company becomes subject to a
corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against
any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if
the Company is successful in defending against any such actions that may be brought against it, its business may be impaired.
If any of the physicians or other providers or entities with whom the Company expects to do business are&#8239;found to not be
in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs and imprisonment. If any of the above occur, the Company&#8217;s ability to operate its business and
its results of operations could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Healthcare
Reform</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors,
whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare
costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases
such as those Scienture LLC is developing. In both the United States and certain foreign jurisdictions, there have been a number
of legislative and regulatory changes to the health care system that could impact Scienture LLC&#8217;s ability to sell its products
profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act of 2010 (collectively, the &#8220;ACA&#8221;) was enacted, which, among other things, subjected biologic products to potential competition
by lower-cost biosimilars; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program;
extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations;
subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a Medicare Part D coverage gap discount
program, in which manufacturers must agree to offer&#8239;70% point-of-sale discounts off negotiated prices of applicable brand drugs
to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered
under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Budget Control Act of 2011 and subsequent&#8239;legislation, among other things, created measures for spending reductions by Congress
    that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2031. Due
    to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021,
    and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation.&#8239;The&#8239;U.S.
    American Taxpayer Relief Act of 2012&#8239;further reduced Medicare payments to several types of providers and increased the statute
    of limitations period for the government to recover overpayments to providers from three to five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual
    and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans
    sold through such marketplaces. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients
    to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation
    for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without
    obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make
    its drug products available to eligible patients as a result of the Right to Try Act.&#8239;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On&#8239;May
    23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.&#8239; Specifically,
there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other
things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between
pricing and manufacturer patient programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), was signed into law. The IRA includes several provisions that
may impact the Company&#8217;s business, depending on how various aspects of the IRA are implemented. Provisions that may impact
the Company&#8217;s business include a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, the imposition of new manufacturer
financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and Part D pricing
for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for
drug prices that increase faster than inflation, and delay until January 1, 2032&#8239;the implementation of the U.S. Department of Health
and Human Services (&#8220;HHS&#8221;) rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further,
under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation
and for which the only approved indication is for that disease or condition.&#8239; If a product receives multiple orphan designations
or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject
to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the
IRA on Company&#8217;s business and the healthcare industry in general is not yet known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President Biden issued multiple executive orders
that sought to reduce prescription drug costs.&#8239;In February 2023, HHS also issued a proposal in response to an October 2022 executive
order from former President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare
payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s
accelerated approval pathway. A number of these and other proposed measures may require authorization through additional legislation
to become effective and the Trump administration may reverse or otherwise change these measures. However, Congress has
indicated that it will continue to seek new legislative measures to control drug costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expects that additional U.S. federal healthcare
reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare
drugs and services, which could result in reduced demand for Scienture LLC&#8217;s drug candidates or additional pricing pressures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk
purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm the Company&#8217;s
business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. This could reduce the ultimate demand for Scienture LLC&#8217;s drugs or put pressure on its
drug pricing, which could negatively affect its business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Pharmaceutical
Coverage, Pricing, and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of Scienture LLC&#8217;s product candidates, if approved, depends on the availability of coverage and adequate reimbursement
from third-party payors. The Company cannot be sure that coverage and reimbursement will be available for, or accurately estimate
the potential revenue from, Scienture LLC&#8217;s product candidates or assure that coverage and reimbursement will be available for any product
that it may develop. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse
all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs,
such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and
treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number
of factors, including the third-party payor&#8217;s determination that use of a product is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under its health plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process
that could require Scienture LLC to provide to each payor supporting scientific, clinical and cost-effectiveness data for the
use of Scienture LLC&#8217;s products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will
be obtained. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS. CMS decides
whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial
degree. Even if Scienture LLC obtains coverage for a given product, the resulting reimbursement payment rates might not be adequate
for Scienture LLC to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally,
third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of
product candidates, once approved. Patients are unlikely to use Scienture LLC&#8217;s product candidates, once approved, unless
coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is significant uncertainty related
to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will
decide with respect to the coverage and reimbursement for Scienture LLC&#8217;s product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in
the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from
list prices and are challenging the prices charged for medical products. Scienture LLC cannot be sure that reimbursement will
be available for any product candidate that it commercializes and, if reimbursement is available, the level of reimbursement. In addition,
many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales
price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices
for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject
to changes in healthcare legislation and regulatory initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expects that healthcare reform measures
that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that
Scienture LLC receives for any approved product. The implementation of cost containment measures or other healthcare reforms may
prevent Scienture LLC from being able to generate revenue, attain profitability, or commercialize Scienture LLC&#8217;s
products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for pharmaceutical products. The Company cannot be sure whether additional legislative changes will be enacted, or
whether existing regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals
or clearances of Scienture LLC&#8217;s product candidates, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to
restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion
of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State
may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement
limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of Scienture LLC&#8217;s
product candidates. Historically, products launched in the European Union do not follow price structures of the United States and
generally prices tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Environmental
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations and those of its third-party
manufacturers and suppliers are subject to national, state and local environmental laws. The Company has made, and intends to
continue to make, expenditures and undertake efforts to comply with applicable laws. The Company believes the safety procedures
utilized by it for the handling and disposing hazardous materials comply with the standards prescribed by applicable laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Human
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> success begins and ends with our
people. The Company&#8217;s solid progress to date reflects the talent and hard work of all of its employees. The Company
considers the intellectual capital of its employees to be an essential driver of its business and key to its future prospects. Attracting,
developing, and retaining talented people in technical, marketing, sales, research, and other positions is crucial to executing its strategy
and its ability to compete effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Talent
Acquisition, Retention and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">key human capital objectives are
to attract, retain and develop the highest quality talent. The Company employs various human resource programs in support of these
objectives. The Company&#8217;s ability to recruit and retain such talent depends on a number of factors, including compensation
and benefits, talent development and career opportunities, and the work environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracts and rewards its employees by providing
market competitive compensation and benefit packages, including incentives and recognition plans that extend to all levels in its <span style="background-color: white">organization.
To that end, </span>Scienture LLC offers a comprehensive total rewards program aimed at health, home-life, and financial needs
of its employees. Scienture LLC&#8217;s total rewards package includes market-competitive pay, broad-based stock grants, bonuses,
healthcare benefits, retirement savings plans, paid time off and family leave, an Employee Assistance Program, and mental health services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is committed to the safety, health, and
security of its employees. The Company  believes a hazard-free environment is critical for the success of its business. Throughout
the Company&#8217;s operations, the Company strives to ensure that all its employees have access to safe workplaces that
allow them to succeed in their jobs. The Company&#8217;s <span>experience and continuing focus on
workplace safety has enabled it to preserve business continuity without sacrificing its commitment to keeping its colleagues and workplace
visitors safe.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Inclusion
and Diversity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">places a strong value on collaboration,
inclusion, and diversity, and believes that working together leads to better outcomes for its customers. This extends to the way the
Company&#8217;s employees <span>treat each other as team members. </span>The Company <span>strives
to create an environment where innovative ideas can flourish by demonstrating respect for each other and valuing the diverse opinions,
backgrounds, and viewpoints of employees. </span>the Company <span>believes a diverse and inclusive
workplace results in business growth and encourages increased innovation, retention of talent, and a more engaged workforce.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Facilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
LLC&#8217;s corporate headquarters is located at 20 Austin Blvd, Commack, NY 11725, which is 2,000 square feet of office space with a
lease termination date of July 31, 2026. Scienture LLC believes its facilities are sufficient to meet its current needs for the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in various claims and legal proceedings. The Company is not currently a party to
any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the Company and Scienture LLC collectively employ approximately fourteen (14) full-time employees and five (5) part-time employees.
We are not a party to any collective bargaining agreements and have not experienced any strikes or work stoppages. We consider our
relations with our employees and consultants to be satisfactory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is not directly affected by seasonal fluctuations but is affected indirectly by the fall and winter flu season, to the extent
it leads to an increased demand for certain generic pharmaceuticals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="me_001"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders, which as used in this prospectus includes donees, pledgees, transferees or other successors-in-interest
selling shares or interests in shares received after the date of this prospectus from the Selling Stockholders as a gift, pledge,
partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of the shares covered
hereby on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions
may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices. The Selling Stockholders may use any one or more of the following
methods when selling the shares, unless they are contractually bound not to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
    as principal to facilitate the transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of shares at a stipulated
    price per security;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell the shares under Rule 144 or any other exemption from registration under the Securities Act,
if available, rather than under this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of the shares,
from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction
a markup or markdown in compliance with FINRA Rule 2121.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the shares or interests therein, the Selling Stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the shares in the course of hedging the positions
they assume. The Selling Stockholders may also sell shares short and deliver these shares to close out their short positions,
or loan or pledge the shares to broker-dealers that in turn may sell these shares. The Selling Stockholders may also enter into
option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholder is, and any broker-dealer or
agent that is involved in selling the shares may be deemed to be, an &#8220;underwriter&#8221; within the meaning of the Securities
Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling
Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with
any person to distribute the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the shares. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities
Act or any other rule of similar effect. The shares will be sold only through registered or licensed brokers or dealers if required under
applicable state securities laws. In addition, in certain states, the shares covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compliance
with the Exchange Act, including Regulation M</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the shares may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common
stock by the Selling Stockholders or any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="me_002"></span>DESCRIPTION
OF cAPITAL sTOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary describes the common stock of the Company, which common stock is registered pursuant to Section 12 of the Exchange
Act. Only the Company&#8217;s common stock is registered under Section 12 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of our common stock is a summary and is qualified in its entirety by reference to our certificate of incorporation,
as amended and our bylaws, as amended, which are incorporated by reference herein, and by applicable law. For purposes of this description,
references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer only to the Company and not to
its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Capitalization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of authorized shares of our common stock is 100,000,000 shares, $0.00001 par value per share. The total number of authorized
shares of our preferred stock is 10,000,000 shares, $0.00001 par value per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Rights</i></b>. Each share of our common stock is entitled to one vote on all stockholder matters. Shares of our common stock do not
possess any cumulative voting rights. Except for the election of directors, if a quorum is present, an action on a matter is approved
if it receives the affirmative vote of the holders of a majority of the voting power of the shares of capital stock present in person
or represented by proxy at the meeting and entitled to vote on the matter, unless otherwise required by applicable law, Delaware law,
our certificate of incorporation, as amended or bylaws, as amended. The election of directors will be determined by a plurality of the
votes cast in respect of the shares present in person or represented by proxy at the meeting and entitled to vote, meaning that the nominees
with the greatest number of votes cast, even if less than a majority, will be elected. The rights, preferences and privileges of holders
of common stock are subject to, and may be impacted by, the rights of the holders of shares of any series of preferred stock that we
have designated, or may designate and issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Rights</i></b>. Each share of our common stock is entitled to equal dividends and distributions per share with respect to the common
stock when, as and if declared by our board of directors, subject to any preferential or other rights of any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation
and Dissolution Rights</i></b>. Upon liquidation, dissolution or winding up, our common stock will be entitled to receive pro rata on
a share-for-share basis, the assets available for distribution to the stockholders after payment of liabilities and payment of preferential
and other amounts, if any, payable on any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fully
Paid Status. </i></b>All outstanding shares of the Company&#8217;s common stock are validly issued, fully paid and non-assessable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Listing.</i></b> Our common stock is listed and traded on Nasdaq under the symbol &#8220;SCNX&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Matters</i></b>. No holder of any shares of our common stock has a preemptive right to subscribe for any of our securities, nor are any
shares of our common stock subject to redemption or convertible into other securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects Under Section 203 of Delaware General Corporation Law, our Certificate of Incorporation and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 of Delaware General Corporation Law (DGCL) prohibits a Delaware corporation from engaging in any business combination with any interested
stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least eighty five percent (85%) of the voting stock of the corporation outstanding at the time the transaction began, excluding
    for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder)
    those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants
    do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or an exchange
    offer; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by our board of directors and authorized at an annual or a special meeting
    of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3 percent of the outstanding voting stock
    that is not owned by the interested stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines &#8220;business combination&#8221; to include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation or any direct or indirect majority owned subsidiary of the corporation and the
    interested stockholder or any other corporation, partnership, unincorporated association, or other entity if the merger or consolidation
    is caused by the interested stockholder and as a result of such merger or consolidation the transaction is not excepted as described
    above;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge, or other disposition (in one transaction or a series) of ten percent (10%) or more of the assets of the corporation
    involving the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
    of the corporation beneficially owned by the interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges, or other financial benefits by or
    through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or a person who, together with the person&#8217;s affiliates
and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own,
fifteen percent (15%) or more of the outstanding voting stock of the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its Certificate of Incorporation. Our
Certificate of Incorporation provides that we shall not be governed by Section 203 of DGCL and as a result, Section 203 of DGCL does
not apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation does not provide that our board of directors will be classified. As a result, a person can gain control
of our board only by successfully engaging in a proxy contest at one annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be
utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage
an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exclusive
forum for certain lawsuits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws require, that unless the Company consents in writing to an alternative forum, the Court of Chancery of the State of Delaware
shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on
behalf of the Company; (b) any action asserting a claim of breach of fiduciary duty owed by, or other wrongdoing by, any director, officer,
employee or agent of the Company to the Company or the Company&#8217;s stockholders; (c) any action asserting a claim arising pursuant
to any provision of the DGCL or the certificate of incorporation or bylaws of the Company; (d) any action to interpret, apply, enforce
or determine the validity of the certificate of incorporation or bylaws of the Company; or (e) any action asserting a claim governed
by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable
parties named as defendants therein (or such indispensable parties consenting to the personal jurisdiction of the Court of Chancery within
10 days following any determination by the Court of Chancery that an indispensable party is not subject to such personal jurisdiction);
provided that, if and only if the Court of Chancery of the State of Delaware dismisses any action for lack of subject matter jurisdiction,
such action may be brought in another state or federal court sitting in the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
any other provisions of law, the certificate of incorporation or the bylaws of the Company, and notwithstanding the fact that a lesser
percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares
of capital stock of the Company entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent
with the exclusive forum requirements in our certificate of incorporation. If any provision or provision of the exclusive forum requirements
in our certificate of incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance
for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions
in any other circumstance and of the remaining provisions and the application of such provision to other persons or entities and circumstances
shall not in any way be affected or impaired thereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, our certificate of incorporation provides that the exclusive forum provision will be applicable to the fullest
extent permitted by applicable law, subject to certain exceptions. However, Section 27 of the Exchange Act creates exclusive federal
jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.
As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act
or any other claim for which the federal courts have exclusive jurisdiction. We also note that investors cannot waive compliance with
the federal securities laws and the rules and regulations thereunder. Section 22 of the Securities Act, creates concurrent jurisdiction
for state and federal courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations
thereunder. The Company believes that the exclusive forum provision applies to claims arising under the Securities Act, but there
is uncertainty as to whether a court would enforce such a provision in this context.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Special
meeting of stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that special meetings of our stockholders may be called only by the chairperson of the board of directors, the chief executive
officer or president (in the absence of a chief executive officer). Because our stockholders do not have the right to call a special
meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling
a special meeting of stockholders prior to such time as the chairperson of the board of directors, the chief executive officer or president
(in the absence of a chief executive officer) believed the matter should be considered or until the next annual meeting provided that
the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal
to replace our board of directors also could be delayed until the next annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance
notice requirements for stockholder proposals and director nominations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election
as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. Separately, pursuant to Rule
14a-8 of the Exchange Act, proposals seeking inclusion in our annual proxy statement must comply with the notice periods contained therein.
Our Bylaws also specify certain requirements as to the form and content of a stockholders&#8217; meeting. These provisions may preclude
our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual
meeting of stockholders and may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the
acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Action
by written consent</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action required or permitted to be taken by our common stockholders may be effected by written consent of the stockholders having not
less than the minimum percentage of the vote required by DGCL for the proposed corporate action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Vacancies
on the Board of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that, subject to the rights of the holders of any outstanding series of preferred stock and unless otherwise required
by law or resolution of our board of directors, vacancies on the board of directors arising through death, resignation, retirement, disqualification
or removal, an increase in the number of directors or otherwise may be filled by a majority of the directors then in office, though less
than a quorum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to Bylaws by Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations preventing amendments which decrease or diminish indemnification rights provided for in our bylaws, our bylaws
provide that any amendment to such bylaws undertaken solely by our stockholders requires the affirmative vote of at least two-thirds
in voting power of the outstanding shares of capital stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="sj_001"></span>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning compensation earned by or paid to certain persons who we refer to as our &#8220;Named
Executive Officers&#8221; for services provided for the fiscal years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and Principal Position</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
                                            Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)*</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                            Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)*</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
                                            Other Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren Ajjarapu</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">484,154</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,923</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<sup>(1)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">570,577</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board, Chief Executive Officer, and Secretary</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">360,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,075</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,934</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">628,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prashant Patel</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,962</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>&#160;</sup></span></p></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">409,462</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Operating Officer, Interim Principal Financial/ Accounting Officer and Director</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,650</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">193,650</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in this column represent the aggregate grant date fair value of awards computed in accordance with Financial Accounting Standards
    Board Accounting Standard Codification Topic 718. Such grant date fair value does not take into account any estimated forfeitures.
    The assumptions used in calculating the grant date fair value of restricted shares and option awards are set forth in the Critical
    Accounting Estimates as disclosed in our Consolidated Financial Statements for the year ended December 31, 2024. The amount reported
    in this column reflects the accounting cost for these awards and does not correspond to the actual economic value that may be received
    by the officer upon the vesting of the restricted shares, the exercise of the stock options, or any sale of the underlying shares
    of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    a car allowance of $1,000 per month and a disability insurance policy paid for by the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to 2024 Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Elements
of Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of our named executive officers generally consists of base salary and long-term incentive compensation in the form of equity
awards and other benefits, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Increased Officer Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2023, the Board and the Compensation Committee, increased the annual salaries of each of Mr. Ajjarapu, Mr. Patel and Ms. Huffman
to the levels of their salaries prior to certain reductions that had been effective since September 1, 2022. Mr. Ajjarapu&#8217;s annual
salary was increased back to $360,000 per year, Mr. Patel&#8217;s annual salary was increased back to $150,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increases in officer salaries were documented by amendments to the employment agreements with each officer. The amendments also clarified
that the equity compensation issuable to each officer was additional compensation and not specifically a result of the reduction in salaries
effective on September 1, 2022, and that the amount of reduced salary from September 1, 2022, to December 31, 2022 was forgiven by each
officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards At Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2024, concerning unexercised options, unvested stock and equity incentive plan
awards for each of the executive officers named in the Summary Compensation Table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Securities Underlying Unexercised Options (#) Exercisable</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Securities Underlying Unexercised Options (#) Unexercisable</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Exercise Price ($)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Expiration Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren Ajjarapu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;5/13/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,111</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prashant Patel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,111</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;39.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2029</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity Grant Timing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Board does not determine the timing or terms of equity awards, including stock options or similar awards
whose exercise price is related to the market value of our common stock, in connection with the release of material nonpublic information
that is likely to result in changes to the price of our common stock, such as a significant positive or negative earnings announcement,
and we do not time the public release of such information based on stock option grant dates. During fiscal year 2024, there were no equity
awards granted to any of our named executive officers within either four business days before or one business day after the filing of
our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and any Current Report on Form 8-K that contained any material nonpublic
information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements with Our Named Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Suren
Ajjarapu</i></b><i>, Chief Executive Officer and Secretary</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on April 14, 2020, we entered into an employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which replaced and superseded
his prior employment agreement with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement, which provides for Mr. Ajjarapu to serve as our Chief Executive Officer, has a term extending through December 31, 2025, provided
that the agreement automatically extends for additional one-year terms thereafter in the event neither party provides the other at least
60 days prior notice of their intention not to renew the terms of the agreement. The agreement also requires the Board, subject to certain
exceptions, to nominate Mr. Ajjarapu to serve on the Board at each stockholders&#8217; meeting which occurs during the term of the agreement
and to serve as the Chairman of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Ajjarapu&#8217;s annual compensation package includes (1) a base salary of $360,000 per year ($300,000
for the 2020 fiscal year), subject to annual increases as determined in the sole discretion of the Compensation Committee of the Board
(the &#8220;Compensation Committee&#8221;), and as discussed below (the &#8220;Base Salary&#8221;), and (2) a performance bonus equal
to up to 100% of his Base Salary each year, based on the Company meeting certain performance metrics as determined from time to time
by the Compensation Committee and Mr. Ajjarapu (&#8220;Performance Metrics&#8221;). Additionally, in the event that Mr. Ajjarapu meets
at least 70% of the requirements for any annual performance bonus, as determined in the reasonable discretion of the Compensation Committee
of the Board (which requirement was met for the 2020 fiscal year, and which salary was automatically increased), Mr. Ajjarapu&#8217;s
Base Salary is increased by 20%. Mr. Ajjarapu is eligible for the Base Salary increase on an annual basis, with such increases being
cumulative. Such increases in Base Salary do not require an amendment to the agreement. Mr. Ajjarapu&#8217;s performance bonus metrics
include specific company performance goals and objectives, including revenue goals, app downloads, and net operating income milestones,
as may be modified or added to from time to time with the mutual approval of Mr. Ajjarapu and the Compensation Committee. The determination
of whether the Performance Metrics have been met are determined in the reasonable discretion of the Compensation Committee, no later
than 90 days after (a) December 31, 2020, in connection with the 2020 Performance Metrics; and (b) the end of such calendar year for
subsequent years. For the year ended December 31, 2020, Mr. Ajjarapu was awarded 49,020 shares of restricted common stock (the &#8220;2020
Restricted Stock&#8221;), valued at $372,062, based on the closing sales price of the Company&#8217;s common stock on the effective date
of grant, which vested in full. Mr. Ajjarapu may also receive additional bonuses awarded from time to time in the discretion of the Board
and/or Compensation Committee and the Board (in cash, options or other forms of equity) or the Compensation Committee may waive or change
the performance metrics associated with his performance bonus in their discretion. Mr. Ajjarapu&#8217;s compensation under his employment
agreement may be increased from time to time, by the Compensation Committee, or the Board (with the recommendation of the Compensation
Committee), which increases do not require the entry into an amended employment agreement. Mr. Ajjarapu is also paid an automobile allowance
of $1,000 per month during the term of the agreement and is eligible to participate in our stock option plan and other benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement requires Mr. Ajjarapu to devote at least 75% of his business time and efforts to Company business. The agreement also prohibits
Mr. Ajjarapu from competing against us during the term of the agreement and for a period of twelve months after the termination of the
agreement in any state and any other geographic area in which we or our subsidiaries provide Restricted Services or Restricted Products,
directly or indirectly, during the twelve months preceding the date of the termination of the agreement. &#8220;Restricted Services&#8221;
means the manufacture, distribution, wholesale and sale of Restricted Products, healthcare services and any other services that we or
our subsidiaries have provided or are researching, developing, performing and/or providing at any time during the two years immediately
preceding the date of termination, or which Mr. Ajjarapu has obtained any trade secret or other confidential information about at any
time during the two years immediately preceding the date of termination of the agreement. &#8220;Restricted Products&#8221; means pharmaceutical
drugs and other healthcare products and any other product, that we or our subsidiaries have provided or are researching, developing,
manufacturing, distributing, purchasing, selling and/or providing at any time during the two years immediately preceding the date the
agreement is terminated, or which Mr. Ajjarapu obtained any trade secret or other confidential information in connection with at any
time during the two years immediately preceding the date of termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Ajjarapu&#8217;s employment (a) for &#8220;cause&#8221; (which is defined to include, a material breach of the agreement
by Mr. Ajjarapu, any act of misappropriation of funds or embezzlement by Mr. Ajjarapu, Mr. Ajjarapu committing any act of fraud, or Mr.
Ajjarapu being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude, or
a felony under federal or applicable state law); (b) in the event Mr. Ajjarapu suffers a physical or mental disability which renders
him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason
without &#8220;cause&#8221;; or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above.
The agreement also automatically terminates upon the death of Mr. Ajjarapu.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Ajjarapu may terminate his employment (a) for &#8220;good reason&#8221; (i.e., (i) if his position or duties are modified to such an
extent that his duties are no longer consistent with the position of CEO of the Company, (ii) there has been a material breach by us
of a material term of the agreement or Mr. Ajjarapu reasonably believes that we are violating any law which would have a material adverse
effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been provided
to us by Mr. Ajjarapu, (iii) Mr. Ajjarapu&#8217;s compensation is reduced without his consent, or we fail to pay to Mr. Ajjarapu any
compensation due to him upon five days written notice from Mr. Ajjarapu informing us of such failure, or (iv) if Mr. Ajjarapu is also
then serving as a member of the Board and is not re-nominated by the Board to serve as a member of the Board at any annual meeting of
stockholders of the Company; provided, however, prior to any such termination by Mr. Ajjarapu for &#8220;good reason&#8221;, Mr. Ajjarapu
must first advise us in writing (within 15 days of the occurrence of such event) and provide us 15 days to cure (5 days in connection
with the reduction of Mr. Ajjarapu&#8217;s salary or the failure to pay amounts owed to him)); (b) for any reason without &#8220;good
reason&#8221;; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Ajjarapu&#8217;s employment is terminated for any reason (not including, however, a termination by us for &#8220;cause&#8221;
or a termination as a result of Mr. Ajjarapu&#8217;s death or disability) during the twelve month period following a Change of Control
(a &#8220;Change of Control Termination&#8221;) or in anticipation of a Change of Control, we are required to pay Mr. Ajjarapu, within
60 days following the later of (i) the date of such Change of Control Termination; and (ii) the date of such Change of Control, a cash
severance payment in a lump sum in an amount equal to 3.0 times the sum of his current base salary and the amount of the last bonus payable
to Mr. Ajjarapu (the &#8220;Change of Control Payment&#8221;), which amount is due within 60 days of the later of (i) the date of such
Change of Control Termination; and (ii) the date of such Change of Control. If Mr. Ajjarapu&#8217;s employment terminates due to a Change
of Control Termination within six (6) months prior to a Change of Control, it will be deemed to be &#8220;in anticipation of a Change
of Control&#8221; for all purposes. In addition, in the event of a Change of Control, all of Mr. Ajjarapu&#8217;s equity-based compensation
immediately vests to Mr. Ajjarapu and any outstanding stock options held by Mr. Ajjarapu can be exercised by Mr. Ajjarapu until the earlier
of (A) one (1) year from the date of termination and (B) the latest date upon which such stock options would have expired by their original
terms under any circumstances, provided that if Mr. Ajjarapu&#8217;s employment ends in anticipation of a Change of Control and such
equity-based compensation awards or stock options have previously expired pursuant to their terms, the Company is required to pay Mr.
Ajjarapu a lump sum payment, payable on the same date as the Change of Control Payment, equal to the Black Scholes value of the expired
and unexercised equity compensation awards and stock options held by Mr. Ajjarapu on the date of termination, based on the value of such
awards had they been exercisable through the end of their stated term and had not previously expired. &#8220;Change of Control&#8221;
for the purposes of the agreement means: (a) any person obtaining beneficial ownership representing more than 50% of the total voting
power represented by our then outstanding voting securities without the approval of not fewer than two-thirds of our Board; (b) a merger
or consolidation of us whether or not approved by our Board, other than a merger or consolidation that would result in our voting securities
immediately prior thereto continuing to represent at least 50% of the total voting power outstanding immediately after such merger or
consolidation, (c) our stockholders approving a plan of complete liquidation or an agreement for the sale or disposition by us of all
or substantially all of our assets, or (d) as a result of the election of members to our Board, a majority of the Board consists of persons
who are not members of the Board on April 14, 2020, except in the event that such slate of directors is proposed by a committee of the
Board or the Board; provided that if the definition of &#8220;Change of Control&#8221; in our Stock Incentive Plans or Equity Compensation
Plans is more favorable than the definition above, then such definition shall be controlling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Ajjarapu&#8217;s employment is terminated pursuant to his death, disability, the end of the initial term (or any renewal term), without
&#8220;good reason&#8221; by Mr. Ajjarapu, or by us for &#8220;cause&#8221;, Mr. Ajjarapu is entitled to all salary accrued through the
termination date and no other benefits other than as required under the terms of employee benefit plans in which Mr. Ajjarapu was participating
as of the termination date. Additionally, any unvested stock options or equity compensation held by Mr. Ajjarapu immediately terminate
and are forfeited (unless otherwise provided in the applicable award) and any previously vested stock options (or if applicable equity
compensation) are subject to the terms and conditions set forth in the applicable Stock Incentive Plan or Equity Compensation Plan, or
award agreement, as such may describe the rights and obligations upon termination of employment of Mr. Ajjarapu.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Ajjarapu&#8217;s employment is terminated by Mr. Ajjarapu for &#8220;good reason&#8221;, or by us without &#8220;cause&#8221;, Mr.
Ajjarapu is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the termination
date for eighteen (18) months, plus the pro rata amount of any discretionary bonus and performance bonus he would have been due for the
following eighteen (18) months (with any metrics being extrapolated based on the last four (4) full prior quarters of the Company&#8217;s
operations prior to termination). Additionally, unvested benefits (whether equity or cash benefits and bonuses) will vest immediately
upon such termination and any outstanding stock options previously granted to Mr. Ajjarapu will vest immediately upon such termination
and will be exercisable until the earlier of (A) one year from the date of termination and (B) the latest date upon which such stock
options would have expired by their original terms under any circumstances. Mr. Ajjarapu is also to receive, if he elects, continued
health insurance under COBRA, paid for by the Company, for eighteen (18) months following the termination date (subject to certain rights
which reduce such obligation if Mr. Ajjarapu is covered by health insurance with a substantially similar level of insurance as prior
to the termination).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mr. Ajjarapu is subject
to non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Mr. Ajjarapu will be prohibited from competing with us while he is employed with us, he will only be prohibited from competing for twelve
months after his employment with us ends pursuant to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;<i>2022 Reduced Officer Compensation</i>&#8221; and &#8220;<i>2023 Increased Officer Compensation</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prashant
Patel</i></b><i>, President, Chief Operating Officer and Interim Principal Financial/Accounting Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 31, 2024, we entered into an employment agreement with Mr. Prashant Patel, our President, Chief Operating Officer and Interim Principal
Financial/Accounting Officer, which replaced and superseded his prior employment agreement with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement, which provides for Mr. Patel to serve as our President Chief Operating Officer, has a term extending through December 31,
2025, provided that the agreement automatically extends for additional one-year terms thereafter in the event neither party provides
the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement also requires the Board,
subject to certain exceptions, to nominate Mr. Patel to serve on the Board at each stockholders&#8217; meeting which occurs during the
term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Patel&#8217;s annual compensation package includes (1) a base salary of $350,000 per year, subject
to annual increases as determined in the sole discretion of the Chief Executive Officer, and as discussed below (the &#8220;Base Salary&#8221;),
and (2) a performance bonus equal to up to 100% of his Base Salary each year, based on the Company meeting certain performance metrics
as determined from time to time by the Compensation Committee of the Board (&#8220;Performance Metrics&#8221;). Additionally, in the
event that Mr. Patel meets at least 70% of the requirements for any annual performance bonus, as determined in the reasonable discretion
of the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;), Mr. Patel&#8217;s Base Salary will increase by
20%. Mr. Patel is eligible for the Base Salary increase on an annual basis, with such increases being cumulative. Such increases in Base
Salary do not require an amendment to the agreement. Mr. Patel&#8217;s performance bonus metrics are to be added to the agreement and
the Company currently contemplates that such metrics will include specific company performance goals and objectives, including revenue
goals, app downloads, and net operating income milestones, as may be modified or added to from time to time with the mutual approval
of Mr. Patel and the Compensation Committee. The determination of whether the Performance Metrics have been met are determined in the
reasonable discretion of the Compensation Committee, no later than 90 days after the end of such calendar year. Mr. Patel may also receive
additional bonuses awarded from time to time in the discretion of the Compensation Committee (in cash, options or other forms of equity).
Mr. Patel is also paid an automobile allowance of $1,000 per month during the term of the agreement and is eligible to participate in
our stock option plan and other benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement requires Mr. Patel to devote at least 75% of his business time and efforts to Company business. The agreement also prohibits
Mr. Patel from competing against us during the term of the agreement and for a period of twelve months after the termination of the agreement
in any state and any other geographic area in which we or our subsidiaries provide Restricted Services or Restricted Products, directly
or indirectly, during the twelve months preceding the date of the termination of the agreement. &#8220;Restricted Services&#8221; means
the manufacture, distribution, wholesale and sale of Restricted Products, healthcare services and any other services that we or our subsidiaries
have provided or are researching, developing, performing and/or providing at any time during the two years immediately preceding the
date of termination, or which Mr. Patel has obtained any trade secret or other confidential information about at any time during the
two years immediately preceding the date of termination of the agreement. &#8220;Restricted Products&#8221; means pharmaceutical drugs
and other healthcare products and any other product, that we or our subsidiaries have provided or are researching, developing, manufacturing,
distributing, purchasing, selling and/or providing at any time during the two years immediately preceding the date the agreement is terminated,
or which Mr. Patel obtained any trade secret or other confidential information in connection with at any time during the two years immediately
preceding the date of termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Patel&#8217;s employment (a) for &#8220;cause&#8221; (which is defined to include, a material breach of the agreement
by Mr. Patel, any act of misappropriation of funds or embezzlement by Mr. Patel, any act of fraud by Mr. Patel, or Mr. Patel being indicted
of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude, or a felony under federal
or applicable state law); (b) in the event Mr. Patel suffers a physical or mental disability which renders him unable to perform his
duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason without &#8220;cause&#8221;;
or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above. The agreement also automatically
terminates upon the death of Mr. Patel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Patel may terminate his employment (a) for &#8220;good reason&#8221; (i.e., (i) if his position or duties are modified to such an extent
that his duties are no longer consistent with the position of Chief Compliance Officer of the Company, (ii) there has been a material
breach by us of a material term of the agreement or Mr. Patel reasonably believes that we are violating any law which would have a material
adverse effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been
provided to us by Mr. Patel, (iii) Mr. Patel&#8217;s compensation is reduced without his consent, or we fail to pay to Mr. Patel any
compensation due to him upon five days written notice from Mr. Patel informing us of such failure, or (iv) if Mr. Patel is also then
serving as a member of the Board and is not re-nominated by the Board to serve as a member of the Board at any annual meeting of stockholders
of the Company; provided, however, prior to any such termination by Mr. Patel for &#8220;good reason&#8221;, Mr. Patel must first advise
us in writing (within 15 days of the occurrence of such event) and provide us 15 days to cure (5 days in connection with the reduction
of Mr. Patel&#8217;s salary or the failure to pay amounts owed to him)); (b) for any reason without &#8220;good reason&#8221;; and (c)
upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Patel&#8217;s employment is terminated for any reason (not including, however, a termination by us for &#8220;cause&#8221;
or a termination as a result of Mr. Patel&#8217;s death or disability) during the twelve month period following a Change of Control (a
&#8220;Change of Control Termination&#8221;) or in anticipation of a Change of Control, we are required to pay Mr. Patel, within 60 days
following the later of (i) the date of such Change of Control Termination; and (ii) the date of such Change of Control, a cash severance
payment in a lump sum in an amount equal to 3.0 times the sum of his current base salary and the amount of the last bonus payable to
Mr. Patel (the &#8220;Change of Control Payment&#8221;), which amount is due within 60 days of the later of (i) the date of such Change
of Control Termination; and (ii) the date of such Change of Control. If Mr. Patel&#8217;s employment terminates due to a Change of Control
Termination within six (6) months prior to a Change of Control, it will be deemed to be &#8220;in anticipation of a Change of Control&#8221;
for all purposes. In addition, in the event of a Change of Control, all of Mr. Patel&#8217;s equity-based compensation immediately vests
to Mr. Patel and any outstanding stock options held by Mr. Patel can be exercised by Mr. Patel until the earlier of (A) one (1) year
from the date of termination and (B) the latest date upon which such stock options would have expired by their original terms under any
circumstances, provided that if Mr. Patel&#8217;s employment ends in anticipation of a Change of Control and such equity-based compensation
awards or stock options have previously expired pursuant to their terms, the Company is required to pay Mr. Patel a lump sum payment,
payable on the same date as the Change of Control Payment, equal to the Black Scholes value of the expired and unexercised equity compensation
awards and stock options held by Mr. Patel on the date of termination, based on the value of such awards had they been exercisable through
the end of their stated term and had not previously expired. &#8220;Change of Control&#8221; for the purposes of the agreement means:
(a) any person obtaining beneficial ownership representing more than 50% of the total voting power represented by our then outstanding
voting securities without the approval of not fewer than two-thirds of our Board; (b) a merger or consolidation of us whether or not
approved by our Board, other than a merger or consolidation that would result in our voting securities immediately prior thereto continuing
to represent at least 50% of the total voting power outstanding immediately after such merger or consolidation, (c) our stockholders
approving a plan of complete liquidation or an agreement for the sale or disposition by us of all or substantially all of our assets,
or (d) as a result of the election of members to our Board, a majority of the Board consists of persons who are not members of the Board
on March 31, 2024, except in the event that such slate of directors is proposed by a committee of the Board or the Board; provided that
if the definition of &#8220;Change of Control&#8221; in our Stock Incentive Plans or Equity Compensation Plans is more favorable than
the definition above, then such definition shall be controlling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Patel&#8217;s employment is terminated pursuant to his death, disability, the end of the initial term (or any renewal term), without
&#8220;good reason&#8221; by Mr. Patel, or by us for &#8220;cause&#8221;, Mr. Patel is entitled to all salary accrued through the termination
date and no other benefits other than as required under the terms of employee benefit plans in which Mr. Patel was participating as of
the termination date. Additionally, any unvested stock options or equity compensation held by Mr. Patel immediately terminate and are
forfeited (unless otherwise provided in the applicable award) and any previously vested stock options (or if applicable equity compensation)
are subject to the terms and conditions set forth in the applicable stock incentive plan or equity compensation plan, or award agreement,
as such may describe the rights and obligations upon termination of employment of Mr. Patel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Patel&#8217;s employment is terminated by Mr. Patel for &#8220;good reason&#8221;, or by us without &#8220;cause&#8221;, Mr. Patel
is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the termination date
for eighteen (18) months, plus the pro rata amount of any discretionary bonus and performance bonus he would have been due for the following
eighteen (18) months (with any metrics being extrapolated based on the last four (4) full prior quarters of the Company&#8217;s operations
prior to termination). Additionally, unvested benefits (whether equity or cash benefits and bonuses) will vest immediately upon such
termination and any outstanding stock options previously granted to Mr. Patel will vest immediately upon such termination and will be
exercisable until the earlier of (A) one year from the date of termination and (B) the latest date upon which such stock options would
have expired by their original terms under any circumstances. Mr. Patel is also to receive, if he elects, continued health insurance
under COBRA, paid for by the Company, for eighteen (18) months following the termination date (subject to certain rights which reduce
such obligation if Mr. Patel is covered by health insurance with a substantially similar level of insurance as prior to the termination).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mr. Patel is subject to
non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Mr. Patel will be prohibited from competing with us while he is employed with us, he will only be prohibited from competing for twelve
months after his employment with us ends pursuant to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;<i>2023 Increased Officer Compensation</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="sj_002"></span>DIRECTOR
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
Non-Employee Director Compensation Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding all compensation awarded to, earned by or paid to each person who served as a non-executive
director of the Company for some portion or all of 2024. Other than as set forth in the table and described more fully below, the Company
did not pay any fees, make any equity or non-equity awards, or pay any other compensation, to its non-employee directors. All compensation
paid to its employee directors is set forth in the tables summarizing executive officer compensation above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees<br/>
                                            Earned or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>paid
                                            in cash</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards*</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards**</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald G.
    Fell<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">149,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190,693</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shankar Hariharan<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Narasimhan Mani<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayur Doshi<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subbarao Jayanthi<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Candice Beaumont <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff Newell<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">163,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">189,986</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael L. Peterson<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">149,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">190,693</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Amounts in this column represent the aggregate grant date fair value of awards computed in accordance with Financial Accounting Standards
Board Accounting Standard Codification Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The
assumptions used in calculating the grant date fair value of restricted shares and option awards are set forth in the Critical Accounting
Estimates as disclosed in our Consolidated Financial Statements for the year ended December 31, 2023. The amount reported in this column
reflects the accounting cost for these awards and does not correspond to the actual economic value that may be received by the director
upon the vesting of the restricted shares, the exercise of the stock options, or any sale of the underlying shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Amounts in this column represent the aggregate grant date fair value of awards computed in accordance with the Black-Scholes option pricing
model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These
variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected
annual dividend yield and the expected stock price volatility over the expected term. The Company estimates volatility by reference to
the historical volatilities of the Company. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon
issues similar in duration to the expected term of the equity-settled award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>As of December 31, 2024, Mr. Fell had been awarded 3,345 vested stock options and 222,217 shares of vested common stock of
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)
</sup>Dr. Hariharan was appointed to the Board on July 25, 2024, in connection with the Company&#8217;s acquisition of Scienture LLC.
As of December 31, 2024. Dr. Hariharan did not receive any fees or other compensation for serving on the Board
during a portion of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)
</sup>Dr. Mani was appointed to the Board on July 25, 2024, in connection with the Company&#8217;s acquisition of Scienture LLC. As of
December 31, 2024. Dr. Mani did not receive any fees or other compensation for serving on the Board
during a portion of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)
</sup>Mr. Doshi was appointed to the Board on May 28, 2024. As of December 31, 2024. Mr. Doshi did not receive any fees or other compensation for serving on the Board
during a portion of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)
</sup>Mr. Jayanthi was appointed to the Board on June 17, 2024. As of December 31, 2024. Mr. Jayanthi did not receive any fees or other compensation for serving on
the Board during a portion of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)
</sup>Ms. Beaumont was appointed to the Board on July 31, 2023, and then resigned from the Board effective April 10, 2024. Ms. Beaumont
did not receive any fees or other compensation for serving on the Board during a portion of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)
</sup>As previously disclosed, Mr. Newell voluntarily resigned from the Board effective May 30, 2024. As of December 31, 2024, Mr. Newell
had been awarded 80,702 shares of vested common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8) </sup>As
previously disclosed, Mr. Peterson voluntarily resigned from the Board effective May 30, 2024. As of December 31, 2024, Mr. Peterson
had been awarded 12,131 in vested stock options and 246,685 in shares of vested common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Independent
Director Compensation Policy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
independent member of the Board is to receive an annual grant of restricted common stock of the Company equal to $55,000 in value, on
April 1st of each year (or such date thereafter as the awards are approved by the Board), and valued on such same date, based on the
closing sales price on such date (or the first business day thereafter), which restricted stock awards will vest at the rate of 1/4th
of such awards over the following four calendar quarters, subject to such directors continued service to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has also entered into an indemnification agreement with each member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Independent Director Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board approved the issuance of 36,163 shares of the Company&#8217;s
common stock to each of Mr. Fell and Mr. Peterson for services rendered to the Company during fiscal 2024, which shares were valued at
$149,443 each. The Board also approved the issuance of 38,526 shares of the Company&#8217;s common stock to Mr. Newell for services rendered
during fiscal 2024, which shares were valued at $163,736. The shares vest immediately on the grant date, subject to each applicable independent
director&#8217;s continued service to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of these awards were issued under the Incentive Plan and all awards
were evidenced by Restricted Stock Grant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
independent director also receives an annual cash retainer of $35,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_002"></span>CHANGE
IN AUDITOR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dismissal
of MaloneBailey, LLP</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2023, the Company dismissed MaloneBailey, LLP (&#8220;MaloneBailey&#8221;) as its independent registered public accounting
firm to audit the Company&#8217;s financial statements, effective as of such date. The dismissal of MaloneBailey was approved by the
Audit Committee. MaloneBailey&#8217;s audit report on the Company&#8217;s financial statements for each of the fiscal years ended December
31, 2022 and 2021 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty,
audit scope, or accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Company&#8217;s two most recent fiscal years and the subsequent interim period through June 30, 2023, there were no (i) disagreements
(as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the related instructions to that Item) with MaloneBailey
on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement,
if not resolved to the satisfaction of MaloneBailey would have caused it to make reference to the subject matter of the disagreement
in connection with its report, or (ii) &#8220;reportable events&#8221; as that term is defined in Item 304(a)(1)(v) of Regulation S-K
under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Engagement
of CM3 Advisory</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2023, the Company engaged CM3 Advisory as its new independent registered public accounting firm of the Company. The engagement
of CM3 Advisory was approved by Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Company&#8217;s two most recent fiscal years and the subsequent interim period through June 30, 2023, neither the Company nor anyone
on its behalf consulted with CM3 Advisory regarding: (i) the application of accounting principles to a specified transaction, either
completed or proposed, (ii) the type of audit opinion that might be rendered on the Company&#8217;s financial statements, and neither
a written report nor oral advice was provided to the Company that CM3 Advisory concluded was an important factor considered by the Company
in reaching a decision as to an accounting, auditing or financial reporting issue, or (iii) any matter that was either the subject of
a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the related instructions to that Item)
or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon by Dykema Gossett PLLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="me_004"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
consolidated financial statements of Scienture Holdings, Inc. at December 31, 2023 and the consolidated financial statements of Scienture
Holdings, Inc. at December 31, 2022 incorporated by reference in this prospectus have been audited by CM3 Advisory and MaloneBailey,
LLP, each an independent registered public accounting firm, as set forth in their reports thereon, appearing therein, and are included
in reliance upon such report given on the authority of such firms as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
financial statements of Scienture, LLC at December 31, 2023 and December 31, 2022 incorporated by reference in this prospectus have been
audited by Suri &amp; Co., an independent registered public accounting firm, as set forth in its report thereon, appearing therein, and
are included in reliance upon such report given on the authority of such firm as an expert in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="me_005"></span>information
incorporated by reference</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &#8220;incorporate by reference&#8221; information that we file with them. Incorporation by reference allows us to disclose
important information to you by referring you to those other documents. The information incorporated by reference is an important part
of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed
a registration statement on Form S-1 under the Securities Act with the SEC with respect to the securities being offered pursuant to this
prospectus. You should refer to the registration statement, including the exhibits and schedules attached to the registration statement
and the information incorporated by reference, for further information about us and the securities being offered pursuant to this prospectus.
The documents we are incorporating by reference into this prospectus are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224015595/form10-k.htm" style="-sec-extract: exhibit">Form 10-K</a> for the fiscal year ended December 31, 2023, filed on April 22, 2024, as amended by our Amendment No.
    1 to <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224017778/form10-ka.htm" style="-sec-extract: exhibit">Form 10-K</a> filed on May 3, 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224025217/form10-q.htm" style="-sec-extract: exhibit">Form 10-Q</a> for the period ended March 31, 2024, filed on June 26, 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224030971/form10-q.htm" style="-sec-extract: exhibit">Form 10-Q</a> for the period ended June 30, 2024, filed on August 9, 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Report on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224043756/form10-q.htm" style="-sec-extract: exhibit">Form 10-Q</a> for the period ended September 30, 2024, filed on November 6, 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Definitive Information Statement on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224034187/formdef14c.htm" style="-sec-extract: exhibit">Schedule 14C</a> filed on August 28, 2024;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">our Definitive Information Statement on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224052473/formdef14c.htm" style="-sec-extract: exhibit">Schedule 14C</a>
    filed on December 30, 2024; </td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">our Definitive Proxy Statement on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315225003726/formdef14a.htm" style="-sec-extract: exhibit">Schedule 14A</a> filed
    on January 27, 2025; and</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying
    such reports that relate to such items) filed on <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224002571/form8-k.htm" style="-sec-extract: exhibit">January
    17, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224007038/form8-k.htm" style="-sec-extract: exhibit">February
    16, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224008947/form8-k.htm" style="-sec-extract: exhibit">March
    6, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224021170/form8-k.htm" style="-sec-extract: exhibit">May
    23, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224021967/form8-k.htm" style="-sec-extract: exhibit">May
    30, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224024424/form8-k.htm" style="-sec-extract: exhibit">June
    20, 2024</a>; and <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224026571/form8-k.htm" style="-sec-extract: exhibit">July
    9, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224029787/form8-k.htm" style="-sec-extract: exhibit">July
    31, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224037953/form8-k.htm" style="-sec-extract: exhibit">September
    24, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224040392/form8-k.htm" style="-sec-extract: exhibit">October
    8, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224040822/form8-k.htm" style="-sec-extract: exhibit">October
    11, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315224047804/form8-k.htm" style="-sec-extract: exhibit">November
    26, 2024</a>; <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315225001429/form8-k.htm" style="-sec-extract: exhibit">January 8, 2025</a>; and <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315225002749/form8-k.htm" style="-sec-extract: exhibit">January 17, 2025</a>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of
Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement of which this prospectus is a part and prior
to the effectiveness of such registration statement and all documents that are filed by us with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy
statements and information statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed
to be modified or superseded for purposes of the document to the extent that a statement contained in this prospectus or any other subsequently
filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral
request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus,
other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus
incorporates. You should direct oral or written requests to our corporate secretary, who can be contacted at 6308 Benjamin Rd, Suite
708, Tampa, Florida 33634 or (800) 261-0281. You may also access these documents, free of charge on the SEC&#8217;s website at <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="me_006"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have filed with the SEC a registration statement on Form S-1, which includes amendments and exhibits, under the Securities Act and the
rules and regulations under the Securities Act for the registration of the common stock being offered by this prospectus. This prospectus,
which constitutes a part of the registration statement, does not contain all the information that is in the registration statement and
its exhibits and schedules. Statements in this prospectus that summarize documents are not necessarily complete, and in each case you
should refer to the copy of the document filed as an exhibit to the registration statement. The registration statement and other public
filings can be obtained from the SEC&#8217;s internet site at <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#8217;s website at <i>www.sec.gov</i>. Copies of documents filed by us with the SEC are also available
from us without charge, upon oral or written request to our Secretary, who can be contacted at 6308 Benjamin Rd, Suite 708, Tampa, Florida
33634 or (800) 261-0281. Our website addresses is <i>https://scienture.com</i>. Information on, or that may be accessed through, our
website is not incorporated by reference into this prospectus and should not be considered a part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="bss_003"></span>INDEX
TO FINANCIAL INFORMATION</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scienture,
LLC (FKA Scienture, Inc.) Financial Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#t_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    Sheets as of June 30, 2024 and December 31, 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#t_2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Operations and Comprehensive Loss for the six months ended June 30, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#t_3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Stockholders&#8217; Equity for the six months ended June 30, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#t_4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Cash Flows for the six months ended June 30, 2024 and 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#t_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to the Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bss_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bss_002">Balance Sheets as of December 31, 2023 and December 31, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Statements
    of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Statements
    of Stockholders&#8217; Deficit for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Statements
    of Cash Flows for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Notes
    to the Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scienture
Holdings, Inc. (FKA TRxADE HEALTH, Inc.) Unaudited Pro Forma Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sl_002">Unaudited
    Pro Forma Consolidated Balance Sheets as of June 30, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sl_003">Unaudited
    Pro Forma Consolidated Statements of Operations for the Six Months Ended June 30, 2024, and the Year Ended December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sl_005">Notes
    to Unaudited Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-39</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 93; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="t_1"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited</b></span></p>

<p id="xdx_11A_hsrt--ConsolidatedEntitiesAxis__custom--ScientureIncMember_zH8jwxL8tGh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_z0jvbN3anNn3" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630_zxarIbUzBn2g" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zI1Qc8ZAQsjh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zkWlG4ubcDo1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zC7wU3KKD81h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashEquivalentsAtCarryingValue_i02I_maACzkt2_zJbxz5a6MBxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzkt2_zQUJdCAXXFbl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0024">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,414</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherReceivablesNetCurrent_i02I_maACzkt2_zMpapIQW0IFc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtACzkt2_maAzrRv_zR1qKU8DRUA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Current Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,695</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190,777</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzrRv_zz4bdr7cvmPh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease, right of use asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,091</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzrRv_z7su1vpeFO72" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,274</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,868</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zsW8Aqv5Jh2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLCzMVt_zXW9jc8U2ip" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,581</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maLCzMVt_zP20c0x8K6bf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198,822</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLCzMVt_zUH0CLTwBYG4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0051">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzMVt_zJWyHXA0hsX4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,567</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,404</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzMVt_maLzz3Z_zA7Qqb0ddNmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Current Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,105,970</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,126,010</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleDebtNoncurrent_i02I_maLzz3Z_zZlTz99IQyE8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible notes, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,734,661</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzz3Z_zOmPVAlo5ehe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating Lease Liability, non current</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,319</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DevelopmentAgreementLiability_i01I_maLzz3Z_zJwc2uXXdeAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Development agreement liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:DevelopmentAgreementLiability" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtLzz3Z_maLASEzC0V_maLASEzads_zjSKtA9cqrV2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,164,950</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,794,020</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzads_z8RiLaqVTGZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Refer Note 8)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0072">-</span></span>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0073">-</span></span>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_i01B_zmUjzBZ9zoc7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&#8217; Deficit:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_maSEzHwe_zy9Zq1pIYxQa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630_zsX3Oa3Q671h" title="Preferred  stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z79CcNjHc78g" title="Preferred  stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000081" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000083" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span>
    par value, <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630_z7swCqfr78R8" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240630_z6unO9RC9WY3" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630_zVpoD6mQdT22" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,365,657</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
    and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zQFplGuwck9d" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231_zbnHgM94DZW8" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20231231_zlPKv495S6gc" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> authorized, issued and outstanding as of June 30, 2024, and December 31, 2023, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockValue_i02I_maSEzHwe_zWoVbw4ZlSH3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zIFf8dEOW0u1" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_znullJwk4JRh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
    par value, <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zPj2gpSskDzb" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20231231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
    authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240630_zumUBYx8EeG1" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zgCBeqQuIgs8" title="Common stock, shares outstanding"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20231231_zr8fqX6uUkt4" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zZHaVwlnetH7" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
    issued and outstanding as of both June 30, 2024, and December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_i02I_maSEzHwe_zNFaR5Qtrfn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,835,257</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,849,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzHwe_zU8X83IJX8n4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000119" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,824,770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000120" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,388,956</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_mtSEzHwe_maLASEzads_zca0Y0iHuzEh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stockholders&#8217; deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000122" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,988,676</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzads_z2ILX6Aitxmk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Liabilities and Stockholders&#8217; Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,274</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,868</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="t_2"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zYuqHVQi4krd" summary="xdx: Statement - Statements of Operations And Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240630_zDy0PkVfFeo4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230630_zUY2ch1iAbTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six
    Months Ended June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzJoh_zFV8eB3ncrQd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zhSE1l5TmFF8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEztjS_z8WYOjo7ev32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,520,947</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">946,435</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEztjS_zeJbOHHggzTf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,413,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,236</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--TerminationFee_i01_maOEztjS_zMkWFT9g1ms9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Termination fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:TerminationFee" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtOEztjS_msOILzJoh_zJwCqkYrGzo8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total operating expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,219,840</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,213,671</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtOILzJoh_maNILzsjy_zx6RK3q5r9af" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from Operations</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000146" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,219,840</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000147" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">413,671</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zq9VHfsPHBJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DividendIncome_i01_maNIEz9ST_zj4F3UJxic31" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Dividend income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maNIEz9ST_zQu8k29HGePe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,931</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestIncomeExpenseNonoperatingNet_i01_maNIEz9ST_zJoWWGqxLwjb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000158" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">227,905</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000159" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,203</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--MiscellaneousIncome_i01_maNIEz9ST_zb1681iFu4vl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Miscellaneous income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEz9ST_maNILzsjy_zfK6IH4WT9na" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total other expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000164" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">215,974</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000165" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,899</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtNILzsjy_z6Ohld6G4TWb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Loss</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000167" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,435,814</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000168" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">471,570</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zJHXsAzDK3Hc" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_z2CZzQ0ux8Jk" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.89</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230630_z2zAlDX2JnEg" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zRaOD3SAnehk" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average shares used to compute net loss per share
    - diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240630_zztfCp00HIDi" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240630_zg3SAartnBIc" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zuuzkmzbj4f2" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_z9qkqkP8mNue" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="t_3"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Stockholders&#8217; Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zX5lvozdVlQi" summary="xdx: Statement - Statements of Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zSCzXF6K3cS" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z288Nb2Sbhb3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6zmvux8rvUf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z0hmnUsBgITi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--StockholdersDeficitMember_zotfNPkWyNr6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Preferred
    Stock</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Common
    Stock</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Additional</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Paid-In</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Accumulated</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Total</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Stockholders&#8217;</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zJvSlbtLi7al" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 23%">Balance at December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFcrhjABRpG2" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1M7PMV7PuBb" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,850,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,111,783</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,439,589</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,919</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zaQblty0m5hb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0196">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoBWyjg7zp5e" title="Common stock issued for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zOKCwzLhux0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zgc3KL7F78y6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20230101__20230630_eus-gaap--StockholdersEquity_iS_z5YnZmhRwmCh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbUMW5CbI4C7" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoQr2mV5UiI" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,355</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,147,967</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,821,872</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zgQFGeBfOLh7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zCuq7dWpBlZb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">471,570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">471,570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20230701__20231231_eus-gaap--StockholdersEquity_iS_z0FuiVYtRWPk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at June 30, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzXdh6A8HXQ5" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLWpsTDIfba8" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,365,079</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,619,537</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000242" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,253,718</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20240101__20240630_eus-gaap--StockholdersEquity_iS_z4Rcyw7CruE7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrUF5ZzJ5FPi" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFN8iVBg9p5i" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,849,064</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000251" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,388,956</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000252" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zxshvl7JYJV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion of notes into preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGMUeqesyzGj" title="Conversion of notes into preferred stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">965,657</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,941,356</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,941,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zXgbzD26Gbcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zkaFBwXYHBJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,435,814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,435,814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240101__20240630_eus-gaap--StockholdersEquity_iE_ziF7BTtCUSTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at June 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztZFq2S1lQj9" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,365,657</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDoh0vcq1IEj" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000286" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,835,257</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,824,770</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,988,676</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="t_4"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_zSqYGMwYNe35" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20240630_zTHi63m80ece" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20230630_zr6I4JEPEwTf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Six
    Months Ended June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zw8EExZ7OAYg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maNCPBUzCX9_zOLz1GgSKSfh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,435,814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">471,570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zJh050OMNsk2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile Net loss to net cash used in operating
    activities:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzCX9_zcQHruAwQY4c" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for services</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzCX9_zrxrsD1VLUdg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,544</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maNCPBUzCX9_zRAUwcuTrlAg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zIJhEX2R5Rlh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Changes in operating assets and liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzCX9_z0idbg2aDFgf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,414</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzCX9_zlZZX8Il9d9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">777,406</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,729</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzCX9_zDh6nUXNWApk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,142,843</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,212</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInDevelopmentAgreementLiability_i03_maNCPBUzCX9_zaffIlUXQ2Xg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Development agreement liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:IncreaseDecreaseInDevelopmentAgreementLiability" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzCX9_z3kLS2uBAn0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability, Net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzCX9_maCCERCzV5E_zjahV0IQvUAg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000324" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,009,668</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">625,905</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z8g7KjqjJ1f1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzYnR_z17fPstJ5UOh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from the issuance of convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_i01_maNCPBUzYnR_zM3BtJBrHN8k" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from the issuance of long-term convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzYnR_maCCERCzV5E_zkE9VJQ3P1Zd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in financing activities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzV5E_zlmPo6pIf28a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,009,668</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">225,905</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zzp5uaIkqqY3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents at beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zg1PCNQt43t6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents at end of period</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,210</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-06-30_custom_ScientureIncMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378,908</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zNErnmdA7TOk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_zw2SR2a4fiu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z0x0Cf6JMWa7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ConversionOfNotesAndAccruedInterestIntoPreferredStock_i01_z7a9JZ8YKjQb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion of notes and accrued interest into preferred
    stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:ConversionOfNotesAndAccruedInterestIntoPreferredStock" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,941,453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--WarrantsIssuedInConnectionWithLongtermConvertibleDebt_i01_z7ZX5QsD1CG7" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued in connection with long-term convertible
    debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_113_hsrt--ConsolidatedEntitiesAxis__custom--ScientureIncMember_zSQ2EZ59xoOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="t_5"></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000363" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zP8RcZ5GbJIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 <span id="xdx_827_zwSYs6RJLtDd">Organization Overview and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (&#8220;the Company&#8221;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements for the periods ending June 30, 2024 and 2023 have been prepared in accordance with accounting principles
generally accepted in the United States (&#8220;U.S.GAAP&#8221;).</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000365" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdQz4Ku2fPp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 <span id="xdx_824_z3Dh44BMJeMb">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000367" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zVPOLExEFmK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zxSDaACjaeD5">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000369" name="SCNX:UnauditedInterimFinancialInformationPolicyTextBlock"><p id="xdx_846_ecustom--UnauditedInterimFinancialInformationPolicyTextBlock_zdFAodwb1E1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zQZJYwAIYHti">Unaudited
Interim Financial Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim
financial information, within the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).
Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis
consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal
recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition
as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial
statements related to the six-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for
the full fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited
financial statements and the notes thereto for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000371" name="SCNX:LiquidityPolicyTextBlock"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2l2P0tZC6o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zODvNvGLoWA7">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000373" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zxhgn6Q5ujW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zuJ78iJTA1a5">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000375" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zE1fnIck2JLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zUHFJGQLSaIh">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20240630_zuRtCDhxAaY" title="Number of reportable segment::XDX::1"><span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20240101__20240630_zhw6TVMnHfrl" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0377"><span style="-sec-ix-hidden: xdx2ixbrl0379">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000381" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGt2pUccSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zIC2blmEuDV8">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000383" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6LqTc1l1NQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zqhJLDK3sSA8">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240630_zRVQFAe6mlOc" title="Allowance for doubtful accounts"><span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zRZgK4nRWgj5" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> as of June 30, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000389" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z9u4ZW4nirW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z8z2xy9MUyg1">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000391" name="SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock"><p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z7hNftnCGULl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zEPGvgYRCnV1">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630_zjwFP8znkrH8" title="Revenue recognized"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span> for the six months
ended June 30, 2023, at the point when the development milestone events occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall pay Kesin a total gross amount of
$<span id="xdx_90F_ecustom--TerminationFee_c20240301__20240331_zbrSruzSNcb4" title="Termination fee"><ix:nonFraction name="SCNX:TerminationFee" contextRef="From2024-03-012024-03-31_custom_ScientureIncMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></span> upon commercialization of product via a royalty arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--TerminationFeeDescription_c20240301__20240331_zUPQA6xR5mOb" title="Termination fee description"><ix:nonNumeric contextRef="From2024-03-012024-03-31_custom_ScientureIncMember" id="Fact000397" name="SCNX:TerminationFeeDescription">This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000399" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zk14AEaP86y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zn0dovk53fB1">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000401" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_ztZeoYC6DQ8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zfSzsnGkNMH9">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the six months ended June 30, 2024, the Company had
one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000403" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9WtrBhyn5m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zfojqVg69RVb">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000405" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjQmab8imlO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z17IT79YgzKj">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option-pricing model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based
awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest
rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company has estimated volatility
by reference to the historical volatilities of the Company and that of similar publicly traded peer companies. The risk-free interest
rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled
award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000407" name="SCNX:WarrantValuationPolicyTextBlock"><p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zT2pXJTCvfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ztSYFFhT3r2e">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000409" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zmhFfpP7PIoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zPnVd1CLtqZg">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000411" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AF_zQuMJxhtbJxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000413" name="SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_842_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zlo6CuWHvH4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zrZL0Sxeovk8">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>
</ix:nonNumeric><p id="xdx_85A_zjHDxiwRn7B1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000415" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z6nQbAnNn1mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span id="xdx_828_z9ydt3frwRMh">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a net loss of ($<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20240101__20240630_zbwI3xn34GRc" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000417" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,435,814</ix:nonFraction></span>) for the six months ended June 30, 2024 and stockholders&#8217; deficit of ($<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20240630_z3BChwnobuFl" title="Stockholders deficit"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,988,676</ix:nonFraction></span>) as of June
30, 2024. The Company&#8217;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000421" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zMWJBk7jTARa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 <span id="xdx_82D_zBHXdH5GoMh4">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000423" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zv1WlyVvSZec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zsVyzOBNOdca" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_z7k7JFqYVou7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zk7nJ4raPtIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zUmGu1ZyI37a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndDueFromBanks" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,107</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndDueFromBanks" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,943</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zr2I2eQW8W4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities(Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,091,935</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zedeZ31xwa1j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,106</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zZkuwK1tR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market securities were considered a Level 1 financial instrument.</span></p>
<!-- Field: Split-Segment; Name: 003 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000434" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z2nIuLKOz38k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 <span id="xdx_829_zphOwAVXZc7f">Convertible Notes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630_zGTjHAXkOp9" title="Convertible notes issued bear interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000436" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and certain notes issued prior to 2022 bear an interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zO3XW6PKEi3h" title="Convertible notes issued bear interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000438" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>% per annum.
As of December 31, 2023, there $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_z0f0CiwB6Lcl" title="Debt outstanding principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></span> in outstanding principal. All the short-term convertible notes matured during the period of
<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20240630_zurlbo1yfv2g" title="Maturity date"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000442" name="us-gaap:DebtInstrumentMaturityDateDescription">December 2023</ix:nonNumeric></span>. In March 2024, the Company had converted the outstanding principal of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331_ziHyENrEbEwi" title="Debt outstanding principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-03-31_custom_ScientureIncMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></span> and the accrued interest through the
date of conversion amounting to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwzhG498PoP3" title="Conversion of debt, amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,233</ix:nonFraction></span> into an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU7Nm1ECNvQ2" title="Conversion of debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">965,567</ix:nonFraction></span> shares of preferred stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000450" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_zW5CLpW9ZERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 <span id="xdx_82A_zjNRTMqmP2Wh">Long-Term Convertible Debt, net of debt discount</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#8216;NVK&#8221;)
for $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJ18I6gnzBxk" title="Long term debt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus <span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIyzq4zfEByg" title="Debt prime rate percentage"><ix:nonFraction name="SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span> percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of June 30, 2024 and December 31, 2023, the interest rate was <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z64kXxDclkgh" title="Debt interest rate percentage"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zcO3JkpuVltl" title="Debt interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000456" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.50</ix:nonFraction></ix:nonFraction></span></span>%. The debt is collateralized by all
of the Company&#8217;s receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof.
The principal is entirely repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing
as defined in the Loan Agreement. Interest expense related to the debt amounted to $<span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8lg9PUiLBVk" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,583</ix:nonFraction></span> for the year ended December 31, 2023 and the
principal amount is entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common
stock of the Company at a fully-diluted Company valuation of $<span id="xdx_90E_ecustom--DebtDilutedValuation_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zHBwABBsNSv4" title="Debt diluted valuation"><ix:nonFraction name="SCNX:DebtDilutedValuation" contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the NVK debt, the Company granted <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIeXGRH57dA7" title="Number of warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> warrants to purchase common stock. The fair value of the warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZTT80t2n69l" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,260</ix:nonFraction></span>
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the six months
ended June 30, 2024, the Company amortized $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZ4axVI8HE5d" title="Debt discount interest expense"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,544</ix:nonFraction></span> of the debt discount to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000470" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zvCGnGQmu78c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zGN7ju9LgRj6" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20240630_z00MVhXvHaE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zjI9lnujWVM6" style="font: bold 10pt Times New Roman, Times, Serif">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzNfR_zA0b4lZdwnR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDzNfR_zS986bttMv36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,339</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,883</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzNfR_zADfD7WvS8Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible notes, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,734,661</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z84O2eGA6Jp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000481" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zycZGLgYnrFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding notes are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zDUR8Jm0s2wh" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_zoa1qBEoQgKd" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_z6K4ui17ZAP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zUwrVOjAZhs1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_z47ICmJNlPLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z5aaWP0cErTd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_zQ8myvEbGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z9wy2NTIIURl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000493" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zb7Cps8qYX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 <span id="xdx_82D_z2eHmy0jfRv8">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>
<!-- Field: Split-Segment; Name: 004 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000495" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3DLDsA4GcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 <span id="xdx_82C_zT7enwhyHBs7">Commitment and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable
in connection with the consummation Scienture&#8217;s business combination with the Company. Scienture has disputed that the amount is
now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution will be obtained.
If Kesin brings a legal action, Scienture will vigorously defend it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000497" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdWL7HZm58T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 <span id="xdx_82C_zkyfIw82Qx2l">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#8220;Kesin&#8221;), in which one of the
company&#8217;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the six months ended June 30, 2024 and 2023 were $<span id="xdx_908_ecustom--MilestonePayment_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_znSrcvphiKB3" title="Milestone structure"><ix:nonFraction name="SCNX:MilestonePayment" contextRef="From2024-01-012024-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--MilestonePayment_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zp6He8NwvfXj" title="Milestone structure"><ix:nonFraction name="SCNX:MilestonePayment" contextRef="From2023-01-012023-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>, respectively.
The Company terminated the agreement with Kesin in March 2024, and recorded a termination fee and related liability of $<span id="xdx_900_ecustom--TerminationFee_c20240101__20240630_z8PwfQfjD2Td" title="Termination fee"><ix:nonFraction name="SCNX:TerminationFee" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></span> as
of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#8220;Saptalis&#8221;) , in which one of the Company&#8217;s Director
is the President and CEO. Lease payments made during the six months ended June 30, 2024 and 2023 are $<span id="xdx_904_eus-gaap--VariableLeasePayment_c20240101__20240630_z1I7ORLwhTYe" title="Lease payments"><ix:nonFraction name="us-gaap:VariableLeasePayment" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,440</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--VariableLeasePayment_c20230101__20230630_zDTUEMVBCA18" title="Lease payments"><ix:nonFraction name="us-gaap:VariableLeasePayment" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively. The
Company has also engaged Saptalis to provide development services and conduct testing and studies for the products under development
by the Company. Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the
Statement of Comprehensive Loss for the six months ended June 30, 2024 and 2023 amounted to $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zj9dkLD2PVJ" title="Research and Development Expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,539</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zqloWiXH0DPg" title="Research and Development Expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,027</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, a related party to a director issued a convertible note to the Company for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zRKYPiMMVevh" title="Convertible note"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-06-30_srt_DirectorMember_custom_ScientureIncMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, officers of the company provided a short term promissory note to the Company for $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYxtGbxPrMO2" title="Short term"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-07-31_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,000</ix:nonFraction></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000517" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ziA8hWcvFLsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Schedule of Relatives or Related Parties to Directors Purchased Securities</span></p>

</ix:nonNumeric><p id="xdx_8A1_zblR3hLN5wsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000519" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuFJPBgZRfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 <span id="xdx_82B_zw2CHRnZrIth">Scienture Inc. 2020 Stock Option and Grant Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NSOs&#8221;).
ISOs may be granted only to the Company&#8217;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#8217;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than <span id="xdx_908_ecustom--StockOptionAndGrantPlanHaveContractualTerm_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zM5yXWy7txMk" title="Stock Option and Grant Plan have a contractual term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000521" name="SCNX:StockOptionAndGrantPlanHaveContractualTerm">10</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000523" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAz4oCnTq9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zEPwYQz0q1kk" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQYBbP7vyD4" title="Outstanding Options, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000525" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9I1eU18C7r6" title="Weighted- Average Exercise Price, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000527" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.90</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQh2YKMpR1f" title="Weighted-Average Remaining Term (Years), Balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000529" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.56</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrX3A081LuFd" title="Outstanding Options, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000531" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,199</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSKNae7R572e" title="Weighted- Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000533" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwqwvTXzfJ0h" title="Outstanding Options, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtnTcNFkyo6" title="Weighted- Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjIJOOjkcmuk" title="Outstanding Options, Cancelled and forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoB1c0zPFsQk" title="Weighted- Average Exercise Price, Cancelled and forfeited" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of June 20, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKAFJJWDVz9" title="Outstanding Options, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">797,199</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqolOmF3c6g" title="Weighted- Average Exercise Price, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000545" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.94</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYZwUH3NUFb" title="Weighted-Average Remaining Term (Years), Balance"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000547" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.21</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSOBa3eFS0O1" title="Outstanding Options, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">499,089</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3aVjlUYnwRe" title="Outstanding Options, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.84</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35p52KHDpka" title="Weighted-Average Remaining Term (Years), Vested and exercisable"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000553" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.62</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zuL98c12J7Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the six months ended June 30, 2024 was $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240101__20240630_zhVrSIq0arV8" title="Weighted-average grant date fair value of options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.76</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000557" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zA9mHBlMjK4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zCRFeMz4FXG9" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240630_zgYROSuwspR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20230630_zOvAbdvSD394" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHT1rvAQ69kl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_z9aWAyPuREK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,837</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,724</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zREz9ZE30fzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Valuation Assumptions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000565" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zUh1LBDNNS4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zqCR334CHUbk" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630_zVuo2lohmhxa" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_z4LkRG3nqdt6" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>%
                                            - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zljFYYmKY537" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zFiDVeQiqpIi" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.1</ix:nonFraction></span>%
                                            - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z097UpEW6FX5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.4</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zvmKUb5HnBM6" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_ztPzr0e0Phxe" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.5</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zChhopV9dZ12" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000581" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.7</ix:nonNumeric></span>
                                            - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zdPjUDSrOtsc" title="Expected term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000583" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.1</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zNjUHg8ibmC6" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000585" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.9</ix:nonNumeric></span>
                                            - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_z3a001C74HX7" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000587" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_z4N0mxuOqB2j" title="Expected dividend"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000589" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zbJfyjIxfY5" title="Expected dividend"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-06-30_custom_ScientureIncMember" id="Fact000591" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 005 -->
</ix:nonNumeric><p id="xdx_8AF_z33Qf1WrClfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000593" name="SCNX:WarrantsTextBlock"><p id="xdx_802_ecustom--WarrantsTextBlock_zs5ChSEdBwgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 <span id="xdx_823_zj9qcNvcwp0c">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, there were <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240630_za8Jnh1Id3k5" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> warrants outstanding and exercisable with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630_zjUzCCAJXFmd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share. The warrants were
granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000599" name="SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock"><p id="xdx_89B_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_zd8wl4CRYuj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Assumptions Used to Estimate Fair Value of Warrants&#160;</span></p>

</ix:nonNumeric><p id="xdx_8A8_zjYeYk9PIra7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000601" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_zpI5X6F2TWMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 <span id="xdx_829_zPgNGc35aJh4">Net Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options to purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZlH0q9KK8Sh" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">799,199</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zTqz0Wh5OdL7" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,000</ix:nonFraction></span> shares of common stock, warrants to purchase <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAGjcOhfypW9" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember_custom_ScientureIncMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOyDZDvZI2Ze" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember_custom_ScientureIncMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> common stock, convertible preferred
stock and convertible notes to purchase <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zssHV9DUz1a2" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,365,669</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zo1dCeTQ1pmh" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,195,911</ix:nonFraction></span> common stock and long-term convertible debt to purchase <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_z1uTG1n0rI04" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zodbNrLFPOve" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,350,000</ix:nonFraction></span>
shares common stock were outstanding at June 30, 2024 and 2023, respectively, that were not included in the computation of diluted weighted
average common shares outstanding because their effect would have been anti-dilutive.</span></p>
<!-- Field: Split-Segment; Name: 006 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000619" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z3FhyxedMUul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 <span id="xdx_828_zKAZ2LWlbJ5d">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#8217;s balance sheets. The ROU assets represent the Company&#8217;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an operating lease for administrative office. The lease has remaining lease term around <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20240630_zJ1RuwwzGLO7" title="Operating lease remaining lease term"><ix:nonNumeric contextRef="AsOf2024-06-30_custom_ScientureIncMember" format="ixt-sec:durwordsen" id="Fact000621" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">three years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000623" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z0rbMW6j7wO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z5eSJ5JVZeMj" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20240101__20240630_zpbNLBX2MlEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20230101__20230630_zB2UTW4TO4O6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zYkQ8sGbfc84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zwsE5EHfvfB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,152</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zR7DkI80V8C" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:OperatingLeaseInterestExpense" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zs9CetL5D4p2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,010</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zH2a7p6aNmIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000637" name="SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zEctMEM8XEdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zVDztYcLInw3" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630_zF5sHwdzuaAl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zVc7zEt5N7Be" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zz2rFE6SIsM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,091</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzXqh_zIwSNLpUL8Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,567</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,404</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzXqh_zi45IHitPcDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,319</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzXqh_zuOQCZv5hxR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">Total Lease Liabilities</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,886</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,297</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zxjGiiZRHSZj" title="Weighted Average Remaining Lease Term (in years)"><ix:nonNumeric contextRef="AsOf2024-06-30_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000651" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.33</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zzrwQa5zgc29" title="Weighted Average Remaining Lease Term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact000653" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.83</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_zgFK4X2ECag8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-06-30_custom_ScientureIncMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zyzWLiMzKH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_ScientureIncMember" escape="true" id="Fact000658" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zpQgvDIgTZag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 <span id="xdx_824_zCnmZ4TY9Ny6">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, the executives of the Company issued a short-term loan to Company for an aggregate amount of $<span id="xdx_90D_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTedmth05S9" title="Short term borrowings"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-07-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, all of the unvested options per the Company&#8217;s Stock Option and Grant Plan became vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, Scienture, Inc. (the &#8220;Company&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#8220;Merger Sub I&#8221;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated subsequent events through August 15, 2024, the date the financial statements were available to be issued.</span></p>
<!-- Field: Split-Segment; Name: 007 -->
</ix:nonNumeric><p id="xdx_810_zBcb5KtvCkvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bss_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of Scienture Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Scienture Inc. (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related
statements of operations and comprehensive loss, statements of stockholders&#8217; deficit and statements of cash flows, and the related
notes collectively referred to as the &#8220;financial statements&#8221; for each of the two years in the period ended December 31, 2023.
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023,
in conformity with Generally Accepted Accounting Principles of United States of America. We were appointed as the independent auditors
of Scienture Inc. since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Matters
related to Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
3 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs, it may be required to
reduce the scope of its planned development. The company has suffered losses from operations and has a net capital deficiency that raise
substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described
in Note 3 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of
this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Responsibilities
of the Management for the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. In preparing the financial statements, management is required
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s
ability to continue as a going concern for one year after the date that the financial statements are available to be issued. Our responsibility
is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect
to the Company in accordance with the applicable rules and regulations of PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company
is not required to have, nor we have engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">relate
    to accounts or disclosures that are material to the financial statements and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(2)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">involved
    our especially challenging, subjective, or complex judgments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditors since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>/s/
Suri &amp; Co., Chartered Accountants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
July 31,2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Place:
Chennai, India</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_04E_c20230101__20231231_zRhcI2xdtwPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bss_002"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p id="xdx_11D_hsrt--ConsolidatedEntitiesAxis__custom--ScientureIncMember_zHPutIZZl0X1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zgnr4Vus5W7" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zUeaHyc1KK29" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_z37CX51pDuQl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zg0kmJ4Jbnm5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrentAbstract_i01B_zy64tWAZNDL" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashEquivalentsAtCarryingValue_i02I_maACzkt2_zeOJBqpQ2QZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzkt2_zYm0a34RAdXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,414</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherReceivablesNetCurrent_i02I_maACzkt2_zmHPENVYZOAe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtACzkt2_maAzrRv_zKAFnZwcEQZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Current Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190,777</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,298</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzrRv_zL9whTxoYcNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease, right of use asset</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,091</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzrRv_zIhUIAATPQxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,868</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,298</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z9BzJKIG8US8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Liabilities and Stockholders&#8217; Deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zDgsC8JhNf2c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLCzMVt_znJOoWH9ZpK5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,676</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maLCzMVt_zn3RqKyo0j6l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,494</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLCzMVt_zSWWvKfA1RHe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,950,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzMVt_zO3eVwEtcEQ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,404</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzMVt_maLzz3Z_zwagLSGc5XNj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Current Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,126,010</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000705" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,427,170</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ConvertibleDebtNoncurrent_i02I_maLzz3Z_zZcEWf71odna" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible debt, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0708">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzz3Z_z9bHB53CMRjk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability, non current</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtLzz3Z_maLASEzC0V_maLASEzads_zpGpeAfdEnYa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,794,020</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,427,170</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzads_zu871U6FZZmd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Refer Note 8)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0717">-</span></span>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_i01B_zqReAcApUrH2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&#8217; Deficit:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i02I_maSEzHwe_zDHRjcJ8t5La" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zxdl9pMsN2R9" title="Preferred  stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zpCUDNkGgAv2" title="Preferred  stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000725" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000727" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zdBMmt1cTK9d" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zz52MM2fyHL7" title="Preferred stock, shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20231231_ztzoo5u0loXl" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231_zDe7vSpPZCf6" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20221231_zmkboX8SbXv3" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231_zOxfo7VIXRWg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span> authorized,
    issued and outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_maSEzHwe_zg8wrvHvjhBc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zsNBUSJKW5el" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zhGDFbK6eiR1" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zresSdKYyuti" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zE1FAKdf97Jf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized,
    <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20231231_zTgUhsoIa3nj" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zbQpIVeaQLX2" title="Common stock, shares outstanding"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20221231_ze0ZQZjTJ5We" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zoPZvzRvFBpb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_i02I_maSEzHwe_ztRTZU5q9MFa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,849,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,355</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzHwe_z2vHMYmBzryf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000763" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,388,956</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000764" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,147,967</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_mtSEzHwe_maLASEzads_zSYFKyUG1xA3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stockholders&#8217; deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000766" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000767" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,821,872</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzads_ze7bjSJYUVz2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Liabilities and Stockholders&#8217; Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,868</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,298</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_zaPojmGebptd" summary="xdx: Statement - Statements of Operations And Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20231231_z97umb0mbhR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zKpmjx636tt8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzJoh_zOBaVl7Q4689" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_ztPcgMtVJiwh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEztjS_zGfJpCPju5L6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,029,812</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,061,493</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEztjS_z7bF5f41zCm8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">719,398</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">880,110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtOEztjS_msOILzJoh_zj5nI9ulNSS7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total operating expenses</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,749,210</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,941,603</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtOILzJoh_maNILzsjy_zBAtd2WR388a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from Operations</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000787" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,949,210</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,641,603</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_z1aNEb1q1zei" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DividendIncome_i01_maNIEz9ST_maNIEz7Ah_zmRE4IHM0bS4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:DividendIncome" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,401</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestIncomeExpenseNonoperatingNet_i01_maNIEz9ST_maNIEz7Ah_zd1gN2aSSHba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income (expense), net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000796" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">312,577</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000797" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,351</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--MiscellaneousIncome_i01_maNIEz9ST_maNIEz7Ah_zeEqY0zAadJ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Miscellaneous income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:MiscellaneousIncome" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,397</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:MiscellaneousIncome" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,574</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_maNILzsjy_mtNIEz7Ah_zA8kMky7BAyd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total other expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000802" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">291,779</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000803" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,777</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtNILzsjy_zMEdO4P4ekW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net Loss</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000805" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zFiRTQcIRGM3" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zAPM7sY2zgF3" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000808" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.45</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zFMzRb6zGZF" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zWtO5PxICqqj" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.74</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average shares used to compute net loss per share
    - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zk5yoXaSrsXe" title="Weighted average shares used to compute net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zaKwIDhPMRW8" title="Weighted average shares used to compute net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zPj7MlNoWhea" title="Weighted average shares used to compute net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zo0mldhl4P85" title="Weighted average shares used to compute net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zIEFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 008 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Stockholders&#8217; Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_zK6fTVRnZRd3" summary="xdx: Statement - Statements of Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zrxKP0h3u3Sl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQ7ByICtemRa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zhhnGEOufb6g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zmaG2lEA0eml" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--StockholdersDeficitMember_zbI5TaoFoPQj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Preferred
    Stock</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Common
    Stock</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Additional</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Paid-In</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><b>Accumulated</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Total</b></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Stockholders&#8217;</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif"><b>&#160;</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zZh0yEbwy2t2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 23%">Balance at December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zlC8gpDR73J9" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000830" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zraFouBEufO8" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,850,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,111,783</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,439,589</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,919</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zJQmqOSsXTOc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zItjzLJLmXph" title="Common stock issued for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_z97tZqKvSNvb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_z1g5xfn7ayNi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000851" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_430_c20230101__20231231_eus-gaap--StockholdersEquity_iS_ztgFf8WWSaq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOJauvy6LBl7" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCs5FiGyYDg7" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,355</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000857" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,147,967</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,821,872</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zwNvNfJbtY01" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance </td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zoiLmC7e8Dpk" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9v00F2YQmH1" title="Balance, shares" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,355</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000867" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,147,967</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000868" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,821,872</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zSsawrMi29aj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued in connection with long-term convertible
    debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,260</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,260</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zzjxKPurquUd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_z6T8I7TimqK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000889" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000890" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_434_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zNAyT96pRyUj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zTwB3MxNfIR7" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmILviITVbN6" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000.00</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,849,064</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000895" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,388,956</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_436_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zEwmDRa9qRC8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance </td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmMeG9bNQ3Vk" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember" id="Fact000902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3DzCTHiGTX" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000.00</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,849,064</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,388,956</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Scienture
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zj3EBwrd5aYd" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_z7XjlTISxnd1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zPhEQ4Op5DRk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z5wtaENMEmB3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maNCPBUzCX9_zW0ZtfS6Mvpe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000915" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000916" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zhal7I0frSQi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile net loss to net cash used in operating
    activities:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzCX9_zpe8KPK5spxl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzCX9_zNe2uv0OxuKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maNCPBUzCX9_zsbffxJmkHpe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zJbGAdrnjczi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Changes in operating assets and liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzCX9_zDkfLYkl3gNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">286,501</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,394</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzCX9_ztunIebaP2m2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,704</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzCX9_zwjDLcZLEMkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating lease liability, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzCX9_z18kuaDkxQdh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,414</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzCX9_maCCERCzV5E_z4q9cr7MEibf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,196,155</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,352,693</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zOmXobJVNFn7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzYnR_zNThC683YuAe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from the issuance of convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_i01_maNCPBUzYnR_zSrt2Q0A2tef" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from the issuance of long-term convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzYnR_maCCERCzV5E_z8CuBEqnLVQ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in financing activities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,715,220</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzV5E_zj31t3TzXJba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,065</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,502,693</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zcDboYIBthYj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents at beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31_custom_ScientureIncMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,107,506</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zPtNRlGX62B5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents at end of year</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zpaGUTzGe3mh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_zvYEDItzlsxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0972">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zUoFOjzs5NP9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of non-cash financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantsIssuedInConnectionWithLongtermConvertibleDebt_i01_z1WF9uiSlBol" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrants issued in connection with long-term convertible
    debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:WarrantsIssuedInConnectionWithLongtermConvertibleDebt" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact000978" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,260</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_047_c20230101__20231231_z61nQmnvwwG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000981" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zXzEGacBJfP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Note
1 <span id="xdx_82E_zO4r7Wp0d86l">Organization Overview and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (&#8220;the Company&#8221;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements for the period ending December 31, 2023 and 2022 have been prepared in accordance with accounting principles
generally accepted in the United States (&#8220;U.S.GAAP&#8221;).</span></p>
<!-- Field: Split-Segment; Name: 009 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000983" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zhOO5ZXcJVxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 <span id="xdx_824_z9tbPbgJ83Fl">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000985" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zDw6Ai1JWhNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z3foTLi5y2t6">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease
    term</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000987" name="SCNX:LiquidityPolicyTextBlock"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_zOvPcfhCQI36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zy4BUgnX5aYh">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000989" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zUDtEgzcnAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zuTRUepB66i4">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000991" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNaP59og6Bre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zDxAsKHKGC07">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_zQFvL72BwS95" title="Number of reportable segment::XDX::1"><span id="xdx_907_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20230101__20231231_zzlYO99If5Lf" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0993"><span style="-sec-ix-hidden: xdx2ixbrl0995">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000997" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJ11pNKLt4j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z2pVeuN5hIU3">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact000999" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zwD0xPUmp2q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z09Lz3B2WS0k">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zjggDz3CdhM3" title="Allowance for doubtful accounts"><span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zPnPWh6lbXf3" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Refer
&#8211; Note 14&#8211; Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001005" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z31KAvzCkY56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z5zx0gMnjcI3">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001007" name="SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock"><p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z2JhbIcHdvOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zd1OqPSy1EC8">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zm95aluQBMk3" title="Revenue recognized"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zYelXpAhKAl7" title="Revenue recognized"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>, respectively,
during the years ended December 31, 2023 and 2022 at the point when the development milestone events occurred. (Refer &#8211; Note 14&#8211;
Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001013" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zpBk8Rxd7OJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXDu1rOp5G12">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Level
    3 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001015" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJrtJLxttz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z1ZC3PGQm9C2">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the years ended December 31, 2023, and 2022, the company
had one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001017" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwCXj4i6zeEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zWKr6Kcp3Zc1">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001019" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIdqihDN0YB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjo7F3n0srO9">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The fair values of stock-based compensations are recognized as compensation expense on a straight-line
basis over the requisite service period in which the awards are expected to vest. The Company estimates the fair value of stock option
awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes model considers several variables and assumptions
in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock,
exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the
expected term. The Company has estimated volatility by reference to the historical volatilities of the Company and that of similar publicly
traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration
to the expected term of the equity-settled award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001021" name="SCNX:WarrantValuationPolicyTextBlock"><p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zeToUOiWtOCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zIq0xJKLreE9">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001023" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zCjnOUHbWpI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z3hwU0J9pJR8">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is incorporated in Delaware and headquartered in New York where the state tax is <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20230101__20231231_z1dGVIh0nh06" title="State income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.70</ix:nonFraction></span>% and <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20220101__20221231_zQnpB8DJfb1" title="State income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.25</ix:nonFraction></span>% respectively. However, due to
losses for the years ended December 31, 2023 and 2022, no provision on state income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Federal
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C Corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners. The company records
income taxes pursuant to the liability method. The Company has a loss before tax of ($<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zaXalyfNxvSa" title="Loss before tax"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001029" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></span>) and ($<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zpYkYtiSAfh" title="Loss before tax"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001031" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,708,378</ix:nonFraction></span>) for years ended December
31, 2023 and 2022 respectively. Therefore, no provision for federal income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001033" name="SCNX:DeferredTaxAssetsAndLiabilitiesPolicyTextBlock"><p id="xdx_847_ecustom--DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_zqIOkbM1Gmn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zAo6Gt6RSIo1">Deferred
Tax Assets and Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial statement and the tax basis of assets and liabilities.
Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company&#8217;s
ability to generate taxable income. Management believes that, at a minimum, it is more likely than not that future taxable income may
not be sufficient to realize the recorded assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a deferred tax asset related to its net operating loss carryforwards, timing difference between written down value
of assets, and unutilized R&amp;D credit, which are expected to reduce future taxable income. The company has assessed the likelihood
of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets may not be realized.
Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its expected realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001035" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the deferred tax assets and related valuation allowance on the Company&#8217;s financial statements is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zGlZeO8SmXN4" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowance</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,173,840</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,491,667</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,635</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,705</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment and operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,229,695</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,548,331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zhfSfKJNG6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001052" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zNuN1XW7SxP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWi4i8AXB54a">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001054" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zC30tXxD2fX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zWcF8MYTuJ24">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements.
The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (ASC 326), which provides guidance on measurement
of credit losses on financial instruments. This ASU adds a current expected credit loss impairment model to U.S.GAAP that is based on
expected losses rather than incurred losses whereby a broader range of reasonable and supportable information is required to be utilized
in order to derive credit loss estimates. The effective date of the new guidance as amended by ASU No. 2019-10 is fiscal years beginning
after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023
the company determined that the update applied to trade receivables, but that there no material impact to the financial statements from
the adoption of ASU 2016-13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No.
2016-2, Leases, to provide guidance for the accounting for leasing transactions. The standard requires the lessee to recognize a lease
liability along with a right-of-use asset for all leases with a term longer than one year. A lessee is permitted to make an accounting
policy election by class of underlying asset to not recognize the lease liability and related right-of-use asset for leases with a term
of one year or less. The provisions of this standard also apply to situations where the Company is the lessor. In March 2019, the FASB
issued ASU 2019-01, &#8220;Lease (842): Codification improvements.&#8221; This updated clarified that entities were exempt from disclosing
the effect of the change on income from continuing operations, net income, and related per-share amounts, if applicable, for interim
periods after the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard was initially effective for annual and interim reporting periods beginning after December 15, 2019. However, in November 2019,
the FASB issued ASU 2019-10, &#8220;Financial Instruments Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates&#8221;, which deferred the effective date of ASU 2016-02 by an additional year. At its April 8, 2020, meeting,
the FASB voted to defer the effective date for ASC 842 another year. As such, the Company is required to adopt the new leases standard
for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company
adopted this new guidance effective January 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001056" name="SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_z7nNPLzwrVpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zujw7gsHWdrk">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>

</ix:nonNumeric><p id="xdx_850_zjgDf1CgbFh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001058" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ziEFDDx0cXUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span id="xdx_82A_zdMta7gfnARl">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a net loss of ($<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zvmxqkOfs1De" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001060" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,240,989</ix:nonFraction></span>) for the year ended December 31,2023 and stockholders&#8217; deficit of ($<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20231231_zXVzdrBmonR7" title="Stockholders deficit"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001062" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,152</ix:nonFraction></span>) as of December
31, 2023. The Company&#8217;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001064" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zNCm8uqMOVk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 <span id="xdx_82C_zkX6sSiSPFs1">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001066" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zGt64svCsyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zBDk2rALlfoa" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zncInLkOg51f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zCOb1TAClbpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zE9DcrJj5NK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndDueFromBanks" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,943</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndDueFromBanks" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zwq44FEW84E" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities (Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,091,935</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zQQGpinOmfaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,878</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,813</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z2yAo3N0APhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market securities were considered a Level 1 financial instrument.</span></p>
<!-- Field: Split-Segment; Name: 010 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001077" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zPnJODd2bSb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 <span id="xdx_822_zCUCyLyL3Ri4">Convertible Notes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231_zQNezyabIvb" title="Convertible notes issued bear interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and certain notes issued prior to 2022 bear an interest at a rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zrKX2zWmVjn3" title="Convertible notes issued bear interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>% per annum.
As of December 31, 2023 and 2022, there were $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_zcPV7uZ5UlVc" title="Debt outstanding principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zRqgJe6P0OG5" title="Debt outstanding principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,950,000</ix:nonFraction></span> in outstanding principal. All such notes have matured on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231_zJBzvxRaRk35" title="Maturity date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001087" name="us-gaap:DebtInstrumentMaturityDateDescription">December
31,2023</ix:nonNumeric></span>. Interest expenses recognized for the years ended December 31, 2023 and 2022 amounted to $<span id="xdx_905_eus-gaap--InterestExpense_c20230101__20231231_zaKb2ySq9qT4" title="Interest expenses"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,423</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--InterestExpense_c20220101__20221231_zd2ER3cvcXuh" title="Interest expenses"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,705</ix:nonFraction></span> respectively. (Refer
&#8211; Note 14&#8211; Subsequent Events &#8211; Short-Term Convertible Notes)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001093" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_znKtDQgX6iid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 <span id="xdx_826_z9iSrcK4bJe3">Long-Term Convertible Debt, net of debt discount</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#8216;NVK&#8221;)
for $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zdKdbMHZJtIi" title="Long term debt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus <span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z63uPOWtJjd" title="Debt prime rate percentage"><ix:nonFraction name="SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span> percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of December 31, 2023, the interest rate was <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zP2DRhKI88J" title="Debt interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.50</ix:nonFraction></span>%. The debt is collateralized by all of the Company&#8217;s
receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof. The principal is entirely
repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing as defined in the Loan
Agreement. Interest expense related to the debt amounted to $<span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2wvzsWEV64a" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,583</ix:nonFraction></span> for the year ended December 31, 2023 and the principal amount is
entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common stock of the Company
at a fully-diluted Company valuation of $<span id="xdx_90E_ecustom--DebtDilutedValuation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zYeOUkAEcixh" title="Debt diluted valuation"><ix:nonFraction name="SCNX:DebtDilutedValuation" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the NVK debt, the Company granted <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zApNldlFqNb2" title="Number of warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> warrants to purchase common stock. The fair value of the warrants was $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zw6wBkBYrpF6" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,260</ix:nonFraction></span>
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the year ended
December 31, 2023, the Company amortized $<span id="xdx_903_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJGwaFucZJS" title="Debt discount interest expense"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,377</ix:nonFraction></span> of the debt discount to interest expense. (Refer &#8211; Note 11&#8211; Warrants)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001111" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zDUVQx5gzkK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z7yY1AXiToTf" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z1y3qGy5kTP5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20221231_z4x8suGki5B2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDz26q_zNPBtZeAKQ3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDz26q_zuIgG5E2buG" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,883</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz26q_zq8bpEhF03c1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible debt, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,117</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zYJCfnsEFDG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001122" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzHcjzc6oJK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding debt are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B1_zl1OwLZPI9l" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z7B3U38IvUe8" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zKUdTbExbrvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zsXMmWheyHy8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z1JkoUkq5Ow8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z9TcDpjMWcN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zdzeMxktg6pk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z6ORxlRme275" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001134" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zUjeuMluJ8q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 <span id="xdx_829_zTJ5EdG9LLy3">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>
<!-- Field: Split-Segment; Name: 011 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001136" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zI8SEr5Urqcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 <span id="xdx_820_zhB6S9qRWi07">Commitment and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001138" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeKlGvgQvELb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 <span id="xdx_820_zNLxZlrX6as2">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#8220;Kesin&#8221;), in which one of the
company&#8217;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the years ended December 31,2023 and 2022 amounted to $<span id="xdx_907_ecustom--MilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zLN4iboufi74" title="Milestone structure"><ix:nonFraction name="SCNX:MilestonePayment" contextRef="From2023-01-012023-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--MilestonePayment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zV3PPzBVMOuj" title="Milestone structure"><ix:nonFraction name="SCNX:MilestonePayment" contextRef="From2022-01-012022-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#8220;Saptalis&#8221;) , in which one of the Company&#8217;s Director
is the President and CEO. Lease payments made during the year ended December 31, 2023 and 2022 are $ <span id="xdx_907_eus-gaap--VariableLeasePayment_c20230101__20231231_zT34zweemnQ2" title="Lease payments"><ix:nonFraction name="us-gaap:VariableLeasePayment" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7200</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--VariableLeasePayment_c20220101__20221231_zw2WkXDhkP5c" title="Lease payments"><ix:nonFraction name="us-gaap:VariableLeasePayment" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> respectively. The company
has also engaged Saptalis to provide development services and conduct testing and studies for the products under development by the Company.
Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the Statement of Comprehensive
Loss for the year ended December 31, 2023 and December 31,2022 amounted to $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_z5GPAw4moWR1" title="Research and Development Expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember" id="Fact001148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,124</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zwRq3Wd8kXG6" title="Research and Development Expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647,566</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001152" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zzU9Pbq43jTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relatives
or related parties to directors purchased securities from the Company on the same terms as unrelated parties as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zBoXafXs0Zrd" style="display: none">Schedule of Relatives or Related
Parties to Directors Purchased Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name of the Related
    Party</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nature of transaction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
                                            during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ended<br/>
                                            December 31</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Balances
    as at <br/> December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zR6kkx46ki05" title="Nature of transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001154" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Issue of Preferred Stock</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zivGRnvleWEj" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zV40BXwTTQU6" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zNDl4oXzZesj" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z1wLxfBRCFc8" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOhisUauXxi2" title="Nature of transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001164" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Issue of Convertible notes</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z6W6IKkBZlE5" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z7OGfBKClH09" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zpYtmDMg5DM9" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z0Aceognm1a5" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zQyYfEK17qp3" title="Nature of transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001174" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Issue of Preferred Stock</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z5BDQxCuCVt2" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zouchw6rWRh5" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_znZTxEUTqbF2" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zoGuiTvg30Hk" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5YiJohKvag5" title="Nature of transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001184" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Issue of Convertible notes</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zEbZL5myDCj3" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOxZS5DRv444" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z2nC6z6G8Aq7" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5rSYyzgbhsl" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Mr. Sandeep Gupta</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_ztVLCAZgv2tl" title="Nature of transaction"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001194" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Issue of Convertible notes</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zKoj3sCeQIcf" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zGceyHaVBx3g" title="Related party Transactions" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zxgpVgY01Fx1" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember" id="Fact001200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zJzlQC2v3Vi4" title="Related party Balances" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231_zQRNccPuZ8Hk" title="Related party Transactions" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_zvvLgQw48Wm2" title="Related party Transactions" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherLiabilities_iI_c20221231_zEeA8I3C5yD3" title="Related party Balances" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-12-31_custom_ScientureIncMember" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,950,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherLiabilities_iI_c20231231_zat80oG25oCd" title="Related party Balances" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,750,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zssJnkBScMA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001212" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zoGdYyjxkLW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 <span id="xdx_825_zQ2GFWOXPWqh">Scienture Inc. 2020 Stock Option and Grant Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NSOs&#8221;).
ISOs may be granted only to the Company&#8217;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#8217;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001214" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhNrbxh7Vzqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zEX7AB5731n2" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF5x1kVqwuDa" title="Outstanding Options, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">560,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVHlBTf7GLX8" title="Weighted- Average Exercise Price, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.83</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc7QdlZQJ6" title="Weighted-Average Remaining Term (Years), Balance"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001220" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.95</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXqqRwitCCTc" title="Outstanding Options, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8MvUFZFumsh" title="Weighted- Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdtQqM0Sdua" title="Outstanding Options, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwVaLBVW3jh" title="Weighted- Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjNTpYy3uVW3" title="Outstanding Options, Cancelled and forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNfp8fCgy9d" title="Weighted- Average Exercise Price, Cancelled and forfeited" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPe12rxIsD85" title="Outstanding Options, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRNV5QtPz1g" title="Weighted- Average Exercise Price, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.90</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztJhWDauLcyh" title="Weighted-Average Remaining Term (Years), Balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001238" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.56</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRoTyGtXL94d" title="Outstanding Options, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">410,065</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7tJg5Iv7kb6" title="Outstanding Options, Vested and exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.84</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ANPWvHvMxl" title="Weighted-Average Remaining Term (Years), Vested and exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001244" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.84</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zXHWXt8CfxK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 are $ <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zqIH4jxa19Jf" title="Weighted-average grant date fair value of options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span> and $ <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zdN2S81axqQ7" title="Weighted-average grant date fair value of options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.52</ix:nonFraction></span> per
share respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001250" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zDwNtRNdfe95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B3_zAAjJGLK9XLc" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zvBe31OrJTE8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_z6yQW4Mm3uI1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6czHCnPZQa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_zZhP0uofZz7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,449</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,087</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zfl0yjTjp1of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Valuation Assumptions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001258" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zF9ofSeWpsqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z5INuepHptRa" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z1JPsxux9Sj1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember" id="Fact001260" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>%
                                            - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zmwIbdNDKs3h" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPozpEI5Z7Yj" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zeCWA87rWms2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zN85UrRSbLZd" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember" id="Fact001268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span>%
                                            - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zZ4Iv5ykoTv9" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.5</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdrIPv15VaOj" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zOhAEVGf5Nl3" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.8</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zM2ArlvlHfid" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.9</ix:nonNumeric></span>
                                            - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zk2fRZ1t86M2" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001278" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z6qQAQxuPRTb" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001280" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.9</ix:nonNumeric></span>
                                            - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zxf2kfBPSH67" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001282" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zPdrvXR87tSe" title="Expected dividend"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6TxcaUKyVrb" title="Expected dividend"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001286" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 012 -->
</ix:nonNumeric><p id="xdx_8AA_z3TAfS65KS5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001288" name="SCNX:WarrantsTextBlock"><p id="xdx_80B_ecustom--WarrantsTextBlock_z2uBaeldUZQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 <span id="xdx_828_zjJYoJPv7vef">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zvrlfNWC7sVe" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> warrants outstanding and exercisable with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zt1f26zAynAe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share. The warrants
were granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001294" name="SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock"><p id="xdx_896_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_z8D6GkXzwMMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the assumptions used to estimate the fair value of the outstanding warrants during the years ended December
31, 2023, and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zVf7q0TpTnJk">Summary
of Assumptions Used to Estimate Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVLmQ77K6JZ" title="Expected dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdsZmmyblyr8" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPewogR85Im6" title="Weighted average expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember" id="Fact001300" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70.52</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY5NOV8FZNWj" title="Weighted average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSwwDS58AMN8" title="Measurement Input, warrant"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.50</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1enIGVpaRie" title="Measurement Input, warrant"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2zkRQoUspJi" title="Expected life of warrants::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1308">5</span></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUByi9mQWN1l" title="Expected life of warrants"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zNIrjYAglo44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001312" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zKG8iYccpH9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 <span id="xdx_828_zWrTvHXZAjZc">Net Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options to purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdcN6ie87LY9" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214078" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">655,000</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyUmj8r75sQ2" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214093" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">560,000</ix:nonFraction></span> common stock, warrants to purchase <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2tUia3qffhb" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_ScientureIncMember" id="Fact001318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,014</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zF43kSNamNv8" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_ScientureIncMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> common stock, convertible preferred stock and
convertible notes to purchase <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zcC7Yl3prK5i" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember" id="Fact001322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,365,669</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zzZf2q1YOI3c" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,195,911</ix:nonFraction></span> common stock and long-term convertible debt to purchase <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zKA0AO7PqBo7" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,529,683</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zBhuCFgfuxv7" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> common
stock were outstanding at December 31, 2023 and 2022, respectively, that were not included in the computation of diluted weighted average
common shares outstanding because their effect would have been anti-dilutive.</span></p>
<!-- Field: Split-Segment; Name: 013 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001330" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zsFEWLecBRa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 <span id="xdx_82B_z0rhTWXvyYeg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#8217;s balance sheets. The ROU assets represent the Company&#8217;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an operating lease for administrative office. The lease has remaining lease term around <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20231231_zaj2Rk7nhTv9" title="Operating lease remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_ScientureIncMember" format="ixt-sec:durwordsen" id="Fact001332" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">three years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001334" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zToErlEKqkZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPaeAyH1ayQb" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_494_20230101__20231231_z2MQND7Kh3e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zh88lqTPybte" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zai3HCkJQOXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zQtTHkBhxP81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,025</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zXZf6aH4AZFl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="SCNX:OperatingLeaseInterestExpense" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,380</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zN8A8EDYU3o2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,021</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2022-01-012022-12-31_custom_ScientureIncMember" id="Fact001346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,677</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zmkUbHMUpZF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001348" name="SCNX:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zBbIItIxlkge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zWFwA36huf6h" style="display: none">Schedule
of Supplemental Cash Flow Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_498_20230101__20231231_zfYsSYsmUmIj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20220101__20221231_zHgs7DhqDWyd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwWHbpwCpoif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for accounts included in the measurements of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_zmn9GUTze486" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating cash flows for Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zjPhnh0I6vf6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right of Use Assets obtained in exchange for new Lease
    Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" id="Fact001356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zj1Jbx3tg6Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001359" name="SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zh5jqRu4f5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zJ8qcezPhf3a" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20231231_zC7qbWjklbBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20221231_zDvlWpkIDcTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zpGFtCgLs6fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,091</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz1rv_zdnfwdzZem13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,404</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz1rv_zYQpA1BfkORc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz1rv_zNVHShUkQBj5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Lease Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,297</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zg4JFaGrPaUj" title="Weighted Average Remaining Lease Term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_ScientureIncMember" format="ixt-sec:duryear" id="Fact001373" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.83</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_znoFu0feokYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zshZMNbRKP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001378" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI93dHWMlht4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities were as follows at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zNjlhPOh32xc" style="display: none">Schedule
of Maturities Of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zC57GLbl5BQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzwiu_zn2eppBoQPoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 82%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzwiu_zzKDdFoEHi0d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,887</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzwiu_zs02qORnNKo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,823</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzwiu_zuCDIapBPvOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,727</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zuEJwBYqRJCk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,430</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z4BMHHSpcT69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31_custom_ScientureIncMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,297</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zQwb8xjZk8W" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ScientureIncMember" escape="true" id="Fact001392" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zp5idgqWE7n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 <span><span><span id="xdx_826_z5viaF1ESI81">Subsequent Events</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-Term
Convertible Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the short-term convertible notes matured during the period of December 2023. The Company has not paid the amounts due including the principal
and the accrued interest. However, in March 2024, the Company had converted the outstanding principal of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLFnovpPvqEi" title="Stock issued during period value conversion of convertible securities"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,665,220</ix:nonFraction></span> and the accrued interest
till the date of conversion amounting to $<span id="xdx_90E_eus-gaap--InterestReceivable_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmimkFfdZ56f" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,233</ix:nonFraction></span> into an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8kl19zbfXIl" title="Stock issued during period shares conversion of convertible securities"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">965,568</ix:nonFraction></span> preferred stock of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, Scienture, Inc. (the &#8220;Company&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#8220;Merger Sub I&#8221;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
of Exclusive License and Commercial Agreement</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (Scienture) and Kesin had entered into two exclusive license commercial agreements where Scienture had granted Kesin the rights
to commercialize the products. In March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall
pay Kesin a total gross amount of $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfVQpz2Lc7J5" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></span> upon commercialization of product via a royalty arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement also requires that if the full $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfph3xQ4yVKl" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,285,000</ix:nonFraction></span> has not been repaid within two years of the early of i) commercial launch or ii)
120 days from FDA approval, then interest will accrue prospectively at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUcEYMBSshb3" title="Debt instrument interest rate stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% annually on unpaid balance. As of the date of issue
of financial statements, the entire amount is outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated subsequent events through July 31, 2024, the date the financial statements were available to be issued.</span></p>

</ix:nonNumeric><p id="xdx_81C_z4gOhiNlA2Oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sl_001"></span>Scienture
Holdings, Inc. (FKA TRxADE HEALTH, Inc.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Pro Forma Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following unaudited pro forma combined financial information presents the unaudited pro forma combined balance sheet and statement of
operations based upon the combined historical financial statements of the Scienture Holdings and Scienture LLC after giving effect to
the acquisition of Scienture LLC by Scienture Holdings (the &#8220;Transaction&#8221;) and the adjustments described in the accompanying
notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma combined balance sheets of the Scienture Holdings and Scienture LLC as of June 30, 2024, have been prepared to reflect
the effects of the Transaction as if it occurred on June 30, 2024. The unaudited pro forma combined statements of operations for Scienture
Holdings and Scienture LLC for the six months ended June 30, 2024, combine the historical results and operations of the Scienture Holdings
and Scienture LLC giving effect to the Transaction as if it occurred on January 1, 2024. The unaudited pro forma combined statements
of operations for Scienture Holdings and Scienture LLC for the year ended December 31, 2023, combine the historical results and operations
of the Scienture Holdings and Scienture LLC giving effect to the Transaction as if it occurred on January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma combined financial information should be read in conjunction with the audited and unaudited historical financial
statements of Scienture Holdings and Scienture LLC and the notes thereto. Additional information about the basis of presentation of this
information is provided in Note 2 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma combined financial information was prepared in accordance with Article 11 of Regulation S-X. The unaudited pro forma
adjustments reflecting the Transaction have been prepared in accordance with business combination accounting guidance as provided in
<i>Accounting Standards Codification Topic 805, Business Combinations and</i> reflect the preliminary allocation of the purchase price
to the acquired assets and liabilities based upon the preliminary estimate of fair values, using the assumptions set forth in the notes
to the unaudited pro forma combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma combined financial information is provided for informational purposes only and is not necessarily indicative of the
operating results or financial position that would have occurred if the transaction had been completed as of the dates set forth above,
nor is it indicative of the future results or financial position of the combined company. In connection with the pro forma financial
information, the Company allocated the purchase price using its best estimates of fair value. Accordingly, the pro forma acquisition
price adjustments are preliminary and subject to further adjustments as additional information becomes available and as additional analyses
are performed. The unaudited pro forma combined financial information also does not give effect to the potential impact of current financial
conditions, any anticipated synergies, operating efficiencies or cost savings that may result from the transaction or any integration
costs. Furthermore, the unaudited pro forma combined statements of operations do not include certain nonrecurring charges and the related
tax effects which result directly from the transaction as described in the notes to the unaudited pro forma combined financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sl_002"></span>Unaudited
Proforma Combined Balance Sheet as of June 30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Scienture</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Scienture</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>Pro Forma</b></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>Pro Forma</b></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Holdings</b></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>LLC</b></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Adjustments</b></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Combined</b></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 36%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,719,993</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">114,210</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,834,203</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,091</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">797,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">797,383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes receivable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,230,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,231,282</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,444</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current assets of discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,297</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,297</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,144,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,695</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,259,139</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,039</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,234,860</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,234,860</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,400,000</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,400,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">175,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61,579</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">237,129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,848,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">176,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83,634,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,659,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">726,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">884,581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,610,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,198,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,699,276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,441</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lease liability - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,608</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,567</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631,974</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current liabilities of discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,902,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,105,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,008,059</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term convertible notes, net of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,734,661</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,734,661</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,315</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Development agreement liability</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,285,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,063,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,164,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,228,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity (deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(337</td><td style="text-align: left">)(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(500</td><td style="text-align: left">)(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,290,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,835,257</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,646,113</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,936,428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,835,257</td><td style="text-align: left">)(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26,504,881</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,824,770</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,824,770</td><td style="text-align: left">(a)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26,504,881</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,785,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,988,676</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83,634,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90,431,632</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,848,533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">176,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83,634,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,659,667</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To record the purchase price allocation of the pro forma acquisition, including the recognition of goodwill and intangible assets, purchase
price consideration by the Scienture Holdings, and elimination of Scienture LLC&#8217;s equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sl_003"></span>Unaudited
Proforma Combined Statement of Operations for the Six Months Ended June 30, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Scienture</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><b>Scienture<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></b></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Pro Forma</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Pro Forma</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holdings</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">LLC</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustments</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Combined</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,699</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,699</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of sales</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(703</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(703</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wage and salary expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">534,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">534,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688,689</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688,689</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting and legal expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">510,755</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">510,755</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Technology expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,289</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138,289</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520,947</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,115,582</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,893</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,529,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Termination fee</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,285,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,285,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,987,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,219,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,207,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,988,662</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,219,840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,208,503</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-operating income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(895,021</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(895,021</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,883</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(374,968</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(374,968</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(103,464</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(227,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(331,369</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total non-operating income (expense)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,269,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(215,974</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,485,475</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,258,163</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,435,814</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,693,977</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income on discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,670,294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,670,294</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income/(loss)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,412,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,435,814</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,976,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss per common share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6.75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.37</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6.75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8.37</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income per common share from discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income/(loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.58</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,224,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,515,892</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,454,558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,746,113</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sl_004"></span>Unaudited
Proforma Combined Statement of Operations for the Year Ended December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Scienture</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Scienture</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Pro Forma</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Pro Forma</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holdings</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">LLC</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustments</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Combined</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,272,214</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">800,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,072,214</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of sales</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,673,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,673,957</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,598,257</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,398,257</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wage and salary expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,698,178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,698,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,466,567</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,466,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting and legal expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,534,377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,534,377</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Technology expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376,908</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,029,812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,029,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,785,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">719,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,505,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,861,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,749,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,610,873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,263,406</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,949,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,212,616</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-operating income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(148,420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(148,420</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest and other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,539</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,129,115</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,129,115</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,198,346</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(312,577</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,510,923</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total non-operating income (expense)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,457,140</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(291,779</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,748,919</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,720,546</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,240,989</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,961,535</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss on discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,123,028</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,123,028</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,843,574</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,240,989</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20,084,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per common share from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(17.96</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(15.12</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5.76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5.97</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss per common share from discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5.40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3.91</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.73</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.54</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(23.35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19.03</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7.49</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7.51</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">764,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,055,613</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,381,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,672,998</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sl_005"></span>Note
1 &#8211; Description of Transaction and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
of Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transaction occurred pursuant to an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), which was entered into and closed
on July 25, 2024, by and among the Scienture Holdings, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of
the Company (&#8220;Merger Sub I&#8221;), MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of
the Company (&#8220;Merger Sub II&#8221;), and Scienture LLC. Pursuant to the Merger Agreement, on July 25, 2024, (i) Merger Sub I merged
with and into Scienture (the &#8220;First Merger&#8221;), with Scienture LLC continuing as the surviving entity and a wholly owned subsidiary
of the Company, and (ii) Scienture LLC merged with and into Merger Sub II (the &#8220;Second Merger&#8221; and, together with the First
Merger, the &#8220;Mergers&#8221;), with Merger Sub II continuing as the surviving entity and Merger Sub II changed its name to &#8220;Scienture,
LLC&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for the Transaction, at the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the shares of
Scienture Holdings common stock issued and outstanding immediately prior to the First Effective Time were converted into the right
to receive, in the aggregate, (i) 291,536 shares of Scienture Holdings&#8217; common stock, par value $0.00001 per share
representing 19.99% of the number of shares of Scienture Holdings&#8217; common stock issued and outstanding immediately prior to
the First Effective Time, and (ii) 6,826,713 shares of the Series X Preferred Stock, each share of which is convertible into one
share of Scienture Holdings&#8217; common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
historical financial information has been adjusted to give pro forma effect to events that are (i) directly attributable to the transaction,
(ii) factually supportable, and (iii) with respect to the unaudited proforma combined balance sheets and unaudited pro forma combined
statements of operations, expected to have a continuing impact on the combined results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transaction was accounted for as a business acquisition wherein Scienture LLC is the accounting acquiree and Scienture Holdings is the
accounting acquirer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Consideration Transferred</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Holdings issued 291,536 shares of its common stock and 6,826,713 shares of Series X Preferred Stock in connection with the Transaction.
The total fair value of the initial purchase price consideration associated with the Transaction was determined as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Common stock issued</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,221,245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Preferred stock issued</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,424,939</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total purchase price</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,646,184</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the preliminary allocation of the purchase price for Scienture LLC to the acquired net identifiable assets and
pro forma goodwill:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Assets acquired</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">176,273</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,234,860</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,400,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Liabilities assumed</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,164,950</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,646,184</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Holdings recorded $7,234,860 in pro forma goodwill representing the remaining excess purchase price of the fair value of net assets acquired
and liabilities assumed. The pro forma intangible assets acquired consist of developed technology and the related intellectual property
and of the Company&#8217;s products. The Company is currently assessing whether the assets are indefinite-lived such as in-process research
and development assets, or whether they will begin amortization upon commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price allocation of intangible assets was evaluated under ASC 805. The identified intangible assets were determined to be product technologies, and were valued accordingly by each
product candidate:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: justify">Product Candidate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">SCN-102</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">23,600,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">SCN-104</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">SCN-106</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">SCN-107</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,800,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">76,400,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the product technologies was determined by the Income Approach: Multi-Period Excess Earnings Methods (&#8220;MPEEM&#8221;).
The MPEEM measures economic benefits by calculating the cash flows attributable to an asset after deducting appropriate returns for contributory
assets used by the business in generating the asset&#8217;s revenue and earnings. The MPEEM utilized revenue and cash flow projections
through 2030 based on each product candidate&#8217;s phase of development.. Key assumptions include a 2% long-term revenue growth rate
and 3% contributory asset charge rate. The Company discounted the expected future cash flows at a 53.0% rate of return, equal to the
WACC plus 10%, to reflect the risk of the cash flows related to the product technologies. The Company then summed the present values
of the estimated future cash flows and included an amortization tax benefit to the value indication of each of the product technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 131; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b3_001.jpg
<TEXT>
begin 644 form424b3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ 2\# 2(  A$! Q$!_\0
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M&IX+T6+[-X3L]=UC0K3[/KJ0C7AJMM'807WV^2^D\V[\P30FU<VZ_P!,0&
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MT>ZEDN](>].F7+F>U?'X/?\ !2[_ (*G?$S3/B;XG_9S_9BUZX\'6G@[4O\
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M,5A\.U&*;O=I)-_%N^JO\_,5&<GB\3%R;C&,&DWHGS6T[72UL?CE_P %2_\
M@I]\0/AS\0-9_9J_9PUQ/"FK^&;:UB^*?Q1LHK:\UW3]7U"SBO8O!?@LW,5W
M9Z7>:?875K<:_KK6\VHP7MS#I6EK9W%K>7+_ )K6_P"SU_P58U/1(_B_#HO[
M55S;7-JNO0:J?B5X@C\73VLD7VI-1B\+/XNC\3N9(66>&V&D+=O&5\NT)(0^
M/>(_'OAKPQ^WYXM^)_Q3TF_\7>%?"_[6/BWQ?XQT:QAM;O4-<TSP[\1M4O$L
M;:VOKBUL[MPUC8HMK=75O!)#!Y#2H"#7[Z?\/WOV6N3_ ,*Q^/.<]1X?\&;N
M>._C7C@>_3&>@KI<9T84XT:,*MUS3DU=\VFE]=[Z+9:=;G%S0Q%6K+$8F=)1
MFXTJ<9N*26G,[:-+2U]VVF]CYH_X)G_\%3/B9K?Q+\,_LY_M.>()?%UKXRO6
M\.?#[XG:U;Q6?BS2/%Q:1+'PCXXEBAMEUFWUJYCETO3M8O+6'6M/ULV^GZM+
M=Q72W%E_2?/+%!#+-/+'#!#&\LTTKK'%%%&I>2661RJ1QQJ"[N[*JJI)( -?
MP<_'KXL>"OBC^V!XC^-?PBT76O!GACQ?\6O!WC70M-UBWLM/UG3M;;4/#MQK
M5_/;Z7=WME:37_B6"_U95MKR;_C[$CN)7<#^RS]M77=3\,_LB?M)ZWH\[6FI
MV/P6^(1M+E"RR6\MQX;O[5IHG4ADFC2X=X9%8-'*$=2"H-88FE%3IN$?9NI%
M<T>TKI/\^FFESJP=>3IUE*?M%0<N6=W>4$I-7;N_LZ-ZV>O<_G3_ &RO^"IO
MQ_\ V@/BA??"#]E'6?$_@[X<CQ#)X0\+W/PZM[E_B?\ &#4TN9+!=0LM2L[>
M;6=(T75;E93H6B^'39W]UII34-6ORLXM+/YT\0_!;_@J?\#=$N/C#K%M^T]X
M4TO2(6U?5?$EA\2=4\07FBVD8$TVH^(-&TWQ5K=Y!8VZ@R7[ZCI4]E;Q!S?J
MD E:OH+_ ((4^#O#^N?M4>.M>U/3X;W4O ?P3NK[PI+*B,=(U#7?$NBZ!?7]
MKN!\N[;16N=.29<&.VOKR-3B=@?ZSIK>&YAEM[B&*:WGB>&>"5$EAGAD5DEA
MFCD5DEAD1F22-U*NK,K#!.;J58X:?LH4X2BE'G<DKROJ];-W\W^",J-&6,@\
M1.M5C*4IJFH2<8P49:>ZK)ZV6EKI7O=GX>?\$M?^"F7B?]HS67_9^^/-QIMU
M\5K;1KK6_ WCRPL[;3(?B-I.D1I)K&EZSIMFL=C:^,-*LW&IK=:9!;Z?KNDP
MW=Q]DL[VPN#>^P_\%7Q^V6W@+X0C]D$_%=KL^,M:/Q%'P?8)XD:R.BP#PQ]N
M:V9-4713?_VA]H%DPMC="R_M ,H@%?S^_!#3K;X:_P#!4WP7X=\'(VCZ1X:_
M;+U;PAHUI Q5;3PU/XXUGP[)I*E?^77^Q;N?31'T^S%4Q@5_;2?\!GOU''K]
M?ZUGB(0HU:<Z<4XRC&?(UHGUNM=-;K=+YLVPTIXBA4I5)R4HR=/VD7RSLMFG
MH[Z/U6^Y_GMZ(/C$?C+9_P#"._\ "=_\+^'Q!N!I_P#9AOO^%E#XHC5;G[6;
M=E/]I?\ "6'6/M@N&)\_[6;@R'&XC]R/V X_^"I:_M6?#?\ X7>/VFO^%0F+
MQ0/'X^+<UV_@XZ6/#FH?8"ZZR[@:N->_LO\ LHZ<%OQ() #]D-SGX*^%&3_P
M5N\/.203^V]XH!(/WL^.?$8.?KSG]>M?VHX]\\YYY_ >F/Y_E6N*K6Y4J<)<
M\$^:3=XWLFHW3V;;Z;)'/@J'-*I/VM5>RK<JC&32G97;EKK?JK;.Q^"7_!;/
M]H#XW?!B3]G;2?A%\4O&7PSM?$__  L:^\1OX*U5M#O=8FT6/PG;Z7'?:C;)
M]M>TLUU2_>.SCFCMWGF$\T<KPPF/]&_^"=WC_P :?%+]BWX ^/?B'XBU#Q9X
MSU[PI?MKGB/56B?4]7FTWQ1KVC6UWJ$L,<*7%Z=/T^U2XN3&LMU*C7$Y>:21
MF_(;_@O]_P A?]EO_KS^+/\ Z,\"5^I7_!+#(_8 _9K]?^$3U[\_^$Z\5=?Z
MUSU+?5J+2BG[5IR6DGY-]4NW^1TTY2>.Q$')N*IQ:BVVEK'5)Z+U7=ZF)_P5
M8^*GQ#^#O[&?CGQ?\+_%NK>!O%DGB7P'H4/B;094MM:L-.UKQ186VIKIMZT<
MCV%S=6JM:F\MPMS%#++Y$D4C"1?FK_@BG\<_C'\:_AI\<V^+OQ(\5?$JY\)_
M$7P]9^']0\8:C_:^J:99:OX5BO;^RBU.9%NYK)[N);F&WN)9DMG>46^Q)&2O
M5?\ @M$,_L(>-,?]#[\,/T\767'Y\?\ UJ^5?^" >?\ A6G[2_;_ (N;X,]\
M'_A"A5Q2^J3ERQO[5+FLN9;:<VZ02FUCZ<%)\OL92<;OE>DM;7M?3M=61]^?
M\%%OVWK/]BOX3:;J^C:38^)?BM\0;Z]T'X;>']3>1=(AGT^WBN=:\4^(!;R1
M74NA^'8+FT\RRM9(;C5-2OM/TY)[:*:XNH/YN="_:2_X*G?M+ZEK?B;X<>.O
MVE/&D-I>/%J:?!_2;O1/!VAW+J)?[,@A\,:;I^DVTD<+*RV<]W=ZBD15Y';>
M'?ZS_P""]]Y=/\??@18M,[6=K\&]>O;>V)_=17=]XSGANYU3IYD\>G622-CE
M;=!V%?N+_P $YO#>B>%_V(OV:[#0K"#3[?4/A;X?\1WX@C1'O=<\21OK6M:G
M=2*JM<7=_J5Y<332R[G*E(]VQ%45%PHX>%3V<9U*C=^>UE:[LFT]%;[*5W>_
M8SDJF)Q-2DJLZ=.BE=0=I2;4>MUWU;O;9+6YC_LU_$;XB_!_]A+PE\4?VQ[_
M ,1:=XY\!_#WQ-XE^)UYXM6VD\8#3]+UG6KC1(-:BMBD4_B>[\.KHMF+9W%Y
M<ZE/%!>,;Z2<U_-]\3?VV/VZ_P!OCXJW'@_X/7/Q&T32=1^VW7A?X,_!S4;O
M16TWPY:2J%U/QQXETZXTZ[U.ZBCEMO[7U?6-7L?#]O>S"UTRR@5H%E_>O_@L
M;J-[IO[!7Q/BLYGB35O$?PVTF_$9*_:-/N?'.BRW$$F,;HY6@CWH20P!!X)K
M\,/^"97[<?P0_8IA^+]_\2_ _CKQ)XH^(%UX5MM%U?P5IF@Z@UCX;T&WU*2Z
MTN\EU?6]'FMA<:M?B\,=NL\-P(H6E*O @+H1O3JUU1C.HY>Y'1J.UU%-;*^N
ME^J)Q4VJM'#RJRI4N1.I4N^9I75FUWLOF[ZGG&NWO_!37]A6_P!"\:^+-<^.
MGPWTZ\U*"WM+_P 2>*G^(GPZUK4<-.FAZ]:76K^)_#4LMY''(8['45L;ZY59
M?[.N!+$7C_I>_P"">G[;6G_MI?!^[\0:CIMAX<^*'@.^M?#WQ+\-:=)(^G)?
MW=NUSI'B;0Q.\ES'X?\ $UM!=2VEO<O)/IVH66IZ7)/="R2[G_+S]J[_ (*Z
M?LL_M%?L[?%KX,1?"_XQ?VGXZ\(7^F>'KG7=!\(0Z7IGBB(Q7OAO6+JX@\67
MEU:KI6LVUG?_ &FUM9KF,0$0QEW KQ__ (()7UY'^T+\<M+%PXLKWX,:/?75
MJK$0S7FF^-[.VM+DH" 9((M2OHD8C<J7+KP#RYPE4HSG4HQI5*=FFOM1NE9*
MVN]WVLK$4:D:6*ITJ-:5:E54N9-M\DDM]=KV7:ZNF?4'_!6/]@SXF?$?QC:_
MM(_!7P[?>-;^7P_IGA[XD^"=(1;CQ&\>A&=-&\4^'K#<'U@)8S_V=K&E6N[4
M$CM;.\L+>Z/VN(?B3\/OV7?VDOBAXIM?!W@WX*?$>[UJYNDMI9-9\*ZSX<T3
M2$>40R7FOZYKME8:=I>GVS%GGGFN&FVHZV\%Q.4A;^N[]KK]M;X2_L?>%M-U
M7QZ;_7?%/B0W(\'> /#OV>3Q'X@:S1?M=[(]S+%:Z5H=B\T$=[K-ZZQ1O-';
MVT5W=.D#?F]\/_\ @N-X&U?Q+;Z=\2O@AK_@GPG>7 AE\4:'XJM/%]QHT,K;
M5N]4T/\ LG2+F[MH0R273Z5-<W*1+(\-G<.!$W]0^'7B-XK9/X?JEEG V$X@
MR?+Z-;#91G^/5?#U:%&G[7]U2H1K4EF]/"3E.,'"$4E'V$JM10M'_-CZ0'@U
M]%3'^,LL?QEXM5.!^).(<9A<;Q'PQ@Z='%X7$8K$O#Q>(Q6->%KQX;J9G3C2
ME6^LSG&]26*C2H<_,_TE_9D_91T3X$_LL:5^SOK5Q#XB&J:!X@M_B+J=NK06
M^NZWXVBN3XJELDES)%8)]M?3M+,P$PL+2U:91(SJ/Y6?VEOV"?V@OV;O&VKZ
M!-X!\6^./ 27TZ>#/B)X1T#4O$6E:SHAD8Z:FJQZ-!>W.A:]!:B.#4M/U&&&
M)[J.6?3Y[FUD1Q_:-X;\3Z+XR\.Z-XH\,:I9:YX=\1:99:MHFKZ;*MS8ZGIM
M_;I<V=Y:SH6$D,T,B2!NHY5MC @?#_Q5_;Y\ ^!_$^H^$?!OAV[^(>H:-=2Z
M?K6J6NIV^D>'+74+:3R;JRM+UH+ZXU6>UF#P74MK;+9QSQR1QW,KHX7\?X5^
MD?G'@AF7$?%>9XG 8C \05YUL^P.:K$TX8C'0K5ZT<1AE@H2Q5'%8=U:U/EI
MTIQ=#]S.*C3A)?TEXR_1N\+?%3@?@GAZMF=7ABCPE@<-EW!><93+"XR4<JEA
M,)!8)T*SE2S/!XFE2PV+=6-6,U6F\5"LE7G&?X/?\$_/^">'QA^+_P 7/!7Q
M!^)'@GQ%\/\ X/\ @;7]+\77]]XNTNZT+4?&]]H=Y%J6D>'/#NC:E';ZG+9W
M&HVUO+K&MSVMOI\.GPRVUK-<WLZK%^XO_!2;]D#7/VK_ (.Z3%X(-JOQ.^&F
MKW7B3P=:WL\=G9Z_:W]G]BUWPO+=RGRK*?4[>*TN--NYC]GCU*PM8KIH[:>6
M6/VOX%_M9^"_C)J2Z!/IM[X.\6R0R3V6CZC=07UCJL4"%YAI&IPQP":YBC#2
MRV4]O;W/E*TD0G2.4I[O\1?B)X3^&'A+5?&WC75(M)T#2(5DN)FC::>YGED\
MNUT^PM4S+>ZC>SE8;6TA5GED8%BD:2.OA9Q])JIXT9Y@?$O*,]RB6%X?=7!9
M;1RJM-X/)EAY2JXS"XR.+E3Q4,35E4E4Q;QD*$ZE.=-TX^P5-OT>!OHO^&?
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MDTY+F7*GK?WGKV^?XD48R6,Q,G&2BXPY9--1=G=V>SWZ=/,_C3U?P[X'L/\
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M>HZ%#=Z7K2^)KC5HHKRSU?5-,E%M=V5XC6UW#YL32Q3Q2F)D3?\ L?\ LE>
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M  I<#T%%%, I"JG&0#C@9 /\Z6B@ HHHH 0@'J ?J :6BB@ (!Z@'ZT444
M '0 ?3B@@'J ?K110 F!G.!GUP,_G2D \$9'H:** $VK_='Y"EHHH ,#T%)M
M7^Z/7H.OK2T4 %( !R  3U( %+10 F!G.!GUP,_G2T44 )@>@_*@ #@  >@&
@*6B@ I-JYS@9]<#/Y]:6B@!" >" 1Z'D?K2T44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b3_002.jpg
<TEXT>
begin 644 form424b3_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #] M # 2(  A$! Q$!_\0
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M[Q[_ -#QXG_\'%Q_\77)8%&!1["E_*ON0>UGW.M_X6]X]_Z'CQ/_ .#BX_\
MBZ/^%O>/?^AX\3_^#BX_^+KDL"C I^PI?RK[D'M9]SK?^%O>/?\ H>/$_P#X
M.+C_ .+H_P"%O>/?^AX\3_\ @XN/_BZY+ HP*/84OY5]R#VL^YUO_"WO'O\
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M:C.MT=1TV*^#HA412GB:W.?XHG!0GUK@!TKJHUH5X*I3=TS*<'!\K"BBBMB
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M6<JIES/-O"$H%*XYKBQ>*A@W%3YG?MTV_P S>E3=5.R6A\SE?!W_ #W\1?\
M?FW_ /BJ"O@X?\M_$/\ WXM__BJ]Z\/?L8?;])M+S5/$-[;2OJTNFM'9:?\
M:$E7S)XH)$93\FZ2##;_ +@<%L#KQ'Q,_9]M_AI\,-+\27/B(3ZQ>2(ITU8
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M&XB/V';/'&I_=H?-F5%;Y@0Q;/./,=8^#.D>&?V@O#7A'PRMIK[W0!FM_%0
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M ,;H_MS+O^?R#ZEB/Y&?(-%?7W_#K'XW?]2S_P"#-O\ XW1_PZQ^-W_4L_\
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MI9_\&;?_ !NC^W,M_P"?R#ZEB/Y&?(-%?7W_  ZQ^-W_ %+/_@S;_P"-T?\
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M^-W_ %+/_@S;_P"-T?\ #K'XW?\ 4L_^#-O_ (W2_MK+/^?T1_4\3_*SX_\
M*7G@4[%?7W_#K'XW?]2S_P"#-O\ XW1_PZQ^-W_4L_\ @S;_ .-T+.LL6U:(
MOJ6(?V&?(-':OK[_ (=8_&[_ *EG_P &;?\ QNC_ (=8_&[_ *EG_P &;?\
MQNG_ &YEO_/Y!]2Q'\C/D$ "BOK[_AUC\;O^I9_\&;?_ !NC_AUC\;O^I9_\
M&;?_ !NC^W,M_P"?R#ZEB/Y&?(-+O;D[WR>IW'GZU]>_\.L?C=_U+/\ X,V_
M^-T?\.L?C=_U+/\ X,V_^-TO[;RU[UD-8/$K:+/D:.[N(L>7<SQ@9("2L,$]
M>_>F>8_E+%YCF)3N$9<[0>Y Z9KZ\_X=8_&[_J6?_!FW_P ;H_X=8_&[_J6?
M_!FW_P ;J?[9RM:^UB/ZIB7]EGR$6+8R20. "<XI*^OO^'6/QN_ZEG_P9M_\
M;H_X=8_&[_J6?_!FW_QNK_MO+?\ G\B?J6(?V&?(-%?7W_#K'XW?]2S_ .#-
MO_C='_#K'XW?]2S_ .#-O_C=']N9;_S^0?4L1_(SY!HKZ^_X=8_&[_J6?_!F
MW_QNC_AUC\;O^I9_\&;?_&Z/[<RW_G\@^I8C^1GR#00#VKZ^_P"'6/QN_P"I
M9_\ !FW_ ,;H_P"'6/QN_P"I9_\ !FW_ ,;H_MO+?^?R#ZEB/Y&?(!0'J,_6
MD\M<8VC'I7V!_P .L?C=_P!2S_X,V_\ C='_  ZQ^-W_ %+/_@S;_P"-U/\
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MW2_MO+7O60?4L0OL,^/_ "DS]T"@1J!C:,?2OL#_ (=8_&[_ *EG_P &;?\
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M "8%&!2T4 )@48%+3=_S8P?K0 N!1@4M% "8%&!2T4 )@48%+10 F!1@4M%
M"8%&!2T4 )@48I&Z=<4BG'8T@'8%&!0*6F F!1@4M% "8%&!2T4 )@48%+10
M F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M%
M "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T
M4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8KQ^+Q7XS^*>MZ
MK%X.O['PSX5TR[DL&URZM/MES?W$9VRB"(L$6)&RA=LEF4X  R?8#7R['>7'
MA/1[CX;ZAXZ?X7:Y8:K=W.EZU/%&;35[">620[6EPAD59F4C<&21%;# \[4H
M\U^Y$CT'PK\0O$.@>,;+PUXLO]+\066IRS6NE^)-'7RE:[B!:2TNHMS".7:&
M*E3@[&!"D#/L"J-H^E?.VBIX9\4Z[X'\%?#D)?\ ACPC?C5M4UFU;S;=)8T<
M1P^?TFGEDD+N03@!BQRP!^B4^X/I4U$DU84+BX%&!2T5F:"8%&!2T4 )@48%
M+10 F!1@4M% "8%&!2T4 )@4%0>HI:* "OE'6)?$&GZI\5+/0&UK6[J8"ZEU
MJV2ZCN;6#[5&)K*-'_=M(L)E,4D(!PO3."?JVN=M/'_AZ_U2ZTZ/4H?M5MNW
MK)E%.U@K;6;"MM8@':3@G!H$>%ZU)>E/!,GPA;4TL[:XU*:2TU);KR=0*VX)
MMY&G^90YR%<\*XX[UZ%\&[CQ5)\//!=I>::\$4VD#[??7UX1>VMQ@X0PLAWD
M<98L/H:]"@\1:9=WRV<%Y%/.T+3@1MN!16"L<CCAB!4=WXKT>PM6N9=1MO)
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MUURROY-2DGBM;N6X2S:';"BO(LNU,-E6#KNW$G.2, <5ZIFB@!%&!3J3-&:
M%HI,T9H 1HU?.1FC8O' I<T<4K(  Q2TF:,TP%HI,T9H 6BDS1F@!:*3-&:
M%HI,T9H 6BDS1F@#COBSX%;XD^![_P /+>?V>;O;_I&S?MPP;ID9Z5\_C]B*
M<]?%RY_Z\O\ [*OK$@$<T;1FNVAC:^&CRTI61X..R/ 9E457%4^:25MWL?)W
M_#$,W_0WK_X!?_94?\,0S?\ 0WK_ . 7_P!E7UC@48%=']JXW^?\$>=_JGD_
M_/G\7_F?)W_#$,W_ $-Z_P#@%_\ 94?\,0S?]#>O_@%_]E7UC@48%']JXW^?
M\$'^J>3_ //G\7_F?)K_ +$$K*5;Q:CJ1@AK+((/4?>K%A_8!U+3D\C3?B-)
M967\-O)IB3>2/1&9LX] <XK[,*@]12>6OI36;8U?;_!&U/AC*J:M&EIZL\#_
M &??V7A\#O$U_JPU]M9EO;=H9GEAVR2,65M[-GL%P !@=J]^IH0 \"G5P5J]
M3$3]I5=V>[A<)2P=/V5%604445@=@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 444E "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M(1GK1FC- !M&<XI:3-&: %HI,T9H 6BDS10!C?:)?^>K_G1]HE_P">K_G4
M=%;V1A=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'11
M9!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=D
MGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7
M_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_
MYT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:
M)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\ GJ_YU'119!=DGVB7_GJ_YT?:)?\
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MC+;Y&D^Z"0,;L?A6_3 **** "BBB@ HHHH **** "BBB@ HHHH PO&/C;1?
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MANTO_O\ 5\$XHQ7H_P!C4_YV?,_Z[8K_ )]1_$^]O^%U> _^AMTO_O\ 4?\
M"ZO ?_0W:7_W^KX)Q1BC^QJ?\[#_ %VQ7_/J/XGWM_PNKP'_ -#;I?\ W^I/
M^%U^ _\ H;=+/_;:O@K%)C%']C4_YV+_ %VQ?_/J/XGZ'>&_'?AWQ?//#HFL
MVFJ2P*'D2V?<4!. 36]7RS^QN!_PD7B;_KTB_P#1AKZF%>#B:*P]5TT[V/TC
M)L?/,L''$U%9N^P4445RGN!1110 4444 %%%% !1110 4444 %%%% !1110
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MMO8^2/\ AC_Q;_T&-'_.3_"C_AD#Q;_T&-'_ #D_PKZWHKI_M/%?S+[CS/\
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M2MJD(S34VG<'!/0P?[/N,_ZH_F*3^S[G_GDWYBM_%&!6GMI&/U>)@?V?<_\
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M_F*V:*.=ARHQOL<__/,_F*/L<_\ SS/YBMFBCG8<J,;['/\ \\S^8H^QS_\
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M8S37CP;<O$C+Y>0P"'.03T8'TWD>M)O [BN;\1:I<V?BKPI:0S;+>\GN$G0
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M9T$D4\+ATD4C(96'!!'<4 3T444 %8EAJNA75S>1V5]I\DXF$-RMO+&7\W!
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M!D16C=@5==IR' 7'_ CS0,]0S1UKR;PA\)-7T3Q#H]]?:Y+=6UA"8X[:.ZF
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M1YJ^HK]./^$)\/\ _0#T[_P$C_PH_P"$)\/_ /0#T[_P$C_PH_M]?\^_Q_X
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M;#_6#*_^?\?O/=:*\*_X;#\'_P#0,UG_ +]1_P#Q='_#8?@__H&:S_WZC_\
MBZ/J&*_Y]L/]8,K_ .?\?O/=:*\*_P"&P_!__0,UG_OU'_\ %T?\-A^#_P#H
M&:S_ -^H_P#XNCZABO\ GVP_U@RO_G_'[SW6BO"O^&P_!_\ T#-9_P"_4?\
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M^[I?_@7_ /8T?7L+_P _$']@9I_SXE]QXUCZ48^E>R_\,G>/?[NE_P#@7_\
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M12L!CV?A+2M,TR\L+&RBL;>[B,4WD#YGRI7))R2<'J>:H6/PS\,V%G96Z:/
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IBBB@ HHHH **** "BBB@ HHHH *EM?\ CXC^M15+:_\ 'Q']:.@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b3_003.jpg
<TEXT>
begin 644 form424b3_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "% M # 2(  A$! Q$!_\0
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MS6^G[1OPTDM]*E7QEIA&J^>+./>1+*83B8>7C<"AX8$ CC/6@#'_ .&=9?\
MHJGQ(_\ !W'_ /&:/^&=9?\ HJGQ(_\ !W'_ /&:T;S]ISX5Z=H]CJEYXZT>
MSL;V26&"2YG\LEXF5)0RL 4*,RAMP&W<,XS5BU_:,^&=]'I3V_C729EU2=[:
MU*S9WR(XC93Q\GSD+\V 20!DD4 8W_#.LO\ T53XD?\ @[C_ /C-'_#.LO\
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M /C-'_#.LO\ T53XD?\ @[C_ /C-'_"Y/'W_ $1#Q+_X-=,_^2*/^%R>/O\
MHB'B7_P:Z9_\D4 '_#.LO_15/B1_X.X__C-'_#.LO_15/B1_X.X__C-'_"Y/
M'W_1$/$O_@UTS_Y(H_X7)X^_Z(AXE_\ !KIG_P D4 '_  SK+_T53XD?^#N/
M_P",T?\ #.LO_15/B1_X.X__ (S1_P +D\??]$0\2_\ @UTS_P"2*/\ A<GC
M[_HB'B7_ ,&NF?\ R10 ?\,ZR_\ 15/B1_X.X_\ XS1_PSK+_P!%4^)'_@[C
M_P#C-'_"Y/'W_1$/$O\ X-=,_P#DBC_A<GC[_HB'B7_P:Z9_\D4 '_#.LO\
MT53XD?\ @[C_ /C-'_#.LO\ T53XD?\ @[C_ /C-'_"X_'W_ $1#Q+_X-=,_
M^2*/^%Q^/O\ HB/B7_P:Z9_\D4 '_#.LO_15/B1_X.X__C-'_#.LO_15/B1_
MX.X__C-8OA7]I7Q/XTM]1GTCX->)KF/3]0N-+N"VHZ<A2X@<I*N#<<@,",]#
M6U_PN/Q]_P!$0\2_^#73/_DB@ _X9UE_Z*I\2/\ P=Q__&:/^&=9?^BJ?$C_
M ,'<?_QFC_A<GC[_ *(AXE_\&NF?_)%'_"Y/'W_1$/$O_@UTS_Y(H /^&=9?
M^BJ?$C_P=Q__ !FC_AG67_HJGQ(_\'<?_P 9H_X7'X^_Z(AXE_\ !KIG_P D
M4?\ "X_'W_1$/$O_ (-=,_\ DB@ _P"&=9?^BJ?$C_P=Q_\ QFC_ (9UE_Z*
MI\2/_!W'_P#&:Q_$/[2/BGPM/HT.I_!CQ-!)J]\FFV8&I:<WF3LCNJG%QP-L
M;')XXK8_X7'X^_Z(AXE_\&NF?_)% !_PSK+_ -%4^)'_ (.X_P#XS1_PSK+_
M -%4^)'_ (.X_P#XS39/C1X[BC9Y/@GXC1%&69]6TP!1W))N.!5>S^/'C#4M
MWV/X/:W>;,;OLVN:5)MSTSMN3C- %K_AG67_ **I\2/_  =Q_P#QFC_AG67_
M **I\2/_  =Q_P#QFC_A<GC[_HB'B7_P:Z9_\D4?\+D\??\ 1$/$O_@UTS_Y
M(H /^&=9?^BJ?$C_ ,'<?_QFC_AG67_HJGQ(_P#!W'_\9H_X7)X^_P"B(>)?
M_!KIG_R10/C)X^/_ #1#Q+_X-=,_^2* #_AG67_HJGQ(_P#!W'_\9H_X9UE_
MZ*I\2/\ P=Q__&:@N_CEXTL(Q)=_!K7K2,L%#W&M:5&I)Z#+7(YJ?_A<GC[_
M *(AXE_\&NF?_)% !_PSK+_T53XD?^#N/_XS1_PSK+_T53XD?^#N/_XS5"Q_
M:$\4:FL#6?PEU>Z%P&:'R=>TEO-"DABF+GY@"",CT-/U+X^>+M%BBDU'X0:W
MI\<TJP1O=ZYI42R2,<*BEKD98]E')H N?\,ZR_\ 15/B1_X.X_\ XS7DWQOT
M34/A)J6A6UKX_P#'FJ#4+>[N72Y\2"&23R##B" +;MOFD\T[0>Z^_'K/_"Y/
M'O\ T1#Q+_X-=,_^2*BF^+/C>X>-I?@7XAD:-MR,^IZ62I]1_I'!H ^8M(^)
MS64&M7WB;Q=\4H=&L6+I?Z?JR96)%B,IEB:,L"AE'*Y!&?0UN:/XLEUCQM<Z
M2GBCXJK9Q&. K_;L)NXYP9S-YB",[558"57[SD@CAA7NVJ?$/Q7K>GSV.H?
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MFM?[1T[ MFE:(/N^T8SO5ACKQ0!N_P##.LO_ $53XD?^#N/_ .,T?\,ZR_\
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MGXTTNRFO+WX,Z_9VD"&26XN-8TM(XU'5F8W. !0!8_X9UE_Z*I\2/_!W'_\
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M_P#QFC_AG67_ **I\2/_  =Q_P#QFC_A<?C[_HB'B7_P:Z9_\D4?\+D\??\
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M22"Z<75S&$E5@<K^\)X[@5V]U^RYX=_X6ROQ$TV^O-%\0Q3V9@:Q2-(XK6"
MP/9[=O,$J$%D/1D1EP17GGP>_:3^'GPWLO&&A>(-:NK/5(/%VM-)#%I%[<*
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M: />P.!1BO$Q^V=\(O\ H8[[_P )_4O_ )'H_P"&SOA%_P!#'?\ _A/ZE_\
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M] 'MF*\,MA_QG!J'_9.[?_TY35/_ ,-G?"+_ *&._P#_  G]2_\ D>O'[?\
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M $./P\_\)V\_^2Z/[!_:&[^,?AY_X3MY_P#)= $W[+;%]!^(!))QX\U[J?\
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M+("I9S&D?(/?')K5U+XG.GQ/^%L$/C&U&F^(-.N&FTQ?)*3MY(>*8-C?RP(
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M)+H__05L?_ A/\:\*^)GA#6=8^-.F>*O#NOV<$#6ME9M<_VLD:6:1732SB2
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M<  ^WM*UW3;33K2&XU33!-'"B/Y$Z+'N"@':,\+GH/2K?_"2Z/\ ]!6Q_P#
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M_AGWQ'XAU3X9^!X?&NF7<MC%8W_AZ"UF\T/&J1S6ZNR^>1*N$20HQ>/++N.
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M?^B4>&__  L6_P#D.N_^%T&HVOPV\*PZON&IQZ7:I<[Q\WF")0V??/7WKJ*
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MH& CL;2#>U[#N+ J9.1LQB3S%S]W@ );3XA2RZ+YGP%\!M)HX_XE@;Q*F;,
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MUM!=Q'[)J5[")055G? R7AYP!@'^[0!J)XY^-X4;?A1X9VXXQXQ./_2.G?\
M"=_''_HE'AO_ ,+$_P#R'7;_  C\#_\ "N/AWHGA]F$EQ:P;KF0$E7G<EY2N
M>B[V; [# [5V% 'B_P#PG?QQ_P"B4>&__"Q;_P"0Z\AM_%WQ=_X:ZOKH?#C0
M#K7_  @T$;6'_"4GRQ!]OE(D\W[+][=D;=O09SSBOL:O#+8?\9P:@<?\T[M_
M_3E-0!<_X3OXX_\ 1*/#?_A8G_Y#H_X3OXX_]$H\-_\ A8G_ .0Z]GHH \8_
MX3OXX_\ 1*/#?_A8G_Y#H_X3OXX_]$H\-_\ A8G_ .0Z]GHH \8_X3OXX_\
M1*/#?_A8G_Y#H_X3OXX_]$H\-_\ A8G_ .0Z]GHH ^=[R#XEZAXEB\17/P*\
M$SZ]$%5-3?Q0#<*%SM D^Q;L#<V.>,GUIM^/B-K6AIX>O/@7X%O-)M2KIIDO
MB=7AA/)4B/[%A3RW..YKZ);I7S;X-\*:]X4^*$FN/X3U634(+K4QK&IPE,:K
M%<7,?V,(2X\P1)EB#CRU1@.3@@$DT7Q!^U:E>2_ GP'Y]U:BUO)G\3IF2W
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M )#H_P"$[^./_1*/#?\ X6)_^0Z]GHH \8_X3OXX_P#1*/#?_A8G_P"0Z/\
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ML>#/^?\ \6_^%9J7_P ?H_X98\&?\_\ XM_\*S4O_C]4?^%O?%[_ *('>_\
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M6]\7O^B!WO\ X5>G?_%4?\+>^+W_ $0.]_\ "KT[_P"*H O?\,L>#/\ G_\
M%O\ X5FI?_'Z\X_:2_9O\):!^SY\2=1MKSQ.]Q:^';^:-;CQ/J$L998'(W(T
MQ5AQR""#7<_\+>^+W_1 [W_PJ]._^*KSG]H[XH_%+4?V?_B/:ZC\$KS2K";P
M]?)/?-XFL)1;H8'#2%%;<VT<X')Q0!WOA#]F'P=>^$M$N'OO%8>6Q@=@GBO4
M5&3&O0"; _"M?_AECP9_S_\ BW_PK-2_^/US?A'XM?%F'PGHD<'P(O9X5L8
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M3_Z&C1?_  80_P#Q587_  S]\+_^B<>$_P#P26W_ ,11_P ,_?"__HG'A/\
M\$EM_P#$4 ;O_"Q_"?\ T-&B_P#@PA_^*H'Q&\)DX'BC1B?^PA%_\56%_P ,
M_?"__HG'A/\ \$EM_P#$4H_9^^%X_P":<>$__!);?_$4 <!^REXZ\-6'P'\.
MP7/B+2;>99K[,<E]$K#-[.1P6]"*];_X6/X3_P"AHT7_ ,&$/_Q5>%_LL_!'
MX=ZQ\"_#]W?^ O#-[=237P>:XT>W=VQ>S@9)3)P !]!7J_\ PS]\+_\ HG'A
M/_P26W_Q% &[_P +'\)_]#1HO_@PA_\ BJ/^%C^$_P#H:-%_\&$/_P 56%_P
MS]\+_P#HG'A/_P $EM_\11_PS]\+_P#HG'A/_P $EM_\10!N'XC>$R"/^$HT
M;_P81?\ Q5?/EJ]]X6^-?B'Q78:IHFK6MW>371>76K$+<VQM8TBMH]P\V*19
M5SN+;-N>N<#U?Q#\$/A=HN@:GJ!^'O@R 6EK+.9;G1;<1)M0MER(\A1CG'.,
MU\C1^,=&T3X7Z_J&K?#7P7'XBA:&Y@>\\'P^5:VS6XG9Y! KJT;\I 2RL0<N
M 5P0#L?$_@O5]1USQX+/Q#HAL]<NKJZGN)-:L<WL#2V[P6T)(,D3JJ21MYA,
M9 '!!&WM_P"TX]-^'O@^WU36=&,>G>+H+Q[&&_M7DBL/.<0B7RL([(7C9BHQ
M@9.<$UI^-/ 7@+3=1^'MSI'@7P"^D:UJ\6FW\,WA^!IF\R%W78V!Y97:,AE)
M.1TK/^''@/P;>_%'QSX:UOP'X1N[73;:WU#3G/ABSMY)89&E5S'Y>\/$#&JA
MG*N6W9&,&@ ^&EY)X-UOQ[JEK<:'IS>(KFT%LMQJNG>9:%4='E*VY6-H8\J5
M4_O'^?<>1CSVV^&UQH*ZHE_=^"_&-I/?7LPMUU:&,W$US80PF^E\YR-_FQOG
M'S .2N1@5/X3E\(:AK_A=-8^'_A.TTB:WT^>\GM/#%@XEEOY)A!$VXAT1 B+
MNC5CG)8@9KJOB/H/@SX=^*[Z[N_AOX.G\+2V,AT=;/0+&47=VEI+.T<SC]Y'
MGR_E(0J1U(R* .9U+0E\+Z#XMMK*]TQK74/#D]CJ$DFK6=PVI:B8H8K:6UVG
MSHAO4LPD;;@*=N1FOJG3?B#X9M]/MHKCQ7HLDZ1(LC_VA#\S!0"?O>N:^3_[
M-T"[\&PC3_"O@U?'J:E;PIHEYX/L"M^T\44RP1M$S!85B=F:7.Y5&6QC#>S_
M  X^%/P]\17GB^RU#X<^$9)-&UR6PBE30;90\7EQRIGY.JB7:3WVY[T >I?\
M+'\)_P#0T:+_ .#"'_XJC_A8_A/_ *&C1?\ P80__%5A?\,_?"__ *)QX3_\
M$EM_\11_PS]\+_\ HG'A/_P26W_Q% &[_P +'\)_]#1HO_@PA_\ BJ0_$;PF
M<?\ %4:-_P"#"+_XJL/_ (9^^%__ $3CPG_X)+;_ .(H/[/WPOX_XMQX3_\
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M0DC?"7&<G$@&3C->N?\ #/WPO_Z)QX3_ /!);?\ Q% &[_PL?PG_ -#1HO\
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M\10!N_\ "Q_"?_0T:+_X,(?_ (JC_A8_A/\ Z&C1?_!A#_\ %5A?\,_?"_\
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MT#Q'XIO8;+P=X)%A_P (^E[>PQ^$[,R:)?R+&T-LKM@32LK2$H^W;B,G&[!
M/HG1_'WAJSTFR@NO%>BR7,<")*_]H0_,X4!C][US5S_A8_A/_H:-%_\ !A#_
M /%5\U_!?P_X2\7:GX6M-<^'?@V5]2LM5BNHD\.6D,EO=6-VD7[P!64,T<BA
ME5BH=3M)%>[_ /#/WPO_ .B<>$__  26W_Q% &[_ ,+'\)_]#1HO_@PA_P#B
MJ/\ A8_A/_H:-%_\&$/_ ,56%_PS]\+_ /HG'A/_ ,$EM_\ $4?\,_?"_P#Z
M)QX3_P#!);?_ !% &[_PL?PG_P!#1HO_ (,(?_BJ/^%C^$_^AHT7_P &$/\
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M-I?!3_HH.F_]^YO_ (B@"]CX]?WOAS_WS?\ ^-&/CU_>^'/_ 'S?_P"-4?\
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M!$&G+?\ DS>6;D7\LABSL^\$8-CT- 'M6/CU_>^'/_?-_P#XT8^/7][X<_\
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MR8;/XR_#73-;UFYA^+GA:[LWTM-&TB*^TV]9K"S54 ARDB@A]I+NH5F.WD!
M* .D^'6K^-=;\0:3=>%X?AY:7K:/-#96[6>I6L<-M'=%+B,1' 259@!(,9X7
MJ*]2Q\>O[WPY_P"^;_\ QKPGX7?%[X1?#S6_"ZO\3M%N-)T'3M1BA\B&>,++
M=W"2>1%&RL5AB2(!=SLQW<FO:/\ AM+X*?\ 10=-_P"_<W_Q% %['QZ_O?#G
M_OF__P :,?'K^]\.?^^;_P#QJC_PVE\%/^B@Z;_W[F_^(H_X;2^"G_10=-_[
M]S?_ !% %['QZ_O?#G_OF_\ \:,?'K^]\.?^^;__ !JC_P -I?!3_HH.F_\
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M^Z/RHHH -B_W1^5&Q?0?E110 ;!Z#\J-B^@_*BB@ V+_ '1^5&Q?[H_*BB@
MV+Z#\J-B^@_*BB@ V+_='Y4;%_NC\J** #8OH/RHV+_='Y444 &Q?[H_*C8O
M]T?E110 ;%]!^5&Q?0?E110 ;%_NC\J-B^@_*BB@ V+_ '1^5&Q?[H_*BB@
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J #8O]T?E1L7T'Y444 &Q?[H_*C8O]T?E110 ;%_NC\J-B^@_*BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b3_004.jpg
<TEXT>
begin 644 form424b3_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "- M # 2(  A$! Q$!_\0
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MVG__ !5'_"U_BI_T0^]_\*;3_P#XJO8\48H \<_X6O\ %3_HA][_ .%-I_\
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M1MG [5E>&/VB?B3=_L[>#/&'B'XAPVWB'QYK!LM&MM%\.VK&!(_/5H]\\R1
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MJ1QP&9-N"1V)%=#2-SCZT 8<W@WPW>&U,NA:7.;.,V]ONLXV\B/O&GR_*O\
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MA;977Q.T#7XK[P[-<W-E]GC2]U9QLVSPE7("1 ['QG)Y.#7NU "  =*6BB@
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M9)^5F R<50^ G[6?COQ5\0]6LI'N?B/HEWX5'B;2+:VTRTTR^FS=B$+$@N'
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MA&PQY&#R?6NA Q0 M>-_ME?\FH_%K_L6K[_T2U>R5XW^V5_R:C\6O^Q:OO\
MT2U #_V8_P#D6/&?_8Z:Y_Z6R5[#7CW[,?\ R+'C/_L=-<_]+9*]AH ****
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MKM[8/':NFHH HZ3HFGZ#;O;Z;8VVGP/(\S16L2QJTCG<[D*!EB223W-7J**
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M   $:M<$*, #CL*;<?$_1[S5X=5N/V8_&T^J0QQQ1WLGAW3FF1(R#&JO]HR
MI QCI@8KZ;%+0!\SS?%C3;F[U*ZF_9G\<RW6I-&]],^@:>7NFC(,9D)N,N5(
M!&<X(XJQ-\9[>YDN'F_9Q\?RO<7,=[,SZ'8$RW"8V2L3<\NN!ACR,#%?2%%
M'S+:_%+2K'Q#=Z_;?LR^.+?7;Q66YU.+P_IRW,P;[P>07&XY[Y//>IX_C!90
MQ6\2?LV>/%BM[5[&&,:#IX6.W?[\*C[1Q&W=1P>XKG?V[O$&O:7X@^#NFZ,/
M%M[;ZGK%]'>Z1X,U,V%_?HEF\BJLFY1\K+NP3S@@<FO,/ ?[67C[P?\ !'X.
M:78W'_"=^*O&,6JWT.I7=I<ZI-;6EK)\EM-';JLDUPN](G? "E6)SW /<=)^
M,-GH#:<VF?LV^/-/.FPO;V1M="T^,VL3G+I'BX&Q6(R0.":WO^&G=8_Z(9\4
M/_!=9_\ R57RO\0/CMXTM/C1IOQ0\6^&ET^S\+?##_A*%\'7=U=6\UI=O<M;
MME5(4R&0@9D4@1=MU>A']L?XM:=X&N[N\\ 6:ZO-KFC:7I-]J5C>Z787XORR
MLH6;,F87 !<95E((':@#V7_AIW6/^B&?%#_P6V?_ ,E4O_#3NL?]$,^*'_@N
ML_\ Y*KRKQG^UU\3/#?Q8O\ P3I7@B'Q3?\ A>'25UZ'1M.O+C[;-=@-*;>5
M1LMDC0[E,V2^TCBK5A^USX]?XBVZ7?A[P\/ K_$&Z\ EX)YCJ32(C/'<X/[L
M !<%>2<G&* /2O\ AI[6/^B&?%#_ ,%MG_\ )5+_ ,-.ZQ_T0SXH?^"ZS_\
MDJO(Q^V;X^M?@#-\8+OP_P"'7\/:Y=1V7AK2;22XEOH9)+W[,ANP!AQ@%RL>
M&SA.IS7LGP&^+_C#QUX%\4ZCXR\+7&AZIH=U-#!+)I]Q8QZI"L0D2>."?]XF
M22I!SRO!YH KG]IW6!_S0SXH?^"ZS_\ DJC_ (:=UC_HAGQ0_P#!=9__ "57
MQ#)XS\36WPN^ ]['<^.=:'B;2/$WBC6['P=K#6-[=7!D$HE+%AE8MV-G/ P%
M/2OLK]GKXV6EO\*/@QH'C?Q6GB?QKXSTHR6U_:02217NV-I&+RA0H98QM);!
M9E;B@#4/[3NL#_FAGQ0_\%UG_P#)5)_PT]K'_1#/BA_X+;/_ .2JR_V&-5NK
MCX3>(=#N+B6ZM_#'B[6="LIII#([6T5TQB!8\G:'VCV45]%4 >$_\-/:Q_T0
MSXH?^"VS_P#DJC_AI[6/^B&?%#_P6V?_ ,E5[M10!X3_ ,-/:Q_T0SXH?^"V
MS_\ DJN7_9S\<W/C;]IOXUWMQX3U_P +-)IN@9MM=@BBD7;'<CD)(X^;.1ST
M!Z5]/5X5\,/^3L/CB?\ J'>'?_15U0![K2'D4M(PR* /@?Q5X,OOB]XK_:0U
M:ZUC3=(_L'Q/IT%T-=FFBL9-*M+ OY4K1'>L9>X:;CJR"KW[./Q0COOB+H6C
M>.HM=U*YN=*MO"NBR7Q58887LS<*]Q"7WF>[BB,S.5(C7RHR0=V?IA/V>O#D
MGCOQWKU\@U33?&4=@VJ:%>0J]J]Q:\1S^I)41@J>#Y8/K71ZI\+/#FH>)IO%
M,6CZ?:^,39O9P>(!:(UU I4J"&/7 /Y<=#0!Y+^P-J-Q=_LUZ-9S2-+#H^HZ
MEI%I([%BUM;WLT</)ZX10/H!7T57$?!?X5:=\$_AEH/@O2IYKNTTJ QF[N<>
M;<R,Q>25\<;G=F8_6NWH Q_&/_(HZW_UXS_^BVKBOV9O^3=OAK_V+UC_ .B%
MKM?&/_(HZW_UXS_^BVKBOV9@3^SM\-<=?^$>L?\ T0M 'S=X@_:X^('@Y/C/
M%X@&EZ9XC\/:5=:SX>T)M-:2VN+&*X6-+M+Q)B)EVL-Z%496/H#7-?M7?'G4
M_'/@_P")>@6VHZ,-/\.3^#KZSOH)B$2XNKI7E$[J_P#JP50X&"%)]:^Q]*^!
M7P^T.ZUZXL/!>AVLVO1O#JCQV29O(W)+I)QRK$DE>A)S5/2_V<?A?HF@WFBV
M'P]\-VNDWGDBYLH]-B$4_E,6B\Q<8;:Q)&<XH ^5]3^._B7Q%X@LO#'C*W\.
M>*]1\,_%31=)BUK24G@M9([BW><.B+*?WT7*X9F4Y&5JGX0_;C^*NH>%]?\
MB%=>"H]1\$QZ3K.H)%':B!+"6T9A;Q^?Y[-/YFTB3]VA0CCBOH_7/V5/"EU=
M^!K?04@\'^&O#.NCQ(^@Z+910PZA>HI$4DC@;AM))X^]P#T%=AI/P'^'FA>)
M-2\0:?X)T.RUK45E2\O(;)%>=9?]:&XP=_\ %_>[YH ^3/B-\1_C.VF? Z]'
MQ+\(17'B#Q99I,^BV<J0".>T>58+D>>=\8PW&5+_ "'C'/HW[</@'4-=\+Z'
MXH;Q-!I>GZ'')%+ 6G662[FDA^SS621'Y[K<ACC5N/WYYZUZ];_LU_"VT\+2
M^&H?A]X=B\/RWB7[Z<FGQB$W"#"2[<?>4< ]AQ78ZQX-T;Q!-H\NI:9:WSZ/
M<K>6'GIN%M.JE5D0= P5B >V>* /@;Q%^T5XAT;X1?''5HAJ]A\6;JQN+LZB
MK));6$%I=QV<]O:HK$Q_9!,<NR@R/YCC(QCL/B3\+/#?P_\ V>+WQ?\ ";QA
MJ^K^)-"@TSQ;)'_PDD]\=0CMI/,ED>-I&QYL;3 X 5L 8XKZWT[X4^#](US7
M=9L_#&DV^J:ZI35+M+1-]ZI^\LIQ\P/<'KWS5'P5\#/A_P##>UU6V\+>"]#T
M"#54\N_CL+%(A<I@C8^!ROS-\O3DT >4?LO>+E^-WQ'^)OQ6L-2N+SPE>3VN
M@>'4\YOLY@MH@\\R)G&7FE92V,_N\5UOQ1_Y.*^"/UUO_P!(UKTCP=X)T+X?
MZ#:Z'X:T>QT'1K7=Y-AIT"PPQ[B6;"J !DDG\:\W^*/_ "<7\$?KK?\ Z1K0
M![+1110 5F>)G:/PWJSHQ1UM)2&!P0=AYK3J.XA2Y@DBD021R*59&&0P/!!H
M _+O]C+QGK/AKQ/X*UK6-1OO!UG+X U/7+N\UO6Y]3M/%7EN<7 BW,(&M\%F
M48<J>!CFNE\=?M9_%'Q/\'_C+9VFO6]G<:7X5T_Q1I/B&VT>72[@V\\Y1ECC
M,[L 54%)&(;!.5K[Q@^$'@JUMM"MX?">C1V^A130:7$MF@6RCE4K*D0Q\JNI
M(8#@CK6=H'[/?PU\+:=J=AI/@3P_I]GJEJ;*^@@L(U6Y@R3Y4@Q\R9)^4\"@
M#Y%\4?M >)/A!XP\;:FUKX>UGQBOA?PO;GQ!_I$=K)->W;PB:5#*RB&,$-\N
M"3G+<U]!_LX?%?Q7XM\<?$OP/XOO='U_4?!EU9QIX@T&!H+>\2Y@\W8T9=PL
MD?0@,>HZ5WUE\"?A]I^DW6EV_@K0H].NK"/2KBU^PH4EM$)9(&!'**6) /0G
M-:_@/X;^&/AAH[:5X2T#3O#NFO*TSVVG6ZQ(\AQEVP.6.!R>>!0!TM%%% !7
MC?[97_)J/Q:_[%J^_P#1+5[)7C?[97_)J/Q:_P"Q:OO_ $2U 'F_P<^.MCX#
MA\<:1/X0\;:Q)'XQUIC=:+X=GN[9MUXYPLJ#!QG!]#D5Z#_PU1IG_1//B7_X
M2%U_A5G]F/\ Y%CQE_V.FN_^ELE>P[A0!XK_ ,-4:9_T3SXE_P#A(77^%'_#
M5&F?]$\^)?\ X2%U_A7M60>]&0* /%?^&J-,_P"B>?$O_P )"Z_PH_X:HTS_
M *)Y\2__  D+K_"O:MPI: /%/^&J-,_Z)Y\2_P#PD+K_  H_X:HTS_HGGQ+_
M /"0NO\ "O:Z3<* /%?^&J-,_P"B>?$O_P )"Z_PH_X:HTS_ *)Y\2__  D+
MK_"O:LBD+ =Z /%O^&J-,_Z)Y\2__"0NO\*/^&J-,_Z)Y\2__"0NO\*]JW#U
MHW"@#Q7_ (:HTS_HGGQ+_P#"0NO\*/\ AJC3/^B>?$O_ ,)"Z_PKVK(I: /%
M/^&J-,_Z)Y\2_P#PD+K_  H_X:HTS_HGGQ+_ /"0NO\ "O:Z* /%/^&J-,_Z
M)Y\2_P#PD+K_  H_X:HTS_HGGQ+_ /"0NO\ "O:Z* /$S^U/IG_1//B7_P"$
MA=?X5Y3X#_:*T^Q_:%^*^I'P/\0)5O;'0U%O%X7N6FBV1W()D0#*!MWRD]<'
M'2OL'%>+?#;_ ).?^-(_ZA_A[_T5=T )_P -4:9_T3SXE_\ A(77^%'_  U1
MIG_1//B7_P"$A=?X5[710!XI_P -4:9_T3SXE_\ A(77^%'_  U1IG_1//B7
M_P"$A=?X5[710!XI_P -4:9_T3SXE_\ A(77^%'_  U1IG_1//B7_P"$A=?X
M5[710!XI_P -3Z9_T3SXE_\ A(77^%</:>.OAE9>!-7\%Q?!;Q\?"VK2SSWV
ME2>#KR2&>29]\K,&R<ECNX/!Y&*^HLT9% 'QH^F_!*3PP?#S_ _XDOI!NC>&
M!M U4DRF/RR2YDW%2GR[<[<=JZ;1/&GPP\->-(/%FD_!?Q_IOB"#3H])CO+7
MPA>QXM(U"QQ;!\A"J  2,@# -?4NX9H#9]: /DWPYX_T'PW\3_B#XJB\&?$V
M;3_&D%HM_HS^"KK:L\,;1&99.N'C*J5QU3.>:Q_%^H>"]?\ "'@'P=I/P_\
MB1X<\&>%-:M=7&C6W@J[D6Y6W9I(H-S'*KYI5R>2=N.*^RMPHW"@#Q3_ (:G
MTP?\T\^)?_A(77^%+_PU1IG_ $3SXE_^$A=?X5[4#FEH \4_X:HTS_HGGQ+_
M /"0NO\ "C_AJC3/^B>?$O\ \)"Z_P *]KHH \4_X:HTS_HGGQ+_ /"0NO\
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M  U1IG_1//B7_P"$A=?X5[5FEH \4_X:HTS_ *)Y\2__  D+K_"C_AJC3/\
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MI.2",BO1=.L8],L+:TB:1HK>-8D,LAD<A1@;F8DL>.23DT 4/&/_ "*.M_\
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M#^)M9TV71=7U'3] >S37M8LXT-OIAN<>5O!8.^%97?8IV*P)H I?\)W\=_\
MHE'AC_PL&_\ D2C_ (3OX[_]$H\,?^%@W_R)78_$GXIQ?#ZY\/:=#I-YK^N>
M(+F2UTW3K)XXS*T<32R,TDC*B@(A/)R3@ 5RE]^U'X;L_A[X3\8II6O7FF>(
MKB*VB2WL=S6C-.MN6N&SL15D8+D,=W5=PYH A_X3OX[_ /1*/#'_ (6#?_(E
M'_"=_'?_ *)1X8_\+!O_ )$KVI<XYZTZ@#Q/_A._CO\ ]$H\,?\ A8-_\B4?
M\)W\=_\ HE'AC_PL&_\ D2O;** /$_\ A._CO_T2CPQ_X6#?_(E'_"=_'?\
MZ)1X8_\ "P;_ .1*]LHH \3_ .$Z^.__ $2CPQ_X6#?_ ")7DTGC#XQG]JZW
MN3\-O#PUG_A"9(_L/_"4MY?D?;T)D\S[+][=@;=O0YSVK[%KQ*;_ )/2M_\
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MV0#4WQ+_ &@_#7PP@\)/?)>ZA+XFNH+>RM["'?(L<C(OVB4$C9$IEC!8]W4
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M+/1;_P 3>)-6$TEKI6F^6K>5$%\V:221E2-%+(N2<EF  /8 X_\ X3OX[_\
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M!IZZWK:>)"EL$B8,RRVL9_TB6-08T.-IW DX7%=Q_P -I?!/_H?]/_[\S_\
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M7P4_Z'^P_P"_,_\ \;H_X;2^"G_0_P!A_P!^9_\ XW0![917B?\ PVE\%/\
MH?[#_OS/_P#&Z/\ AM+X*?\ 0_V'_?F?_P"-T >V45XG_P -I?!3_H?[#_OS
M/_\ &Z/^&TO@I_T/]A_WYG_^-T >V5X7\+_^3L/CC_V#O#O_ **NJL?\-I?!
M3_H?[#_OS/\ _&Z\?^'W[5?PGTW]I+XOZS<^-;*+3=2L-"2TN#%-B5HXKD2
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M&:'X'M/A !%:V,T%G:GQ4L1TRY!Q%-+(F!,&)\QC\QW9RI)KO/\ AM+X)_\
M0_V'_?F?_P"-T?\ #:7P3_Z'^P_[\S__ !N@#U#P3IVIZ1X0T2QUN^CU/6;6
MQ@AO;V)-BW$ZQ@22!>P+ G'O7F_[97_)J/Q:_P"Q:OO_ $2U5_\ AM+X*?\
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M5Z_MXQDUXEJ/[%_PAUC6=4U6_P##$]WJ&J7DU_=3'5KR/?-*Y=R%255 R>@
MJ'_AB#X+?]"A+_X.K_\ ^/T >M^+O!VD>._#UUH>O6:ZAI=SM\R!V9>58.K!
ME(965E5@P(((!!JGX-^'.@> AJ!T:S>*XU&83WMW<W$ES<73A0JF265F=MJ@
M  G ' Q7F'_#$'P6_P"A0F_\'5__ /'Z/^&(/@M_T*$W_@ZO_P#X_0![F$QC
MD\4% 3G)S7AG_#$'P6_Z%";_ ,'5_P#_ !^C_AB#X+?]"A-_X.K_ /\ C] '
MH7Q"^$^A_$M[%]6>^ADM4F@\RPNF@::WE"B:WD*_>C<*N1_LC!%+?_"/PSJ'
MB32=<:Q-O?:7'Y=J+9S%&J\]47@]3UKSS_AB#X+?]"A-_P"#J_\ _C]'_#$'
MP6_Z%";_ ,'5_P#_ !^@#TWP9\.-$\!>?_8\4L/G06UN_F2E\I A2/KZ*>?6
MM#PYX1TGPC:W5MH]FEA;75W-?2PQ$[#/*Y>1P"?EW,2Q P,D\<UY%_PQ!\%O
M^A0F_P#!U?\ _P ?H_X8@^"W_0H3?^#J_P#_ (_0![H%P:R=(\*:5H.I:Q?Z
M?:+;7FKW"W5]*K$^?*L:QAB"<#Y$4<8Z5Y#_ ,,0?!;_ *%";_P=7_\ \?H_
MX8@^"W_0H3?^#J__ /C] '6P?LZ_#R"]DN#X<CGC9KEULKFXFFM(6N PN&CM
MW<Q1F0,P8JHSN;U.?0K>TBM((X((UAAC4(D:#"JH&  !T %>(?\ #$'P6_Z%
M";_P=7__ ,?H_P"&(/@M_P!"A-_X.K__ ./T >Y[?<UE>(O">D^+8;*'6+-+
M^&RO(K^".0G:L\3;HWP#SM;D Y&0#C@5Y#_PQ!\%O^A0F_\ !U?_ /Q^C_AB
M#X+?]"A-_P"#J_\ _C] 'N@XI:\*_P"&(/@M_P!"A-_X.K__ ./T?\,0?!;_
M *%";_P=7_\ \?H ]UKQ;X;*1^T_\:#CC^S_  __ .BKNJ?_  Q!\%O^A0E_
M\'5__P#'ZJ0?L&?!&WU.\OE\(W!FNEC20'6K[&$SC'[_ #_$>M 'T!17A7_#
M$'P6_P"A0F_\'5__ /'Z/^&(/@M_T*$W_@ZO_P#X_0![K17A7_#$'P6_Z%";
M_P '5_\ _'Z/^&(/@M_T*$W_ (.K_P#^/T >ZT5X5_PQ!\%O^A0F_P#!U?\
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M_P '5_\ _'Z/^&(/@M_T*$W_ (.K_P#^/T >ZT5X5_PQ!\%O^A0F_P#!U?\
M_P ?H_X8@^"W_0H3?^#J_P#_ (_0![K17A7_  Q!\%O^A0F_\'5__P#'Z/\
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M.K__ ./T?\,0?!;_ *%";_P=7_\ \?H ]SV#\/2C8/4UX9_PQ!\%O^A0F_\
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M(/@M_P!"A-_X.K__ ./T?\,0?!;_ *%";_P=7_\ \?H ]SV<8R:7;[FO"_\
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/B<KK5_G!&#C,Y'Z4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b3_005.jpg
<TEXT>
begin 644 form424b3_005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &W M # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SO^QO_P @7XD?]CGJ/_H8KZ$-?/?[&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'S7\;?A[KNB>-_$7Q&G^,E_P##;PHUA:VS
MV]I;1SJTB%AN(=3\QW  +R:\S^'WBNTU[XV?#^ ?''Q#XY<74SKH^J:%]EBD
M(B/S^8(UP1Z$U] ?M5ZS%X=^$%UJ,FHV&C+;7MJXU7483-%9'S1B8)_$R]AW
M->._#WXLS^)_BUX+TYOCCHWC%)IY6.CVOAT6DD^(R=PDQ\N.OO0!]@+U-.IJ
MCK3J "BBB@ HHHH **** /G?]C?_ ) OQ(_['/4?_0Q7O]R0EO*W=48Y_"O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5YH3T3/@/X"6[Q_ K5M5Z"T\66-R&'H).?\ T*OT0NK*'6=-FMIU+6US$8Y
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MVH,MK-YL,MO.#M*D\Y4J5(KO9O$ND6\S12ZI912J<,CW"!@?0@F@#PG]C?\
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M'>>!;/P^)II+%+: G67,JEFMMX8J8U))#8SC H ^K!UI:1:6@ HHHH ****
M"BBB@#YW_8W_ .0)\2/^QSU'_P!#%-_:P\5:I)\+?'WAV+2XHX&T9YC>7$X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '@W[6NA^*/%G@BRT+1_!6G>--$O;Z#^U;>^U'[((X5<,3N
M(Z<<G/'I7F?PN^&MO:_%[PIJ7_"L_!7@G[#),4O-.\1K>74N4("1QJ.??/:O
M9?VKM/NK_P""FK?9-,AUDP303RV-S?\ V*":-9 7$LN1A,=?45X9\(/!2'XH
M> =<L/A1X(T>QG\ZX@UWP_XA-Y*(MA!:-,#>I/!(SB@#[2%+35[TZ@ HHHH
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MSN?,B(]L,1^%>Q@@CKQ2H->S5BL*TZ,;=#E/BIX/B\?_  X\2^'95!74K"6
M9[,5.T_@<5R?[+OC&7QI\$O#<]VV=2L8CIUZ#U$T)*,/T%>L$ $5\X?!;6++
MX;_M _$CX<7=PMLVJW*^(M)@?CS4E&)@OKAAG'O7NX:+KX2K22NXVDO39_FG
M\C=Z23/I!._K3J:G.:=7E+8L****8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML6D=]IE["T,\$HR&4_U]Z\1^#WBC4O@[XT7X/^+[R2[@=6E\)ZU.<_;+4?\
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M*KVMS'<@M%(LJ^J,"/TJQ33N4G?8****8PHHHH **** "BBB@ HHHH ****
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MWQ5\-M+.A^(- TC0H;VTUK4_%C*)=11F8V\29):5P-I+>QH ^P@.*6D!%+0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1E/+Y\W*]5;6W?S_ $ZGL0'O3JC#$<?K3P<@&N\^4%HHHH **** "BBB@!"
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MZTA8"@!U%)N'K1UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEX@_9V^'/B7<;SPEIZRD8\VUC\AQ]"F*^8_CY^SYX=\+>,/#^GZ#JOBS3GU
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MCW%<SIOQ.\*ZN<67B+3;D^D=TI_K2Z[X_P!/T<01Q%M3O+C/E6MF0[OCJ>N
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M(>+_ /HAWC/\X/\ XJ@#WJBO!?\ AI#Q?_T0[QG^<'_Q5'_#2'B__HAWC/\
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MH:MH5CK< AO[*"\BSG9.@8"O&/\ AI#Q?_T0[QG^<'_Q5'_#2'B__HAWC/\
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M&U3-\94?QV-@?L]%/]7XY\5H.P^W@_S6E'P$OEQY?Q!\3KZ;KE3_ .RUC?\
M#1_B_P#Z(?XS_.#_ .+H_P"&D/%__1#_ !E^<'_Q55["GV,O[3Q?\_X+_(V7
M^!NMQC]W\1_$2^FYT;_V6N5\:_!;Q98SZ9J2>.]=U."SD)>)88I)(P1C>JX^
M8C\_2M _M'^+N_P/\9_G!_\ %4A_:-\6D?\ )#O&?X&#_P"*I/#P:L:TLWQ5
M.7-=/Y+_ ".>L_AIXO\ %7B+3YK#QYK\<%IN9[V\TZ.$KD?=4$ MG\J[?_A3
M?C?/_)5]6_\  .'_  K)/[1WBTC_ )(?XS_.#_XJG#]I#Q?_ -$.\9?G!_\
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M\0E_X)Y^)YFW-\0R6]?LJ?\ Q-5G_P""<?B&0DM\09,GTA _E7O'_#2'B_\
MZ(=XS_.#_P"*H_X:0\7_ /1#O&?YP?\ Q52\77?VOP7^1/UE/_EU#_P%'@(_
MX)L:XK97X@SJ>Q 8?UJS%_P3N\6P "+XHZA#CIY;R#_V:O=?^&C_ !?_ -$.
M\9_G!_\ %4O_  TAXO\ ^B'^,OS@_P#BJQE5J2W?X(7UB/\ SZA_X"CQ!/V
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M;_M3:O));^(6T6R3P-/XK_X117\Q_MPEWF,3D?=V;QC'7'-?22YR: '4444
M%%%% !1110 4444 %%%% !1110 5YK\-OA"? /Q%^(GB@ZD;P>+;R"[^S[,?
M9_+CV;<]\]:9^T)\2-=^$WPZNO$^A:;8ZH]G+$+B&^F:,"-Y%0E=HY(W=*YC
MXY?%[Q9X+U71;#PO)X7LFN;-[V[NO%#7 A1 0 %,(/.3SGM0![I165X8U-]7
M\.Z;>RW%I=2W$"2/-I[E[=V(Y,9/)7/3-:M !1110 4444 %)2T4 %%%% !1
M110 445@^,;[7+#P_=2>'-.@U36B MM!=2^5#N)^\[#G:.IQS0!RNM_"4ZM\
M=_#7Q%_M$QC1])NM,^P;,^9YS*V_=VQMZ>]>CU\N6?[3WCG28]1T#Q)X7TA/
M&*>(K3P]876FW$CZ7=/.I?S-S#>/+4'<O7->L?!OXI7WCS4/&&B:S9V]IKWA
M?41I]X;-F-O-N0.DD>[D @]#W% 'IE%%% !1110 4444 %%%% !1110 E+11
M0 5YY\?/A4?C5\*]8\'#4/[+_M PG[4$W[-DJ2=/?9C\:] D)4$@$X&<#O7@
M>H_&/XE^%/BSX>T?Q!X2T=O"WB&6YAM7TR[DEU"R$432"6X4C9Y9"X)7H2!0
M![U:Q>3;11YW;%"Y]<#%2UX)\#?C%XP\?^+);7Q%?>#(K":W>XM-/TF6Y&HX
M#8!=90%( Z[>AKWN@ HHHH **** "BBB@ HHHH **** $(YKP*V_9=2WU&WT
MW^W2W@BW\0_\)1%I!@_?_:]Q<1F7/^J#G=C&>V:]^I,4 "]*6BB@ HHHH **
M** "BBB@ HHHH **** "FOTIU% 'F/Q7^&_B#XDZ9J6@0:[8Z9X>U:W^RWNZ
MP$MVD9X<1.3MY'=@<=J[CPOH%KX4\/Z9HMEYGV/3[:.UA\UMS%$4*,GN<"M6
MEH **** "BBB@ HHHH **** "BBB@ HHHH 0\5Y+XB^%WB?6/CMX?\>6VMZ9
M!IFD6<UB--DLW:66.4J78R;\!AMXP,>M>MTF* / (/V68XM3@T\Z\S>"(/$?
M_"4QZ28/W_VS<7"&7/\ J@YW8QGMFO?P.]+10 4444 %%%% !1110 444E "
MT444 %%%% 'FOQ_^&VL_%OX>7GA;1]6L]%:]>,SW5W;-/M17#C8H8<Y4=>U+
MXK\'>,_$/AN'2[77='L9+BR-G?SMIIEQN&&>$%N#C/#9%>D4M '+?#'X?:?\
M+/ >B^%=+DGFL=+@$$<EPVYW[EC]23P*ZFBB@ HHHH **** "BBB@ HHHH *
M*** "N4^)&C^)]=\)W=CX0UVV\-ZW+@1:C=6GVE8AW_=D@$X]ZZNB@#YTL_V
M<?&&K>'X[;Q9XYL=2U/2]3M]7T.XTS1ULXK.XB)),B!CYF_<0V3GFO2/A+\+
M/^%=S>)-2O=0_M3Q!XDO_P"T=2NDC\N+?M"JD:9)"JHP,DFO0J6@ HHHH **
M** "BBB@ HHHH **** "BBB@"*?=L;80'VG:2,@'M7A6@_";XN6_C]-:UCXE
MZ/>Z69F:6TMO#J17#0\[(1,7)" XSQSCFO>J* /(],^#6IZE\4]"\<>*=9M;
MR[T"WN+;2[/2[/[/$HF&V224DDLVT8"C"CKBO7*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?'.L^)=+.F1>&M$@UB
M>ZGV3O=7'DQVT8&2Y(!)],5U55KZX>TM9YHX'NGC0LL$6-TA ^Z,X&30!X)\
M)/VA_%WQ/TV76F\'V-EH-GK5UH^H3KJ.Z2V$#%7GQMP4R.G7%=AX3^._AFXT
M32)M;\8^&I;W5Y9EL&TJY9H;M48\1[N68 <@=ZX+]D'PSXL\"?#WQCIWBGPA
M>:/=SZYJ&J6T$L\,OVF*>0NB JQ ;'!!XKRGX<?"SQ[ID7P=AU#X9W=G_P (
MUXGU#4+UVN+5A!;S;]C+AN?O#(% 'U9;?&_P'>C3VA\6:;(M_/\ 9;=A-P\W
M3RR?X6]C@UHZE\4?">C^(8]"OO$%E;:K(RQBVDDP0[?=4GH&/8$Y-?)&J?"S
MQ[-\,/'FG0?#J[&I:C\0%URSA%Q;*9+02H_F[MV 0$/'7FM&3X$>)_\ A9?B
M[3M?\ W7C#PSXEU^/Q#:ZJNNBVBLSA2(YXOO%HF7Y2O!H ^HOB?\2-+^%7@^
M[\0ZJ7>*)DAAMXN9+B9V"QQ(/5F(%>::I\>M>\&_%GPIX:\7:?I&D:/K.C76
MIRW:3N\UM)#@F+&,'@\D>AJE^V5X8U#4_AYX7UBQADNK?PQXCL-8OK>(%F>V
MB?$AQWV@[OPIGCC3-9\3_M'> /&&C>&IM?\ "EGH%_$^K6\T)CWSJ#&%5FR<
MXP3[T >EZU\>/AYX<TG2]4U/QGI%CI^J1-/97$URH2X11EBA[X%9VB?&JQO_
M !YIN@3R6TEEK]F;_P /:M:2[H-0B4 NGLX!!]Q7S)X2^$GCFR\(_!;3M7^&
M5S=-X<\37E]J4,LUK*L-M()0I&6PP_>*=H]#7K?Q5T=/%7[1'P>T#P[!'"GA
M>6XUC4?LJ!4L[<Q[$C('"EV. OH* /H[-+24M !1110 4444 %%%% !1110
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M_AKZVX_XM7\2^?\ J7C_ /%T >_T5\__ /#7UMG_ ))7\2__  GC_P#%T?\
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M-?6W_1*_B7_X3Q_^+H ^@**^?_\ AKVV_P"B5_$O_P )\_\ Q='_  U[;?\
M1*_B7_X3Y_\ BZ /H"BOG_\ X:^MO^B5_$O_ ,)X_P#Q='_#7UM_T2OXE_\
MA/'_ .+H ^@**^?_ /AKZV_Z)7\2_P#PGC_\71_PU];?]$K^)?\ X3Y_^+H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.:^(O@'1?BCX-U7PKXBMFO-%U.+R;F%7*%UR",,.1R!7DB?L1?#M$5%O?%:J
MH"A1XCN@ !T'WZ** %_X8D^'G_/]XL_\*.[_ /BZ/^&)?A[_ ,_WBS_PH[O_
M .+HHH 7_AB7X>?\_P!XL_\ "CN__BZ/^&)?AY_S_>+/_"CN_P#XNBB@!/\
MAB3X>?\ /]XL_P#"CN__ (NC_AB3X>?\_P!XL_\ "CN__BZ** #_ (8D^'G_
M #_>+/\ PH[O_P"+H_X8D^'G_/\ >+/_  H[O_XNBB@ _P"&)/AY_P _WBS_
M ,*.[_\ BZ4?L3?#T?\ +]XL_P#"CN__ (NBB@ _X8F^'O\ S_>+/_"CN_\
MXN@?L2_#T?\ +]XL_P#"CN__ (NBB@ _X8F^'O\ S_>+/_"CN_\ XNC_ (8E
M^'O_ #_>+/\ PH[O_P"+HHH /^&)OA[_ ,_WBS_PH[O_ .+H_P"&)OA[_P _
MWBS_ ,*.[_\ BZ**  ?L2_#W_G^\6?\ A1W?_P 71_PQ-\/?^?[Q9_X4=W_\
M7110 ?\ #$WP]_Y_O%G_ (4=W_\ %T?\,3?#W_G^\6?^%'=__%T44 !_8E^'
MI_Y?O%G_ (4=W_\ %T?\,3?#W_G^\6?^%'=__%T44 '_  Q+\/?^?[Q9_P"%
M'=__ !='_#$OP]_Y_O%G_A1W?_Q=%% !_P ,3?#W_G^\6?\ A1W?_P 71_PQ
M-\/3_P OWBS_ ,*.[_\ BZ** #_AB7X>_P#/]XL_\*.[_P#BZ/\ AB;X>_\
M/]XL_P#"CN__ (NBB@ _X8F^'O\ S_>+/_"CN_\ XNC_ (8F^'O_ #_>+/\
MPH[O_P"+HHH /^&)OA[_ ,_WBS_PH[O_ .+H_P"&)OA[_P _WBS_ ,*.[_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>scnx-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGO+bP9z5Z8eekhvWB6bUmK7yYrmXh6TyWzn/pGkWYO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:SCNX="http://scienture.com/20240630" elementFormDefault="qualified" targetNamespace="http://scienture.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://scienture.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Statements of Operations And Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/StatementsOfStockholdersDeficit" id="StatementsOfStockholdersDeficit">
          <link:definition>00000005 - Statement - Statements of Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" id="OrganizationOverviewAndBasisOfPresentation">
          <link:definition>999007 - Disclosure - Organization Overview and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999009 - Disclosure - Going Concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
          <link:definition>999010 - Disclosure - Cash and Cash Equivalents</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ConvertibleNotes" id="ConvertibleNotes">
          <link:definition>999011 - Disclosure - Convertible Notes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" id="Long-termConvertibleDebtNetOfDebtDiscount">
          <link:definition>999012 - Disclosure - Long-Term Convertible Debt, net of debt discount</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
          <link:definition>999013 - Disclosure - Fair Value of Financial Instruments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/CommitmentAndContingencies" id="CommitmentAndContingencies">
          <link:definition>999014 - Disclosure - Commitment and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999015 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" id="ScientureInc.2020StockOptionAndGrantPlan">
          <link:definition>999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/Warrants" id="Warrants">
          <link:definition>999017 - Disclosure - Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>999018 - Disclosure - Net Loss per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/Leases" id="Leases">
          <link:definition>999019 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999020 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
          <link:definition>999023 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" id="Long-termConvertibleDebtNetOfDebtDiscountTables">
          <link:definition>999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999025 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" id="ScientureInc.2020StockOptionAndGrantPlanTables">
          <link:definition>999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>999027 - Disclosure - Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999028 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999030 - Disclosure - Going Concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" id="ScheduleOfCashAndCashEquivalentsDetails">
          <link:definition>999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ConvertibleNotesDetailsNarrative" id="ConvertibleNotesDetailsNarrative">
          <link:definition>999032 - Disclosure - Convertible Notes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" id="ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails">
          <link:definition>999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" id="ScheduleOfMaturitiesNotesDetails">
          <link:definition>999034 - Disclosure - Schedule of Maturities Notes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" id="Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative">
          <link:definition>999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999036 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfStockOptionActivityDetails" id="SummaryOfStockOptionActivityDetails">
          <link:definition>999037 - Disclosure - Summary of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" id="ScheduleOfStockOptionValuationAssumptionsDetails">
          <link:definition>999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" id="ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative">
          <link:definition>999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
          <link:definition>999041 - Disclosure - Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/NetLossPerShareDetailsNarrative" id="NetLossPerShareDetailsNarrative">
          <link:definition>999042 - Disclosure - Net Loss per Share (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" id="ScheduleOfLeaseExpenseDetails">
          <link:definition>999043 - Disclosure - Schedule of Lease Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" id="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
          <link:definition>999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999045 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" id="ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails">
          <link:definition>999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" id="ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails">
          <link:definition>999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" id="SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails">
          <link:definition>999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
          <link:definition>999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
          <link:definition>999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://scienture.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999051 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="scnx-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="scnx-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="scnx-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="scnx-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="SCNX_ScientureIncMember" name="ScientureIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_StockholdersDeficitMember" name="StockholdersDeficitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_KesinPharmaCorporationMember" name="KesinPharmaCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_SaptalisPharmaceuticalsLlcMember" name="SaptalisPharmaceuticalsLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" name="ConvertiblePreferredStockAndConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_LongTermConvertibleDebtMember" name="LongTermConvertibleDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_MsPushpaShankarMember" name="MsPushpaShankarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_IssueOfPreferredStockMember" name="IssueOfPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_IssueOfConvertibleNotesMember" name="IssueOfConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_MsYogitaDesaiMember" name="MsYogitaDesaiMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_MrSandeepGuptaMember" name="MrSandeepGuptaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DevelopmentAgreementLiability" name="DevelopmentAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_TerminationFee" name="TerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DividendIncome" name="DividendIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_MiscellaneousIncome" name="MiscellaneousIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" name="IncreaseDecreaseInDevelopmentAgreementLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" name="ConversionOfNotesAndAccruedInterestIntoPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" name="WarrantsIssuedInConnectionWithLongtermConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" name="ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_WarrantValuationPolicyTextBlock" name="WarrantValuationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" name="DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" name="SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_TerminationFeeDescription" name="TerminationFeeDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" name="DebtInstrumentInterestRateStatedPrimeRatePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_DebtDilutedValuation" name="DebtDilutedValuation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_StockOptionAndGrantPlanHaveContractualTerm" name="StockOptionAndGrantPlanHaveContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SCNX_OperatingLeaseInterestExpense" name="OperatingLeaseInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>scnx-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://scienture.com/role/Cover" xlink:href="scnx-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheets" xlink:href="scnx-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheetsParenthetical" xlink:href="scnx-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="scnx-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:href="scnx-20240630.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfCashFlows" xlink:href="scnx-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:href="scnx-20240630.xsd#OrganizationOverviewAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcern" xlink:href="scnx-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalents" xlink:href="scnx-20240630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotes" xlink:href="scnx-20240630.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscount" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:href="scnx-20240630.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CommitmentAndContingencies" xlink:href="scnx-20240630.xsd#CommitmentAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactions" xlink:href="scnx-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Warrants" xlink:href="scnx-20240630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShare" xlink:href="scnx-20240630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Leases" xlink:href="scnx-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEvents" xlink:href="scnx-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:href="scnx-20240630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsTables" xlink:href="scnx-20240630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesTables" xlink:href="scnx-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:href="scnx-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:href="scnx-20240630.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:href="scnx-20240630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsDetailsNarrative" xlink:href="scnx-20240630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:href="scnx-20240630.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesDetailsNarrative" xlink:href="scnx-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:href="scnx-20240630.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:href="scnx-20240630.xsd#SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:href="scnx-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DevelopmentAgreementLiability" xlink:label="loc_SCNXDevelopmentAgreementLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_SCNXDevelopmentAgreementLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations And Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_SCNXTerminationFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DividendIncome" xlink:label="loc_SCNXDividendIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SCNXDividendIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MiscellaneousIncome" xlink:label="loc_SCNXMiscellaneousIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SCNXMiscellaneousIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:label="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:title="999007 - Disclosure - Organization Overview and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcern" xlink:title="999009 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalents" xlink:title="999010 - Disclosure - Cash and Cash Equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotes" xlink:title="999011 - Disclosure - Convertible Notes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:title="999012 - Disclosure - Long-Term Convertible Debt, net of debt discount" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:title="999013 - Disclosure - Fair Value of Financial Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/CommitmentAndContingencies" xlink:title="999014 - Disclosure - Commitment and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactions" xlink:title="999015 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:title="999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Warrants" xlink:title="999017 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShare" xlink:title="999018 - Disclosure - Net Loss per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Leases" xlink:title="999019 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEvents" xlink:title="999020 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:title="999023 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:title="999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:title="999025 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:title="999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsTables" xlink:title="999027 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesTables" xlink:title="999028 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:title="999030 - Disclosure - Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="loc_us-gaapCashAndDueFromBanks" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCashAndDueFromBanks" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999032 - Disclosure - Convertible Notes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:title="999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:title="999034 - Disclosure - Schedule of Maturities Notes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:title="999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999036 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:title="999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsDetailsNarrative" xlink:title="999041 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:title="999042 - Disclosure - Net Loss per Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="999043 - Disclosure - Schedule of Lease Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapShortTermLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapShortTermLeaseCost" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_OperatingLeaseInterestExpense" xlink:label="loc_SCNXOperatingLeaseInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapShortTermLeaseCost" xlink:to="loc_SCNXOperatingLeaseInterestExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesDetailsNarrative" xlink:title="999045 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:title="999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:title="999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:title="999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:title="999051 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>scnx-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://scienture.com/role/Cover" xlink:href="scnx-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheets" xlink:href="scnx-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheetsParenthetical" xlink:href="scnx-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="scnx-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:href="scnx-20240630.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfCashFlows" xlink:href="scnx-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:href="scnx-20240630.xsd#OrganizationOverviewAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcern" xlink:href="scnx-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalents" xlink:href="scnx-20240630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotes" xlink:href="scnx-20240630.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscount" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:href="scnx-20240630.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CommitmentAndContingencies" xlink:href="scnx-20240630.xsd#CommitmentAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactions" xlink:href="scnx-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Warrants" xlink:href="scnx-20240630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShare" xlink:href="scnx-20240630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Leases" xlink:href="scnx-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEvents" xlink:href="scnx-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:href="scnx-20240630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsTables" xlink:href="scnx-20240630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesTables" xlink:href="scnx-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:href="scnx-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:href="scnx-20240630.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:href="scnx-20240630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsDetailsNarrative" xlink:href="scnx-20240630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:href="scnx-20240630.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesDetailsNarrative" xlink:href="scnx-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:href="scnx-20240630.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:href="scnx-20240630.xsd#SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:href="scnx-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_40" xlink:to="loc_us-gaapAssetsCurrentAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_40" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_40" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_40" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_40" xlink:to="loc_us-gaapAssetsCurrent_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_40" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_40" xlink:to="loc_us-gaapAssets_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapAccountsPayableCurrent_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapLiabilitiesCurrent_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapConvertibleDebtNoncurrent_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_40" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DevelopmentAgreementLiability" xlink:label="loc_SCNXDevelopmentAgreementLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_SCNXDevelopmentAgreementLiability_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_us-gaapLiabilities_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_us-gaapCommitmentsAndContingencies_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_us-gaapStockholdersEquityAbstract_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_40" xlink:to="loc_us-gaapPreferredStockValue_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_40" xlink:to="loc_us-gaapCommonStockValue_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_40" xlink:to="loc_us-gaapAdditionalPaidInCapital_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_40" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_40" xlink:to="loc_us-gaapStockholdersEquity_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_40" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_40" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations And Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_SCNXTerminationFee_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_50" xlink:to="loc_us-gaapOperatingExpenses_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DividendIncome" xlink:label="loc_SCNXDividendIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_SCNXDividendIncome_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapOtherNonoperatingIncome_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MiscellaneousIncome" xlink:label="loc_SCNXMiscellaneousIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_SCNXMiscellaneousIncome_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapNonoperatingIncomeExpense_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockholdersDeficitMember" xlink:label="loc_SCNXStockholdersDeficitMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SCNXStockholdersDeficitMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:label="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_50" xlink:to="loc_us-gaapInterestPaidNet_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:label="loc_SCNXConversionOfNotesAndAccruedInterestIntoPreferredStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_SCNXConversionOfNotesAndAccruedInterestIntoPreferredStock_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:label="loc_SCNXWarrantsIssuedInConnectionWithLongtermConvertibleDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50" xlink:to="loc_SCNXWarrantsIssuedInConnectionWithLongtermConvertibleDebt_50" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:title="999007 - Disclosure - Organization Overview and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcern" xlink:title="999009 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalents" xlink:title="999010 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotes" xlink:title="999011 - Disclosure - Convertible Notes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:title="999012 - Disclosure - Long-Term Convertible Debt, net of debt discount">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:title="999013 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/CommitmentAndContingencies" xlink:title="999014 - Disclosure - Commitment and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactions" xlink:title="999015 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:title="999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Warrants" xlink:title="999017 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsTextBlock" xlink:label="loc_SCNXWarrantsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXWarrantsTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShare" xlink:title="999018 - Disclosure - Net Loss per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Leases" xlink:title="999019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEvents" xlink:title="999020 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventsTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_SCNXUnauditedInterimFinancialInformationPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXUnauditedInterimFinancialInformationPolicyTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LiquidityPolicyTextBlock" xlink:label="loc_SCNXLiquidityPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXLiquidityPolicyTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:label="loc_SCNXExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantValuationPolicyTextBlock" xlink:label="loc_SCNXWarrantValuationPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXWarrantValuationPolicyTextBlock_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_SCNXAccountingPronouncementsNotYetAdoptedPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXAccountingPronouncementsNotYetAdoptedPolicyTextBlock_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:label="loc_SCNXDeferredTaxAssetsAndLiabilitiesPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXDeferredTaxAssetsAndLiabilitiesPolicyTextBlock_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:title="999023 - Disclosure - Cash and Cash Equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:title="999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:title="999025 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:title="999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsTables" xlink:title="999027 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:label="loc_SCNXSummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXSummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesTables" xlink:title="999028 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_SCNXScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="loc_SCNXScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXTerminationFee_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFeeDescription" xlink:label="loc_SCNXTerminationFeeDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXTerminationFeeDescription_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:title="999030 - Disclosure - Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="loc_us-gaapCashAndDueFromBanks_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndDueFromBanks_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999032 - Disclosure - Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:title="999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:title="999034 - Disclosure - Schedule of Maturities Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:title="999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LoanAgreementMember" xlink:label="loc_SCNXLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SCNXLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLongTermDebt_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:label="loc_SCNXDebtInstrumentInterestRateStatedPrimeRatePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SCNXDebtInstrumentInterestRateStatedPrimeRatePercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestExpense_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtDilutedValuation" xlink:label="loc_SCNXDebtDilutedValuation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SCNXDebtDilutedValuation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999036 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_KesinPharmaCorporationMember" xlink:label="loc_SCNXKesinPharmaCorporationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXKesinPharmaCorporationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SaptalisPharmaceuticalsLlcMember" xlink:label="loc_SCNXSaptalisPharmaceuticalsLlcMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXSaptalisPharmaceuticalsLlcMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_PromissoryNoteMember" xlink:label="loc_SCNXPromissoryNoteMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SCNXPromissoryNoteMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MilestonePayment" xlink:label="loc_SCNXMilestonePayment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SCNXMilestonePayment_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SCNXTerminationFee_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaapVariableLeasePayment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapVariableLeasePayment_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings_150" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:title="999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockOptionAndGrantPlanHaveContractualTerm" xlink:label="loc_SCNXStockOptionAndGrantPlanHaveContractualTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SCNXStockOptionAndGrantPlanHaveContractualTerm_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsDetailsNarrative" xlink:title="999041 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:title="999042 - Disclosure - Net Loss per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" xlink:label="loc_SCNXConvertiblePreferredStockAndConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SCNXConvertiblePreferredStockAndConvertibleNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LongTermConvertibleDebtMember" xlink:label="loc_SCNXLongTermConvertibleDebtMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SCNXLongTermConvertibleDebtMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="999043 - Disclosure - Schedule of Lease Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_OperatingLeaseInterestExpense" xlink:label="loc_SCNXOperatingLeaseInterestExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXOperatingLeaseInterestExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesDetailsNarrative" xlink:title="999045 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:title="999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:title="999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsPushpaShankarMember" xlink:label="loc_SCNXMsPushpaShankarMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMsPushpaShankarMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsYogitaDesaiMember" xlink:label="loc_SCNXMsYogitaDesaiMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMsYogitaDesaiMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MrSandeepGuptaMember" xlink:label="loc_SCNXMrSandeepGuptaMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMrSandeepGuptaMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfPreferredStockMember" xlink:label="loc_SCNXIssueOfPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SCNXIssueOfPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfConvertibleNotesMember" xlink:label="loc_SCNXIssueOfConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SCNXIssueOfConvertibleNotesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherLiabilities_250" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:title="999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_20" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:title="999051 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermBorrowings_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestReceivable_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRoyaltyExpense_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_40" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>scnx-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="SCNX_ScientureIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScientureIncMember" xlink:to="SCNX_ScientureIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ScientureIncMember_lbl" xml:lang="en-US">Scienture Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockholdersDeficitMember" xlink:label="SCNX_StockholdersDeficitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_StockholdersDeficitMember" xlink:to="SCNX_StockholdersDeficitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_StockholdersDeficitMember_lbl" xml:lang="en-US">Stockholders Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LoanAgreementMember" xlink:label="SCNX_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LoanAgreementMember" xlink:to="SCNX_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_KesinPharmaCorporationMember" xlink:label="SCNX_KesinPharmaCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_KesinPharmaCorporationMember" xlink:to="SCNX_KesinPharmaCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_KesinPharmaCorporationMember_lbl" xml:lang="en-US">Kesin Pharma Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SaptalisPharmaceuticalsLlcMember" xlink:label="SCNX_SaptalisPharmaceuticalsLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_SaptalisPharmaceuticalsLlcMember" xlink:to="SCNX_SaptalisPharmaceuticalsLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_SaptalisPharmaceuticalsLlcMember_lbl" xml:lang="en-US">Saptalis Pharmaceuticals LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_PromissoryNoteMember" xlink:label="SCNX_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_PromissoryNoteMember" xlink:to="SCNX_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" xlink:label="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" xlink:to="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Preferred Stock and Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LongTermConvertibleDebtMember" xlink:label="SCNX_LongTermConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LongTermConvertibleDebtMember" xlink:to="SCNX_LongTermConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_LongTermConvertibleDebtMember_lbl" xml:lang="en-US">Long Term Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsPushpaShankarMember" xlink:label="SCNX_MsPushpaShankarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MsPushpaShankarMember" xlink:to="SCNX_MsPushpaShankarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_MsPushpaShankarMember_lbl" xml:lang="en-US">Ms. Pushpa Shankar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfPreferredStockMember" xlink:label="SCNX_IssueOfPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IssueOfPreferredStockMember" xlink:to="SCNX_IssueOfPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_IssueOfPreferredStockMember_lbl" xml:lang="en-US">Issue of Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfConvertibleNotesMember" xlink:label="SCNX_IssueOfConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IssueOfConvertibleNotesMember" xlink:to="SCNX_IssueOfConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_IssueOfConvertibleNotesMember_lbl" xml:lang="en-US">Issue of Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsYogitaDesaiMember" xlink:label="SCNX_MsYogitaDesaiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MsYogitaDesaiMember" xlink:to="SCNX_MsYogitaDesaiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_MsYogitaDesaiMember_lbl" xml:lang="en-US">Ms. Yogita Desai [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MrSandeepGuptaMember" xlink:label="SCNX_MrSandeepGuptaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MrSandeepGuptaMember" xlink:to="SCNX_MrSandeepGuptaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_MrSandeepGuptaMember_lbl" xml:lang="en-US">Mr. Sandeep Gupta [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Long-term convertible debt, net of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non current</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DevelopmentAgreementLiability" xlink:label="SCNX_DevelopmentAgreementLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DevelopmentAgreementLiability" xlink:to="SCNX_DevelopmentAgreementLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_DevelopmentAgreementLiability_lbl" xml:lang="en-US">Development agreement liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Refer Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.0001 par value, 2,400,000 authorized, issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 10,000,000 authorized, 5,000,000 issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="SCNX_TerminationFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_TerminationFee" xlink:to="SCNX_TerminationFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_TerminationFee_lbl" xml:lang="en-US">Termination fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DividendIncome" xlink:label="SCNX_DividendIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DividendIncome" xlink:to="SCNX_DividendIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_DividendIncome_lbl" xml:lang="en-US">Dividend income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MiscellaneousIncome" xlink:label="SCNX_MiscellaneousIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MiscellaneousIncome" xlink:to="SCNX_MiscellaneousIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_MiscellaneousIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares used to compute net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used to compute net loss per share - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Stock-based compensation expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of notes into preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of notes into preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued in connection with long-term convertible debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:label="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:to="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_lbl" xml:lang="en-US">Development agreement liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from the issuance of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from the issuance of long-term convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:label="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:to="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock_lbl" xml:lang="en-US">Conversion of notes and accrued interest into preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:label="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:to="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_lbl" xml:lang="en-US">Warrants issued in connection with long-term convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xml:lang="en-US">Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization Overview and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-Term Convertible Debt, net of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitment and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Scienture Inc. 2020 Stock Option and Grant Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsTextBlock" xlink:label="SCNX_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantsTextBlock" xlink:to="SCNX_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_WarrantsTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LiquidityPolicyTextBlock" xlink:label="SCNX_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LiquidityPolicyTextBlock" xlink:to="SCNX_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:label="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:to="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_lbl" xml:lang="en-US">Exclusive License and Commercial Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risks and Major Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research &amp; Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantValuationPolicyTextBlock" xlink:label="SCNX_WarrantValuationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantValuationPolicyTextBlock" xlink:to="SCNX_WarrantValuationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_WarrantValuationPolicyTextBlock_lbl" xml:lang="en-US">Warrant Valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:label="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:to="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements Recently Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Related Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long Term Convertible Debt Net of Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Relatives or Related Parties to Directors Purchased Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:label="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:to="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US">Summary of Assumptions Used to Estimate Fair Value of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related To Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related To Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities Of Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFeeDescription" xlink:label="SCNX_TerminationFeeDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_TerminationFeeDescription" xlink:to="SCNX_TerminationFeeDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_TerminationFeeDescription_lbl" xml:lang="en-US">Termination fee description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Loss before tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="us-gaap_CashAndDueFromBanks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndDueFromBanks" xlink:to="us-gaap_CashAndDueFromBanks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndDueFromBanks_lbl" xml:lang="en-US">Balances with banks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market securities (Highly liquid investments)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Convertible notes issued bear interest rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt outstanding principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: Unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term convertible debt, net of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">Year 1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">Year 2</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Year 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:label="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:to="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage_lbl" xml:lang="en-US">Debt prime rate percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debt interest rate percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtDilutedValuation" xlink:label="SCNX_DebtDilutedValuation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DebtDilutedValuation" xlink:to="SCNX_DebtDilutedValuation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_DebtDilutedValuation_lbl" xml:lang="en-US">Debt diluted valuation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Debt discount interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MilestonePayment" xlink:label="SCNX_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MilestonePayment" xlink:to="SCNX_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_MilestonePayment_lbl" xml:lang="en-US">Milestone structure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeasePayment" xlink:to="us-gaap_VariableLeasePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeasePayment_lbl" xml:lang="en-US">Lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding Options, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Remaining Term (Years), Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Outstanding Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Outstanding Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Outstanding Options, Cancelled and forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Cancelled and forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding Options, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Outstanding Options, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding Options, Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Term (Years), Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockOptionAndGrantPlanHaveContractualTerm" xlink:label="SCNX_StockOptionAndGrantPlanHaveContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_StockOptionAndGrantPlanHaveContractualTerm" xlink:to="SCNX_StockOptionAndGrantPlanHaveContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_StockOptionAndGrantPlanHaveContractualTerm_lbl" xml:lang="en-US">Stock Option and Grant Plan have a contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of ROU Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_OperatingLeaseInterestExpense" xlink:label="SCNX_OperatingLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_OperatingLeaseInterestExpense" xlink:to="SCNX_OperatingLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_OperatingLeaseInterestExpense_lbl" xml:lang="en-US">Interest on Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short term lease costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of Use Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short term Lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long term Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted Average Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Operating lease remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment and operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Nature of transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Related party Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Measurement Input, warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected life of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2_lbl" xml:lang="en-US">Cash paid for accounts included in the measurements of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows for Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of Use Assets obtained in exchange for new Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_2_lbl" xml:lang="en-US">Short term borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3_lbl" xml:lang="en-US">Stock issued during period value conversion of convertible securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock issued during period shares conversion of convertible securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xml:lang="en-US">Debt instrument interest rate stated percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScientureIncMember" xlink:to="SCNX_ScientureIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ScientureIncMember_doc" xml:lang="en-US">Scienture Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DevelopmentAgreementLiability" xlink:to="SCNX_DevelopmentAgreementLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_DevelopmentAgreementLiability_doc" xml:lang="en-US">Development agreement liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_TerminationFee" xlink:to="SCNX_TerminationFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_TerminationFee_doc" xml:lang="en-US">Termination fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantsTextBlock" xlink:to="SCNX_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:to="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_doc" xml:lang="en-US">Increase decrease in development agreement liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:to="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock_doc" xml:lang="en-US">Conversion of notes and accrued interest into preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_UnauditedInterimFinancialInformationPolicyTextBlock_doc" xml:lang="en-US">Unaudited Interim Financial Information [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LiquidityPolicyTextBlock" xlink:to="SCNX_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" xlink:to="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ConvertiblePreferredStockAndConvertibleNotesMember_doc" xml:lang="en-US">Convertible Preferred Stock and Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LongTermConvertibleDebtMember" xlink:to="SCNX_LongTermConvertibleDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_LongTermConvertibleDebtMember_doc" xml:lang="en-US">Long Term Convertible Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MilestonePayment" xlink:to="SCNX_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_MilestonePayment_doc" xml:lang="en-US">Milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_KesinPharmaCorporationMember" xlink:to="SCNX_KesinPharmaCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_KesinPharmaCorporationMember_doc" xml:lang="en-US">Kesin Pharma Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_SaptalisPharmaceuticalsLlcMember" xlink:to="SCNX_SaptalisPharmaceuticalsLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_SaptalisPharmaceuticalsLlcMember_doc" xml:lang="en-US">Saptalis Pharmaceuticals LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_LoanAgreementMember" xlink:to="SCNX_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_PromissoryNoteMember" xlink:to="SCNX_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:to="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_doc" xml:lang="en-US">Exclusive License and Commercial Agreements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MiscellaneousIncome" xlink:to="SCNX_MiscellaneousIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_MiscellaneousIncome_doc" xml:lang="en-US">Miscellaneous income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_TerminationFeeDescription" xlink:to="SCNX_TerminationFeeDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_TerminationFeeDescription_doc" xml:lang="en-US">Termination fee description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:to="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage_doc" xml:lang="en-US">Debt instrument interest rate stated prime rate percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DividendIncome" xlink:to="SCNX_DividendIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_DividendIncome_doc" xml:lang="en-US">Dividend income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantValuationPolicyTextBlock" xlink:to="SCNX_WarrantValuationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_WarrantValuationPolicyTextBlock_doc" xml:lang="en-US">Warrant Valuation [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:to="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_doc" xml:lang="en-US">Warrants issued in connection with long term convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:to="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_doc" xml:lang="en-US">Summary of Assumptions Used to Estimate Fair Value of Warrants Granted [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_StockOptionAndGrantPlanHaveContractualTerm" xlink:to="SCNX_StockOptionAndGrantPlanHaveContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_StockOptionAndGrantPlanHaveContractualTerm_doc" xml:lang="en-US">Stock option and grant plan have contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DebtDilutedValuation" xlink:to="SCNX_DebtDilutedValuation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_DebtDilutedValuation_doc" xml:lang="en-US">Debt diluted valuation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MsPushpaShankarMember" xlink:to="SCNX_MsPushpaShankarMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_MsPushpaShankarMember_doc" xml:lang="en-US">Ms. Pushpa Shankar [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IssueOfPreferredStockMember" xlink:to="SCNX_IssueOfPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_IssueOfPreferredStockMember_doc" xml:lang="en-US">Issue of Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:to="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Deferred Tax Assets and Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IssueOfConvertibleNotesMember" xlink:to="SCNX_IssueOfConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_IssueOfConvertibleNotesMember_doc" xml:lang="en-US">Issue of Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MsYogitaDesaiMember" xlink:to="SCNX_MsYogitaDesaiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_MsYogitaDesaiMember_doc" xml:lang="en-US">Ms. Yogita Desai [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_MrSandeepGuptaMember" xlink:to="SCNX_MrSandeepGuptaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_MrSandeepGuptaMember_doc" xml:lang="en-US">Mr. Sandeep Gupta [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_StockholdersDeficitMember" xlink:to="SCNX_StockholdersDeficitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_StockholdersDeficitMember_doc" xml:lang="en-US">Stockholders Deficit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_OperatingLeaseInterestExpense" xlink:to="SCNX_OperatingLeaseInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SCNX_OperatingLeaseInterestExpense_doc" xml:lang="en-US">Operating lease interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:to="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_IncreaseDecreaseInDevelopmentAgreementLiability_3_lbl" xml:lang="en-US">IncreaseDecreaseInDevelopmentAgreementLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:to="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt_3_lbl" xml:lang="en-US">WarrantsIssuedInConnectionWithLongtermConvertibleDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_2_lbl" xml:lang="en-US">Short-Term Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>scnx-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://scienture.com/role/Cover" xlink:href="scnx-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheets" xlink:href="scnx-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/BalanceSheetsParenthetical" xlink:href="scnx-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="scnx-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:href="scnx-20240630.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/StatementsOfCashFlows" xlink:href="scnx-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:href="scnx-20240630.xsd#OrganizationOverviewAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcern" xlink:href="scnx-20240630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalents" xlink:href="scnx-20240630.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotes" xlink:href="scnx-20240630.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscount" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:href="scnx-20240630.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CommitmentAndContingencies" xlink:href="scnx-20240630.xsd#CommitmentAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactions" xlink:href="scnx-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Warrants" xlink:href="scnx-20240630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShare" xlink:href="scnx-20240630.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Leases" xlink:href="scnx-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEvents" xlink:href="scnx-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:href="scnx-20240630.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsTables" xlink:href="scnx-20240630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesTables" xlink:href="scnx-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="scnx-20240630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:href="scnx-20240630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:href="scnx-20240630.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:href="scnx-20240630.xsd#Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="scnx-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:href="scnx-20240630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:href="scnx-20240630.xsd#ScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:href="scnx-20240630.xsd#ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/WarrantsDetailsNarrative" xlink:href="scnx-20240630.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:href="scnx-20240630.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:href="scnx-20240630.xsd#ScheduleOfLeaseExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/LeasesDetailsNarrative" xlink:href="scnx-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:href="scnx-20240630.xsd#ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:href="scnx-20240630.xsd#SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="scnx-20240630.xsd#ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:href="scnx-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DevelopmentAgreementLiability" xlink:label="loc_SCNXDevelopmentAgreementLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_SCNXDevelopmentAgreementLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations And Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_SCNXTerminationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DividendIncome" xlink:label="loc_SCNXDividendIncome" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_SCNXDividendIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MiscellaneousIncome" xlink:label="loc_SCNXMiscellaneousIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_SCNXMiscellaneousIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockholdersDeficitMember" xlink:label="loc_SCNXStockholdersDeficitMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_SCNXStockholdersDeficitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IncreaseDecreaseInDevelopmentAgreementLiability" xlink:label="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SCNXIncreaseDecreaseInDevelopmentAgreementLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:label="loc_SCNXConversionOfNotesAndAccruedInterestIntoPreferredStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SCNXConversionOfNotesAndAccruedInterestIntoPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:label="loc_SCNXWarrantsIssuedInConnectionWithLongtermConvertibleDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SCNXWarrantsIssuedInConnectionWithLongtermConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation" xlink:title="999007 - Disclosure - Organization Overview and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcern" xlink:title="999009 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalents" xlink:title="999010 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotes" xlink:title="999011 - Disclosure - Convertible Notes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount" xlink:title="999012 - Disclosure - Long-Term Convertible Debt, net of debt discount">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/FairValueOfFinancialInstruments" xlink:title="999013 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/CommitmentAndContingencies" xlink:title="999014 - Disclosure - Commitment and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactions" xlink:title="999015 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan" xlink:title="999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Warrants" xlink:title="999017 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureWarrantsAbstract" xlink:label="loc_SCNXDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantsTextBlock" xlink:label="loc_SCNXWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShare" xlink:title="999018 - Disclosure - Net Loss per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Leases" xlink:title="999019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureLeasesAbstract" xlink:label="loc_SCNXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEvents" xlink:title="999020 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="loc_SCNXUnauditedInterimFinancialInformationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXUnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LiquidityPolicyTextBlock" xlink:label="loc_SCNXLiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:label="loc_SCNXExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXExclusiveLicenseAndCommercialAgreementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_WarrantValuationPolicyTextBlock" xlink:label="loc_SCNXWarrantValuationPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXWarrantValuationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_SCNXAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:label="loc_SCNXDeferredTaxAssetsAndLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXDeferredTaxAssetsAndLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/CashAndCashEquivalentsTables" xlink:title="999023 - Disclosure - Cash and Cash Equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables" xlink:title="999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsTables" xlink:title="999025 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables" xlink:title="999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsTables" xlink:title="999027 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureWarrantsAbstract" xlink:label="loc_SCNXDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:label="loc_SCNXSummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXSummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesTables" xlink:title="999028 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureLeasesAbstract" xlink:label="loc_SCNXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_SCNXScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="loc_SCNXScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXTerminationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFeeDescription" xlink:label="loc_SCNXTerminationFeeDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXTerminationFeeDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/GoingConcernDetailsNarrative" xlink:title="999030 - Disclosure - Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="loc_us-gaapCashAndDueFromBanks" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndDueFromBanks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ConvertibleNotesDetailsNarrative" xlink:title="999032 - Disclosure - Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails" xlink:title="999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesNotesDetails" xlink:title="999034 - Disclosure - Schedule of Maturities Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative" xlink:title="999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LoanAgreementMember" xlink:label="loc_SCNXLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SCNXLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:label="loc_SCNXDebtInstrumentInterestRateStatedPrimeRatePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SCNXDebtInstrumentInterestRateStatedPrimeRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DebtDilutedValuation" xlink:label="loc_SCNXDebtDilutedValuation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SCNXDebtDilutedValuation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999036 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_KesinPharmaCorporationMember" xlink:label="loc_SCNXKesinPharmaCorporationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXKesinPharmaCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_SaptalisPharmaceuticalsLlcMember" xlink:label="loc_SCNXSaptalisPharmaceuticalsLlcMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXSaptalisPharmaceuticalsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_PromissoryNoteMember" xlink:label="loc_SCNXPromissoryNoteMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SCNXPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MilestonePayment" xlink:label="loc_SCNXMilestonePayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SCNXMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_TerminationFee" xlink:label="loc_SCNXTerminationFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_SCNXTerminationFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaapVariableLeasePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapVariableLeasePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999037 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails" xlink:title="999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative" xlink:title="999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_StockOptionAndGrantPlanHaveContractualTerm" xlink:label="loc_SCNXStockOptionAndGrantPlanHaveContractualTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SCNXStockOptionAndGrantPlanHaveContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/WarrantsDetailsNarrative" xlink:title="999041 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureWarrantsAbstract" xlink:label="loc_SCNXDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/NetLossPerShareDetailsNarrative" xlink:title="999042 - Disclosure - Net Loss per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ConvertiblePreferredStockAndConvertibleNotesMember" xlink:label="loc_SCNXConvertiblePreferredStockAndConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SCNXConvertiblePreferredStockAndConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_LongTermConvertibleDebtMember" xlink:label="loc_SCNXLongTermConvertibleDebtMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SCNXLongTermConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfLeaseExpenseDetails" xlink:title="999043 - Disclosure - Schedule of Lease Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureLeasesAbstract" xlink:label="loc_SCNXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_OperatingLeaseInterestExpense" xlink:label="loc_SCNXOperatingLeaseInterestExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SCNXOperatingLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureLeasesAbstract" xlink:label="loc_SCNXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/LeasesDetailsNarrative" xlink:title="999045 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_DisclosureLeasesAbstract" xlink:label="loc_SCNXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SCNXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails" xlink:title="999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails" xlink:title="999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsPushpaShankarMember" xlink:label="loc_SCNXMsPushpaShankarMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMsPushpaShankarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MsYogitaDesaiMember" xlink:label="loc_SCNXMsYogitaDesaiMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMsYogitaDesaiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_MrSandeepGuptaMember" xlink:label="loc_SCNXMrSandeepGuptaMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SCNXMrSandeepGuptaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfPreferredStockMember" xlink:label="loc_SCNXIssueOfPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SCNXIssueOfPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_IssueOfConvertibleNotesMember" xlink:label="loc_SCNXIssueOfConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_SCNXIssueOfConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails" xlink:title="999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://scienture.com/role/SubsequentEventsDetailsNarrative" xlink:title="999051 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="scnx-20240630.xsd#SCNX_ScientureIncMember" xlink:label="loc_SCNXScientureIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_SCNXScientureIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142732320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">424B3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scienture Holdings, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001382574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968143134672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 114,210<span></span>
</td>
<td class="nump">$ 1,123,878<span></span>
</td>
<td class="nump">$ 604,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,414<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">114,695<span></span>
</td>
<td class="nump">1,190,777<span></span>
</td>
<td class="nump">605,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use asset</a></td>
<td class="nump">61,579<span></span>
</td>
<td class="nump">64,091<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">176,274<span></span>
</td>
<td class="nump">1,254,868<span></span>
</td>
<td class="nump">605,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">884,581<span></span>
</td>
<td class="nump">107,175<span></span>
</td>
<td class="nump">393,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,198,822<span></span>
</td>
<td class="nump">332,211<span></span>
</td>
<td class="nump">83,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,665,220<span></span>
</td>
<td class="nump">2,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">22,567<span></span>
</td>
<td class="nump">21,404<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,105,970<span></span>
</td>
<td class="nump">4,126,010<span></span>
</td>
<td class="nump">3,427,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long-term convertible debt, net of debt discount</a></td>
<td class="nump">1,734,661<span></span>
</td>
<td class="nump">1,625,117<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non current</a></td>
<td class="nump">39,319<span></span>
</td>
<td class="nump">42,893<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_DevelopmentAgreementLiability', window );">Development agreement liability</a></td>
<td class="nump">1,285,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">5,164,950<span></span>
</td>
<td class="nump">5,794,020<span></span>
</td>
<td class="nump">3,427,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Refer Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.0001 par value, 2,400,000 authorized, issued and outstanding</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 10,000,000 authorized, 5,000,000 issued and outstanding</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">10,835,257<span></span>
</td>
<td class="nump">6,849,064<span></span>
</td>
<td class="nump">6,325,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,824,770)<span></span>
</td>
<td class="num">(11,388,956)<span></span>
</td>
<td class="num">(9,147,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(4,988,676)<span></span>
</td>
<td class="num">(4,539,152)<span></span>
</td>
<td class="num">(2,821,872)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">$ 176,274<span></span>
</td>
<td class="nump">$ 1,254,868<span></span>
</td>
<td class="nump">$ 605,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_DevelopmentAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development agreement liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_DevelopmentAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140241392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - Scienture Inc [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,365,657<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">3,365,657<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">3,365,657<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140438432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations And Comprehensive Loss - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,520,947<span></span>
</td>
<td class="nump">946,435<span></span>
</td>
<td class="nump">2,029,812<span></span>
</td>
<td class="nump">3,061,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,413,893<span></span>
</td>
<td class="nump">267,236<span></span>
</td>
<td class="nump">719,398<span></span>
</td>
<td class="nump">880,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_TerminationFee', window );">Termination fee</a></td>
<td class="nump">1,285,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,219,840<span></span>
</td>
<td class="nump">1,213,671<span></span>
</td>
<td class="nump">2,749,210<span></span>
</td>
<td class="nump">3,941,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(4,219,840)<span></span>
</td>
<td class="num">(413,671)<span></span>
</td>
<td class="num">(1,949,210)<span></span>
</td>
<td class="num">(3,641,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_DividendIncome', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,401<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">11,931<span></span>
</td>
<td class="nump">18,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="num">(227,905)<span></span>
</td>
<td class="num">(76,203)<span></span>
</td>
<td class="num">(312,577)<span></span>
</td>
<td class="num">(76,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,397<span></span>
</td>
<td class="nump">9,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(215,974)<span></span>
</td>
<td class="num">(57,899)<span></span>
</td>
<td class="num">(291,779)<span></span>
</td>
<td class="num">(66,777)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (4,435,814)<span></span>
</td>
<td class="num">$ (471,570)<span></span>
</td>
<td class="num">$ (2,240,989)<span></span>
</td>
<td class="num">$ (3,708,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute net loss per share - basic</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute net loss per share - diluted</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_DividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_DividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_MiscellaneousIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_MiscellaneousIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140504528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Deficit - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Stockholders Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">$ 6,111,783<span></span>
</td>
<td class="num">$ (5,439,589)<span></span>
</td>
<td class="nump">$ 672,919<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">4,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">145,485<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,087<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,708,378)<span></span>
</td>
<td class="num">(3,708,378)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">6,325,355<span></span>
</td>
<td class="num">(9,147,967)<span></span>
</td>
<td class="num">(2,821,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39,724<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">39,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(471,570)<span></span>
</td>
<td class="num">(471,570)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">6,365,079<span></span>
</td>
<td class="num">(9,619,537)<span></span>
</td>
<td class="num">(3,253,718)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">6,325,355<span></span>
</td>
<td class="num">(9,147,967)<span></span>
</td>
<td class="num">(2,821,872)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">79,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,240,989)<span></span>
</td>
<td class="num">(2,240,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with long-term convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">444,260<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">444,260<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">6,849,064<span></span>
</td>
<td class="num">(11,388,956)<span></span>
</td>
<td class="num">(4,539,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Stock-based compensation expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,837<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,435,814)<span></span>
</td>
<td class="num">(4,435,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of notes into preferred stock</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,941,356<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,941,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of notes into preferred stock, shares</a></td>
<td class="nump">965,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">3,365,657<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 10,835,257<span></span>
</td>
<td class="num">$ (15,824,770)<span></span>
</td>
<td class="num">$ (4,988,676)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968136023664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,435,814)<span></span>
</td>
<td class="num">$ (471,570)<span></span>
</td>
<td class="num">$ (2,240,989)<span></span>
</td>
<td class="num">$ (3,708,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">109,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,378<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="nump">44,837<span></span>
</td>
<td class="nump">39,724<span></span>
</td>
<td class="nump">79,449<span></span>
</td>
<td class="nump">68,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">66,414<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(66,414)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">777,406<span></span>
</td>
<td class="nump">29,729<span></span>
</td>
<td class="num">(286,501)<span></span>
</td>
<td class="nump">65,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,142,843<span></span>
</td>
<td class="nump">76,212<span></span>
</td>
<td class="nump">248,716<span></span>
</td>
<td class="nump">76,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_IncreaseDecreaseInDevelopmentAgreementLiability', window );">Development agreement liability</a></td>
<td class="nump">1,285,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability, net</a></td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,009,668)<span></span>
</td>
<td class="num">(625,905)<span></span>
</td>
<td class="num">(2,196,155)<span></span>
</td>
<td class="num">(3,352,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">715,220<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from the issuance of long-term convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">2,715,220<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,009,668)<span></span>
</td>
<td class="num">(225,905)<span></span>
</td>
<td class="nump">519,065<span></span>
</td>
<td class="num">(2,502,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">1,123,878<span></span>
</td>
<td class="nump">604,813<span></span>
</td>
<td class="nump">604,813<span></span>
</td>
<td class="nump">3,107,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">114,210<span></span>
</td>
<td class="nump">378,908<span></span>
</td>
<td class="nump">1,123,878<span></span>
</td>
<td class="nump">604,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock', window );">Conversion of notes and accrued interest into preferred stock</a></td>
<td class="nump">$ 3,941,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt', window );">Warrants issued in connection with long-term convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of notes and accrued interest into preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_IncreaseDecreaseInDevelopmentAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in development agreement liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_IncreaseDecreaseInDevelopmentAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in connection with long term convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142455600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization Overview and Basis of Presentation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zP8RcZ5GbJIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 <span id="xdx_827_zwSYs6RJLtDd">Organization Overview and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (&#8220;the Company&#8221;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements for the periods ending June 30, 2024 and 2023 have been prepared in accordance with accounting principles
generally accepted in the United States (&#8220;U.S.GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zXzEGacBJfP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Note
1 <span id="xdx_82E_zO4r7Wp0d86l">Organization Overview and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (&#8220;the Company&#8221;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s fiscal year ends on December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements for the period ending December 31, 2023 and 2022 have been prepared in accordance with accounting principles
generally accepted in the United States (&#8220;U.S.GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142624448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdQz4Ku2fPp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 <span id="xdx_824_z3Dh44BMJeMb">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zVPOLExEFmK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zxSDaACjaeD5">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--UnauditedInterimFinancialInformationPolicyTextBlock_zdFAodwb1E1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zQZJYwAIYHti">Unaudited
Interim Financial Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim
financial information, within the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).
Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis
consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal
recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition
as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial
statements related to the six-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for
the full fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited
financial statements and the notes thereto for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2l2P0tZC6o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zODvNvGLoWA7">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zxhgn6Q5ujW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zuJ78iJTA1a5">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zE1fnIck2JLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zUHFJGQLSaIh">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20240630_zuRtCDhxAaY" title="Number of reportable segment::XDX::1"><span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20240101__20240630_zhw6TVMnHfrl" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0377"><span style="-sec-ix-hidden: xdx2ixbrl0379">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGt2pUccSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zIC2blmEuDV8">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6LqTc1l1NQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zqhJLDK3sSA8">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240630_zRVQFAe6mlOc" title="Allowance for doubtful accounts"><span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zRZgK4nRWgj5" title="Allowance for doubtful accounts">0</span></span> as of June 30, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z9u4ZW4nirW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z8z2xy9MUyg1">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z7hNftnCGULl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zEPGvgYRCnV1">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630_zjwFP8znkrH8" title="Revenue recognized">800,000</span> for the six months
ended June 30, 2023, at the point when the development milestone events occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall pay Kesin a total gross amount of
$<span id="xdx_90F_ecustom--TerminationFee_c20240301__20240331_zbrSruzSNcb4" title="Termination fee">1,285,000</span> upon commercialization of product via a royalty arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--TerminationFeeDescription_c20240301__20240331_zUPQA6xR5mOb" title="Termination fee description">This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zk14AEaP86y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zn0dovk53fB1">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_ztZeoYC6DQ8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zfSzsnGkNMH9">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the six months ended June 30, 2024, the Company had
one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9WtrBhyn5m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zfojqVg69RVb">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjQmab8imlO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z17IT79YgzKj">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option-pricing model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based
awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest
rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company has estimated volatility
by reference to the historical volatilities of the Company and that of similar publicly traded peer companies. The risk-free interest
rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled
award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zT2pXJTCvfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ztSYFFhT3r2e">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zmhFfpP7PIoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zPnVd1CLtqZg">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;</span></p>

<p id="xdx_8AF_zQuMJxhtbJxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zlo6CuWHvH4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zrZL0Sxeovk8">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>
<p id="xdx_85A_zjHDxiwRn7B1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zhOO5ZXcJVxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 <span id="xdx_824_z9tbPbgJ83Fl">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zDw6Ai1JWhNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z3foTLi5y2t6">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease
    term</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_zOvPcfhCQI36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zy4BUgnX5aYh">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zUDtEgzcnAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zuTRUepB66i4">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNaP59og6Bre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zDxAsKHKGC07">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_zQFvL72BwS95" title="Number of reportable segment::XDX::1"><span id="xdx_907_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20230101__20231231_zzlYO99If5Lf" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0993"><span style="-sec-ix-hidden: xdx2ixbrl0995">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJ11pNKLt4j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z2pVeuN5hIU3">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zwD0xPUmp2q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z09Lz3B2WS0k">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zjggDz3CdhM3" title="Allowance for doubtful accounts"><span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zPnPWh6lbXf3" title="Allowance for doubtful accounts">0</span></span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Refer
&#8211; Note 14&#8211; Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z31KAvzCkY56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z5zx0gMnjcI3">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z2JhbIcHdvOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zd1OqPSy1EC8">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zm95aluQBMk3" title="Revenue recognized">800,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zYelXpAhKAl7" title="Revenue recognized">300,000</span>, respectively,
during the years ended December 31, 2023 and 2022 at the point when the development milestone events occurred. (Refer &#8211; Note 14&#8211;
Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zpBk8Rxd7OJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXDu1rOp5G12">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Level
    3 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJrtJLxttz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z1ZC3PGQm9C2">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the years ended December 31, 2023, and 2022, the company
had one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwCXj4i6zeEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zWKr6Kcp3Zc1">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIdqihDN0YB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjo7F3n0srO9">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The fair values of stock-based compensations are recognized as compensation expense on a straight-line
basis over the requisite service period in which the awards are expected to vest. The Company estimates the fair value of stock option
awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes model considers several variables and assumptions
in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock,
exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the
expected term. The Company has estimated volatility by reference to the historical volatilities of the Company and that of similar publicly
traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration
to the expected term of the equity-settled award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zeToUOiWtOCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zIq0xJKLreE9">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zCjnOUHbWpI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z3hwU0J9pJR8">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is incorporated in Delaware and headquartered in New York where the state tax is <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20230101__20231231_z1dGVIh0nh06" title="State income tax rate">8.70</span>% and <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20220101__20221231_zQnpB8DJfb1" title="State income tax rate">7.25</span>% respectively. However, due to
losses for the years ended December 31, 2023 and 2022, no provision on state income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Federal
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C Corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners. The company records
income taxes pursuant to the liability method. The Company has a loss before tax of ($<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zaXalyfNxvSa" title="Loss before tax">2,240,989</span>) and ($<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zpYkYtiSAfh" title="Loss before tax">3,708,378</span>) for years ended December
31, 2023 and 2022 respectively. Therefore, no provision for federal income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_zqIOkbM1Gmn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zAo6Gt6RSIo1">Deferred
Tax Assets and Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial statement and the tax basis of assets and liabilities.
Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company&#8217;s
ability to generate taxable income. Management believes that, at a minimum, it is more likely than not that future taxable income may
not be sufficient to realize the recorded assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a deferred tax asset related to its net operating loss carryforwards, timing difference between written down value
of assets, and unutilized R&amp;D credit, which are expected to reduce future taxable income. The company has assessed the likelihood
of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets may not be realized.
Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its expected realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the deferred tax assets and related valuation allowance on the Company&#8217;s financial statements is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zGlZeO8SmXN4" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowance</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">3,173,840</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,491,667</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,635</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment and operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,220</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,229,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,548,331</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zhfSfKJNG6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zNuN1XW7SxP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWi4i8AXB54a">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zC30tXxD2fX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zWcF8MYTuJ24">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements.
The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (ASC 326), which provides guidance on measurement
of credit losses on financial instruments. This ASU adds a current expected credit loss impairment model to U.S.GAAP that is based on
expected losses rather than incurred losses whereby a broader range of reasonable and supportable information is required to be utilized
in order to derive credit loss estimates. The effective date of the new guidance as amended by ASU No. 2019-10 is fiscal years beginning
after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023
the company determined that the update applied to trade receivables, but that there no material impact to the financial statements from
the adoption of ASU 2016-13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No.
2016-2, Leases, to provide guidance for the accounting for leasing transactions. The standard requires the lessee to recognize a lease
liability along with a right-of-use asset for all leases with a term longer than one year. A lessee is permitted to make an accounting
policy election by class of underlying asset to not recognize the lease liability and related right-of-use asset for leases with a term
of one year or less. The provisions of this standard also apply to situations where the Company is the lessor. In March 2019, the FASB
issued ASU 2019-01, &#8220;Lease (842): Codification improvements.&#8221; This updated clarified that entities were exempt from disclosing
the effect of the change on income from continuing operations, net income, and related per-share amounts, if applicable, for interim
periods after the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard was initially effective for annual and interim reporting periods beginning after December 15, 2019. However, in November 2019,
the FASB issued ASU 2019-10, &#8220;Financial Instruments Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates&#8221;, which deferred the effective date of ASU 2016-02 by an additional year. At its April 8, 2020, meeting,
the FASB voted to defer the effective date for ASC 842 another year. As such, the Company is required to adopt the new leases standard
for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company
adopted this new guidance effective January 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_z7nNPLzwrVpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zujw7gsHWdrk">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>

<p id="xdx_850_zjgDf1CgbFh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142825424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z6nQbAnNn1mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span id="xdx_828_z9ydt3frwRMh">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a net loss of ($<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20240101__20240630_zbwI3xn34GRc" title="Net loss">4,435,814</span>) for the six months ended June 30, 2024 and stockholders&#8217; deficit of ($<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20240630_z3BChwnobuFl" title="Stockholders deficit">4,988,676</span>) as of June
30, 2024. The Company&#8217;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ziEFDDx0cXUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 <span id="xdx_82A_zdMta7gfnARl">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a net loss of ($<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zvmxqkOfs1De" title="Net loss">2,240,989</span>) for the year ended December 31,2023 and stockholders&#8217; deficit of ($<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20231231_zXVzdrBmonR7" title="Stockholders deficit">4,539,152</span>) as of December
31, 2023. The Company&#8217;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968146889440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zMWJBk7jTARa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 <span id="xdx_82D_zBHXdH5GoMh4">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zv1WlyVvSZec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zsVyzOBNOdca" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_z7k7JFqYVou7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zk7nJ4raPtIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zUmGu1ZyI37a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">116,107</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">31,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zr2I2eQW8W4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities(Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,091,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zedeZ31xwa1j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">116,106</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,123,878</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zZkuwK1tR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market securities were considered a Level 1 financial instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zNCm8uqMOVk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 <span id="xdx_82C_zkX6sSiSPFs1">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zGt64svCsyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zBDk2rALlfoa" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zncInLkOg51f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zCOb1TAClbpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zE9DcrJj5NK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">31,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">604,813</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zwq44FEW84E" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities (Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,091,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zQQGpinOmfaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,123,878</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">604,813</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z2yAo3N0APhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
market securities were considered a Level 1 financial instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142635424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z2nIuLKOz38k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 <span id="xdx_829_zphOwAVXZc7f">Convertible Notes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630_zGTjHAXkOp9" title="Convertible notes issued bear interest rate percentage">8</span>% per annum and certain notes issued prior to 2022 bear an interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zO3XW6PKEi3h" title="Convertible notes issued bear interest rate percentage">2</span>% per annum.
As of December 31, 2023, there $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_z0f0CiwB6Lcl" title="Debt outstanding principal amount">3,665,220</span> in outstanding principal. All the short-term convertible notes matured during the period of
<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20240630_zurlbo1yfv2g" title="Maturity date">December 2023</span>. In March 2024, the Company had converted the outstanding principal of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331_ziHyENrEbEwi" title="Debt outstanding principal amount">3,665,220</span> and the accrued interest through the
date of conversion amounting to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwzhG498PoP3" title="Conversion of debt, amount">276,233</span> into an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU7Nm1ECNvQ2" title="Conversion of debt, shares">965,567</span> shares of preferred stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zPnJODd2bSb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 <span id="xdx_822_zCUCyLyL3Ri4">Convertible Notes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231_zQNezyabIvb" title="Convertible notes issued bear interest rate percentage">8</span>% per annum and certain notes issued prior to 2022 bear an interest at a rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zrKX2zWmVjn3" title="Convertible notes issued bear interest rate percentage">2</span>% per annum.
As of December 31, 2023 and 2022, there were $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_zcPV7uZ5UlVc" title="Debt outstanding principal amount">3,665,220</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zRqgJe6P0OG5" title="Debt outstanding principal amount">2,950,000</span> in outstanding principal. All such notes have matured on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231_zJBzvxRaRk35" title="Maturity date">December
31,2023</span>. Interest expenses recognized for the years ended December 31, 2023 and 2022 amounted to $<span id="xdx_905_eus-gaap--InterestExpense_c20230101__20231231_zaKb2ySq9qT4" title="Interest expenses">152,423</span> and $<span id="xdx_903_eus-gaap--InterestExpense_c20220101__20221231_zd2ER3cvcXuh" title="Interest expenses">76,705</span> respectively. (Refer
&#8211; Note 14&#8211; Subsequent Events &#8211; Short-Term Convertible Notes)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142720672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Convertible Debt, net of debt discount<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Convertible Debt, net of debt discount</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_zW5CLpW9ZERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 <span id="xdx_82A_zjNRTMqmP2Wh">Long-Term Convertible Debt, net of debt discount</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#8216;NVK&#8221;)
for $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJ18I6gnzBxk" title="Long term debt">2,000,000</span>. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus <span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIyzq4zfEByg" title="Debt prime rate percentage">7</span> percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of June 30, 2024 and December 31, 2023, the interest rate was <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z64kXxDclkgh" title="Debt interest rate percentage"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zcO3JkpuVltl" title="Debt interest rate percentage">15.50</span></span>%. The debt is collateralized by all
of the Company&#8217;s receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof.
The principal is entirely repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing
as defined in the Loan Agreement. Interest expense related to the debt amounted to $<span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8lg9PUiLBVk" title="Interest expense">95,583</span> for the year ended December 31, 2023 and the
principal amount is entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common
stock of the Company at a fully-diluted Company valuation of $<span id="xdx_90E_ecustom--DebtDilutedValuation_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zHBwABBsNSv4" title="Debt diluted valuation">60,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the NVK debt, the Company granted <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIeXGRH57dA7" title="Number of warrant to purchase">509,014</span> warrants to purchase common stock. The fair value of the warrants was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZTT80t2n69l" title="Fair value adjustment of warrants">444,260</span>
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the six months
ended June 30, 2024, the Company amortized $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZ4axVI8HE5d" title="Debt discount interest expense">109,544</span> of the debt discount to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zvCGnGQmu78c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zGN7ju9LgRj6" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20240630_z00MVhXvHaE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zjI9lnujWVM6" style="font: bold 10pt Times New Roman, Times, Serif">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzNfR_zA0b4lZdwnR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDzNfR_zS986bttMv36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">265,339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">374,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzNfR_zADfD7WvS8Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible notes, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,734,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z84O2eGA6Jp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zycZGLgYnrFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding notes are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zDUR8Jm0s2wh" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_zoa1qBEoQgKd" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_z6K4ui17ZAP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zUwrVOjAZhs1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_z47ICmJNlPLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z5aaWP0cErTd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_zQ8myvEbGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_z9wy2NTIIURl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_znKtDQgX6iid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 <span id="xdx_826_z9iSrcK4bJe3">Long-Term Convertible Debt, net of debt discount</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#8216;NVK&#8221;)
for $<span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zdKdbMHZJtIi" title="Long term debt">2,000,000</span>. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus <span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z63uPOWtJjd" title="Debt prime rate percentage">7</span> percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of December 31, 2023, the interest rate was <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zP2DRhKI88J" title="Debt interest rate percentage">15.50</span>%. The debt is collateralized by all of the Company&#8217;s
receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof. The principal is entirely
repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing as defined in the Loan
Agreement. Interest expense related to the debt amounted to $<span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2wvzsWEV64a" title="Interest expense">95,583</span> for the year ended December 31, 2023 and the principal amount is
entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common stock of the Company
at a fully-diluted Company valuation of $<span id="xdx_90E_ecustom--DebtDilutedValuation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zYeOUkAEcixh" title="Debt diluted valuation">60,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the NVK debt, the Company granted <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zApNldlFqNb2" title="Number of warrant to purchase">509,014</span> warrants to purchase common stock. The fair value of the warrants was $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zw6wBkBYrpF6" title="Fair value adjustment of warrants">444,260</span>
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the year ended
December 31, 2023, the Company amortized $<span id="xdx_903_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJGwaFucZJS" title="Debt discount interest expense">69,377</span> of the debt discount to interest expense. (Refer &#8211; Note 11&#8211; Warrants)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zDUVQx5gzkK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z7yY1AXiToTf" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z1y3qGy5kTP5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20221231_z4x8suGki5B2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDz26q_zNPBtZeAKQ3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDz26q_zuIgG5E2buG" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">374,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz26q_zq8bpEhF03c1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible debt, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zYJCfnsEFDG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzHcjzc6oJK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding debt are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B1_zl1OwLZPI9l" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z7B3U38IvUe8" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zKUdTbExbrvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zsXMmWheyHy8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z1JkoUkq5Ow8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z9TcDpjMWcN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zdzeMxktg6pk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z6ORxlRme275" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142205264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zb7Cps8qYX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 <span id="xdx_82D_z2eHmy0jfRv8">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zUjeuMluJ8q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 <span id="xdx_829_zTJ5EdG9LLy3">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142768848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3DLDsA4GcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 <span id="xdx_82C_zT7enwhyHBs7">Commitment and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable
in connection with the consummation Scienture&#8217;s business combination with the Company. Scienture has disputed that the amount is
now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution will be obtained.
If Kesin brings a legal action, Scienture will vigorously defend it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zI8SEr5Urqcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 <span id="xdx_820_zhB6S9qRWi07">Commitment and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142467376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdWL7HZm58T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 <span id="xdx_82C_zkyfIw82Qx2l">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#8220;Kesin&#8221;), in which one of the
company&#8217;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the six months ended June 30, 2024 and 2023 were $<span id="xdx_908_ecustom--MilestonePayment_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_znSrcvphiKB3" title="Milestone structure">0</span> and $<span id="xdx_904_ecustom--MilestonePayment_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zp6He8NwvfXj" title="Milestone structure">800,000</span>, respectively.
The Company terminated the agreement with Kesin in March 2024, and recorded a termination fee and related liability of $<span id="xdx_900_ecustom--TerminationFee_c20240101__20240630_z8PwfQfjD2Td" title="Termination fee">1,285,000</span> as
of June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#8220;Saptalis&#8221;) , in which one of the Company&#8217;s Director
is the President and CEO. Lease payments made during the six months ended June 30, 2024 and 2023 are $<span id="xdx_904_eus-gaap--VariableLeasePayment_c20240101__20240630_z1I7ORLwhTYe" title="Lease payments">14,440</span> and $<span id="xdx_901_eus-gaap--VariableLeasePayment_c20230101__20230630_zDTUEMVBCA18" title="Lease payments">0</span>, respectively. The
Company has also engaged Saptalis to provide development services and conduct testing and studies for the products under development
by the Company. Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the
Statement of Comprehensive Loss for the six months ended June 30, 2024 and 2023 amounted to $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zj9dkLD2PVJ" title="Research and Development Expenses">106,539</span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zqloWiXH0DPg" title="Research and Development Expenses">189,027</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, a related party to a director issued a convertible note to the Company for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zRKYPiMMVevh" title="Convertible note">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, officers of the company provided a short term promissory note to the Company for $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYxtGbxPrMO2" title="Short term">265,000</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ziA8hWcvFLsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Schedule of Relatives or Related Parties to Directors Purchased Securities</span></p>

<p id="xdx_8A1_zblR3hLN5wsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeKlGvgQvELb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 <span id="xdx_820_zNLxZlrX6as2">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#8220;Kesin&#8221;), in which one of the
company&#8217;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the years ended December 31,2023 and 2022 amounted to $<span id="xdx_907_ecustom--MilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zLN4iboufi74" title="Milestone structure">800,000</span> and $<span id="xdx_904_ecustom--MilestonePayment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zV3PPzBVMOuj" title="Milestone structure">300,000</span>
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#8220;Saptalis&#8221;) , in which one of the Company&#8217;s Director
is the President and CEO. Lease payments made during the year ended December 31, 2023 and 2022 are $ <span id="xdx_907_eus-gaap--VariableLeasePayment_c20230101__20231231_zT34zweemnQ2" title="Lease payments">7200</span> and $<span id="xdx_90A_eus-gaap--VariableLeasePayment_c20220101__20221231_zw2WkXDhkP5c" title="Lease payments">0</span> respectively. The company
has also engaged Saptalis to provide development services and conduct testing and studies for the products under development by the Company.
Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the Statement of Comprehensive
Loss for the year ended December 31, 2023 and December 31,2022 amounted to $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_z5GPAw4moWR1" title="Research and Development Expenses">355,124</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zwRq3Wd8kXG6" title="Research and Development Expenses">647,566</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zzU9Pbq43jTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relatives
or related parties to directors purchased securities from the Company on the same terms as unrelated parties as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zBoXafXs0Zrd" style="display: none">Schedule of Relatives or Related
Parties to Directors Purchased Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name of the Related
    Party</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nature of transaction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
                                            during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ended<br/>
                                            December 31</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Balances
    as at <br/> December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zR6kkx46ki05" title="Nature of transaction">Issue of Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zivGRnvleWEj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zV40BXwTTQU6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zNDl4oXzZesj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances">750,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z1wLxfBRCFc8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances">750,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOhisUauXxi2" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z6W6IKkBZlE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z7OGfBKClH09" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zpYtmDMg5DM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">550,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z0Aceognm1a5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zQyYfEK17qp3" title="Nature of transaction">Issue of Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z5BDQxCuCVt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zouchw6rWRh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_znZTxEUTqbF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zoGuiTvg30Hk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5YiJohKvag5" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zEbZL5myDCj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOxZS5DRv444" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z2nC6z6G8Aq7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5rSYyzgbhsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Mr. Sandeep Gupta</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_ztVLCAZgv2tl" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zKoj3sCeQIcf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zGceyHaVBx3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zxgpVgY01Fx1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zJzlQC2v3Vi4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231_zQRNccPuZ8Hk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">400,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_zvvLgQw48Wm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">200,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherLiabilities_iI_c20221231_zEeA8I3C5yD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">1,950,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherLiabilities_iI_c20231231_zat80oG25oCd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">1,750,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zssJnkBScMA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142776192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Scienture Inc. 2020 Stock Option and Grant Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Scienture Inc. 2020 Stock Option and Grant Plan</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuFJPBgZRfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 <span id="xdx_82B_zw2CHRnZrIth">Scienture Inc. 2020 Stock Option and Grant Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NSOs&#8221;).
ISOs may be granted only to the Company&#8217;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#8217;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than <span id="xdx_908_ecustom--StockOptionAndGrantPlanHaveContractualTerm_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zM5yXWy7txMk" title="Stock Option and Grant Plan have a contractual term">10</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAz4oCnTq9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zEPwYQz0q1kk" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQYBbP7vyD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance">655,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9I1eU18C7r6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance">0.90</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQh2YKMpR1f" title="Weighted-Average Remaining Term (Years), Balance">7.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrX3A081LuFd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted">142,199</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSKNae7R572e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted">1.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwqwvTXzfJ0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtnTcNFkyo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjIJOOjkcmuk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoB1c0zPFsQk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of June 20, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKAFJJWDVz9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance">797,199</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqolOmF3c6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance">0.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYZwUH3NUFb" title="Weighted-Average Remaining Term (Years), Balance">6.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSOBa3eFS0O1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">499,089</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3aVjlUYnwRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35p52KHDpka" title="Weighted-Average Remaining Term (Years), Vested and exercisable">5.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zuL98c12J7Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the six months ended June 30, 2024 was $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240101__20240630_zhVrSIq0arV8" title="Weighted-average grant date fair value of options granted">0.76</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zA9mHBlMjK4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zCRFeMz4FXG9" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240630_zgYROSuwspR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20230630_zOvAbdvSD394" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHT1rvAQ69kl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">44,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">39,724</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_z9aWAyPuREK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">44,837</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">39,724</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zREz9ZE30fzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Valuation Assumptions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zUh1LBDNNS4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zqCR334CHUbk" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630_zVuo2lohmhxa" title="Expected volatility">72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_z4LkRG3nqdt6" title="Expected volatility">65</span>%
                                            - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zljFYYmKY537" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zFiDVeQiqpIi" title="Risk-free interest rate">4.1</span>%
                                            - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z097UpEW6FX5" title="Risk-free interest rate">4.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zvmKUb5HnBM6" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_ztPzr0e0Phxe" title="Risk-free interest rate">3.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zChhopV9dZ12" title="Expected term">5.7</span>
                                            - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zdPjUDSrOtsc" title="Expected term">6.1</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zNjUHg8ibmC6" title="Expected term">5.9</span>
                                            - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_z3a001C74HX7" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_z4N0mxuOqB2j" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zbJfyjIxfY5" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_z33Qf1WrClfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zoGdYyjxkLW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 <span id="xdx_825_zQ2GFWOXPWqh">Scienture Inc. 2020 Stock Option and Grant Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#8220;ISOs&#8221;), non-statutory stock options (&#8220;NSOs&#8221;).
ISOs may be granted only to the Company&#8217;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#8217;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhNrbxh7Vzqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zEX7AB5731n2" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF5x1kVqwuDa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance">560,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVHlBTf7GLX8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance">0.83</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc7QdlZQJ6" title="Weighted-Average Remaining Term (Years), Balance">7.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXqqRwitCCTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted">185,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8MvUFZFumsh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted">1.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdtQqM0Sdua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwVaLBVW3jh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjNTpYy3uVW3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited">(90,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNfp8fCgy9d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPe12rxIsD85" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance">655,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRNV5QtPz1g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance">0.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztJhWDauLcyh" title="Weighted-Average Remaining Term (Years), Balance">7.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRoTyGtXL94d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">410,065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7tJg5Iv7kb6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ANPWvHvMxl" title="Weighted-Average Remaining Term (Years), Vested and exercisable">6.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zXHWXt8CfxK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 are $ <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zqIH4jxa19Jf" title="Weighted-average grant date fair value of options granted">0.55</span> and $ <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zdN2S81axqQ7" title="Weighted-average grant date fair value of options granted">0.52</span> per
share respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zDwNtRNdfe95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B3_zAAjJGLK9XLc" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zvBe31OrJTE8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_z6yQW4Mm3uI1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6czHCnPZQa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">79,449</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">68,087</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_zZhP0uofZz7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">79,449</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">68,087</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zfl0yjTjp1of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Valuation Assumptions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zF9ofSeWpsqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z5INuepHptRa" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z1JPsxux9Sj1" title="Expected volatility">65</span>%
                                            - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zmwIbdNDKs3h" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPozpEI5Z7Yj" title="Expected volatility">65</span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zeCWA87rWms2" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zN85UrRSbLZd" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zZ4Iv5ykoTv9" title="Risk-free interest rate">3.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdrIPv15VaOj" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zOhAEVGf5Nl3" title="Risk-free interest rate">2.8</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zM2ArlvlHfid" title="Expected term">5.9</span>
                                            - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zk2fRZ1t86M2" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z6qQAQxuPRTb" title="Expected term">5.9</span>
                                            - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zxf2kfBPSH67" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zPdrvXR87tSe" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6TxcaUKyVrb" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AA_z3TAfS65KS5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142757984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_802_ecustom--WarrantsTextBlock_zs5ChSEdBwgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 <span id="xdx_823_zj9qcNvcwp0c">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, there were <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240630_za8Jnh1Id3k5" title="Warrants outstanding">509,014</span> warrants outstanding and exercisable with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630_zjUzCCAJXFmd" title="Exercise price">0.01</span> per share. The warrants were
granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_zd8wl4CRYuj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Assumptions Used to Estimate Fair Value of Warrants&#160;</span></p>

<p id="xdx_8A8_zjYeYk9PIra7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_ecustom--WarrantsTextBlock_z2uBaeldUZQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 <span id="xdx_828_zjJYoJPv7vef">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zvrlfNWC7sVe" title="Warrants outstanding">509,014</span> warrants outstanding and exercisable with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zt1f26zAynAe" title="Exercise price">0.01</span> per share. The warrants
were granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_z8D6GkXzwMMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the assumptions used to estimate the fair value of the outstanding warrants during the years ended December
31, 2023, and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zVf7q0TpTnJk">Summary
of Assumptions Used to Estimate Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVLmQ77K6JZ" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdsZmmyblyr8" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPewogR85Im6" title="Weighted average expected volatility">70.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY5NOV8FZNWj" title="Weighted average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSwwDS58AMN8" title="Measurement Input, warrant">4.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1enIGVpaRie" title="Measurement Input, warrant"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2zkRQoUspJi" title="Expected life of warrants::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1308">5</span></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUByi9mQWN1l" title="Expected life of warrants"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zNIrjYAglo44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140889792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_zpI5X6F2TWMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 <span id="xdx_829_zPgNGc35aJh4">Net Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options to purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZlH0q9KK8Sh" title="Antidilutive securities excluded from computation of earnings per share, amount">799,199</span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zTqz0Wh5OdL7" title="Antidilutive securities excluded from computation of earnings per share, amount">655,000</span> shares of common stock, warrants to purchase <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAGjcOhfypW9" title="Antidilutive securities excluded from computation of earnings per share, amount">509,014</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOyDZDvZI2Ze" title="Antidilutive securities excluded from computation of earnings per share, amount">0</span> common stock, convertible preferred
stock and convertible notes to purchase <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zssHV9DUz1a2" title="Antidilutive securities excluded from computation of earnings per share, amount">3,365,669</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zo1dCeTQ1pmh" title="Antidilutive securities excluded from computation of earnings per share, amount">3,195,911</span> common stock and long-term convertible debt to purchase <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_z1uTG1n0rI04" title="Antidilutive securities excluded from computation of earnings per share, amount">0</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zodbNrLFPOve" title="Antidilutive securities excluded from computation of earnings per share, amount">3,350,000</span>
shares common stock were outstanding at June 30, 2024 and 2023, respectively, that were not included in the computation of diluted weighted
average common shares outstanding because their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zKG8iYccpH9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 <span id="xdx_828_zWrTvHXZAjZc">Net Loss per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options to purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdcN6ie87LY9" title="Antidilutive securities excluded from computation of earnings per share, amount">655,000</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyUmj8r75sQ2" title="Antidilutive securities excluded from computation of earnings per share, amount">560,000</span> common stock, warrants to purchase <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2tUia3qffhb" title="Antidilutive securities excluded from computation of earnings per share, amount">509,014</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zF43kSNamNv8" title="Antidilutive securities excluded from computation of earnings per share, amount">0</span> common stock, convertible preferred stock and
convertible notes to purchase <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zcC7Yl3prK5i" title="Antidilutive securities excluded from computation of earnings per share, amount">3,365,669</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zzZf2q1YOI3c" title="Antidilutive securities excluded from computation of earnings per share, amount">3,195,911</span> common stock and long-term convertible debt to purchase <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zKA0AO7PqBo7" title="Antidilutive securities excluded from computation of earnings per share, amount">9,529,683</span> and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zBhuCFgfuxv7" title="Antidilutive securities excluded from computation of earnings per share, amount">0</span> common
stock were outstanding at December 31, 2023 and 2022, respectively, that were not included in the computation of diluted weighted average
common shares outstanding because their effect would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142222128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z3FhyxedMUul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 <span id="xdx_828_zKAZ2LWlbJ5d">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#8217;s balance sheets. The ROU assets represent the Company&#8217;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an operating lease for administrative office. The lease has remaining lease term around <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20240630_zJ1RuwwzGLO7" title="Operating lease remaining lease term">three years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z0rbMW6j7wO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z5eSJ5JVZeMj" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20240101__20240630_zpbNLBX2MlEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20230101__20230630_zB2UTW4TO4O6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zYkQ8sGbfc84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zwsE5EHfvfB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,152</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zR7DkI80V8C" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zs9CetL5D4p2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,010</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zH2a7p6aNmIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zEctMEM8XEdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zVDztYcLInw3" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630_zF5sHwdzuaAl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zVc7zEt5N7Be" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zz2rFE6SIsM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">61,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">64,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzXqh_zIwSNLpUL8Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,567</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,404</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzXqh_zi45IHitPcDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">39,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzXqh_zuOQCZv5hxR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">Total Lease Liabilities</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">61,886</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zxjGiiZRHSZj" title="Weighted Average Remaining Lease Term (in years)">2.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zzrwQa5zgc29" title="Weighted Average Remaining Lease Term (in years)">2.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_zgFK4X2ECag8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zyzWLiMzKH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zsFEWLecBRa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 <span id="xdx_82B_z0rhTWXvyYeg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#8217;s balance sheets. The ROU assets represent the Company&#8217;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an operating lease for administrative office. The lease has remaining lease term around <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20231231_zaj2Rk7nhTv9" title="Operating lease remaining lease term">three years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zToErlEKqkZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPaeAyH1ayQb" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_494_20230101__20231231_z2MQND7Kh3e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zh88lqTPybte" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zai3HCkJQOXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zQtTHkBhxP81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zXZf6aH4AZFl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,380</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zN8A8EDYU3o2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">34,021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,677</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zmkUbHMUpZF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zBbIItIxlkge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zWFwA36huf6h" style="display: none">Schedule
of Supplemental Cash Flow Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_498_20230101__20231231_zfYsSYsmUmIj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20220101__20221231_zHgs7DhqDWyd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwWHbpwCpoif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for accounts included in the measurements of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_zmn9GUTze486" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating cash flows for Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zjPhnh0I6vf6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right of Use Assets obtained in exchange for new Lease
    Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zj1Jbx3tg6Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zh5jqRu4f5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zJ8qcezPhf3a" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20231231_zC7qbWjklbBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20221231_zDvlWpkIDcTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zpGFtCgLs6fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">64,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz1rv_zdnfwdzZem13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,404</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz1rv_zYQpA1BfkORc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz1rv_zNVHShUkQBj5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Lease Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zg4JFaGrPaUj" title="Weighted Average Remaining Lease Term (in years)">2.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_znoFu0feokYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zshZMNbRKP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI93dHWMlht4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities were as follows at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zNjlhPOh32xc" style="display: none">Schedule
of Maturities Of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zC57GLbl5BQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzwiu_zn2eppBoQPoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 82%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzwiu_zzKDdFoEHi0d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,887</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzwiu_zs02qORnNKo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,823</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzwiu_zuCDIapBPvOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76,727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zuEJwBYqRJCk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,430</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z4BMHHSpcT69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zQwb8xjZk8W" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141153488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zpQgvDIgTZag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 <span id="xdx_824_zCnmZ4TY9Ny6">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, the executives of the Company issued a short-term loan to Company for an aggregate amount of $<span id="xdx_90D_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTedmth05S9" title="Short term borrowings">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2024, all of the unvested options per the Company&#8217;s Stock Option and Grant Plan became vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, Scienture, Inc. (the &#8220;Company&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#8220;Merger Sub I&#8221;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated subsequent events through August 15, 2024, the date the financial statements were available to be issued.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zp5idgqWE7n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 <span><span><span id="xdx_826_z5viaF1ESI81">Subsequent Events</span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-Term
Convertible Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the short-term convertible notes matured during the period of December 2023. The Company has not paid the amounts due including the principal
and the accrued interest. However, in March 2024, the Company had converted the outstanding principal of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLFnovpPvqEi" title="Stock issued during period value conversion of convertible securities">3,665,220</span> and the accrued interest
till the date of conversion amounting to $<span id="xdx_90E_eus-gaap--InterestReceivable_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmimkFfdZ56f" title="Interest receivable">276,233</span> into an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8kl19zbfXIl" title="Stock issued during period shares conversion of convertible securities">965,568</span> preferred stock of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combination</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 25, 2024, Scienture, Inc. (the &#8220;Company&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#8220;Merger Sub I&#8221;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Merger Sub II&#8221;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
of Exclusive License and Commercial Agreement</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scienture
Inc. (Scienture) and Kesin had entered into two exclusive license commercial agreements where Scienture had granted Kesin the rights
to commercialize the products. In March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall
pay Kesin a total gross amount of $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfVQpz2Lc7J5" title="Royalty expense">1,285,000</span> upon commercialization of product via a royalty arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement also requires that if the full $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfph3xQ4yVKl" title="Royalty expense">1,285,000</span> has not been repaid within two years of the early of i) commercial launch or ii)
120 days from FDA approval, then interest will accrue prospectively at a rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUcEYMBSshb3" title="Debt instrument interest rate stated percentage">8</span>% annually on unpaid balance. As of the date of issue
of financial statements, the entire amount is outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated subsequent events through July 31, 2024, the date the financial statements were available to be issued.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140233312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zVPOLExEFmK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zxSDaACjaeD5">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zDw6Ai1JWhNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z3foTLi5y2t6">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#8217;s estimates and the actual results, the Company&#8217;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fair
    value of long-term convertible debt and warrants issued in connection with such debt;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accruals
    for estimated liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease
    term</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation of stock-based compensation awards ; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    for income taxes and related valuation allowances and tax uncertainties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p id="xdx_846_ecustom--UnauditedInterimFinancialInformationPolicyTextBlock_zdFAodwb1E1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zQZJYwAIYHti">Unaudited
Interim Financial Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim
financial information, within the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;).
Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis
consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal
recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition
as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial
statements related to the six-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for
the full fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited
financial statements and the notes thereto for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2l2P0tZC6o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zODvNvGLoWA7">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_zOvPcfhCQI36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zy4BUgnX5aYh">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zxhgn6Q5ujW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zuJ78iJTA1a5">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the six months ended June 30, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zUDtEgzcnAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zuTRUepB66i4">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss includes net loss as well as other changes in stockholder&#8217;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zE1fnIck2JLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zUHFJGQLSaIh">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20240630_zuRtCDhxAaY" title="Number of reportable segment::XDX::1"><span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20240101__20240630_zhw6TVMnHfrl" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0377"><span style="-sec-ix-hidden: xdx2ixbrl0379">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNaP59og6Bre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zDxAsKHKGC07">Segment
Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_zQFvL72BwS95" title="Number of reportable segment::XDX::1"><span id="xdx_907_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20230101__20231231_zzlYO99If5Lf" title="Number of operating segment::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0993"><span style="-sec-ix-hidden: xdx2ixbrl0995">single</span></span></span></span> reportable segment and operating segment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGt2pUccSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zIC2blmEuDV8">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJ11pNKLt4j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z2pVeuN5hIU3">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6LqTc1l1NQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zqhJLDK3sSA8">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240630_zRVQFAe6mlOc" title="Allowance for doubtful accounts"><span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zRZgK4nRWgj5" title="Allowance for doubtful accounts">0</span></span> as of June 30, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zwD0xPUmp2q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z09Lz3B2WS0k">Accounts
Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zjggDz3CdhM3" title="Allowance for doubtful accounts"><span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zPnPWh6lbXf3" title="Allowance for doubtful accounts">0</span></span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Refer
&#8211; Note 14&#8211; Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z9u4ZW4nirW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z8z2xy9MUyg1">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z31KAvzCkY56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z5zx0gMnjcI3">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock', window );">Exclusive License and Commercial Agreements</a></td>
<td class="text"><p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z7hNftnCGULl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zEPGvgYRCnV1">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630_zjwFP8znkrH8" title="Revenue recognized">800,000</span> for the six months
ended June 30, 2023, at the point when the development milestone events occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall pay Kesin a total gross amount of
$<span id="xdx_90F_ecustom--TerminationFee_c20240301__20240331_zbrSruzSNcb4" title="Termination fee">1,285,000</span> upon commercialization of product via a royalty arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--TerminationFeeDescription_c20240301__20240331_zUPQA6xR5mOb" title="Termination fee description">This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z2JhbIcHdvOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zd1OqPSy1EC8">Exclusive
License and Commercial Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#8220;the Products&#8221;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zm95aluQBMk3" title="Revenue recognized">800,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zYelXpAhKAl7" title="Revenue recognized">300,000</span>, respectively,
during the years ended December 31, 2023 and 2022 at the point when the development milestone events occurred. (Refer &#8211; Note 14&#8211;
Subsequent Events &#8211; Termination of Exclusive License and Commercial Agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zk14AEaP86y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zn0dovk53fB1">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zpBk8Rxd7OJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXDu1rOp5G12">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Level
    3 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risks and Major Customers</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_ztZeoYC6DQ8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zfSzsnGkNMH9">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the six months ended June 30, 2024, the Company had
one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJrtJLxttz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z1ZC3PGQm9C2">Concentration
of Credit Risks and Major Customers</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the years ended December 31, 2023, and 2022, the company
had one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research &amp; Development Expenses</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9WtrBhyn5m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zfojqVg69RVb">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwCXj4i6zeEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zWKr6Kcp3Zc1">Research
&amp; Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjQmab8imlO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z17IT79YgzKj">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option-pricing model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based
awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest
rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company has estimated volatility
by reference to the historical volatilities of the Company and that of similar publicly traded peer companies. The risk-free interest
rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled
award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIdqihDN0YB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjo7F3n0srO9">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The fair values of stock-based compensations are recognized as compensation expense on a straight-line
basis over the requisite service period in which the awards are expected to vest. The Company estimates the fair value of stock option
awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes model considers several variables and assumptions
in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock,
exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the
expected term. The Company has estimated volatility by reference to the historical volatilities of the Company and that of similar publicly
traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration
to the expected term of the equity-settled award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_WarrantValuationPolicyTextBlock', window );">Warrant Valuation</a></td>
<td class="text"><p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zT2pXJTCvfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ztSYFFhT3r2e">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zeToUOiWtOCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zIq0xJKLreE9">Warrant
Valuation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per share</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zmhFfpP7PIoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zPnVd1CLtqZg">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;</span></p>

<p id="xdx_8AF_zQuMJxhtbJxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zNuN1XW7SxP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWi4i8AXB54a">Net
Loss per share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recent
Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_842_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zlo6CuWHvH4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zrZL0Sxeovk8">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>
<span></span>
</td>
<td class="text"><p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_z7nNPLzwrVpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zujw7gsHWdrk">Accounting
Pronouncements Not Yet Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-07, &#8220;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221; (&#8220;ASU 2023-07&#8221;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#8221;
(&#8220;ASU 2023-09&#8221;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zCjnOUHbWpI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z3hwU0J9pJR8">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is incorporated in Delaware and headquartered in New York where the state tax is <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20230101__20231231_z1dGVIh0nh06" title="State income tax rate">8.70</span>% and <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20220101__20221231_zQnpB8DJfb1" title="State income tax rate">7.25</span>% respectively. However, due to
losses for the years ended December 31, 2023 and 2022, no provision on state income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Federal
Income Tax:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a C Corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners. The company records
income taxes pursuant to the liability method. The Company has a loss before tax of ($<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zaXalyfNxvSa" title="Loss before tax">2,240,989</span>) and ($<span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zpYkYtiSAfh" title="Loss before tax">3,708,378</span>) for years ended December
31, 2023 and 2022 respectively. Therefore, no provision for federal income tax has been recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_ecustom--DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_zqIOkbM1Gmn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zAo6Gt6RSIo1">Deferred
Tax Assets and Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are determined based on the differences between the financial statement and the tax basis of assets and liabilities.
Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company&#8217;s
ability to generate taxable income. Management believes that, at a minimum, it is more likely than not that future taxable income may
not be sufficient to realize the recorded assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a deferred tax asset related to its net operating loss carryforwards, timing difference between written down value
of assets, and unutilized R&amp;D credit, which are expected to reduce future taxable income. The company has assessed the likelihood
of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets may not be realized.
Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its expected realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the deferred tax assets and related valuation allowance on the Company&#8217;s financial statements is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zGlZeO8SmXN4" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowance</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">3,173,840</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,491,667</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,635</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment and operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,220</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,229,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,548,331</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zhfSfKJNG6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zC30tXxD2fX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zWcF8MYTuJ24">Accounting
Pronouncements Recently Adopted</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements.
The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (ASC 326), which provides guidance on measurement
of credit losses on financial instruments. This ASU adds a current expected credit loss impairment model to U.S.GAAP that is based on
expected losses rather than incurred losses whereby a broader range of reasonable and supportable information is required to be utilized
in order to derive credit loss estimates. The effective date of the new guidance as amended by ASU No. 2019-10 is fiscal years beginning
after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023
the company determined that the update applied to trade receivables, but that there no material impact to the financial statements from
the adoption of ASU 2016-13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No.
2016-2, Leases, to provide guidance for the accounting for leasing transactions. The standard requires the lessee to recognize a lease
liability along with a right-of-use asset for all leases with a term longer than one year. A lessee is permitted to make an accounting
policy election by class of underlying asset to not recognize the lease liability and related right-of-use asset for leases with a term
of one year or less. The provisions of this standard also apply to situations where the Company is the lessor. In March 2019, the FASB
issued ASU 2019-01, &#8220;Lease (842): Codification improvements.&#8221; This updated clarified that entities were exempt from disclosing
the effect of the change on income from continuing operations, net income, and related per-share amounts, if applicable, for interim
periods after the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standard was initially effective for annual and interim reporting periods beginning after December 15, 2019. However, in November 2019,
the FASB issued ASU 2019-10, &#8220;Financial Instruments Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates&#8221;, which deferred the effective date of ASU 2016-02 by an additional year. At its April 8, 2020, meeting,
the FASB voted to defer the effective date for ASC 842 another year. As such, the Company is required to adopt the new leases standard
for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company
adopted this new guidance effective January 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets and Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exclusive License and Commercial Agreements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited Interim Financial Information [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_WarrantValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Valuation [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_WarrantValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142466112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Related Valuation Allowance</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the deferred tax assets and related valuation allowance on the Company&#8217;s financial statements is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zGlZeO8SmXN4" style="display: none">Schedule
of Deferred Tax Assets and Related Valuation Allowance</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year
    Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Net operating loss carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">3,173,840</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,491,667</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,635</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment and operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,220</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,960</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,229,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,548,331</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142776688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zv1WlyVvSZec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zsVyzOBNOdca" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_z7k7JFqYVou7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zk7nJ4raPtIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zUmGu1ZyI37a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">116,107</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">31,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zr2I2eQW8W4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities(Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,091,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zedeZ31xwa1j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">116,106</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,123,878</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zGt64svCsyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zBDk2rALlfoa" style="display: none">Schedule
of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zncInLkOg51f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zCOb1TAClbpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zE9DcrJj5NK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Balances with banks</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">31,943</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">604,813</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zwq44FEW84E" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Money market securities (Highly liquid investments)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,091,935</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zQQGpinOmfaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Cash and Cash Equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,123,878</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">604,813</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142653728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Convertible Debt, net of debt discount (Tables) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long Term Convertible Debt Net of Discount</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zvCGnGQmu78c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zGN7ju9LgRj6" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_495_20240630_z00MVhXvHaE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zjI9lnujWVM6" style="font: bold 10pt Times New Roman, Times, Serif">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzNfR_zA0b4lZdwnR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDzNfR_zS986bttMv36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">265,339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">374,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzNfR_zADfD7WvS8Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible notes, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,734,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zDUVQx5gzkK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
convertible debt, net of debt discount, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z7yY1AXiToTf" style="display: none">Schedule of Long Term Convertible
Debt Net of Discount</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z1y3qGy5kTP5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_494_20221231_z4x8suGki5B2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDz26q_zNPBtZeAKQ3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">Principal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDz26q_zuIgG5E2buG" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">374,883</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz26q_zq8bpEhF03c1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long-term convertible debt, net of debt discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Maturities Notes</a></td>
<td class="text"><p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zycZGLgYnrFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding notes are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zDUR8Jm0s2wh" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_zoa1qBEoQgKd" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_z6K4ui17ZAP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zUwrVOjAZhs1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_z47ICmJNlPLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z5aaWP0cErTd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_zQ8myvEbGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzHcjzc6oJK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maturities
of the outstanding debt are as follows</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B1_zl1OwLZPI9l" style="display: none">Schedule of Maturities Notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Years Ending December 31</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z7B3U38IvUe8" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zKUdTbExbrvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zsXMmWheyHy8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 2</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z1JkoUkq5Ow8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z9TcDpjMWcN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Year 3</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zdzeMxktg6pk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142779776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Relatives or Related Parties to Directors Purchased Securities</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ziA8hWcvFLsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Schedule of Relatives or Related Parties to Directors Purchased Securities</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zzU9Pbq43jTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relatives
or related parties to directors purchased securities from the Company on the same terms as unrelated parties as set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zBoXafXs0Zrd" style="display: none">Schedule of Relatives or Related
Parties to Directors Purchased Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name of the Related
    Party</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Nature of transaction</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
                                            during the year</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ended<br/>
                                            December 31</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Balances
    as at <br/> December 31</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zR6kkx46ki05" title="Nature of transaction">Issue of Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zivGRnvleWEj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zV40BXwTTQU6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zNDl4oXzZesj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances">750,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z1wLxfBRCFc8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances">750,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Pushpa Shankar</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOhisUauXxi2" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z6W6IKkBZlE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z7OGfBKClH09" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zpYtmDMg5DM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">550,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z0Aceognm1a5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zQyYfEK17qp3" title="Nature of transaction">Issue of Preferred Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z5BDQxCuCVt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zouchw6rWRh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_znZTxEUTqbF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zoGuiTvg30Hk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Ms. Yogita Desai</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5YiJohKvag5" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zEbZL5myDCj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOxZS5DRv444" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z2nC6z6G8Aq7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5rSYyzgbhsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Mr. Sandeep Gupta</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_ztVLCAZgv2tl" title="Nature of transaction">Issue of Convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zKoj3sCeQIcf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zGceyHaVBx3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zxgpVgY01Fx1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zJzlQC2v3Vi4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231_zQRNccPuZ8Hk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">400,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_zvvLgQw48Wm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions">200,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--OtherLiabilities_iI_c20221231_zEeA8I3C5yD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">1,950,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherLiabilities_iI_c20231231_zat80oG25oCd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances">1,750,000</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141559232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Scienture Inc. 2020 Stock Option and Grant Plan (Tables) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAz4oCnTq9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_zEPwYQz0q1kk" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQYBbP7vyD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance">655,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9I1eU18C7r6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance">0.90</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQh2YKMpR1f" title="Weighted-Average Remaining Term (Years), Balance">7.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrX3A081LuFd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted">142,199</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSKNae7R572e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted">1.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwqwvTXzfJ0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtnTcNFkyo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjIJOOjkcmuk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoB1c0zPFsQk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of June 20, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKAFJJWDVz9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance">797,199</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqolOmF3c6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance">0.94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYZwUH3NUFb" title="Weighted-Average Remaining Term (Years), Balance">6.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSOBa3eFS0O1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">499,089</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3aVjlUYnwRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35p52KHDpka" title="Weighted-Average Remaining Term (Years), Vested and exercisable">5.62</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhNrbxh7Vzqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s stock option activity under the Plans is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zEX7AB5731n2" style="display: none">Summary of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding<br/>
    Options</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Exercise<br/> Price</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<br/>
    Average<br/> Remaining<br/> Term<br/> (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%">Balance as of December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF5x1kVqwuDa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance">560,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVHlBTf7GLX8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance">0.83</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc7QdlZQJ6" title="Weighted-Average Remaining Term (Years), Balance">7.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXqqRwitCCTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted">185,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8MvUFZFumsh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted">1.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdtQqM0Sdua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwVaLBVW3jh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cancelled and forfeited</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjNTpYy3uVW3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited">(90,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNfp8fCgy9d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPe12rxIsD85" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance">655,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRNV5QtPz1g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance">0.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztJhWDauLcyh" title="Weighted-Average Remaining Term (Years), Balance">7.56</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Vested and exercisable as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRoTyGtXL94d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">410,065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7tJg5Iv7kb6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable">0.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ANPWvHvMxl" title="Weighted-Average Remaining Term (Years), Vested and exercisable">6.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zA9mHBlMjK4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B6_zCRFeMz4FXG9" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240630_zgYROSuwspR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20230630_zOvAbdvSD394" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHT1rvAQ69kl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">44,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">39,724</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_z9aWAyPuREK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">44,837</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">39,724</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zDwNtRNdfe95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B3_zAAjJGLK9XLc" style="display: none">Schedule of Stock-based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zvBe31OrJTE8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_z6yQW4Mm3uI1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6czHCnPZQa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">General and Administrative Expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">79,449</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">68,087</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_zZhP0uofZz7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total stock-based compensation expense</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">79,449</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">68,087</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zUh1LBDNNS4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BA_zqCR334CHUbk" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630_zVuo2lohmhxa" title="Expected volatility">72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_z4LkRG3nqdt6" title="Expected volatility">65</span>%
                                            - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zljFYYmKY537" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zFiDVeQiqpIi" title="Risk-free interest rate">4.1</span>%
                                            - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z097UpEW6FX5" title="Risk-free interest rate">4.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zvmKUb5HnBM6" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_ztPzr0e0Phxe" title="Risk-free interest rate">3.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zChhopV9dZ12" title="Expected term">5.7</span>
                                            - <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zdPjUDSrOtsc" title="Expected term">6.1</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zNjUHg8ibmC6" title="Expected term">5.9</span>
                                            - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_z3a001C74HX7" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_z4N0mxuOqB2j" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zbJfyjIxfY5" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zF9ofSeWpsqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_z5INuepHptRa" style="display: none">Schedule of Stock Option Valuation Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z1JPsxux9Sj1" title="Expected volatility">65</span>%
                                            - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zmwIbdNDKs3h" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPozpEI5Z7Yj" title="Expected volatility">65</span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zeCWA87rWms2" title="Expected volatility">75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zN85UrRSbLZd" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zZ4Iv5ykoTv9" title="Risk-free interest rate">3.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdrIPv15VaOj" title="Risk-free interest rate">0.5</span>%
                                            - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zOhAEVGf5Nl3" title="Risk-free interest rate">2.8</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zM2ArlvlHfid" title="Expected term">5.9</span>
                                            - <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zk2fRZ1t86M2" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z6qQAQxuPRTb" title="Expected term">5.9</span>
                                            - <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zxf2kfBPSH67" title="Expected term">6.0</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zPdrvXR87tSe" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6TxcaUKyVrb" title="Expected dividend">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968146938672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock', window );">Summary of Assumptions Used to Estimate Fair Value of Warrants</a></td>
<td class="text"><p id="xdx_89B_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_zd8wl4CRYuj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Assumptions Used to Estimate Fair Value of Warrants&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_896_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_z8D6GkXzwMMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the assumptions used to estimate the fair value of the outstanding warrants during the years ended December
31, 2023, and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zVf7q0TpTnJk">Summary
of Assumptions Used to Estimate Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVLmQ77K6JZ" title="Expected dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdsZmmyblyr8" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPewogR85Im6" title="Weighted average expected volatility">70.52</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY5NOV8FZNWj" title="Weighted average expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSwwDS58AMN8" title="Measurement Input, warrant">4.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1enIGVpaRie" title="Measurement Input, warrant"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life of warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2zkRQoUspJi" title="Expected life of warrants::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1308">5</span></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUByi9mQWN1l" title="Expected life of warrants"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Assumptions Used to Estimate Fair Value of Warrants Granted [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141308096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z0rbMW6j7wO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z5eSJ5JVZeMj" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20240101__20240630_zpbNLBX2MlEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_490_20230101__20230630_zB2UTW4TO4O6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June
    30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zYkQ8sGbfc84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zwsE5EHfvfB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">2,152</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zR7DkI80V8C" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zs9CetL5D4p2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,010</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zToErlEKqkZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zPaeAyH1ayQb" style="display: none">Schedule
of Lease Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_494_20230101__20231231_z2MQND7Kh3e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zh88lqTPybte" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zai3HCkJQOXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zQtTHkBhxP81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Amortization of ROU Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5,025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zXZf6aH4AZFl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest on Lease Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,380</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zN8A8EDYU3o2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term lease costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">34,021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,677</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related To Leases</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zEctMEM8XEdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zVDztYcLInw3" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49B_20240630_zF5sHwdzuaAl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zVc7zEt5N7Be" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zz2rFE6SIsM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">61,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">64,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzXqh_zIwSNLpUL8Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,567</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,404</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzXqh_zi45IHitPcDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">39,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzXqh_zuOQCZv5hxR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">Total Lease Liabilities</span></td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">61,886</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zxjGiiZRHSZj" title="Weighted Average Remaining Lease Term (in years)">2.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zzrwQa5zgc29" title="Weighted Average Remaining Lease Term (in years)">2.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_zgFK4X2ECag8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zh5jqRu4f5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
balance sheet information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zJ8qcezPhf3a" style="display: none">Schedule
of Supplemental Balance Sheet Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20231231_zC7qbWjklbBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20221231_zDvlWpkIDcTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Operating Leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zpGFtCgLs6fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Right of Use Assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">64,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz1rv_zdnfwdzZem13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,404</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz1rv_zYQpA1BfkORc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term Lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz1rv_zNVHShUkQBj5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Total Lease Liabilities</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted Average Remaining Lease Term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zg4JFaGrPaUj" title="Weighted Average Remaining Lease Term (in years)">2.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_znoFu0feokYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Weighted Average Discount Rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related To Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zBbIItIxlkge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zWFwA36huf6h" style="display: none">Schedule
of Supplemental Cash Flow Information Related To Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_498_20230101__20231231_zfYsSYsmUmIj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_495_20220101__20221231_zHgs7DhqDWyd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December
    31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwWHbpwCpoif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Cash paid for accounts included in the measurements of lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_zmn9GUTze486" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left">Operating cash flows for Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zjPhnh0I6vf6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Right of Use Assets obtained in exchange for new Lease
    Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">205</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities Of Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI93dHWMlht4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities were as follows at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zNjlhPOh32xc" style="display: none">Schedule
of Maturities Of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zC57GLbl5BQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzwiu_zn2eppBoQPoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 82%; text-align: left">2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">29,017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzwiu_zzKDdFoEHi0d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29,887</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzwiu_zs02qORnNKo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,823</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzwiu_zuCDIapBPvOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76,727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zuEJwBYqRJCk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: Imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,430</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z4BMHHSpcT69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">64,297</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141296800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_TerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 1,285,000<span></span>
</td>
<td class="nump">1,285,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_TerminationFeeDescription', window );">Termination fee description</a></td>
<td class="text">This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,435,814<span></span>
</td>
<td class="nump">$ 471,570<span></span>
</td>
<td class="nump">$ 2,240,989<span></span>
</td>
<td class="nump">$ 3,708,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_TerminationFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_TerminationFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140265392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details Narrative) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 4,435,814<span></span>
</td>
<td class="nump">$ 471,570<span></span>
</td>
<td class="nump">$ 2,240,989<span></span>
</td>
<td class="nump">$ 3,708,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders deficit</a></td>
<td class="nump">$ 4,988,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,539,152<span></span>
</td>
<td class="nump">$ 2,821,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142193504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash and Cash Equivalents (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndDueFromBanks', window );">Balances with banks</a></td>
<td class="nump">$ 116,107<span></span>
</td>
<td class="nump">$ 31,943<span></span>
</td>
<td class="nump">$ 604,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market securities (Highly liquid investments)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,091,935<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total Cash and Cash Equivalents</a></td>
<td class="nump">$ 116,106<span></span>
</td>
<td class="nump">$ 1,123,878<span></span>
</td>
<td class="nump">$ 604,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndDueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndDueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141314656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details Narrative) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes issued bear interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt outstanding principal amount</a></td>
<td class="nump">$ 3,665,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,665,220<span></span>
</td>
<td class="nump">$ 2,950,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">December 2023<span></span>
</td>
<td class="text">December
31,2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,423<span></span>
</td>
<td class="nump">$ 76,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of debt, amount</a></td>
<td class="nump">$ 276,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of debt, shares</a></td>
<td class="nump">965,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968235279744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long Term Convertible Debt Net of Discount (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized debt discount</a></td>
<td class="nump">265,339<span></span>
</td>
<td class="nump">374,883<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term convertible debt, net of debt discount</a></td>
<td class="nump">$ 1,734,661<span></span>
</td>
<td class="nump">$ 1,625,117<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141023568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities Notes (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Year 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Year 2</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Year 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141199856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Convertible Debt, net of debt discount (Details Narrative) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">$ 1,734,661<span></span>
</td>
<td class="nump">$ 1,625,117<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,423<span></span>
</td>
<td class="nump">$ 76,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SCNX_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage', window );">Debt prime rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_DebtDilutedValuation', window );">Debt diluted valuation</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrant to purchase</a></td>
<td class="nump">509,014<span></span>
</td>
<td class="nump">509,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 444,260<span></span>
</td>
<td class="nump">$ 444,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Debt discount interest expense</a></td>
<td class="nump">$ 109,544<span></span>
</td>
<td class="nump">$ 69,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_DebtDilutedValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt diluted valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_DebtDilutedValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest rate stated prime rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SCNX_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SCNX_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968137075968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_TerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 1,285,000<span></span>
</td>
<td class="nump">$ 1,285,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520,947<span></span>
</td>
<td class="nump">946,435<span></span>
</td>
<td class="nump">2,029,812<span></span>
</td>
<td class="nump">3,061,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note</a></td>
<td class="nump">$ 3,665,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Promissory Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_KesinPharmaCorporationMember', window );">Kesin Pharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_MilestonePayment', window );">Milestone structure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_SaptalisPharmaceuticalsLlcMember', window );">Saptalis Pharmaceuticals LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,539<span></span>
</td>
<td class="nump">189,027<span></span>
</td>
<td class="nump">$ 355,124<span></span>
</td>
<td class="nump">$ 647,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SCNX_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SCNX_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_KesinPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_KesinPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_SaptalisPharmaceuticalsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_SaptalisPharmaceuticalsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140418464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - Scienture Inc [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Balance</a></td>
<td class="nump">655,000<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Balance</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Term (Years), Balance</a></td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">7 years 6 months 21 days<span></span>
</td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Outstanding Options, Granted</a></td>
<td class="nump">142,199<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Outstanding Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Outstanding Options, Cancelled and forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Cancelled and forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Balance</a></td>
<td class="nump">797,199<span></span>
</td>
<td class="nump">655,000<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Balance</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding Options, Vested and exercisable</a></td>
<td class="nump">499,089<span></span>
</td>
<td class="nump">410,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Outstanding Options, Vested and exercisable</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Term (Years), Vested and exercisable</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">6 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141695056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 44,837<span></span>
</td>
<td class="nump">$ 39,724<span></span>
</td>
<td class="nump">$ 79,449<span></span>
</td>
<td class="nump">$ 68,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 44,837<span></span>
</td>
<td class="nump">$ 39,724<span></span>
</td>
<td class="nump">$ 79,449<span></span>
</td>
<td class="nump">$ 68,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968148902128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Valuation Assumptions (Details) - Scienture Inc [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141181328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative) - Scienture Inc [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_StockOptionAndGrantPlanHaveContractualTerm', window );">Stock Option and Grant Plan have a contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_StockOptionAndGrantPlanHaveContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option and grant plan have contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_StockOptionAndGrantPlanHaveContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142652672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants (Details Narrative) - Scienture Inc [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">509,014<span></span>
</td>
<td class="nump">509,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968143235136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details Narrative) - Scienture Inc [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">799,199<span></span>
</td>
<td class="nump">655,000<span></span>
</td>
<td class="nump">655,000<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">509,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">509,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_ConvertiblePreferredStockAndConvertibleNotesMember', window );">Convertible Preferred Stock and Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">3,365,669<span></span>
</td>
<td class="nump">3,195,911<span></span>
</td>
<td class="nump">3,365,669<span></span>
</td>
<td class="nump">3,195,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_LongTermConvertibleDebtMember', window );">Long Term Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,350,000<span></span>
</td>
<td class="nump">9,529,683<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_ConvertiblePreferredStockAndConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_ConvertiblePreferredStockAndConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_LongTermConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SCNX_LongTermConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141714384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Expense (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of ROU Assets</a></td>
<td class="nump">$ 2,152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SCNX_OperatingLeaseInterestExpense', window );">Interest on Lease Liabilities</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,380<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">$ 17,010<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34,021<span></span>
</td>
<td class="nump">$ 32,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SCNX_OperatingLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SCNX_OperatingLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SCNX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968145529680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Supplemental Balance Sheet Information Related To Leases (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of Use Assets</a></td>
<td class="nump">$ 61,579<span></span>
</td>
<td class="nump">$ 64,091<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term Lease liabilities</a></td>
<td class="nump">22,567<span></span>
</td>
<td class="nump">21,404<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term Lease liabilities</a></td>
<td class="nump">39,319<span></span>
</td>
<td class="nump">42,893<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease Liabilities</a></td>
<td class="nump">$ 61,886<span></span>
</td>
<td class="nump">$ 64,297<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term (in years)</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">2 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140883008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details Narrative)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember', window );">Scienture Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141809696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Related Valuation Allowance (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,173,840<span></span>
</td>
<td class="nump">$ 2,491,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">6,635<span></span>
</td>
<td class="nump">2,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment and operating lease liability</a></td>
<td class="nump">49,220<span></span>
</td>
<td class="nump">53,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(3,229,695)<span></span>
</td>
<td class="num">(2,548,331)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140215088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Relatives or Related Parties to Directors Purchased Securities (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="nump">1,950,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsPushpaShankarMember', window );">Ms. Pushpa Shankar [Member] | Issue of Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Nature of transaction</a></td>
<td class="text">Issue of Preferred Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsPushpaShankarMember', window );">Ms. Pushpa Shankar [Member] | Issue of Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Nature of transaction</a></td>
<td class="text">Issue of Convertible notes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsYogitaDesaiMember', window );">Ms. Yogita Desai [Member] | Issue of Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Nature of transaction</a></td>
<td class="text">Issue of Preferred Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsYogitaDesaiMember', window );">Ms. Yogita Desai [Member] | Issue of Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Nature of transaction</a></td>
<td class="text">Issue of Convertible notes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MrSandeepGuptaMember', window );">Mr. Sandeep Gupta [Member] | Issue of Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Nature of transaction</a></td>
<td class="text">Issue of Convertible notes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party Transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party Balances</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsPushpaShankarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsPushpaShankarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=SCNX_IssueOfPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=SCNX_IssueOfPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=SCNX_IssueOfConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=SCNX_IssueOfConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsYogitaDesaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MsYogitaDesaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MrSandeepGuptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SCNX_MrSandeepGuptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140241056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Assumptions Used to Estimate Fair Value of Warrants (Details) - Scienture Inc [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, warrant</a></td>
<td class="nump">0.7052<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input, warrant</a></td>
<td class="nump">0.0450<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968142205264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information Related To Leases (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Cash paid for accounts included in the measurements of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for Operating leases</a></td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of Use Assets obtained in exchange for new Lease Liabilities</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968140946288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities Of Lease Liabilities (Details) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 61,886<span></span>
</td>
<td class="nump">$ 64,297<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45968141168464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Scienture Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during period value conversion of convertible securities</a></td>
<td class="nump">$ 3,665,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 276,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period shares conversion of convertible securities</a></td>
<td class="nump">965,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 1,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate stated percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=SCNX_ScientureIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ME1V4#<#YO93FTK$+M/^*Y U02P,$%     @ IH!86AE\+&LR!@  $AP  !@
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M2-S5AX$\/YA.H@$&L3.U!_:1/;TPP]XL0;M;&G?8#P?6KFYVI/OSHF#J  U
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M>P&UNQ'5IGDE<U\)417-Y9H225,!Y/>K2OJ$]D:]Y>E> R[^!U!+ P04
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M>X6@"VBD.ZWVQK@T$]ELRN@C8@HMV=27QOTF6OI5U"I1[@63OQ8R3LSN129
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M0:OFZP:R')@"R-]7E(JG W6!_C7/[#]02P,$%     @ IH!86I80::E-!@
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M<?UDOGWHDA9B1A1%^T[FF/*=H*9XFG/*\OK*,V4\?<PHV-!'KB3,E, T!11
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M>P&(8&IGFE.6&=F'W/2P3W B*<RQ^XA&_$]- 8%ZOTH)EW0<!>NUS6*FWBN
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M8##"9>22?6\UCA/VW&;W)E!R[@)NHD4P&V;V1'A--)?-<VW@:P['2:?;4O%
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MP[2EN&@HV L44[A6TN8&WLD,LQ[\:A@_9@,$(>GI1+$G41=LD/%C+8\ACD;
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M>SZHY@7;3(Q<N4?@3!IZ4KKADA[]J*P![<\E5:&=6 ?=OQ'C/P%02P,$%
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M-'0,<\N,#LJHK  ]7TI*M;FQ#KJC]_0O4$L#!!0    ( *: 6%JB<B+7S04
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M9DDW.&H70/.%HDW7==P"PS_!ZA=02P,$%     @ IH!86H[DSF-Y @  P 8
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M?MD'6K2NY:R%-@W,#4OSBT%I$\SZ1IAZ#('=8/QI93\!4$L#!!0    ( *:
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MCFL5-)ZO:XL5OT6\$49I$(^%5L7=CO?P[H9&CG1<P$QHD:AE*;]!+B!OB2K
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M6\$UHV(PKE6UW3C#*$NHG\WC3KE+H5 E5@=RM2:-+G(GA+IP>J!&[Q1=J]*
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M]2>64SGL70E<P?\=T=6RVDZ\U7;2;[4529,1-MX62)!+^<;3_MO 0UW&7._
M.X2DFTWTSD:RL_$K ]QF*%*R-AEK.\1.9G4@95FR2&Y /B!WL51FN@&B*$U&
MO._%K"0YRUBB*428(I(K WK#RBO3Y!Z1\R9/F!NL./E4T#ZN:V*9:Y4VANB-
MGG]]FRZ28DX\LP2"QOT?XEO(PY/1T^O75_1I_/3A4%Q9N=D2;T7FY&>#>J'
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M0SN@0-%VVV'80;&96(@LI9*<M/]^E.QX&>!X/>RP2TS)?$_D,T5FO)5JI7,
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MNJG9X9KNTBB- +U?"J%W$V.@OIW/_P502P,$%     @ IH!86K=L,Y#X @
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MF+%*V,]J^P$;/U/'ERAA_"]LZ]C9.("D,E85#9@4%%S67_;4Y&$7,-D#B!M
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M6:L2WUP@FZ)V O1]II1]Z3@#Q>U>_W]02P,$%     @ IH!86B_#4>TC P
M/ D  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULK59M;],P$/XK5D (
MI+*\M]EH([&VP- &$Q7P8=H'-[DVUA*[V.ZZ_7O.3A:Z+JV&M"^M7^YY[I[S
MQ>?A1L@;50!H<E>57(V<0NO5B>NJK("*JB.Q HX["R$KJG$JEZY:2:"Y!56E
M&WA>WZTHXTXZM&N7,AV*M2X9ATM)U+JJJ+P_A5)L1H[O/"S\8,M"FP4W':[H
M$F:@?ZXN)<[<EB5G%7#%!"<2%B/GHW\RC8V]-?C%8*.VQL0HF0MQ8R9G^<CQ
M3$!00J8- \6_6QA#61HB#.-/P^FT+@UP>_S _LEJ1RUSJF LRM\LU\7(21R2
MPX*N2_U#;+Y H\<&F(E2V5^R:6P]AV1KI475@#&"BO'ZG]XU>=@"($\W(&@
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MAP%E W!_(:5YF=B>U/^SLK]02P,$%     @ IH!86A8"F6"= P  Y@X  !D
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M-QA(5B=.U=$BMS5X)316=-O<X2$-TDS \8W @EMW3%EOCOWH'U!+ P04
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M2Y:%K&.1:"$5SPHP6I E+/^GST4<U@#(4PUP"X#[%N#O '@%P'L+:.T ^ 7
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M'* DOA+8\J,QRE694_J63YZBD>7D)X(80I%38/FW@2G$<<XDS_%?26I5>^;
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M4R%HHH8KP!&P7$ ^7U J]I-\@ZK!/?X?4$L#!!0    ( *: 6%HOK!<O,0,
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M)A<SC'1W/;K JCI,V%99-Z]A6;D_"FB?X,YW2MECX(=V^$?E?P%02P,$%
M  @ IH!86N:QHS X!   P!<  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULS9A=;]LV%(;_"J$!Q0:DT;=B9;:!Q-+0#$EJU-MZ4>R"EHYM(1+ID52<
M_ON1LBQ;CJPY +'F)M;'>1^2YR5/1 XWE#WQ%8! +T5.^,A8";&^-DV>K*#
M_)*N@<@W"\H*+.0M6YI\S0"GE:C(3<>R K/ &3'&P^K9E(V'M!1Y1F#*$"^+
M K/OMY#3S<BPC=V#+]ER)=0#<SQ<XR7,0/RYGC)Y9S:4-"N \(P2Q& Q,F[L
MZ]CVE*"*^"N##3^X1FHH<TJ?U,U=.C(LU2/((1$*@>7/,TP@SQ5)]N.?&FHT
M;2KAX?6._ELU>#F8.>8PH?G7+!6KD3$P4 H+7.;B"]U\@GI ON(E-.?57[2I
M8RT#)247M*C%L@=%1K:_^*5.Q(% <KH%3BUPC@7>"8%;"]QC07!"X-4"[]P6
M_%I0#=W<CKU*7(0%'@\9W2"FHB5-7539K]0R7QE1$V4FF'R;29T8/\JY>$\Y
M1VM@:+;"#-#/$0B<Y1P]8L:P\O$7]!'-D@R(*.7[.Y*@;P]0S(']+5]P)>)#
M4\C>**:9U"W?;EMV3K0<H =*Q(JCF*20=NBC?KWM] !,F88F%\XN%[=.+_'W
MDEPBU[I CN5X'1V:G"]WN\;3+X\@D7+[I#P^7^[T),-M)H9;\;P3O&HN?+R5
M:S!%4_Q=U@:!;N1\($M0UQ?H\[I:Z;N9T#4!>EM0)?":KW$"(T/6. [L&8SQ
MAY_LP/JU*_DZ89%.6*P)UK+):VSR*KI[PJ8;(K(TRTNU3-$,DI)E(@.Y)EZ2
MO)3+ BT8+="$%NM2X,HPND Q9B0C2XZFS:+_=B_!Z$Y P3NM]'1:J1,6Z83%
MFF M*_W&2K]WQ;6LY'LKH65ETK82=E:J^EV5X@N$"UH2T>7BM@-!U0'U"?$\
MO@I#.PR'YO.A/Z_# M^W+*L=%IT7%K\.\P/K,*R5K:#)5M";K:_JGY.L27WU
MIY?PUDFK$Q;IA,6:8"T;KAH;KMY%_;G2::5.6*03%FN"M:P<-%8.?G3]&;PN
M!59HV=Y1_7D==EQZS@/%?:!6CL(F1V%OCB:4/ ,3V3P'-)5;&F!,)F8F:/*$
M,$G1X?M'*F3V^NI3;UMOG=0Z89%.6*P)UC+,MO8;'.M=5*BZ&YK<U$J+M-)B
M7;2VH0<[5OM'UZFZ!X>%PW4#/PB.OY2Z NW0#VW[J&"=2XS/(+;SYNSSYO3F
M[9Z2)?H#6-&J4A',^S^B^JEOGM<Z:9%66JR+UO9GO^&VW?=1J+1NR[72(JVT
M6!>M;>A^:V[W;A?_ET+E_=>GTJ0CQ'5]Z_5VKB,P])TP&+C'):JOT6VNS(,3
MR0+8LCH*YG*L<AS;,ZCF:7/<?%,=LAX]O[6O)W;'\T@=3U<GH'O\]FS[ ;-E
M1CC*82&;LBZOY/Z3;8^+MS>"KJOST#D5@A;5Y0IP"DP%R/<+*C_<ZAO50'-H
M/_X74$L#!!0    ( *: 6%H-FE5#W0(  -0(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;*5676_:,!3]*U:TAU;:FF_H$$3B:UJG5JN*NCU,>S#)
MA5A-8F8[T.W7[]H)&840=>H+\<<]Y]Q[<'PSW''Q)%, 19[SK) C*U5J,[!M
M&:>04WG%-U#@SHJ+G"J<BK4M-P)H8D!Y9GN.T[-SR@HK&IJU>Q$->:DR5L"]
M(++,<RI^3R#CNY'E6ON%![9.E5ZPH^&&KF$!ZG%S+W!F-RP)RZ&0C!=$P&ID
MC=W!/-3Q)N ;@YT\&!-=R9+S)SVY24:6HQ."#&*E&2@^MC"%+--$F,:OFM-J
M)#7P<+QG_V1JQUJ65,*49]]9HM*1=6V1!%:TS-0#WWV&NAZ38,PS:7[)KHKM
MHV)<2L7S&HSSG!75DS[7/AP D*<=X-4 [Q@0G 'X-< _!O3. ((:$+Q6(:P!
MIG2[JMT8-Z.*1D/!=T3H:&33 ^.^0:-?K-#G9*$$[C+$J6B!!R\I,R!\16X!
M'2?S9SR#^+R8@:(LDY?D UG$# I5"B W14Q^W$&^!/$3-QX7,W+Q[G)H*\Q%
M,]IQK3NI=+TSNCURQPN52C(O$DA:\+-NO.MU$-AH0N.$MW=BXG4R?BF+*^([
M[XGG>$%+0M/7P_VV>KKA,X@1[IZ%SU\/]SK,\)MCX1N^X S?..="L3_4O,QX
M-!Z^/I*QE*!DVU]=<86&2U],V\AS0TQC>VA?IZ"^#@=R0V,867C?21!;L"+2
MYN.I6.AXX4NQ^=O%7M@6-+8%G;;=% J04!%TK7J;;AE=LHPI!JW.572]@V)<
M]Z-SY%RGYG\X=RKF^=='8O.WB[UP+FR<"SN=6Z1XX BZEY/,&!=SV7[8PI/_
MW^T[[K%GG6K_X=FIFA\XGGMD6DN4U^OWFZC*$OO@FLY!K$U_E%AI6:CJU6Q6
MFQ8\-IWG:'WB#J9NR_H,6W;58?_15_W^CHHU*R1ZNT(IYZJ/N8JJAU83Q3>F
M22RYPI9CABE^=H#0 ;B_XESM)UJ@^9")_@)02P,$%     @ IH!86O+Z\=<B
M P  % H  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULE59=;]HP%/TK
M5C9-G;21[P =1&H;3>O42A6TZ\.T!Y-<P*H39[8#[;^?[:01I2&#%[#C>T[N
M.;[Q]63+^)-8 TCTG--"3*VUE.6Y;8MT#3D6 U9"H5:6C.=8JBE?V:+D@#,#
MRJGM.4YDYY@45CPQS^YX/&&5I*2 .XY$E>>8OUP"9=NIY5JO#V9DM9;Z@1U/
M2KR".<B'\HZKF=VR9"2'0A!6( [+J77AGB=#'6\"?A'8BITQTDH6C#WIR74V
MM1R=$%!(I6; ZF\#5T"I)E)I_&TXK?:5&K@[?F7_;K0K+0LLX(K11Y+)]=0:
M62B#):ZHG+'M#VCTA)HO95287[1M8AT+I960+&_ *H.<%/4_?FY\V %XX0&
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M(/$+QDLO';JQB4J'<FT$+V&BB%X7!5.[6Q!R._)ZWGY@RI<K8P?\=%BQ)<S
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MJ9AX=>A8W4B6E>=V#TQ*EI276Z A\,) /5\SM4KKFV*"YNAW^C]02P,$%
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M@^!/]?&G_=*\.46^Q6PCO48YK*74N1C+B<B:@]FF(.BN/DA<42%H45]N 6?
M5 -9OZ94/!=4@.YX?/X?4$L#!!0    ( *: 6%HQII3+-0,  # 3   -
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M$4<P!^ !0Y+$[8-[^U&\WJ?BS?_(1K\!4$L#!!0    ( *: 6%J7BKL<P
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M*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\?;'83
MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=H]XU@=XUZEW_I]XIG_<QW7MN
M:WS^?U*=+_?&^^.OR]O)P4NXXAS@A_3+-U!+ P04    " "F@%A:*+1H$\,!
M  ")'@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B
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M4$L! A0#%     @ IH!86D/+#.W$ @  I H  !@              ("!!1$
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *: 6%J[SZ8
MC 4  /(9   8              " @?\3  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "F@%A:EA!IJ4T&   I*   &
M@('!&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ IH!8
M6NRE'? 6!P  ?"8  !@              ("!1"   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *: 6%H.H[1(9 0  + .   8
M      " @9 G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "F@%A:>$(/JR\=  #,@P  &               @($J+   >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ IH!86BFRAW00!0  NA$  !@
M             ("!CTD  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *: 6%J#G*E]% ,  / (   9              " @=5.  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ IH!86H'X9WO& @
M]@<  !D              ("!(%(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "F@%A:)4LWRO$#  !2#   &0              @($=
M50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *: 6%KJ
M4=XL_P(  &X)   9              " @459  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ IH!86HO+(Y"%!   S0T  !D
M     ("!>UP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *: 6%JX@M?7Z 8  *D9   9              "
M@9!R  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ IH!8
M6@ZJ!I5A!0  :Q   !D              ("!KWD  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "F@%A:-?:1G"\?   _DP  &0
M        @(%'?P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *: 6%HT81PZ9@,  (,(   9              " @:V>  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ IH!86EG=^2'P @  ,P@
M !D              ("!2J(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "F@%A:+!3LD4,#  #_"0  &0              @(%QI0
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *: 6%JDZ1 )
M6@,  $<)   9              " @>NH  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ IH!86DEB2>S!!   J0\  !D
M ("!?*P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "F
M@%A:MVPSD/@"  #>!P  &0              @(%TL0  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *: 6%JKH>&,Q 0  .$/   9
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M970S,BYX;6Q02P$"% ,4    " "F@%A:/2^61H\"  #G!@  &0
M    @('%R   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *: 6%HC!"[-9P(   ((   9              " @8O+  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ IH!86JEG<R.K!   S1@  !D
M             ("!*<X  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "F@%A:H*73"]$%   1+P  &0              @($+TP  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *: 6%J(4<2TCP0
M "L6   9              " @1/9  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ IH!86C^MH;U! P  D0P  !D              ("!
MV=T  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "F@%A:
M5QE$4R($  #L%@  &0              @(%1X0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *: 6%HOK!<O,0,  &H+   9
M      " @:KE  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ IH!86L*$$ET/ @  KP0  !D              ("!$ND  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "F@%A:YK&C,#@$  # %P
M&0              @(%8ZP  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( *: 6%H-FE5#W0(  -0(   9              " @<?O  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ IH!86O+Z\=<B
M P  % H  !D              ("!V_(  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " "F@%A:! [5G L"   3!0  &0
M@($T]@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *:
M6%KV969ZT (  %('   9              " @7;X  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ IH!86D0;K&J\!   !AX  !D
M         ("!??L  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " "F@%A:#'ZRZD4#  "*#P  &0              @(%P  $ >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *: 6%I',$H+T0(  "X'
M   9              " @>P# 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ IH!86J9-NEG/ @  %@H  !D              ("!] 8!
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "F@%A:@JXJ
M5PL$   J%P  &0              @('Z"0$ >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( *: 6%HQII3+-0,  # 3   -
M  "  3P. 0!X;"]S='EL97,N>&UL4$L! A0#%     @ IH!86I>*NQS
M$P(   L              ( !G!$! %]R96QS+RYR96QS4$L! A0#%     @
MIH!86G$^E5FF!   ^"$   \              ( !A1(! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( *: 6%JAE^J4R0$  * >   :              "
M 5@7 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *:
M6%HHM&@3PP$  (D>   3              "  5D9 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     [ #L %!   $T; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>138</ContextCount>
  <ElementCount>195</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations And Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations And Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/StatementsOfStockholdersDeficit</Role>
      <ShortName>Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>999007 - Disclosure - Organization Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation</Role>
      <ShortName>Organization Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://scienture.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Long-Term Convertible Debt, net of debt discount</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount</Role>
      <ShortName>Long-Term Convertible Debt, net of debt discount</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/CommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan</Role>
      <ShortName>Scienture Inc. 2020 Stock Option and Grant Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://scienture.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/CashAndCashEquivalents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables</Role>
      <ShortName>Long-Term Convertible Debt, net of debt discount (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/RelatedPartyTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables</Role>
      <ShortName>Scienture Inc. 2020 Stock Option and Grant Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/Warrants</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://scienture.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/GoingConcern</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Convertible Notes (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://scienture.com/role/ConvertibleNotesDetailsNarrative</Role>
      <ShortName>Convertible Notes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/ConvertibleNotes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails</Role>
      <ShortName>Schedule of Long Term Convertible Debt Net of Discount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Maturities Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://scienture.com/role/ScheduleOfMaturitiesNotesDetails</Role>
      <ShortName>Schedule of Maturities Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative</Role>
      <ShortName>Long-Term Convertible Debt, net of debt discount (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails</Role>
      <ShortName>Schedule of Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative</Role>
      <ShortName>Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/WarrantsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Net Loss per Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/NetLossPerShareDetailsNarrative</Role>
      <ShortName>Net Loss per Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/NetLossPerShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfLeaseExpenseDetails</Role>
      <ShortName>Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Balance Sheet Information Related To Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/LeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails</Role>
      <ShortName>Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails</Role>
      <ShortName>Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information Related To Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Maturities Of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://scienture.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://scienture.com/role/SubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="424B3" isDefinitelyFs="true" isUsgaap="true" original="form424b3.htm">form424b3.htm</File>
    <File>scnx-20240630.xsd</File>
    <File>scnx-20240630_cal.xml</File>
    <File>scnx-20240630_def.xml</File>
    <File>scnx-20240630_lab.xml</File>
    <File>scnx-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form424b3_001.jpg</File>
    <File>form424b3_002.jpg</File>
    <File>form424b3_003.jpg</File>
    <File>form424b3_004.jpg</File>
    <File>form424b3_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="709">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form424b3.htm": {
   "nsprefix": "SCNX",
   "nsuri": "http://scienture.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "form424b3.htm"
     ]
    },
    "schema": {
     "local": [
      "scnx-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "scnx-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "scnx-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "scnx-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "scnx-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 23,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 13,
   "hidden": {
    "total": 120,
    "http://fasb.org/us-gaap/2024": 108,
    "http://scienture.com/20240630": 8,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 138,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 352,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 709,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/srt/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://scienture.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://scienture.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://scienture.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Statements of Operations And Comprehensive Loss",
     "shortName": "Statements of Operations And Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-06-30_custom_ScientureIncMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://scienture.com/role/StatementsOfStockholdersDeficit",
     "longName": "00000005 - Statement - Statements of Stockholders' Deficit",
     "shortName": "Statements of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://scienture.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_ScientureIncMember",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation",
     "longName": "999007 - Disclosure - Organization Overview and Basis of Presentation",
     "shortName": "Organization Overview and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://scienture.com/role/GoingConcern",
     "longName": "999009 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://scienture.com/role/CashAndCashEquivalents",
     "longName": "999010 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://scienture.com/role/ConvertibleNotes",
     "longName": "999011 - Disclosure - Convertible Notes",
     "shortName": "Convertible Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
     "longName": "999012 - Disclosure - Long-Term Convertible Debt, net of debt discount",
     "shortName": "Long-Term Convertible Debt, net of debt discount",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://scienture.com/role/FairValueOfFinancialInstruments",
     "longName": "999013 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://scienture.com/role/CommitmentAndContingencies",
     "longName": "999014 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://scienture.com/role/RelatedPartyTransactions",
     "longName": "999015 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
     "longName": "999016 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan",
     "shortName": "Scienture Inc. 2020 Stock Option and Grant Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://scienture.com/role/Warrants",
     "longName": "999017 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "SCNX:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "SCNX:WarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://scienture.com/role/NetLossPerShare",
     "longName": "999018 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://scienture.com/role/Leases",
     "longName": "999019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://scienture.com/role/SubsequentEvents",
     "longName": "999020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999022 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://scienture.com/role/CashAndCashEquivalentsTables",
     "longName": "999023 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
     "longName": "999024 - Disclosure - Long-Term Convertible Debt, net of debt discount (Tables)",
     "shortName": "Long-Term Convertible Debt, net of debt discount (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://scienture.com/role/RelatedPartyTransactionsTables",
     "longName": "999025 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
     "longName": "999026 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Tables)",
     "shortName": "Scienture Inc. 2020 Stock Option and Grant Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://scienture.com/role/WarrantsTables",
     "longName": "999027 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://scienture.com/role/LeasesTables",
     "longName": "999028 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://scienture.com/role/GoingConcernDetailsNarrative",
     "longName": "999030 - Disclosure - Going Concern (Details Narrative)",
     "shortName": "Going Concern (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
     "longName": "999031 - Disclosure - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashAndDueFromBanks",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:CashAndDueFromBanks",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
     "longName": "999032 - Disclosure - Convertible Notes (Details Narrative)",
     "shortName": "Convertible Notes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_ScientureIncMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
     "longName": "999033 - Disclosure - Schedule of Long Term Convertible Debt Net of Discount (Details)",
     "shortName": "Schedule of Long Term Convertible Debt Net of Discount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
     "longName": "999034 - Disclosure - Schedule of Maturities Notes (Details)",
     "shortName": "Schedule of Maturities Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
     "longName": "999035 - Disclosure - Long-Term Convertible Debt, net of debt discount (Details Narrative)",
     "shortName": "Long-Term Convertible Debt, net of debt discount (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999036 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-03-012024-03-31_custom_ScientureIncMember",
      "name": "SCNX:TerminationFee",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:VariableLeasePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://scienture.com/role/SummaryOfStockOptionActivityDetails",
     "longName": "999037 - Disclosure - Summary of Stock Option Activity (Details)",
     "shortName": "Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999038 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
     "longName": "999039 - Disclosure - Schedule of Stock Option Valuation Assumptions (Details)",
     "shortName": "Schedule of Stock Option Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
     "longName": "999040 - Disclosure - Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)",
     "shortName": "Scienture Inc. 2020 Stock Option and Grant Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://scienture.com/role/WarrantsDetailsNarrative",
     "longName": "999041 - Disclosure - Warrants (Details Narrative)",
     "shortName": "Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://scienture.com/role/NetLossPerShareDetailsNarrative",
     "longName": "999042 - Disclosure - Net Loss per Share (Details Narrative)",
     "shortName": "Net Loss per Share (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
     "longName": "999043 - Disclosure - Schedule of Lease Expense (Details)",
     "shortName": "Schedule of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
     "longName": "999044 - Disclosure - Schedule of Supplemental Balance Sheet Information Related To Leases (Details)",
     "shortName": "Schedule of Supplemental Balance Sheet Information Related To Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://scienture.com/role/LeasesDetailsNarrative",
     "longName": "999045 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
     "longName": "999046 - Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "SCNX:DeferredTaxAssetsAndLiabilitiesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "SCNX:DeferredTaxAssetsAndLiabilitiesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails",
     "longName": "999047 - Disclosure - Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)",
     "shortName": "Schedule of Relatives or Related Parties to Directors Purchased Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails",
     "longName": "999048 - Disclosure - Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)",
     "shortName": "Summary of Assumptions Used to Estimate Fair Value of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock",
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock",
       "SCNX:WarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "longName": "999049 - Disclosure - Schedule of Supplemental Cash Flow Information Related To Leases (Details)",
     "shortName": "Schedule of Supplemental Cash Flow Information Related To Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SCNX:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SCNX:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "999050 - Disclosure - Schedule of Maturities Of Lease Liabilities (Details)",
     "shortName": "Schedule of Maturities Of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ScientureIncMember",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://scienture.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999051 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_ScientureIncMember",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b3.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "auth_ref": []
    },
    "SCNX_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Pronouncements Not Yet Adopted",
        "documentation": "Accounting Pronouncements Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r508"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r508",
      "r616"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r555",
      "r556",
      "r557",
      "r558",
      "r587",
      "r617"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount interest expense",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expenses",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in connection with long-term convertible debt",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r21",
      "r68"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r180",
      "r184"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r58",
      "r233",
      "r594"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r86",
      "r110",
      "r129",
      "r158",
      "r160",
      "r173",
      "r174",
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r301",
      "r303",
      "r329",
      "r375",
      "r431",
      "r486",
      "r487",
      "r508",
      "r519",
      "r578",
      "r579",
      "r600"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r113",
      "r129",
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r301",
      "r303",
      "r329",
      "r508",
      "r578",
      "r579",
      "r600"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r109",
      "r478"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://scienture.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r379"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashAndDueFromBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndDueFromBanks",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "documentation": "For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r126"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r59"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r612"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash financing activities:",
        "verboseLabel": "Cash paid for accounts included in the measurements of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://scienture.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrant to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://scienture.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Refer Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r80",
      "r378",
      "r418"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://scienture.com/role/CommitmentAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r194",
      "r195",
      "r472",
      "r571",
      "r576"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r555",
      "r556",
      "r558",
      "r587",
      "r614",
      "r617"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r419"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48",
      "r419",
      "r437",
      "r617",
      "r618"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value, 10,000,000 authorized, 5,000,000 issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r381",
      "r508"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risks and Major Customers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r93"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/BalanceSheetsParenthetical",
      "http://scienture.com/role/CashAndCashEquivalents",
      "http://scienture.com/role/CashAndCashEquivalentsTables",
      "http://scienture.com/role/CommitmentAndContingencies",
      "http://scienture.com/role/ConvertibleNotes",
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/FairValueOfFinancialInstruments",
      "http://scienture.com/role/GoingConcern",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/Leases",
      "http://scienture.com/role/LeasesDetailsNarrative",
      "http://scienture.com/role/LeasesTables",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
      "http://scienture.com/role/NetLossPerShare",
      "http://scienture.com/role/NetLossPerShareDetailsNarrative",
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation",
      "http://scienture.com/role/RelatedPartyTransactions",
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/RelatedPartyTransactionsTables",
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails",
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/StatementsOfStockholdersDeficit",
      "http://scienture.com/role/SubsequentEvents",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative",
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails",
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails",
      "http://scienture.com/role/Warrants",
      "http://scienture.com/role/WarrantsDetailsNarrative",
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r102",
      "r130",
      "r301",
      "r302",
      "r303",
      "r304",
      "r365",
      "r473",
      "r542",
      "r543",
      "r544",
      "r577",
      "r580",
      "r581"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/BalanceSheetsParenthetical",
      "http://scienture.com/role/CashAndCashEquivalents",
      "http://scienture.com/role/CashAndCashEquivalentsTables",
      "http://scienture.com/role/CommitmentAndContingencies",
      "http://scienture.com/role/ConvertibleNotes",
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/FairValueOfFinancialInstruments",
      "http://scienture.com/role/GoingConcern",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/Leases",
      "http://scienture.com/role/LeasesDetailsNarrative",
      "http://scienture.com/role/LeasesTables",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
      "http://scienture.com/role/NetLossPerShare",
      "http://scienture.com/role/NetLossPerShareDetailsNarrative",
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation",
      "http://scienture.com/role/RelatedPartyTransactions",
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/RelatedPartyTransactionsTables",
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails",
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/SubsequentEvents",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative",
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails",
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails",
      "http://scienture.com/role/Warrants",
      "http://scienture.com/role/WarrantsDetailsNarrative",
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r102",
      "r130",
      "r301",
      "r302",
      "r303",
      "r304",
      "r365",
      "r473",
      "r542",
      "r543",
      "r544",
      "r577",
      "r580",
      "r581"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://scienture.com/role/GoingConcern",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "presentation": [
      "http://scienture.com/role/GoingConcern",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]",
        "documentation": "Disclosure of information about effect of change in parent's ownership interest in subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities Notes",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r554"
     ]
    },
    "SCNX_ConversionOfNotesAndAccruedInterestIntoPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ConversionOfNotesAndAccruedInterestIntoPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of notes and accrued interest into preferred stock",
        "documentation": "Conversion of notes and accrued interest into preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term convertible debt, net of debt discount",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "SCNX_ConvertiblePreferredStockAndConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ConvertiblePreferredStockAndConvertibleNotesMember",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Convertible Notes [Member]",
        "documentation": "Convertible Preferred Stock and Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_DebtDilutedValuation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DebtDilutedValuation",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt diluted valuation",
        "documentation": "Debt diluted valuation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r128",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r200",
      "r201",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r227",
      "r234",
      "r235",
      "r236",
      "r338"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r38",
      "r39",
      "r77",
      "r79",
      "r130",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r506",
      "r551",
      "r572",
      "r573",
      "r574",
      "r593",
      "r595"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal",
        "verboseLabel": "Total",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r237"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt outstanding principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r338",
      "r339",
      "r492",
      "r493",
      "r506"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes issued bear interest rate percentage",
        "verboseLabel": "Debt interest rate percentage",
        "terseLabel": "Debt instrument interest rate stated percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r213"
     ]
    },
    "SCNX_DebtInstrumentInterestRateStatedPrimeRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DebtInstrumentInterestRateStatedPrimeRatePercentage",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt prime rate percentage",
        "documentation": "Debt instrument interest rate stated prime rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r130",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r506",
      "r551",
      "r572",
      "r573",
      "r574",
      "r593",
      "r595"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Unamortized debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r592",
      "r593",
      "r595"
     ]
    },
    "SCNX_DeferredTaxAssetsAndLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DeferredTaxAssetsAndLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets and Liabilities",
        "documentation": "Deferred Tax Assets and Liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment and operating lease liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_DevelopmentAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DevelopmentAgreementLiability",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development agreement liability",
        "documentation": "Development agreement liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r565",
      "r615"
     ]
    },
    "SCNX_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scienture Inc. 2020 Stock Option and Grant Plan",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r250",
      "r277",
      "r278",
      "r279",
      "r498"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28"
     ]
    },
    "SCNX_DisclosureWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DisclosureWarrantsAbstract",
     "auth_ref": []
    },
    "SCNX_DividendIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "DividendIncome",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend income",
        "documentation": "Dividend income."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r533",
      "r534"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r146",
      "r148",
      "r150",
      "r151",
      "r152",
      "r157",
      "r296",
      "r299",
      "r312",
      "r313",
      "r374",
      "r387",
      "r480"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r148",
      "r150",
      "r151",
      "r152",
      "r157",
      "r296",
      "r299",
      "r312",
      "r313",
      "r374",
      "r387",
      "r480"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r154"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://scienture.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r153",
      "r155",
      "r156"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r499",
      "r553",
      "r584"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r105",
      "r117",
      "r118",
      "r119",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r144",
      "r159",
      "r182",
      "r183",
      "r185",
      "r241",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r340",
      "r342",
      "r358",
      "r386",
      "r392",
      "r393",
      "r394",
      "r407",
      "r461"
     ]
    },
    "SCNX_ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License and Commercial Agreements",
        "documentation": "Exclusive License and Commercial Agreements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r502"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r502"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://scienture.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r373",
      "r500",
      "r503"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r441"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r192",
      "r193",
      "r317",
      "r319",
      "r323",
      "r389",
      "r391",
      "r446",
      "r476",
      "r501",
      "r613"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r317",
      "r319",
      "r323",
      "r389",
      "r391",
      "r446",
      "r476",
      "r501",
      "r613"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r290",
      "r401"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "SCNX_IncreaseDecreaseInDevelopmentAgreementLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "IncreaseDecreaseInDevelopmentAgreementLiability",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Development agreement liability",
        "documentation": "Increase decrease in development agreement liability.",
        "label": "IncreaseDecreaseInDevelopmentAgreementLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r549"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r163",
      "r164",
      "r174",
      "r337",
      "r486",
      "r487"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income (expense), net",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r548",
      "r561"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r125"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r619"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for services",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SCNX_IssueOfConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "IssueOfConvertibleNotesMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Convertible Notes [Member]",
        "documentation": "Issue of Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_IssueOfPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "IssueOfPreferredStockMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Preferred Stock [Member]",
        "documentation": "Issue of Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_KesinPharmaCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "KesinPharmaCorporationMember",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kesin Pharma Corporation [Member]",
        "documentation": "Kesin Pharma Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://scienture.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://scienture.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities Of Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://scienture.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r596"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://scienture.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r38",
      "r39",
      "r40",
      "r43",
      "r44",
      "r45",
      "r46",
      "r129",
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r302",
      "r303",
      "r304",
      "r329",
      "r417",
      "r481",
      "r519",
      "r578",
      "r600",
      "r601"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r81",
      "r383",
      "r508",
      "r552",
      "r570",
      "r591"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r108",
      "r129",
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r302",
      "r303",
      "r304",
      "r329",
      "r508",
      "r578",
      "r600",
      "r601"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity",
        "documentation": "Liquidity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_LongTermConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "LongTermConvertibleDebtMember",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Convertible Debt [Member]",
        "documentation": "Long Term Convertible Debt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term convertible debt, net of debt discount",
        "label": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r224",
      "r238",
      "r492",
      "r493",
      "r506",
      "r610"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 2",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r130",
      "r229"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 3",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r130",
      "r229"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year 1",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Convertible Debt, net of debt discount",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r246",
      "r280",
      "r316",
      "r371",
      "r388",
      "r390",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r490",
      "r496",
      "r497",
      "r502",
      "r503",
      "r504",
      "r505",
      "r509",
      "r582",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r502"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r502"
     ]
    },
    "SCNX_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone structure",
        "documentation": "Milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r246",
      "r280",
      "r316",
      "r371",
      "r388",
      "r390",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r490",
      "r496",
      "r497",
      "r502",
      "r503",
      "r504",
      "r509",
      "r582",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "SCNX_MiscellaneousIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "MiscellaneousIncome",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous income",
        "documentation": "Miscellaneous income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market securities (Highly liquid investments)",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_MrSandeepGuptaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "MrSandeepGuptaMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Sandeep Gupta [Member]",
        "documentation": "Mr. Sandeep Gupta [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_MsPushpaShankarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "MsPushpaShankarMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms. Pushpa Shankar [Member]",
        "documentation": "Ms. Pushpa Shankar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_MsYogitaDesaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "MsYogitaDesaiMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms. Yogita Desai [Member]",
        "documentation": "Ms. Yogita Desai [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/StatementsOfStockholdersDeficit",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "negatedLabel": "Loss before tax",
        "negatedTerseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r61",
      "r82",
      "r106",
      "r114",
      "r115",
      "r119",
      "r129",
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r149",
      "r181",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r296",
      "r299",
      "r313",
      "r329",
      "r385",
      "r439",
      "r459",
      "r460",
      "r518",
      "r578"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Pronouncements Recently Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r560"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r489",
      "r560"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r482",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_ShortTermLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r507"
     ]
    },
    "SCNX_OperatingLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "OperatingLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_ShortTermLeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on Lease Liabilities",
        "documentation": "Operating lease interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lease Liabilities",
        "label": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "verboseLabel": "Short term Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, non current",
        "verboseLabel": "Long term Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows for Operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r349"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, right of use asset",
        "verboseLabel": "Right of Use Assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_ShortTermLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of ROU Assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r507"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r507"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Overview and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r74",
      "r398",
      "r399"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party Balances",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r376",
      "r413",
      "r414",
      "r519",
      "r611",
      "r615"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517",
      "r614",
      "r617"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r239"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r419"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r239"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://scienture.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r419",
      "r437",
      "r617",
      "r618"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.0001 par value, 2,400,000 authorized, issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r380",
      "r508"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the issuance of convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the issuance of long-term convertible debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r402"
     ]
    },
    "SCNX_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r244",
      "r246",
      "r273",
      "r274",
      "r275",
      "r280",
      "r316",
      "r369",
      "r370",
      "r371",
      "r388",
      "r390",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r490",
      "r496",
      "r497",
      "r502",
      "r503",
      "r504",
      "r505",
      "r509",
      "r512",
      "r575",
      "r582",
      "r589",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r196",
      "r197",
      "r198",
      "r199",
      "r244",
      "r246",
      "r273",
      "r274",
      "r275",
      "r280",
      "r316",
      "r369",
      "r370",
      "r371",
      "r388",
      "r390",
      "r397",
      "r409",
      "r410",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r490",
      "r496",
      "r497",
      "r502",
      "r503",
      "r504",
      "r505",
      "r509",
      "r512",
      "r575",
      "r582",
      "r589",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r245",
      "r362",
      "r363",
      "r377",
      "r384",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r436",
      "r438",
      "r466"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party Transactions",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r362"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r599"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r111",
      "r354",
      "r356",
      "r357",
      "r361"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r442",
      "r443",
      "r446"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r245",
      "r362",
      "r363",
      "r377",
      "r384",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r436",
      "r438",
      "r466",
      "r599"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r404",
      "r405",
      "r406",
      "r444",
      "r445",
      "r446",
      "r464",
      "r465"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and Development Expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r476",
      "r486",
      "r608"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r68",
      "r382",
      "r395",
      "r396",
      "r403",
      "r420",
      "r508"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r144",
      "r182",
      "r183",
      "r185",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r305",
      "r307",
      "r308",
      "r310",
      "r311",
      "r340",
      "r342",
      "r392",
      "r394",
      "r407",
      "r617"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net revenue",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r158",
      "r161",
      "r162",
      "r172",
      "r174",
      "r176",
      "r177",
      "r178",
      "r242",
      "r243",
      "r372"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r477",
      "r479"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of Use Assets obtained in exchange for new Lease Liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r507"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "SCNX_SaptalisPharmaceuticalsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "SaptalisPharmaceuticalsLlcMember",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saptalis Pharmaceuticals LLC [Member]",
        "documentation": "Saptalis Pharmaceuticals LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://scienture.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long Term Convertible Debt Net of Discount",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r22",
      "r23",
      "r33",
      "r66",
      "r67",
      "r492",
      "r494",
      "r554",
      "r593"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Related Valuation Allowance",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24",
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r442",
      "r443",
      "r446"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Relatives or Related Parties to Directors Purchased Securities",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "SCNX_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://scienture.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Balance Sheet Information Related To Leases",
        "documentation": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://scienture.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Cash Flow Information Related To Leases",
        "documentation": "Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_ScientureIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "ScientureIncMember",
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/BalanceSheetsParenthetical",
      "http://scienture.com/role/CashAndCashEquivalents",
      "http://scienture.com/role/CashAndCashEquivalentsTables",
      "http://scienture.com/role/CommitmentAndContingencies",
      "http://scienture.com/role/ConvertibleNotes",
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/FairValueOfFinancialInstruments",
      "http://scienture.com/role/GoingConcern",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/Leases",
      "http://scienture.com/role/LeasesDetailsNarrative",
      "http://scienture.com/role/LeasesTables",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
      "http://scienture.com/role/NetLossPerShare",
      "http://scienture.com/role/NetLossPerShareDetailsNarrative",
      "http://scienture.com/role/OrganizationOverviewAndBasisOfPresentation",
      "http://scienture.com/role/RelatedPartyTransactions",
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/RelatedPartyTransactionsTables",
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfRelativesOrRelatedPartiesToDirectorsPurchasedSecuritiesDetails",
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/StatementsOfStockholdersDeficit",
      "http://scienture.com/role/SubsequentEvents",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative",
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails",
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails",
      "http://scienture.com/role/Warrants",
      "http://scienture.com/role/WarrantsDetailsNarrative",
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scienture Inc [Member]",
        "documentation": "Scienture Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r175",
      "r177",
      "r484",
      "r485",
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expenses",
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding Options, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding Options, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Outstanding Options, Cancelled and forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding Options, Balance",
        "periodEndLabel": "Outstanding Options, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- Average Exercise Price, Balance",
        "periodEndLabel": "Weighted- Average Exercise Price, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative",
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Exercise Price, Cancelled and forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://scienture.com/role/ScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Remaining Term (Years), Vested and exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Remaining Term (Years), Balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value of options granted",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term",
        "verboseLabel": "Short term borrowings",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r77",
      "r508",
      "r609"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r507"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r127"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48",
      "r51",
      "r52",
      "r105",
      "r117",
      "r118",
      "r119",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r142",
      "r144",
      "r159",
      "r182",
      "r183",
      "r185",
      "r241",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r340",
      "r342",
      "r358",
      "r386",
      "r392",
      "r393",
      "r394",
      "r407",
      "r461"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/BalanceSheetsParenthetical",
      "http://scienture.com/role/CashAndCashEquivalents",
      "http://scienture.com/role/CashAndCashEquivalentsTables",
      "http://scienture.com/role/CommitmentAndContingencies",
      "http://scienture.com/role/ConvertibleNotes",
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/FairValueOfFinancialInstruments",
      "http://scienture.com/role/Leases",
      "http://scienture.com/role/LeasesDetailsNarrative",
      "http://scienture.com/role/LeasesTables",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
      "http://scienture.com/role/NetLossPerShare",
      "http://scienture.com/role/RelatedPartyTransactions",
      "http://scienture.com/role/RelatedPartyTransactionsTables",
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/StatementsOfStockholdersDeficit",
      "http://scienture.com/role/SubsequentEvents",
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://scienture.com/role/Warrants",
      "http://scienture.com/role/WarrantsDetailsNarrative",
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r159",
      "r342",
      "r372",
      "r400",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r441",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r513"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/BalanceSheetsParenthetical",
      "http://scienture.com/role/CashAndCashEquivalents",
      "http://scienture.com/role/CashAndCashEquivalentsTables",
      "http://scienture.com/role/CommitmentAndContingencies",
      "http://scienture.com/role/ConvertibleNotes",
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/FairValueOfFinancialInstruments",
      "http://scienture.com/role/Leases",
      "http://scienture.com/role/LeasesDetailsNarrative",
      "http://scienture.com/role/LeasesTables",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscount",
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountTables",
      "http://scienture.com/role/NetLossPerShare",
      "http://scienture.com/role/RelatedPartyTransactions",
      "http://scienture.com/role/RelatedPartyTransactionsTables",
      "http://scienture.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://scienture.com/role/ScheduleOfDeferredTaxAssetsAndRelatedValuationAllowanceDetails",
      "http://scienture.com/role/ScheduleOfLeaseExpenseDetails",
      "http://scienture.com/role/ScheduleOfLongTermConvertibleDebtNetOfDiscountDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesNotesDetails",
      "http://scienture.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlan",
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanTables",
      "http://scienture.com/role/StatementsOfCashFlows",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/StatementsOfStockholdersDeficit",
      "http://scienture.com/role/SubsequentEvents",
      "http://scienture.com/role/SummaryOfSignificantAccountingPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://scienture.com/role/Warrants",
      "http://scienture.com/role/WarrantsDetailsNarrative",
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r159",
      "r179",
      "r342",
      "r372",
      "r400",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r441",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r513"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt, shares",
        "verboseLabel": "Stock issued during period shares conversion of convertible securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22",
      "r48",
      "r51",
      "r68",
      "r228"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of notes into preferred stock, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r22",
      "r47",
      "r48",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://scienture.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r48",
      "r68",
      "r259"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/ConvertibleNotesDetailsNarrative",
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt, amount",
        "verboseLabel": "Convertible note",
        "terseLabel": "Stock issued during period value conversion of convertible securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48",
      "r51",
      "r52",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of notes into preferred stock",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r48",
      "r51",
      "r52",
      "r68"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_StockOptionAndGrantPlanHaveContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "StockOptionAndGrantPlanHaveContractualTerm",
     "presentation": [
      "http://scienture.com/role/ScientureInc.2020StockOptionAndGrantPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option and Grant Plan have a contractual term",
        "documentation": "Stock option and grant plan have contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_StockholdersDeficitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "StockholdersDeficitMember",
     "presentation": [
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Deficit [Member]",
        "documentation": "Stockholders Deficit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://scienture.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/BalanceSheets",
      "http://scienture.com/role/GoingConcernDetailsNarrative",
      "http://scienture.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "negatedLabel": "Stockholders deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r63",
      "r421",
      "r437",
      "r462",
      "r463",
      "r508",
      "r519",
      "r552",
      "r570",
      "r591",
      "r617"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://scienture.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r367"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r367"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r367"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r367"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r367"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://scienture.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r368"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://scienture.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "SCNX_SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock",
     "presentation": [
      "http://scienture.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Assumptions Used to Estimate Fair Value of Warrants",
        "documentation": "Summary of Assumptions Used to Estimate Fair Value of Warrants Granted [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_TerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "TerminationFee",
     "crdr": "debit",
     "calculation": {
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination fee",
        "documentation": "Termination fee."
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_TerminationFeeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "TerminationFeeDescription",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination fee description",
        "documentation": "Termination fee description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r567",
      "r568",
      "r569"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://scienture.com/role/Long-termConvertibleDebtNetOfDebtDiscountDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "SCNX_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Interim Financial Information",
        "documentation": "Unaudited Interim Financial Information [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r91",
      "r92",
      "r94",
      "r95"
     ]
    },
    "us-gaap_VariableLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeasePayment",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease payments",
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://scienture.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r514",
      "r515",
      "r516",
      "r517"
     ]
    },
    "SCNX_WarrantValuationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "WarrantValuationPolicyTextBlock",
     "presentation": [
      "http://scienture.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Valuation",
        "documentation": "Warrant Valuation [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, warrant",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://scienture.com/role/SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of warrants",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ]
    },
    "SCNX_WarrantsIssuedInConnectionWithLongtermConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "WarrantsIssuedInConnectionWithLongtermConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://scienture.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued in connection with long-term convertible debt",
        "documentation": "Warrants issued in connection with long term convertible debt.",
        "label": "WarrantsIssuedInConnectionWithLongtermConvertibleDebt"
       }
      }
     },
     "auth_ref": []
    },
    "SCNX_WarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://scienture.com/20240630",
     "localname": "WarrantsTextBlock",
     "presentation": [
      "http://scienture.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares used to compute net loss per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r152"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://scienture.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares used to compute net loss per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://scienture.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001493152-25-008044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-008044-xbrl.zip
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M&3!<<4M/@Y!6V+2TY&?)[U&1WU*:L9;H+-$],J*[E]$TM?&&EGPL^3P^\GF
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MM%M"."-,08M%*MW#P\/J6KWC$PV;%P<=)TN& B!,W8LP&U6!Z9B@\S>'\;F
M4T]E"0:LHG[V,9=A+*1T>PE.G4QBZ?X1)7T KG>RZQ(@65#;%3^@5G,0(K<*
M$8)0>W<%KIZ((KA;E_I(C."B10G<^CW2D64"5VSHFW"0H%(R:^ 9N"^#^&]!
MZO#7) VE"/"KY^$+=[OS;FN'?K+_^7C79>>/^]R33B &@(V!VQ=1<@%X^CR$
MQ]]<M;S[W,"K0Z0D0%T@V7&8H>/./1!"O4 CF!MB/F> L)OH['K2]1R__.4
M?IE/X#WX G$I?"(/?+_G3O+4'WE2N-XP%>3B=,GYZ!XEY^RAA VZ.*&L A]M
M]T3]UNGJWY9T"?N%#?/!;NU<N6_<A=>/1.,^8M<+@A#AA0^J>W(FAEF.L%6
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MQS#V>U^_?(%;6NBYOS+.?67)8Z?-"T ODUMXF19X])L;*XSSK]L\\J^]?71
M .J#UK*WV%-_]>IQB(0W;5Y ;__S9_3P(FQ4+8.59_L+QO_[O8F6\?]MF\?/
M[N\3\K !'7#.W-?3W4]=((SN'Z?[)( 7>QD[JT\6E[ZR&FKG:;A#FTYU(<?Y
M=D5QNR\;C_#CU][AT7ZOMZ#3>K>RR->>)Z2X@K'@*SCYW*6SWSOLG9T>?B2E
MG<]?\8&VK^'-F]5"VD6=_=8,^N]V3P[/NI]U)>DB[^!>&<=B^+#\%R/P_C^!
M\9X=_D5!KI/]HUZW1.&VS^WMO5KZ+3)<.BS$N,/3?;0Y[N.L[I7.%X-C)*?@
MV%04]?#([7[=.X3S6]"1W:N$6E[6N/WLP^?]/X 3?NF>G9&!L$!>^.Y>#>25
M4 M>(5<]V3\]>TPGO[SHOO/LP^'1P?'I%\Y^F)O3\X@N8R7(X/6S#]\POXNR
MIG9!33XX/-ISOQQ3WE5Q7X_H5EJU\"0S<CBR_7]B1@\<7O=H]Q"X^LSAM7UJ
M!VNU.)B*_*]28E=3E/>*-),MFU'2<D:)32FQ*27S8%>K4^DUIIF_=_/)1*2^
M)P5EF_![L!.HSC#@35)Z@#.3'K":F2C7'<+]MOM:1&YM^&%N\R:L" LSK"(K
M^S2[,N_+, B]-%3%6" +!96B90E5$6)AC2QJ*_3:]<9-6).@6C3IKW37CZ:^
M3T:GDJ;63WD<83,D+G10S;_C +@LMK]*L/CH(I1B'5/=5_>>-*[=ZQ[NNV<9
MUHYY:<8]65*C-RN\#6Z3.AY@H0W0HMM;VX0KQR)!;%> Q=Y%]X*OZSWLM%(4
M0B+>[%_Z(R\>"NY'(B7U&C.+:O=W=:U0I=O.]2TQ.K--U3K<%(->3#6125HB
MHAN$<I)(795K5$J6Y44.%_W,K^"D&J+&=A9S^EA<T:VB"HBC^WGP+\97-@0@
M,+! WXMD0M> C9;*"Y7 ,"-U;ZD+N\[6!"S/%4]4VTS?%=7*S3<^*&ZAVHT
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ML5_L2VDDQ8X\\W*HP;[UO?QT!L%V8Z,*FTQPTV2";@KFCS^;2+!Y7WD$*W#
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M#G62)B96H3E^/3$(/6#(,SHN4S_MJQCME4)(T2]WU5-]H$7@J-TCKX.G^$?
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M#F0=%'J)+ BO= 4P?'5SWJV:\_/L]F8[WU+$4Z:(O9REH&[  >^A*!65C4O
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MJF':0:QF6H@B4FJ@'>#4Z$+U5J$H;Q.)8T14G),6/)?*2:ND9F][74HBC_)
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M[Z&!:#9$#\(H)WU/V3;B,I3D!)3F;TG7Q+0KGAW'Y:=H#&I,]M4 ;6YWV0P
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M(61,-L!9K4E:B4EYG+\ R#[)^U'HNX,H\6P=X9-&NC/,MZW;14:WYR@$6SS
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M3WAFVVAQA+&R)T*\R"Q,!38H.1N),O.RS.XG-+P0[,D)A/33L"\"1Z>H48U
MC,.NL8OK@*12T8O!BZ?F ,VYRU.F!B> PDH_XN0BYC&#G O+)0RJ2@P>"(08
MN^%8EX$YJ'MZD4Q4GEHUF<WHF4A;3'Q>2&F0W*_=O"8>K,8F/5XN#N^DGF\1
M][_UD# &^)4VM+!JW%$66D)!_L! D75W5XU*I(G?8UUU2;<HN7B=DGYOAJBU
MW^'C@$477AJL14GR ]E(^9YU) 2./QC(UB%^H9C!KD=!8R^=ND<)H-NI&,):
M>(L':MG/O"Q7G=*RFFG@3:IEOB%BN7_#>>T"9SP O=?Y@J\]+%];AC#"E>76
MCT'B])L;X'U4%+/:6WL,UP,ZP3?AJ,HFD/R8/D%:.1 V*,S],)E@TKGGBYR[
MU2A>RV*R=#0JU@>DR][WJ=DE?^S] *:05>.2 DO$:283MCU@ANM4NM'J)#I\
M0'G557TC?7UNI+FWGZ%Z[37<@W9_I7W_#>1D II _<Z<G[^S=;='SD \Z<^?
M=]T+4!^0I;+.M+6Q^8[[ &2FJ*.T&[Q'DMH4"%<O<-#OD@Z]./Q/X7')0&[B
M'W3I#%:G%*"3R(MC*F=-O9"**GQO$F;8+T#I;U.]DC&Q ==J:)6AE$@GPPHI
M:@B#>4\"V]I';BS2<VPH(Z<2!$U15K)[U*O4G_@HGY)S3_H4QRD>^ZM\+ @E
MZL58YT)R& %J*I9T=)$OH;;:J%)0 I3:/[AEO]#7"8<%FJ>J62D^S% -D?6;
MPGP$U&RF JA,C.%:,I;HP"D:YI\X:OX)1F_G3DB76%D3YZC>Y2F/F]&G3,&M
MLO&4*WW*\$I="@H/A9J_9M82(98DKDRHA1U<6%^,O&C@4'?<F!;%+#&I\B**
M><O8$9'-DU@@Y:/N,*B,8RNOWFB$Q4I ]9"*5)\9_'<4_E.14D$MR+4D;1MK
M7*74*'0=.S+S.<SZTE(/G26T,(H<4+J2/,Z*LB'"<LTQN0&P-E6,*>NDM(&9
M%$VO8=G*<Y\"006X@J[5&J"#1*%E 95S0X2J="+#UC54P$LY?LV;H.:$Y>:#
M1*GD7A"D>)(5(P84N\H!F&_K,!9ISD$I QC.$.GZP_'DAY8):'1HG$R N$SC
M1'?7FJ0AO ;T!3>?*%HT+E2SV8YFL+K:N:&?7:5Y1M50+K(TU*-.^>A[U1QN
MJZ/^\4K_X[5"0OKC#<WI)7./! NVF9MY;Z=<:U!8-:!H(/8JMH)!T/ \P>9>
MFH<ZFK$JR<6OU>GX_:)#%W>^XY9]F$G K;=GEBOXM/9:J.[ANNE?R(<\"2<"
M<U.+\)E3AB6:AM>7L^21ND-,JR'Z-B<9'S==\$AXYR%9R?7+;9B4Z>!KU"&R
MA#8I.O* :8T*)T!MF*;*D^ ,W[&XX?[I7E5Z!9K?<&N"IK' O>D+T/F:94O%
M:;F>REY6HH<:#9EK\K@#\P=ZD!D!:$HM%%JXB2)S1,O'P,$%](Q:;KRNML]2
M2F$.O9> -B.70 KHN#%8/_H;O!0M[E)SJ;6HX_8>PAR6X[!B4RH$%45@9IEX
MF!#Y&4Z(>HFI]J3 9@8A>_QY_Y*!1IR/$I1V>&O" XAY"K #..:SJH[_F+!X
M/0+AH!['98H)$Y0<,XB2"\E'.\*FF5R92KD-,R>&3W5(M*BB5J&\*^P#4U$[
MP%8DZO JV1Z7(&5(I;"A7[;7W[A Q!'ZOA"*7[;6MXH/3%>CG.-K9,K0GSJE
M!Q)[.^BFS;>!Z-7ZJRI$K]YLHM,RE_B7!DF&ERY(WFRDX?J?'-C']@:_W<%'
MX1^OZF!TB43,9Y'#SE47"YS7^"X53K"L]_U\G#-&!@*3!4@'^F5S9_VMWL*Z
M\TT8F5)7DX(Z"KU']'I*P3WK6*DJN+%>D7A@<8*X),_V(Q]G^3;LH3J7SI)!
M1]6OBQ^-NBX"TIG?9^RI*A3?D$& %AEB>PJ'W*,LWB>Z-306L.D;,2I$L(FY
M.G-/(N]YOR2'N)+%HZW4B2[S\-9K@\$+\'Z!K/%T^XDY+@2=#-(D=']U6\I*
M^OG+;?<ZF4A6]39GX7\$5[+B%(;2EHM6YDC<4BTIU*5&*O2RF9[GDPB'9M3<
M8I8FE^K^+4TNWYV,=!,\(Z%14U''_7?ND;. IK\F\,$80S#XC21*12W>,%JI
MSQ/17]G[CKR"$\KI0 6_T5Y-!K.4KSL$UJC?DO12H8\EZ>6[DS(8H'HLE199
M&%-"%@46T& NW0#P(X\JES(YWSVEHG><-E1&9F9\3Y-4K)6.-:;D(L)5A'#F
MD')+J='E?ZL6W]4IRELV1?FN*<J;&S9'>7ERE*^DA:?F_;!BPMB 3C/04F):
M8]O52;5FZ!VS=22B#DYWH !(QXS1QZH/<MCGGC"^-_%TMV,S,$B!+IYVCM&-
M^7X7J_,M%>)8G6_Y[J1PK51B]JJADJG'F7;>U7%[[>PT LJEEF>4TAGYZ:DQ
MC9+KX4JS4+7_I3QF2^'+C4V6PI?O3O2LO(YJP\+F&EM;U)]7JG!\TV &=+\,
MP%9)'MNE6CIK/2BX6F7L#T.*2FF&GV.S@UATW#29>A&/0%'Y3CQU$L1F+E0]
M'.K8*E.TE).L9NO&^N18P3H[^BV5N2P!>MP[&:P6/BP)&5L:O1F-=HH>]#>E
MUK)-1/$#E=G./U(UHL8T](5V?5C)U*&/]3QT1YL!%;L"=9Q(5IK+YI-!"F#J
MV@_.-@(C)D]5;EHEM1)+4+G+''HT$IQ^$S;9.IRK-("W.9196N2T%Z,/T,B!
M17V>:T6Y;V+"'C/I#40VY;S)"#!K."=K5Q6!%"UOO+(^(!7AN)^G4FBON:,F
MR)4^%^ST%.+[=!4S("V5!>/6ROI/-+URB;VB5'LHS/Y#2,)SL>YV?3^AHDK,
MD3<KAG6=L$IRHY1!V7&X?%?Y9RABET@L4ZF4S6(Z>.1-KRE*T 4,7)10*3MH
M"@-V7,I;I(T[-RP\4V4 -$^&RI'9C56,(L4-4[D9B-><D]5JM1IPMV6IAMDC
M5E*R(Y7'>%2(,%4#R(@!7& /Q#X-UJ4$<RR\BA+@".EL'17A3_G'H)J\8%0N
MU5/K*6.^D6@DI1HCN&692!ZK[,FX2,CK5"ZGH^9HJWE2E4MDKL;USS0]F/]9
ME,LC^H]"024BL[':LN292ET \9YREF19=@XTYU02)+E[=1&/ZXMIHD:@<'HK
MWPQBE4K/+FH/5$]L3-8OA!#10$H<R60^>39*TL)5J^H4G%IN#%VI I1;S2;4
M4;M>\<YP495X.& >1(!1WT3&'\P-U_Y@0F/D?A-X2R:,DC'ZQI":5&I +B.=
MOU,4 M8@5;G!M8P!53__A'-TVZ_]5>T"''6NXA($":7P)\A%L/TZA3[+"'/9
M'F->8@=BC#<A]E668.#5(R8;40,E,1^F>+?M<]0X<.];:4;)8Z(1K/.:EG?J
MZ#LUG;X]X.JQV_W7OX"M3/*.NSOR0A _L;I)]V/BI0%^'(J!NU^@QS$OI0JV
M!'"WS,.:;_SS)/7D"%4S'$4(&M$)R"AR4:MEG.-"7A;+'*) "\?P+( 63@"K
M#G3-QTM4:/+8?)[+,8!+HJSJS* H>J:IC$3H\:9-N.K\!*ZZWT;8<*:YT*.!
M>*CZ10VA/A<U&+&JRDFI!0;//Z5]L+8P,I_U.).J7#_"7>@;VE7EJJJI"57\
M%#JQ^8#6=;BVAHI%]#DY5+95EG2;^5E4,%(I#JWLVFRIKX97HGC"4<@=U:R<
MM5\25U269%GUS["8;\*)!1;@&GE[RD J.RUH7?8<S!RZAPN<X(:_$]0%.8FK
MYH9AXN# =-EA@8_:NZ?:;)M3/Y*\#W03UP?C%C4X5#_-96CP&9! O.Z>JDK^
M!KC+V2+U>2)F<V^J;P+-0'7;*=$4B\>5NJ1&^J9880@?R)$>,:S6:U 8W+-$
MD14-3#5[FT>)A^<4(W$@4&HM3\K$#ZD4BM#=+'1U$-/Z\!5WKR@;GHM G6FM
MJWGS7I]F*PL45V73;J<H]W.-+D9E=PE@=!/JY%TV'8.;R<<3/E2ET%9K#)L0
ML[%.SF"8SC4E<%NOUW>*$CBW.\@4,.KG!8?\\J6'^1$X)90[(IE,&=_QRW:Y
M$&G'(#^Y@92&!*?]AEC!^LN;ZJ-?@((0<%3Z49$C@<=XC:<8:3^7%A8U6*XM
M%B3P-C?>=38V-AP%FFJ, ?] V@.Q6,PP_F4'GT.XQDDLIMH)8O2G>@JLO_G]
MC=+3,9)LX!H,S\"L_T/K)Z;VIFK<;]$XI(-N(P\]M%.:';:&;J%\C#U7'#9:
MPW-1;9N&;_:Y-P-J%-05@ZME]40=@9707Q)N)\&=O#I&!6?%()XM$"TR57U,
M("<_CE/P5UW57!Y4AUVNU) EFI95H,S?ZY;DO+K/:I<1H^:^4@3JF/)B_QR8
M3Z@:_K*YC")5N9<:ZE;(:KZB]IQ+LHOR2E6"34+7<'"2.\ZIRYZZUXC:E.AW
MS<""_06+QO'(!^(<?HW];^:UR:N_3Z<(.[.5M8UI)<J;D<=>PT1$0#SE6_?&
ME)FLS,^+)/UA-/W1PIW;RRT'Z[@ZFWC;9A/?.9MXTV83KTHV\0/0XE=@3Q%;
MR"B^.@XP9!R$T=&" !0VW=&@8KMH)J6:')CR";@3JYRB9F PZRMZV:#.TYG1
M?#H88$FS-;2?G#)((U7Q>QE4Q-]D:HA,/RMCC(K]JJ 7228=PF33664:Z) E
MSY'!OFF%6E@/8#HJUT#.)!M([<,PE= ^F$WB7%=:DD>6]#RIQ07%S^C?H#V<
MBF%(D;.0)D0K#;TP;\J9$AAG&PNA&_BQ;67R=#=@+S%))+AL+,?@AA<=?A4!
M-B [D42;F@MQ 2<U+"0_.MA!1Z+.1*7A6\H0"9<*^HLC$SA1ZO$:EY=?=G!!
MO, D*M IR,Y&<]+#H$^#X9JD.L['5ZGV9I2^)?':;#N6,_3XX&9T^]UTUC8V
M0L]8<@._Q_7R&''0YT%"]>EOV'=57'JHB'7TM'92>(HM*-0KP7=4*Z"&O:G%
M8VR]C#A-$7(D$>\\X="#4NN+7BR$91Q+'0*,.M"H:$@HM>E":#S3+7X=8_P(
M'B&[WF95JS*^AD5%RZ()/$B@*0-BFV2,:XY"P4;D&=,48)0X&)'Q. 3#G8P"
M;PIB<"W 3L:&5ETZD503'E2NRR;'AKM'9Q8W*<G'9<"U28MC4N-.58C@8^)9
MLQ.,^GE&OBS=JB]+;/^0A^X?\J;U!B(+S@*[R9AYFT%5;$ /L),^,-R.,M(Z
M2.5#;,W884M4>?.QI1C[+$)X'MT)G8H+HEXA6C?,]5BIN88T3TBS!0/+B2N/
M#WZ+4@]^)8^$?\8Y]0[$-I4UIE?D]@PH<C7;\S.YN7?1,L2ENOS'![]%J0>_
MDD?"$%5"L?+Z4_)IGE'J,\Z6*ME@*LY#6+R:ZF=YX<K=^^.#__^S]ZY-;AM9
MMNCW_!6,&W-NV!%0C:RV>[J/3DQ$C?S2Z;:ML-WCN!]!(DG" @$V'E7F_/J[
MGYD[ 9!5;MD62^2'CK8D$DSD8^=^K+W6=4N]]R7YD&SAI+K*??M2$^7<_2@M
M/%=C';?9HTQ%B@\PQ58J1E"U585K"1.HE89.NZ7D63-=4DF%/B*@:.R=)(*9
MY)MK#U>K?%8[\,,;_W5+O?<E^8"L,IK$M'DEU5TPV)T!<<X,V;JZJ$]RX3^\
M\5^WU'M?D@_(&+(G)ZXC0?P0<TWUH'59J3^)7<34DX*E^9Q@]-("(OVFRF&C
M7_#8L1ID>^>I:QAL+QQUA+CVC*[@)NB9KSQ3R9Q5E9>[Q '&[_#?<C^EZ=@/
M2'%6P5WCV^%72!6+!8OMKRD]L1WDU:B?U0;^\,9_W5+O?4D^$*,>FOZX:Y\=
M5ZH[H<@7HOZ,OFJ?MQO?HTDG;-:^V6OO'D,5"6RG5CP\!%E"ZQ9!1(2@GWR9
M"3^Y>>RJVW#.F^;#&_]U2[WW)7GBAA3EY<@GC3A(]6X#0IPAWY$JN?;W60*,
MM4#L(]120OP3-0^Y,5<3MHA\YW$$TK@'$[[Z74E._ LD=LRXH[]XM=9GM3,_
MO/%?M]1[7Y(G;JU/Y3(4GCZ6BT_0\-&D)CEAPWN?&<%Z2W_/4M01P:")@W%W
M:!2LOO?:R3/3DWHUMF>UL3Z\\5^WU'M?D@_$V(;6RDE_(O4=C;K?0Q;B:AL_
MF(W\H8W_NJ7>^Y(\<=NHO">JU9+W?9LCO>96=5J0.J^$'WM;5A5R=ZB0YM6X
MG=5"?GCCOVZI][XD3]RXS>1$8_(SGR,V1U92JO]#O#RL* ZG?@!A(S \3 OJ
M*D4*$TID*D5[RJ).?B55]9]A5?\04 ,;_')-G]GGAZ:]5IC.:^=\>.._;JGW
MOB1/W)JFI7J&HZ[:QJ^:NMF5JT7?>A)L-GJ::U'3)#^2J62"U$E[A9V>W1)_
M>.._;JGWOB1/W.SE18'T(LBAS-Z;5?$AJ/UAL=JB>TBFK1WVH7S.<A17&W=6
MZ_GAC?^ZI=[[DCQQ&S=U[9 WF8L9L8M36XV$7\]0*+$PY-7.G=.:?GCCOVZI
M][XD'XJ=8TV-OHE57)6F)P$P),DE&E/5D<NB_ Z!=4QG^\V\V3L7:<W3A."?
M7@G!WYD0_,65$/Q*"'[T+/YD)11<$+T2TF=RM82'-G)#@UT:ND!8W6_;9MBP
MJ!T"4_ [0IC,#8C+/CLEL=34AAN95920E1P5::LJ$X_N0*@8.-]%)I)'5N/!
M2@(%NO%$%XB(=4V=94)-S03**;UN5-+)%II&!$L+1J8?.YN&S#FJ@P9B7JRF
M1%..LT!R/'7#?"7,T8NR'FU3L7)-V74#,ZJOG1EEE(+!*?7T*RDO>J;JC_NF
MZTIY815%TZ=F1CH*/RLO@<4EK["B;INC7C#Q%6.[D;]QK]=370I5Z)U1IQH)
MFI0]O_G03AB1-VUSSQ=7$]GG!6<JJ*B.A47"BKBH!\2D*3 +,(3#S>)+^ &8
MEQW8JBPRG,.6P]Y9)B:GQ$?&,X\P*[@YZ6;%W0<_T$<& LO#2DRN.3;('H/
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MB:L@/%?Q-B'2]55;[NFB+-HA\"ETF:$34(9XL0EB0^S=Q_17U&FQVN)O[,!
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M0?U%Z]ZGL4#R>5$1)303!!,*?%JU@P^2U-)4A$0:Z"3C./[ROV!!ZX&24DT
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MD[]"?8!H/X-S:7:1JF+0?=AIH8ZOL,1'S'6B_TOU$FY5C$]G5RFA1"LN#SK
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M!W7J@_IZBQY>H?F5(#G?:.P6>?3'=4,24*8FIK9<#C7I"5+0CX<PEEB3>$1
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M=2B??HY)G6[>U$L+*-*SBSW!XU8REQ7\?.&UA2=8V43(1\56;X@5F;K04)!
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MKX[3@LN<M^DD!V<RKFTK5'MVS<DO%.2_.'^P&U6A.,G^ZT/=)#&S;!GUL#Q
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MAPQP+% -BB_0JU5^*F'*Y51?"OUQ8)WD=DK</PN5!]8(JXUGB]EBRG#PETF
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MW'(('-F6,O+P]Z<F7T<JL,WCR9!?.D?M3G&)%/TO=+-1,ZCJ8VB5".E%^=X
M/ZUT!3D,^)IC)79AJ ,"(H16]%?6A(T(.Y$<-*O.N+J@+> "0HH\,)70%<6;
MLR:,=GND%Y*$D9).K*9?EX@8RM=G6>8(Y59R<+T\+PBD'8Z=O_N=X1NYNAK]
M "DQ6!G3>'!,*(R"G86,CQ@?BHP0L_K,02\='<&UW,4 5<<V G7N3%!7Q918
MBVP1<V1=7:SG9973]>;)E>VHZG)]"F-%E]+71:LX>D?)))3O.$F12SC*0,^
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M#O7N*#E&7^;Z<G1 ??II8@BX0Q,Z+C:1 \.3]G#J#.>F@=H.)UO:(U\0GH&
M &2K=0K< 9=%)0L@PQ&731?>9D7$0H60"@S,7"/\4Y5!X'9A_[L!K!C=IXX=
M6NDZ6P@H&'4KP"/*)7#8(39#6U0FQRY7 D4#A!CJ8P#82$9Z<\VND?T/)$/D
M_C&XSX$@5T=2!,A_5I7I8JAXF-#XOPI.,$&N[FH!?* 1?\[PA;XA5XUQPEW8
MD9BS@[>M3*30.>H6")8SP _RU! A5!!TX81,$9ZK?EE6"E%?&"#LC[.*D3X(
M56K@!$8]($$AF&>8$<$7$3B:291V>$*7PJ-!1"Z&DNEL=@=39B_^"$3!C/02
M((. I*RL:JRR- ^5%[T_&G\_(//-S*8$I"[\K&BJ,D^HO"ZME9D05J@0V0-5
MJ,"_B73E7-2R8Q/NP-I$?+E\ MS?.F/M"PUI:4,-O8[W4C6Y#> TR1K0 C!I
ML[W\5G8%6.UO>%#VX7B=9&>PR&WQN2C/"P"3%NQ"ZC$6*&&B\,"7#9-M.%0S
MM1".P!6FR:"_,##!EHM1*=@+!U.:M##4T9=$!#IDOVS.[-U'%-3S=.4NNA3(
M7:6)#_>%V:#P6K8O,E07.2-4X"<IW?>(]X:& 7Q@X*YCG%0"%0)(M+8 &EM3
MR(I%LNUVQW##-3GT&&TT=Q8RVK =:4ZC!(,@1EA?A"E:,7]]C1V+AHB#SS+8
M[TF-[?"$CH&KV/%VS U*766$:$/A4@FLVB+=H/#@=F,A;Y>7RM$V"5AMO,J*
M;$6TDT06#^R4 /6'.L@*9V46$:H%J^@$F!?HJ/&(HPG*':^(T]N8=+&1GMD!
M8BQ6&Z!\/3--W2)FM^AAP!FGD^H0N LQ$2-AXBIBQ?=NC68DEE^7=9VA'J-6
M7+0Z097QFN HC"#,R=@ZMD7_F@#[9 %47^4:'C4S]KC6P#QO%HSB"V8X/PTY
MP12CCUPN8@G+!=*].X9,X(MNL23R%K!\K@W>OB_!4]<N!6.G#SD0GJNKTPVM
MP,SP2HF4JP$RH7PA-R/3AWBK.[ 3]E\KN#^<^X";PJW6\;(2!AOEJ%SDE* #
M!6BH=C37XI9<Z,#=(Q5T#[R,CPH@/V+521C[BXZ4-J<5X.@2#NO2RE"#7D0Y
M:Y UC+!8094A'GF3U<N-_3#G"KS:_;[IT $HGCY2N]&PU$Q E[L^H3_@_K4J
M(9)[)AG!_&4^!VL_KM9H^0%T(%ROB'L,=WJV8.!>=%3[TH2J>T5\<8!$/X=Q
MH4&79^:,+CADL1AY*@X _U0S;27Q)H+4CZ-> D@_VAC\G;02GXAA[9D)I@1'
M'6WU$.8X7:_M[4*U8_;=;0Z6KYW+^^%50NNAM5=\A929[K8GS$P[F+.R\4I<
M'>0DM@Y+K&@R?TOK1?IO8L>,"(T((,WI8#XB6\7;&]+;A+.D1Q(<\AE@TR+>
MVR9DNV0O"ZUZAKT6%T2==+0Q[,X4\>'^CW+*$7%9,R+X]>^NO9TNPBI9_[,!
MWVD- $L%_@T:\>&I\<5/Q<<]1F9 W+4(/#-P*=*JD<7D5?\?NZ6PDM9QHOT=
M'EO'CF H:27>80L9,(V:/ ]&U0/C3L18VR#8/',UDI]$5ZS<T6X/0*3]XA,[
MD>=8'V%+&61*22+:4)C&LJVP"(R)5X(]F97E9X*GYB8X,/3<B_DV$2-N+_[8
MHM<KQ!6X2,#I4IOJ# ^2*4Y15F10]D(JTA-L2Q;L6-V9M[(7#UX^'!V0J0HN
MNH#0XO&@E>8Q^>.*05F#;@&($OZW8BXNQ?B&T;BU\L.Z+FN&RH#MUWO%U_BW
M?F'S]R3D>S85E7]S4?G15%0^%97?O.5WW<J"GXZ7/[B1/\56/9K*6EB&/ I\
M3[;XKQ_2_V]___D/8J__X^/;Z/W/\8??W[]^^_;-Q]NRY&][^K*Q]\I/@7S!
M1S98M+LH%@=VT<=H1=']:RW%N3&+VIFF0'X2D%.%EMUR:8 T!)E/,#@+00OX
MOT*B%6$4 P)850G!BJ:U1O/Q?&ZUE1T4,/9:F\M%E-R(K G@AD(/OW@P+F\!
M"3<[3S^JJ#NJ>&!4]VC;[Y][2ME4$8]V#1OX'\_VD_U]_%^PFM.3$P@96D/W
MQ&YJ[>6G+1:&^,C>_O+^=?Q!L@S']OMH"0Y1F@6))F_K=WG(CBM3I/'?\G*6
MYBYO9(>:2#C:\^@DL<G9IUNEGZW9/7YH)/0W,MXH738\HX#T4A^Q/Y ,E=,X
M8DF/'ZE@ECVVM6"65GFZ.@U[C*V%#6.@U%#U&32->$MV.M83,NPE>\N;SCN&
M9BE*J<F&SGAF3$&Q=<C1R) OW/'IL&^;T%6F,;UOYP7D5^MD1)(H@"@1WKE]
M[5!@[/\K-,3%"A8RQ/9;T:/LL<L:+4*0;<Y"$1D7U''!6,._JNA766U<7,OG
MAZIRT<Z;^L_QHPQ?5"-!6%W.,TRHD&(W!I04AM(D"@%*"]8C!P4-1590'69]
M(31"&C/W377=M]C72/@'2$)]?58'0'?69CF1AD(4D&\7.P2NYJ !+*NT;BK(
MU&"PC6+N&""!J@0(=T <B*+TICJ#+ VL (1&<31GCYFOU$I.K1!Z><0(W+NT
M'GWI'HX4R>8DFT=$EP?O@+CLD]P^W#Y#<@(;^V(@5,[FFNBS9@6-#V="/**5
ML9*;8^;6.GB=]0FG:8?-H_9#Z8T_-Y#JQ !88]*5&[TU!ZHVHR()C(?Y-!]^
M;V6@VJ/&>GK['KM73"&Y*,_MC6\W.,W"4./"S!H=JXYHK9LF!S:G#9'4V<G@
M=WWBD\Z2?:T]2A1:KMN5W5F,0@IODZ-=0J?X6NES=N;>N5+$XO)3O5QLH]M<
MW8UF4/BJ7ZE^4?0+9WYN('0-#\D7PX[JSVV!BH+B'V'%=N?GO#CNE0=Z/0>*
MOJ]IA!_HJ%[G .U&P/[_UP^'W4#4MP[V</_P67>D \,:>%X8B+H#\WS^0.;Y
MXB',\U-I79_KF&B_0V=8H5GU:$=J?5YK8(&*+*N?XNID]NAP_VER>/0R.7SV
M['%?Z;'>/'KVX^! _O:_TM7ZS\?=>?"O#G_<JJY$)Q_\.+9U5WO.CT-!Z/\8
M>>:KSK<QY?C#7PZ25_LODZ?[^R,_&W[)KHS^T.[D<PATW-'1/WUQ=]?^>?+\
M\#!Y^0VC_Y:3_,=IUICA[KHMRHC&\#L>XC=_>LW>U)_BWYWW)),96L7.TF];
MZ$NL[L"2/DN>O]H?$N>+I.#ZA_(\.;"RN1-#.3A(GKTZVHVQ'!XE3Y\?7'TL
M-WMI#=VW%Z_$-?H\'U__]N1@__ _ZW;]ET<'CZWS8_\CZ'6\B<UXNO]L-Z3B
MY=&.')6=&<AALO_REH_)R(VP(V?C*9V-P]LZ&T?)RU<[<CJLD?9L1VZUG=$8
MSY-G7[,F#^(:>4Y'Y>BVCLK+7;&YK-+<E:&\2HYVY<P>'"9'1[=\5G;[+GE!
M!^3I;1V09_N[(@I2US -)5 ;7[5!-WN7#,3.KK7/Y[7+G-%A>.8.P^PR!^+&
M-^4H.3JP:_.J%ZO_#D9/\FQ7AO(L>;$K0SDXLB;8T^3ERRN.Y3:"5M=\5M[I
M%/X'3N'3L7F^8\?FY8[HU(-=4>X'NV*&W;H-]OWOF+\*1> ;7VU#Q^;%CAV;
MG;'0GN_*0%[LRD .($6R$][+I7(C[PN#)R-^71;X1BA<>0/E/Q^HSN>[ROEA
M\O+YCD1PL'OOL)>'>\ #^<K-N>4[8JO0?\22MN\NYJ]>[HB0'^V*%MT9(3](
M#K]F<[Y+,&J+G;1E70:^/5B[\XU/O50%P@6_<C9R<O3T>?*\[U9>ZJTWLFC7
M.;VCY-71X9#7?"^F=[B?/#]Z=6]W[^FKY-7!R^1Y/\[0+7Y[OOYR834=-QJC
M$_+2.2%:PPB8\+VIG;Z!:5SGD!\=/(X^*82&M+!J/5NG#2#T4:= S(BZTCP:
M-)1P"TC\VYMCCTB2,O)?GK;%_!1^QQ46U]J@=?-K<WA]:[/,L%MWN'F%<^P$
M@0@X//A; -1LYTUD7Y*G!> @?L#^FX,8WFW]FD4)[-9-NT"4O%.3YLTI8("U
M>8. DU!KG:@.A;J=K;):6C#L(KW[[4T",)(P<OO? $@WSPT Z $D"OSUYS?'
M=VS/CJYGS_ /=1UV*I7K)EME_Y-2WZ?K9FH 3,6.Z:^_'$<7GH'G=VP]GU[/
M>F(OD%TL\Z1=VR]2U]>Z,FX1&6\1T%XZQR/AE7MQQU;NV3>O7+9"T%5<*_O?
M.;<U4[/2<.?5'5NCY]^\1M#X!0A8TO<%[6)%W9<BAL63WC?=(PCO*P#Z6)H"
M"9F[J?LM=G=L>5]<S^&=2219:4-U8#T&=+?%,/)RRFH3WK,QC8"T@2&6+3-$
MVLRJQ1/J5*2FP]M8:VN%QGJ%%J5]'D!6^*6BWL>LB1A<@Y#84H>B%:<KA %S
MY(RP9/8A!NZ/M$)<K'0.0)YY5I]J>$\[:^FE1XDCB*^@H]_CV;6U6>Q=PU*,
M+(28KNMOYO&X>9C,^]/D_[ZMH"^6L&89&N$&^[4=0%]-[;MM51%.!L.&U]',
M_L".9%T6W&*,7T<#E#J4G2IP<.\(2@'?0\BX4T.>(QJPR&?*;;*5.2E!*W0
M(*SN.$60PC+ DH@$-C)SJH+Z;6>F;AQ>GH*$A--[MY3S]3N+WQ_^FR^1$?B2
MA/#J"P29)MD#,$7KGLSA!P[T&/";[&=6%.KA:\D#LJ X+<M*@.91F49>OZ8S
M:S^1L>G?;:5ZD<T;,@O8;F@V 5Z2)X9I13L/W8Z(EX_@-8LNRDLT<@@9?]OP
MM>%G0PBL6.4 ".-K@'%@"AX<0TV(WW;(."FB!I&'H+>180-[P"N#V@4.:EL9
MAH=:&'PTGO&BM;<SH)</\":@IA% @]@#&C#2<&(?M()/!(5< !0(8M;SV:#+
M&XD[Q%<D0XHO3#VOLAFH'%1>:.@6#GX&W=#* !@50/%9%0"!]$-[:K*__)[5
MG^.?Z3D 18R?'/R9],068*JH' .M6>;F2\98E@ \M%[G&R&0N&ZE''G,FOBX
M<)01'C(+1T0XX6"A,5%$&1NB@Z;/C%7"Y2J;)P+V3+#XM,;6+P!4<3*Z%.W&
M#*D8 ,/('I(:M;[]^+0\'X(40B!5?-49+A8$'7!\##*-']F[HQ)1O"S8T0 H
M:\3/5/#39$HYG&N<%X*3V7WQ,$X*CKT"B9F55441#_Q]<"W<,8R9^QS&O.EI
MW*.K=9K*3H-,AAB;+]PD/[[]Y9=WO_TM^OCI_>O_\_?WO[QY^_L$M'F7A'44
M:#,'TAD' D3X.-9EL9<H(G3W( #QTF*()S#SB@W<5<KB9//!&WGTM*UXFW\
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ME\?4B*^&J7&E<5R,OX'_',P_3"II4DF32OIFE22GG)-=<- 7/LF&4#8YV %
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MRN L%^#,4)D5MD,MEUD.5@+CU)OB!%(M5@-0*A=DB"G6J_B4)2BHS>JZ;%T
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M1[8L5B[<VH?!F7 N0]]0N,]B-[HK;]"D:=2TB05_5@PRV(06-[8"R8:VI ]
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MVN)O;ZW$S9'Z_S !(Q75JQ7AT6]/6%M!+!:66$S@DXD#B?^"+*W$UW8._GH
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MEH_!)^7CP4GTZ.3)[Q:/H8K'3\B0@\/H! 5GCTF$G&E?%'!*1I^:;M/#I.1
M.A89![E#XA\>/CF(]I^<_D'QSD>-//Q1D0QM&5XGKYB ^Q\@#<4.>NUGVAZ>
MI"GX4/P9KOR#1QHZP,Z]1-T?]%;<>SC&]OF\,;@^#I6A W'V6\M_!UM<2T>"
M,$< \\2+BH0OOV0,/7S9&)'>BP/^$[U9>0_=B]<S'W[F,.PXI&MAE4\-:FXE
M)-1>C-5"?4![VSR]+8CH  Q)[2YA:[<B"G>2W=8+E7FV&YSR7]#:9FF.UXV8
M20"K]:6;B&$T/"4I;']5@[6K*A/?26CX[??T,N>VEK[C;,"V:D^@O2ER3"O7
M"%"?)7'N5#OGN%;%K98\-UR'SEJU!WC#6@6R5FMY&58'L);<]]:\N3S7U@BY
M=V'O'C;];YIEC6[U;KY]]\*9\V6++?X\2F5M?\_NX7?!CX:OI$H::K;6/?,O
MZW/W<8RDN4+.!"Y;@/E Y,XG*=SZFY[CH>T7BF/5H7!EEA8T(Y%.<!QSB6RD
MW?D540!!"QO[Y.A3-O:*9\%2[C1Z?'A*'L;1[2ST?Y(OE^W]/6>/XKR)EP0=
MQZ,O\O+/]9$79IIS#>^U46*Y&I !/8G[V'W5 VU-^C]HTC]+RD4N";BO73ST
M;>[/UX) _2WYZ?+MY;N/$43?/1"L?ZN[=U] $K>7#2 "OVH\J 9*WJJ$%J_N
ML-T.L<,FR28K;CA0JVP_/E<V+0?4]E]L_Z@H=A^/T0-G:9@FX2!F:4+ZP"%)
M81;0].L)V:FDIBU:M$8O4_R+:=V!M06<Q;*]=A"D@T 6YU;>FL]%;WF8\!OQ
MW$X.OD?"OIM!/W["O^XLRB#D]X;C! 4B56 [@M"$F'P@M5U!U/EH-@6,62O
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MH9D2 L(BA,=;T&2OXN;Z,"2MI$$DX'&#S5!8N,5(8G*C)G("\"T)),1@1YI
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M8)20EP\%&B)>,#X$,*!8BV&LSS]<=H,#,I(F+3$4P=3OTR-M(10AEFX8?#J
M(7$#M[C.Z-'RT?6! 0:0+)*1HI/P%#JL:7X-CCD6.6[,TT("%;U\7PW/I]JY
MMCR$9YJ 20@%/Q"VS'M/@F[T <-W"R<ON_?S=0^IC"_S%DD%?/Y+)%;/&)5.
MAH1_U_O*9#X-RV*$EQ7SX\/CX='_[>\?#GY;3+^#&OSO[[[[X2Z%\5:@;I9
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MPP1Z?.RD[NS1W<3$L<@N45WMHQ:HJ#-QR:TQZ])U2;Y*QO16D\U@[HWMF8)
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MA16;NL"F$!1YZX"IF=7H/T1V&!D5"X2X&5BG]JW77D[("+S*8:8MM>9_E>4
M8R_ 5!B%55*E)@JX!D9U'*2R8-]YLI910@!IX7OR]#/&$*OY&.XP9'+B,U]U
MEVW7/G >?S"RA#PT4;$.[2AP*BZHZT&,S>QZY-<9&8:S9.&&+![QJM$#9)@6
M(Y=:R<R!+&5;16R0@?U#.D=BO4:PQ>B1")GQ+WAIKLF<19F385M];.99 UIG
M.TR@>&IE5<E>,SWO[VM&";G)AC!<J+E 4YV@U*L;J&6*TP- .0N A OK%E^:
M!.Q.H^O?C*__M< O-\'"GFQA89\-"WNTA84]-%C8?5L4=\L$ HZA'N0WC$N/
MC<@ GYPFI/4TM2-\Q%H+Q#%Z+5&SX3J-O?8$Q1W!UBC-,ZE2//_EK1Q% 1 S
M,ED^KU$XEUX*.:/EO4?BRDS&58Y(I]GR+F]4ZX8BGQ-(<_C!+(-ADC-A%&;%
M8>IJZ=4QP2"ZID'BOY9BW>;!ECB%K'\G*%1J%;^E)A[+7+>)JPTY^&T7R\:A
M04[59-K)99.BBK,Q&5 (@J*OA\MN66@_;?[_U)E!^N1(XMM<&V'YNR( __<:
MWC".E';J= /G' MIEBL_D&APG/:483 O#0^GFU5:J<#PKRJR(&:ZU.B4A;($
M_;?9@OK;V/U3,3.;I%I/F@XIH;Z"B= 53/BC#+R,<UDGHJDPPHFX&RWY).'>
M3U5;N(H.5GK^>B^YX$ES$69.=BVOB3<+FGK@"9BUE.;;VWR?^)A'P<[3>I%<
MQ2,F?GB59].],PF,OW05=UNPS*;(W#XNB6OI0V[WD_/(*?91$QQ-^4]#:=EE
M98U9ON:+!)6+$&-3,A-&#I="LX&CK**5Y%5%[KV4,*?YB&NO.7LDV3/[_7@0
MW'GM:G_&QY^N-[-(1>*C2++K68Y:=^:<+!=H?; GZ*'.8@R]"\$K8(G81!TQ
M25H"OM!T.8>+QL_PGEI:,A);HQKX.2/DKFBF9&<+X<Z5:4<-3_8>:;#S_:RQ
ML4;TR(3S$(E7VHKG6GA4NG3OP'(@]&6*.6_6GMVM@-]>H/YWLL)VU%=#IJ]W
MB=DM6^\&"8/O?N)>&P$39ZRI7'TA=:%Q,1:7(RFM:](U>+RJ</E0Y]P)Y[/:
M6*!1 +T]G=_,!(*K/6HLA*H0]@O'E-"!SNHYXGQ(PRB\/58;<JR^,/\ 8JNC
M9!%73*7!;+>2B!>*Z6P,4'6PBJ2.?-CX'T)S^S#RN+DU<4FRO;3\9PUQ3- E
MCE%ULCVH7WWP-Q@^?QNR.1N#<1.*][65+6*V#K>FZX:(%8Z3P>C(EG<O5,36
M*B4]Q:RL+?76>M':HV0-2FNW-O:/):U%) !E^66LQ"1(XZMQ].O@<B"05N:Y
MDB !6=$<]64,6*.7-0$L! "FEJ !6V19PBPB04,B@'B=<D#(8/*Z K603;SS
M>V$LVL5-W) \5MEAG:1C90/VZ UX'AATHY(54I=G@3>QR"U!S&DKF[P3\BQZ
MM2"J0KZ'X5M07&GX+FH9 OQG/WO:,N3M%&^W78/@+0()NED6]'>[[T9BY^AW
M>Y?!FX,@SQ0X*2OHZ)KS23#AN&5EXCF=T*ND8)B0/--/1%[I._(YF4FSF#%Q
MS?N0-F48#7TN!;80$(E?6(^A8ZX)+\2\+\IPY_;'^=")D%_.+VZYKIH3UN_M
MLE05-B!+[&-HE^*&"U4/GK^-\[P2;Y#FQ*@XS,#O+V>C4G916T4?EEAYA-,;
MN'@;?4W1?]X1QNBF<*,T4QLOF8(#H>6I<?R6]F0QA@2I&SV:_K5I1(B><#[=
M02PDFWL"UP!W5\EL'>IN%7]L.XXN7OWQW>#X/N?-,W?2W+4M-8,MP<A2SJ6/
M6V0<WEX^V:/9[]&DX#9(>![G>10OQ.01043#("L(KP"QF$HLY-!).M Z5+7N
M\[!F*"&FL) 1S')THHC3LBV=>-8-"14VQ]O-9A;T_$E!+D91 P!K(G(UZ+*[
M% J:A?"M5.J6I.K>(*7;$U.0":86[@9Y(HG/3Y%?MV4L&:8EIQ&KH%$IJ/I9
MW@/B_5NF$/V*-N(Y8T=H^[>6X>99AO/XM]QE/V\R#D3<<>%MZ\8ROY0%_K<
M\!W-,V205MOV"EI2CJL22&HL?7FGC/DJ*7,2(O0=8<&K"YJC!$A*I#8M>$QM
MQ[SU&"<6(P[429A.^>^<0!571JS$D3VV42O:UY0;3,R8DZ_*@%5I5XED2]F]
MB5)(_%/>7ZA$4[$ILA5)FR22;MC$+^C%WO#6QE6YNSTSV90LY#&\O-),!<6I
M+F7',:55KIE$EM,A$%7HHZ+E7'R KX0.NH@7R3A5'EZFWWN-=4IAB74?BL\/
M$\!D%8H:./^79.TH'@-"TI*)D6?GXP%3DS6263WJFHS#D3:B2*ZD$6MIN!^6
M[]")NO!];*T.6M1%62.9SZD>+V-.*^,DNI3.6A"/U,YJ7YXR% + !3:1_V'+
M9_ECFDGC$3A:1L]O=TF8P XD9*Y'9\VJ2RY$A=^0>+]W"_J30,W3_2U0\[.!
MFH^W0,V'!=2\[<79^K\;:<@PU.>7)8I6!/FQQ?)LSM;X^Q+L<&NZ88JZ;X2,
M44"S*[B5\[]?-IP;Z&=G;'1?/F:- OGR%?W2I"6^6N6Y=+S;.3C>_^')?CB?
M_\(&!7YIBMU!>#8:Y8H-8!1(<,ZB7CC7GR4EM[ _E]HW<EV] 4?V.9TQDS4F
M72S"C,PNL@5G<3H1)A";BN6<0I; '6<>B9*?=7#P9/ DI)5,A84^7P#TV%JC
MI*E1DI9_2_*,8>^UA\ UO<?=V5H'/E[[G94%:K]>-J-(R@\!BO+5M".[./\@
MUN_,:##5,/^08*IA9P*[S+P *#:5'G\&Y.%^XN@%/U*M0O+M"UYZADS2&_&=
M67R%AS1K'G@'@(/H?PWSE*L_I_1ZLHZ953K2CF0PG:\-"L8PP7QH,$;TSY _
M+V;+$OH+^!^.H$;\IKTR3C$G(X'2<9%D'^2XY.&<BZ_343[+TT'072J+!J$'
MTJ)/,T:Y)A,]OYW59R!N7'(9*(JFKG-N3FB8"X&+)\6&7K/AA2QP"2P,5U;A
M*WCH?_['X\?[)S^ZTT!S^$'M\;4GP3XL7/,P>TZ^(>O[8<M1N.2^:++A^IF0
MG?!-&C=X<R_;D,9U)A7,MH!A2&8%MY7PD&\ 2M,Q7-+UAK/9U"_@:<TC<.&*
M9!2@OPX[>,BZZN, &D1@D6],&5[0-;I*2**^RGG,&5JY_#L&L]DYL%K_-O,H
M/,.)S$'5%85O$A(SB.WQ+7P/YK!T[Y^O!N'[IG7?0MQ*"*592VIZ4D97!C7'
M0]1AYS&[ZRE*'9E-J+<+C4.#I0R50='J--&1[RDG&CYGLG\OR<G=.3M_CM;%
M3"*4%^W/!R]?NIYPN'FC#YS1/'OWM-R-PJ>FBO>>ZF\CTD!T(3F)Q>$RDC7H
MSWZNN5/[N>U%W)"+V *.V;C]W3<I704G:M\E.FCOGKYZ^;>R7OST_C50'/3#
MSJN\C-&9*WR+"W[9@* /]N?3'^:O=A4>#+GO6IGF^*P'F*:[G-KG2-F'E2L]
M[4WYM++^1N>TO.1(F!L&Z\;FPN%L8]P2*,)U9BWORS/%$^>9PWRP?5)6K+1&
M13($ ME%H%PODB;:- C.E5BH']+K=WMV\^2,BL,""\U/J2N#X$9I;1P5)S:E
M;\-?DFZ)PS3Y5YVT8-:#8"WXE$2<OXFRAYSMZ4WN2-9E*);2)"EH359?U]J]
MO-5EB%\XSDVIK<0$WFIG(+A$X;8KC!32R7Z&VAH(?V7X.:=QRIDA8S=-)HR0
M+7*4TY@YI[0Q5;(W $K8RJL-D5?(QFC/TZU?O#G;8O=$:EE0LS"IR5:2 L./
MY%?6A6NA-T91X=BX9M#LZ4Q@89"\8]M%OB[T51]4PD!@>7W-D$V=+P!?L_6J
MN=SB0>C&TC14CME;!!6+UZ;1BJ4B'P[M:Z.0E@GT<&1=TN"8V9H53&J]L!)"
M1AQ3/[6;P4^4)LU7^3QQC8R"?^0%23L%A?D@NQ#E.=.\8$)/U\<W;NF,.1F0
M6"_@9T"\;<:2W$G3#"$#YAU-Q]?)V"C'Q1SF+*W4.YM!>8'A"C1PW?OP(NE)
MS*\#NR2(NBO[&JMV^%TR<XT3'.!/QV*FSG): /(JQXZML S1M1ZS83O>OK(<
M!':'N!FY=KT4Q2.D5%QA<]1$%J 4KY)Q#<87SS3>7O[-N/QJIP1K[!27@6P,
M$]O?LZ?Y>>3@A><_O[L JXNVJR:/8P1O0EI5PW,3]A]N*$B.U-CLJG$C0H@-
MME8.4&R-!)$QL0NXQN#@<;CSALP@,XK"7X?TR*LEO)J\RC]&SAEDQ)DXBZ'O
M+%9%LJA 6[_SDBY]8>@KK^./=->CX)U)%_''7;DPIICFX,7Y$*<Y66'ASG/\
M@M8[$WOD63);CHO<-+_=>?;+\]W=;=?KAW$%[LN-LK3JQY'4D*,T2_ !L;3)
MW.,B&W*)M.BQVW=3F"#2R5Y3<RJ<5#?X2C?4.2:9GX$/;"*=F[Y[+7WIYJS>
M?(79%X[H+ZZ+V%6A]SP"?7S!DFZ?$)H%F1;C+89J8ZX%6>OOA;2_DKAR\':D
M3,8@_T?KXW#G_.]GSW:!.M$"VZU=OSD;:'>IM#SFK,?#:KD0>M7PG-LJI.'?
M38;N\&<,_P^?&;!E.M)C[+ E/59PI_ -*QD%BR2VWO=*FI<&-1"8B!?<*(;D
M#;,N!D,3UJ4ENIGE125.//VK\>CA/#0M7ZH$B"5.JH@>XYAQ5E>%YN9 ?)/+
MNY:1)A88Z*0IAL:FL1V) Q94:3)/Q/@@&V F:$Z>/7D@N3#I9>$C9\-B#<01
M2;(2<2*$FVA!$:+V']Z;;1N$?&_LK$9V5[ I*2<3$0"#X<\>%U?^-Y(;+QU*
ML411U(O*41FUB/Y9*)L&Z\30U#RU."XFW%1P$WDDWG-DDQ@=:;-F,.6U8"-.
M?9IO&TVW,T"Q31J/E*:\F612-OX/@O_21Y9VEG5473;S%/] XOKV" 0<#IS8
M-><:(7(01V 4+G.HN$G%=2S8"%?A/)9#FQ=-)X:*.1/)04%+V"%TTLGC[_T=
MP$-ER)9QTDJ[*!#6&D;[6I(6YCUMWBB?KD7SP?DLR9+6(!8G6!5M5B4+ZQ':
M%V]5W(9(R/NV_$ZCU>8X 3?'\>@AVF;9VL9;]MP[*C.M']30K8/U'YT<['S8
MY6[:U[%P*C4L0M^2];4!9).G!UL,XV=C&)]L,8P/"\.X[?9X[XJ-?+<+,K^T
MNO/*!!=DEV]]L\W9H O+$V6*92#)"V88_)"![H",[(6_?9K> %%0;/O7Q4UU
M^$>X,=*K3(QC=+92PC!GOP_""Z[DEMPQ0^,XAQ*3/S4?F@+L@8*S*[W>.G\5
M&U9=1O<PA8>!*D%M6U=(+#%3WQGA-XVEJ8Y.>1">DWF2)2.9$ :5<<\85!('
MFAQR,W2V2V%F4BNM;^JDCR*/]K!D]*.MKW&+L#W_FW'^;=J!V=U<GSP;("R]
M=$,[']$";:S>$9=_>/EWJ5(JN,8=/'M\JA$FE69,RJ-G2KADB# $4LYI"OJL
MEDN!I,__C?+T(4C HVGCUN3%GTHZG)O4##G7\+^FBKFYYO./"&X G;9$ C *
MWB#CFE7:4N ,D-=Y7BQFV].[(:?WOOU&R[#HL2 &DB+H9Z*D<^?1CD;,6-D^
M_U''S5QEGFQH)NT@NMR(0S1]]H@MFW@_N"KI!TD2<-%BB-8,E=?UTG)H\"L\
M)DRA=/3I-!S7R'HNQ^T]V< R;*^WWK;Z>K/DV1>E"FLB66.S8,8?;?YE*7X:
M@'@P;W5@;%<0NX3$Z[=-#T=N I6FG;;V#:N-WR:R:A*?*A2+^+KI1Q2!!9^9
M;@*O:Z[]AJ*&5"*3??HAGBK_K50M,#E&"J3TN,7X1;+3>,/3]GO>6-1 UKZR
MB\+82HZ@1;MNZZJ[ 4 'IH3C@$H3GKOIK C]9#F&O/["WE)PR\H6Q4?@U Z>
M7\B+5KL+K00@+6?;NBUQ-=4YIF2$-YWKJWV:(+<(E32+DC)ONZK-V+O+T9PV
M25.5#6\3X/TU,\@QQ1!2ECS8]D!ML\K\FPJ&/FSY](494A7[X,A\Q4Z!G&%X
M GF9A>UY';RAPSFS6#VRW6NT*%,[G0P7QW^6+ Q*259MN-)V\>3G"\^;$/^3
M=PO<XA4Z9693]JR](V_/94=&LE1RTJBTK52W)W<S3N[+20=Z/R&_UK+# <C6
M(57R=(PG?E5B"@:^[.OSIDCZ4MI((.F9+N$2)%+LZ=[J-X0&M5(V5?O<=B+V
M.Q:OT#8)&;NOS,HNKS62M?1'(SGGTE9#=9MA^%0@+JEZFZ6 NC6MQIR8RQB:
MO/5UE[:5P $9H; 9CI[\R';GK9@ Z2X'* 9=[>Z]>@49O=75H.LFL:6TVU@!
M),[**Y*AY)\V;>&W%'8;)E??9L%KDC2'IU%XN'^XWY5"G'QDA4T"XH4A.:BL
MXI?,6"X-L),Y2;3WS)W_6IV 3@OX=O_B\&66Y2/ @UP_3R;F?#KX^\!Y)_8S
M'F2J=!TJ2<P],R.#<'MXR",_#'<@I#I?#O4 -@^!73$R124QSLJDJ='NV-HB
M->#>I*7?H+S[M*CYS12=.8%0:O<X:DH20O.1L3&H2Z<=,F65(W!4Y$OP].T-
MR15I1!\XH.@%T!F!_,BZPXX7U/-0,CQ YWXXGBCIRMQB?G(!INQW=#\)+T#A
M%&?<L+9__NWI=MK,<YO5-+]6AON]<3)-N.$Q4MGP%73R39MS";EQ\"K#7F1&
MV1(#3DCP2[T0L9VY0-FK&9TM*7(6&OS4:N\1VJL7M,C+/?TQ5$U.2_V;=.3E
M$-ZU(^/GH3H6@]@F/H))CAI!P:G=[B5=?ZJS2(69UYDXF&YY[;PZFXCW=Q>A
M.P7 \/#9O^P/CAW:SC_K37< ^L;'9.1W^-(F>B"E'>+M> '@A=#\]OL^H%G/
MC>U3YHXU]\@;N\+.(7WA^A/+P&=EM<'7ZK/=80GJ!;Y(-_KH]/C'P\$CKT!&
M 'W3*3J'(,C;(0SO>1K6K/7 @\>#QX].;GBF .DXGHK>8\'$"#.&?G]_<-A\
M6XYSNHP\6E[;MD8.KS?529(RXHW.4)+*.9#&VBLVZI#N; 9W&XP6P>UO4]2>
M*ND2-U*:@)P"[7=/%V"<2#W2=5S87. -VS((SG@9WI+#SU+YA,7R<5=6S&(L
MW]A;TF;@-#1W%W"6#Z+]0_K?XR>#(Q9AY+EE&HAWI A=V?1U:T5Z=3.]^6';
M!-^<D8.P;/>@,+I6VM?#11LN0Y-P%7C[O.:%=R8EW$IW;>=H?Y<S))JS FDC
M:C9:K>Y1^\U)?WD+MUJ40.W8R._$(YT"8DV.936+;-M&&1S91DI$ V@W71:N
ML<RK<,*&6&JB=C1/_WJ56*?SMSS1>+%">?WB<L6RHX^DX(R9/7CBT :-(%<A
MN'+5N )F95V!06 (QK"9NH+5$1NU8>)PR)T" D46K#R&5X*T)'=/K[,14^P(
M*J.["5*L,[$;*&L\22RE #T@3Z],-EJ&-=MTW *^\<X1/Z73& 66CYC9D2"9
MTOAZ&P#Z;&%XKV^^"51ZN 65?BZH]'1_"RI]6*#2_MOR];J:?\54^4O/OP\N
MU+_?!J V<;^2G]Y>(>5BKK?@VLVRF[\<G(&1>;5DD;G+%X?\^X-R2&5/2/_F
M/H")_ENI/VC3A94?4'01HVA=_J!C[*,!6FG#;,W3F?JQ, $3.9&ESW$ P2IT
M.JAIBEQ*_E(I"KIU#F-[V#?EL'\Y)*+#X>4<O4...K%93)RV0*Y EE_%30&J
MG#I3Q<6R.4W#)9WJ.1JQ2 <!U$Y.&7N3"H\/'V*O3>UJO[^8>11]9(]DX:/@
M/,[B<>PW*)#8ID0+R</UKD*[2Q9[?MRI6>!)!6(]I1D5!M<0J/R]67X=M>:$
MWZ9F/.6('0L%;F3@KK*T<K!K$NE-VY.8J&!B(!_JS/7^<@ZO#=;%#A7D+65>
M)BN]X' SR8E&C363JK(;*HM9NA"IC?H+#-/ <>:X'K_!"/U:WP8HK8/_%;RR
M[Z-P7\<!"I8[O1,BQA#!R?9;,+2&ZT&0S$?EEK)34"_<_I,_KS$_.RN>"" :
MS4O=S%O!AKHT8*A"<D%E)<"ROA3FR$6[C=WJ6J\.7D<7!>34ZZBT:9I6QB/D
MC7@(F*Q(661;;KK[2?(F/UWP5@475C]OS;?/T&B'=UV]YC^)WS4V(VWH^E<)
MA@%;]=U/RD/Z]>$4W];^W35:3W8E$,D'R@;NGPF2\5R0;<,\_Q"F25G90*9C
M#F4F4-%O6D=6S03<#UH(*_Y]B^"M8]R;<U%$*KRR25G6I!1V]*+_!PWN('K\
M9#\Z?'04A2_QU_ 9_>VOX0LS+&HHUE.;^JF2BK283<J_>GMY]N[]V9OPU<O_
M]^O+9^&+M^]>__KJ[/W+MV\NP[,WS\+7S]__\O;99?CV1?CKY7/-V7-93Z+L
M'/(BS3$%C_">XX-=!P367DHKZE3FD^;7HD<T=<0S"R>&*YXX8?8_-6DU#!S#
M#W?.Z F#\$T^" \>_W!\>! =@T7]A1A8,I3_B3-,.;!?NILYH\&!LA%V9F&M
MB_;8]D]I2PZ>_!BTQN80$I**._S16\F_8KJP!3B@;I-V=D&WRO2!2O#CK03?
M0 E^',RX[<?MY;-_Z^V5]V6U?_T?_?#HY%'TY/"X*YIJ$NB'1ZMWW__[ <N&
MHY/ME7^H5_[T/C"P6_S!'Q #I\H+;0F3/;H@A7)G);I\-TSQUD^6YK_(:W>
MT2WHE(N1HE?O-?J"=+LTPMEVC2)7PIP-_[X^?2L3'JA,>+0U S;P_C_ZPF;
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MNF[\%7C00]T>J<T<ZL/1 "6)PW+"P*$E#[(CHC.6_F?CJZ1$$NO<>?H2'H@
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M3QTJCMT">]284W2@3,'MR:=QQA)2G<A^>T,ZR6<<-^, C'5A&A,@X,)66V,
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M&.%,<]?Q2LX2HN").)?.-V\"U.ZL75FZLT'X5AH6&Q^PCF@<#\&,6V^U5J.
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MN%9:Z'INKLS[X7])9BGYLT^1D1)(]-%9F)",Z ^CO)A: CH9V@,6/_1%C\J
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M<3NF9N'+Y\]. V@LX*HSL&B4QK->XOEEOG$M]=+3KQ"1;#V%O?E<7DGQ9W9
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M3F/E8DR$"6X3,3)>Y T2"!&0B ^0N9BG7DY9+YQC#I#1@(%X:>>Z]N/DDUH
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M59.O-U,X8#^/X7LATRC:J#93J%XTPA:T'0G5RD<4H,E?V3G*'(%DZJAP7'1
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M!NP<D3=<^ )TZ47D.)?V'Y+A,9R'AI]<H VH%O1#92Z355T:KLLQDH;48N(
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M+)I+*<^R0.:MDI*4F=T<],G:RSJ 4M@JT]$^1)I]QM0[?#]V%=N@_JFTPN$
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M4VYR"F9Q\V7P@)F9YRM(S^ -X0<R#Q_@*X\8HP91B<^GD=[+\OF)1CH8KM0
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M/^:N9\%UT(6A@C+U'8(1<TT5>6A$<4<#)6=RXPOW9:3,0,%>1TXDMY+]/4Q
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M-%=B<+9$,4+6 -PT)'95PZ0Q55)@/I*Q>A9BC]1]HHR):@85TPVTZZ,#4>9
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MZ/F#6Y^WL[[2#?(R8.HZ;/56 @,I:1=PA$_Z4UN66^V>ZWA[>U$KZMCR"$)
MZ\EPVVT-VW9V?V\O.&9\RE^(P=P>?FK\?GPZ;W@?>_4, 8VUD&9ZP&::ZN9$
M*Y>:F'!R>UCZ_="Y**O6A55^PW "GLE'WD6 ]/=&_-$,=$IW66Q2X"=ZMXQ^
MOV.;^KP/"5:"=PX']]\W2G@>E>9!&YR[4JU<:@^?5.>T<S<\L)3[-YE>G,R
MW(W,;T^K($P9"%.6\7_:PU/YJ];XU?KJ_N[E29BH]YPC<?(<8K E_#Q7V=E"
M9T9C8)O/R"NE2'DYW!L(([XUD._NW:OJ8&^OY;KX+FAU7(+/W#8.VL,_W\V/
M%;^C'=ERACMB4F@B>VY[(7K2_253-"MGS$V3<5]H&M?.^T3'N._E_,@\%EG0
M;JH0'HP)(<,"#F6Q)&-I/*P_WI4_?SYJR*.W9;[2.+5<(),(4D)PA&.ZQW<%
M-Q62N&&26(U((A0C0=_;@VI"Q+[E':J. Y.*OJFFC[!(*J?MOMHZ'/[QE/;P
MK/,TK*JU+P=/RY7-/*O F*-6J_R3**U0C$6PL> ?**1$]A-A+U3^R8D-N:>9
MN/[_++Q.>90PC#'_-9[>6;9U JH9(N*6VL>/9XSS;CK?O"$06?B9UY!':KF7
M73!\]TJU/>PHTK!&>SRJ0?VG$_R^$OX_!1MC%-WJOV^,)^^=Y?=UV].19O15
M\XW(_N&2 (%O&?15=S=';S[(,N8<N?3OV_@./BQ.JL0C6%2""WY)YI?RGJSL
M8?\Y+;\HF?E%PGZZU*@WUL$QB1JZ%K65:->+>XW=?4R^CHDND,>,C%']_/7N
M3#]L_?AQTC'79SMEN[7X-D4GV.=KN/YCX54R.<AXVNL9NH[P9S S*,93QS$Q
M=U?>?-B+%2IMPI:VBM)3]=,T*<M%.U6S:J=:3:K(E1Q54P9]=!C11Y< #QJ2
MR9VLC;X,U,'IU^^ETQ-M:ZS%<>*0_4:TTG)B*_FUO*85IN6\,96P36:A7 S'
M>E91JS2J*Y.S@G]6QC_SJNK&-O!/HIYN38JQ@6J^Q;K98[H9*^FA<_W0'E[+
M?S_?-8ZN[UI;&6R[M3W5%.,AMR6D1O):;@ZYFRRV3903\M"PY=(BKGFMF59*
MUDOIU\D*<RK+<O8HC20W2U*]7E\M,R3JS7+4OJ6E[=;].5)== U4O>S>N8B0
M#G(4IZ'V'%8ZNE/7'OI7VQ,/3;!P^8[QSWC+$F4E*//W722JL._"9EG89IG&
M5KDHY7)F#U.6JO5F8?F^2"Z:5Y]7,G-112HUY?7:O[4Q^Q<4-C5\J<:NN[[\
M,$ GEW5EBPW>91NZB1RN[%?Q0W7;QR[70J4_$S(1RWWI'.91+MJXEMDNJM<D
MI9XVX+?!)G+!1 LKX\R1+!F;B16I44N;TLK?N-X*:_@UY3^*(IU-I=W,E,NY
MH78,DW:&6'H4BXI"5D>J6;?,J.%5JY$=DFJ<R?#<!;L5HKIAHEI)%M7D\E;W
M>Z/U]Z%ZUE-^;T3(*(=*U\B>BW+70CPW33S+"<545^HS9 Y'"A?.#X=?OGGM
MX8_OS=]:XTXQ!EM;136@&]PXEEJ@_C!S34_\L//P[BN9JWD:C8I4;:PN3%8<
M_:RCG],GKV0/[)3JDEQ?<X7 05P9.C[2X]X%J:V(_&I4-UXI):WTU/A<ZW0W
MPG[)K"=AZR)Z&B#+1='!UV:X]XT3H7641<YFD5PT:N:B&\@C-Z0& (J^/IVZ
M10PQKYYM9F6(<EF1%'G-F2@YVF-E6T3O05$Q(*E--S[O/I4.SV\?#WY^K&R;
M]1G9* R'?R4*-&4%?U4N*OB7J9FF2UD>*JF:N<.H+-5J54E1\NQ)6[#Q,UY)
MP)7W\P2E=/;]^=./5JGG_EBN4EIIH5-@ZBTGJ/R*"U-&V2D/"[&:N3)%4:1J
M+6V9X<8IX8*-IK/1O$H\<^A&D:5*:8,:L<93#4&5/U/;6'\/A^5?[6&K_O5O
MIZ3K%WUCRQ*$267^Y[,\]%=<X#W.%+GHWLR%*(HDEZI2LY[6\MG@>J9-6.#R
M.&)>-9J]24J2E9I42HW/L,RZ_V:REWZ$.MZ%;6DCMC#5I;_,VV&S>?KU^;BQ
MQ:;PN6W=[WG(Z0,OQ)UV2;00J?[7,1E$W7!)*+UP,"<R2!X:MI:]I4JJERO8
MOWR5.:4-9X(YE6IM@6:JFE*59'EU7DZB/E5F!Q@FZM7+_M6WEFE740]M6]PS
MC"N0O08&ZC-6I9B#V'X+X9G)$KEHTLQ]4.6F5):WM@_J%7#"O.HT<\2HHDB-
M9GF]NK3>1AP _@@](-,> *IYZ]Y!!-X\H!EO265J].Q14_P?/W34VN:6U,B.
M195ON8C7+BZ -X<7/]Y-Y:=<='#V(AE):50E_(AM5<,OC8M29C=K]>5G-V>:
MG/&R)=KW2=4B5H^MF^/A8>D;_Z>JN^WA[YO/7JNI_76^;7,WZ$KBH:OHYIN#
MOU?;TI=SL5,M<VT+]O%J%:E9?0'AU(*A\BN6JF>.'E6E>K,BE5)7)A2-HB_>
M<RO:6S:5=C,Q+P[M?M_PR.S5EJ4?XM=B%QM9&C.(3F/&3^/:.%?_?KO]^*NV
M;0&WR#XI>'MTI^(.5F_($:$*3&SLO@:VBUGINN$.3/7Y'<0>V566?9Q=2O._
MKD3-_]A4R$*-;.-YEE=\GC/A+*=UO9/&VO[=[^'!K^;0UK),1-RHQMJD[O<C
MU#4TPRL:; O5L6D62+2L^,J!N]=!%*4B-D0&VQV?'E%[^-S\]5<>G/Y\^JIN
MF]T1[ X_#&]/$O\3#N8%6C1+QQ-I<:4ZEPZ93JH3LEPAYZ:G.I@\IVTMG*+I
M_BA?JN6OM3J,O_(,#Y8<OI:_=Z ZX@.9G/%A= 6'F5? QE76FX?:Q>]/6KUQ
MGW(%4UW==&O((ZS2D*.N[NG%2=S9O2(O<I>XWCF]]D8YW7KW\6>3JCO&?A&]
MK@G;!X<DB:-L<C213>AK6[[7LQUL.N@C#%IW'P__=IUZX[J1P!Z,.USR#%$-
M'C+.IY49"SAU77_LY37?NFQ>'S:__RS/?+E!'C#^8F7&BR]]S_6P5X$=BI&W
M?QO81[7^5_T69LW,>+L=/F4^CALE?RZ2D;;H.<Z$600F>GBY+#UMZ6E>2X\<
M?R[K3QOK35Y_62K7JE*MFE38,Y]"B.H%\)E'Q6+R+3Y)(;#[XNO)P/SH/VI_
MFOI""D&>7R[9"CK6I_LOS<K1K^^S55)<+A?22>SMYM7GATJS>E.[U]+KI+P5
MPIQ73S-MI=FJI&K>]:<M\EF!0IMWZ8OI8D6JE$H3$N29%$)$)B7&GQ0-(3PQ
M476A'IA/8A=!"TKD0]$9Y/#KLB3B50X0?M\#,E\%6-L\O)3;<,1ZYO+[<GEK
M.^%>Y,'/F^G+G#K&1NQZ"]K*(XD*VYH<(_AN?^L\5GZ9-Y_*&Q',RYZFL*V)
ML8)*,D%2!@I.3[H-_?CR>\F7 [,C_L(I08)FME<SB\?R3?/L\4_E[+J7XM4S
MZNEGOCP'?2F7TB;(LT8-LNYC/O&72VDA"";OH[24<,)!,D/-B"5<_5;N!S?N
MGZ-A9P(CI? ;&BE?'3+P0-?G>%W:<U^"XRZ7TI8P9[%SYUW[O+R:M@@T>>TR
ML7+36KKC+F[$JDVI_:;$G?S^W<'/I\8Q^CA)V<X(.IU,>^7DB-/]X0'Z^]4_
MO7<;T]\[U:T=+1&8LE^FX9U&]^^/FG_WQZMDV^_QG/ME[_WU2?WV:%K(^U2?
M9[_SL7ENP2FYE-8,ST4\\XU,R7*V.S'CXG-SH&4YVQVX)*+/N_C%%'IU'IV8
M*1P0U:%3HP'8J.ZE"@D4ON"HMY-'!*"9&9*ANKW-%2_OU.<-'F:.^ZSRU!/=
M_ZA%T-)U U:@FE>JH9]:A^K \%1S- IP<:)>5[]Z3M=J;ENE0+A#[#49^IYA
MB1K=9"$8$TX_%YMF 71FJ5&N2DIBIJU0CNOD@7E-K,PW8TUJ5)I2J;9FD*^H
MKWB-/-6PD'ZL.A:VO=R6IOE]WX3@$JL('%6:=XT?C?+IV8^&M<U0C9%]XA,C
M&RW:-6<+W<YTJ9O-3;DHX3ER%"Y>_7_?[(UIXZK4P Y%/35N6+836DYS0,%3
M*7AJ3J6NS-'A-HFG9*G<:$C-:FT5/)6AH#V ;V2J/-JLHZFEGR7CDS\\7BZL
MPW([E=V$PO9"N^<EB>,<E8<V5^9 O9X@>16IB06O5E^)X!4LM'P6FE=YSP')
M-)&%JN6F)%>7.^5CFNX^3@::2!S(&:)/! I<.3W_46L9WE/_ST:8Y7FB3DP<
MV7DT3;<O#41@3%:6/F ZGS?.BQR0R'JYJ/S,&-DO>WAYP5B+7@2+X$*M<Z#Y
M6P]FB7P0A'\'\ROOONK<&_CQ\-'@O_$W\SG(L?[<A3I]^2Y84F^ UR[\^S][
M>^*)@4S]G7BEWJ/W^-M_?61I^%O-BKBWQ\1 -Q[2<B7=6_#W&FDR)L3">S+-
M@:I#RI <*/R,5Z/QG^-OP->7J0Y<O!+^K_?BHZ%[/=A0Z9^D7N80/&3T>O3L
M0=+)1KADG/BQU[WY<+(7I1:GTWOQ]GF 5]!RL+!H[\4++$*4EA<VT$^)?NDM
M_Q;\)>0GSDS_OL5T3J"X@]0_>QV$Y00_>D".B5$9;VN+2!PCYZA0)1$A2CH@
M*6'(94G<;ZRQC.[SDD5NV>IB)2_)C4#_=B)U0EY;><.K#8)[0\ 7Q_Z_;SL?
M5DK%/#=("C\),HE@=T6&<VI;U$8^M/L#!_60Y1H/2#RW77>K]WIGJ;YN>$C?
MWETDR6PZW<H]PW*IW);E<GOXT__[Z=M7H_+'T;'F]?MX/\_D(_CZX$PA[H7_
M)E4T$09I)3)(!F<QG;I_DQF :P20)-DW71;6UD+&/28$'/1_WRCA^56:AVU2
M<"F7Y'8[++T\>BY=_?G6/4%V9?0B78:-SED;%I#?SE=!/@6(5@[(5Z;DN_NI
M:#W9:'5N]163;T+!62;R$?L_1Y2ZS9:*VBI/ZL9X(BOX@A_5<\5C2T=Z4$^8
M]Q'F"C6XV8>H%-IJS13)70%-ZZ2[1@_(\M&)8_<![P^B(M\-KW=( C+(.7[2
M3!]LF);K(OP?_59]:O?5R]/SX9G=:P]/OC700=G2G*_Z1H2ET[R5&3&U"K9A
MV/:S)P'8PY1_<JJMXA;6/ZF"?O,_M_)/<FPO';";K#3RP.F>NLE%:\E>RHG,
MJ)J86VSC 5CX)@G EN0]*(^ ?\T5X\_<2-R8V(&P='9:#6SP@N7 KZG(LT#J
MVU3:39HI,SZ?Z_AI@"RL94(\S8/VL'=S+)O5V_[)R69,.5P@GQ-.Y^([+4 T
M"]'<--&LQFQZ%ZF.UFM9>F14#^->J"T!"_YXZ/V^:0\;WW]>_K;KZ*&\QA$F
MV6C"MTE"XWJXT=? 8;.LPRD,D&@'5@([<,Y:CW+F(6FR5%5*4K-2-,QL)DMD
M=@W*F<M_FI6:5"E7U]L^$\41_(@L?/F;F&@MO6]8!E@X $V6K$O16>?RTZ?[
M^^%M=R.,GFP$8GLF6E6-[;J0HAG\D+-JS=R()DL5N;S2$90%4\S'%-F5:^8.
M;J56QQICN37T:<;M\:FDM\C!U%)A#2=H5)5^^?/]Y+9Y+_?=K6O=CNQ+[*+E
M*,T7UE4P9=9HG$OR5;"5S&//BC&C&\9 *=,7%7E-8T9/ID7.2+M'N^\QY==W
M@_3:V>/AWS\_G8]#>^O#:+3KPPZ":8AM?GDU^)O0))#!G!ACCYR57N;Y]I@]
MY*;42(T#N\'M&9NPP*6Q1F;;LK) +$?!#D>MGH0+NH+VBB*?MR&.4I$TV%3:
M)5HES22K!"L'NX^@=KAM$*N$&2-]]0+_R_W]W!X^U:X_E_]6G::Z&8&N!=0)
M[%/L8L49*:5^A??.C+[N!.;(V2J9H[-O8HOWRLR3"5 !!8?,YI#LQLD<T=!)
M'+(J&V4<!Z P3U[^%5O0;IGE1EX/.1>V9<?U#'.$8K5'?YO?/G7=JT\'9\L=
M3+Z*VB/8M4BW*NZPS;Z*D>2%J&XJ[2;%-WE>Y\AX,'1DZ91K65[GXO1XV+RY
M;0]_5T[*=V=/AE:6,PAGJM;!-<DJW[=HD(T7C%8(Z88):67V?3HJKE_]QA^E
M^>DCND+;EH>E=^?K$<89_EGR>>?KQ5>S S_)4K.<UC,K5,NJ."&SMU[-CM34
MD,JE#4+0/H6^3.1Z,7\C2KX+Y(UJS3/[^_>/?Y_.'W]W-L(#R48FOG.>JBT*
M$1:.DJ5AIIQ5\ASU8A/"9HI2EYJEY5;E%N"K:V2N[%I^<:1V 'PL+;=.=1HJ
M:S7T6[\8+F#TJ!:R?3?9&N[(M89LG/B5!W,3G==LY(GM>YGV\@N3QJUR?@O:
M+VH31H=@3HQ#\TH^KC$B.?/NY]KII\KWVZ:E;C$"OTV<ZJD&X5; YR["LTO,
MHDYDK'R-PMH<A5Z3C$*Y*C57@=2\Q%Q[P65IN"RS=5B;(QHT@<NJ=:G1;+ZP
MA'U^YMQK"FIME;GUJFB7:"X=1LTEY(T6%09F4>VR9^JUCY7;[\L-E2W++,)[
M8T"\6WM+K6&4P*P+*LHP.9L^.92108^ZU) +X^?%L55V6V?Q,&NE+DO5U ,+
M"V.GN+ +8V>MQLYVE4. H6)"LP/V_$2WISI(W,-O=@V-XB<9ID^0^#>,018
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MO*7SL\;CK((M*]D+\ WF +Q3$G1'L_A+8]HYTLI=2$X8\"^\*&'V6>0N&@\
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MR4RQ/?NXKGR)DZ:<*QU/;<EFM8!L7 NX>2T@DXR+ 8^[&/#(5.$A)7F8A6+
ME@U\@&>A%SO*2+]2$'?B)C)5]O$^DTX0Q> /:<^R\L].4:[+S*![-&(;.9W(
M=102*6K.]V21[UF8\GJJITZ:]_VS'WC3E+'KV+\\E') 7'[%V9%B9'_\N0"(
M[^3HNJ 3,Q+2>6VQWN9% R2<L4#"\6"+SJ26^I)3Z:MFUP()KQNO637.PO42
M/T3\X-?>==%SP1'Q ;3N_\[.YZ'QTW0ZE:'S3-H/&O\OCZ$57JU]I'4<8NQ]
M18*R0J,X$Z-9=LG\KL73N'3*%\>7J[A@#!U)S3X3?!*I4KD_D97.Z%*R3L+Y
M1?-UJTYE\67NHREJ#[T0!U*(X$ *^3R=S67]#X3#K W43YC4=UGD=EFLJ!NQ
M7943H9>(<T+@4#Q(<8J,WS.0@:Q)C0"N _00\1 U^.:[0DHRL= S6YUD1*^$
M/A$DP._!O!$[X@=2$VWB1AI#.@,<).4Z2,H>KVHAY>M.I$U'\(E,J;1J2!-D
M*I&93H-+::*1DBI2W;4\,F+#ZNK%^8G_0N(<8YN:+X3L^:@'EUL@N)L# 4E@
M$]$!AZM&!&3"'I!I-.T-)65*D$X<;T/_VQ.)]6X%Y*!E;22=5JG1T2S^GI,Y
M,E(E@>NH24R!C,S1<+T8B:"2_-50XF0<""*8-[J;?8C 0U)L*.H8OPPQN, ;
M>,D<3!"=&@WOY /P5W<C^Z)DFQLDAG0%%+>A!P)*"'Z:P4>P1+VO*J/WO@%7
M0OB95$';_!QSV7Y$I2HD2!D K@)0,8JP"=ILLB"968*$&)ECK,PQ%!18"C"'
MFNO"0&'S0RZ@Y5K/&&@\DLV_&Q+-EF,)&^[&D2 PWD+#]P?<E !^XV@E3RJ%
ML #3G2.)@?W@2D"IIJ.UUPQV$E0;&!^(/]F!VE9!0V2R<9.M^T6&4BW*1&QB
M0/DIWA\9N^VA"G@%%UB8[1ZX9A47PSCP+@90HV(\F%3(DCL.23P52'1J^#I'
ML_AY=\J6P@XC$70]H&>3LYJ7S&0@'6TU&-F-\59@G39@QO&=6C1).8@L)#S!
MQX,9-<9((P 7@9%&1KS;8<88J.^>#$Q*D,!T.24.W%<PBEU$>.(TP/J _ZG:
M"#-V$L<O%E5T]J8&?49[=O]R4_K,?3P6F]S1A:+2"Z&H2GM6NO[%7V>NE/M^
M^NQ'V43LP3\X:'&:8:F=<>T"QHU=7.;->TNKU"J>56I!'M2>C9D7:?H\;KT)
MQQ-*A2TE/'&D'&@F6 ";/N;?)\&D[LM:RK=GVO-T]E"J/_!=6_JXJMG.?I@,
M@2'<5E[GN9$) 9).P4FX.CV5CW*8 DE6;H)>ZTQFS7^_HR"+=\V'6"M!&P=Z
M_]\9>V:=9[K .D+"N<_<S>7OUV=E-#\K*N"+W:Q)<I]G/\R8:G1[V@5ALG@(
M-,/"0,W/G'R35KF&7ON(DC!6L4**B9(X44(Q'PD_!ZPHB.#,X+8< R/OE"*I
M[7"O=1F3Y44[N4+&J9<X^5-KB[7V@"L7R]7BC*OFVK.GP=6(>9O64KDP!K+W
M)4"Z!!'O755&,@_Z1%'_IM3WSI]L,DVSJ3S-9C)_13!()YO^PZOVH41&QAJ=
MIQW8M3?1UW@5^X<W'X5]'N.Y\O]LO$YFGB0JQ%I6I<,\^"2*?!@;?F0WDZ69
M9,XC";8I?3SIODS,Q$RR)I.DSADV^-3K-)L-RR3(%"BD4_O@$4_!FW8(WGMD
MVD_O,0[B)8"(%_6R@7".!W$N"&&5K;'"SY?\2QA\C> R^*4OZL(F@G>1+'BG
M)N2CW=/XYS7!99!$Y,1 !' L&"'@O\*>S]*[%4QYA]NBMW38SAO-F^CT4,\1
M6<_%K_.^R/,"^@QB-U;\ZJ@2NCSYLQ_GKI$,T9SJ9@+Q6YW44IFY0@Y$(C_7
M*#J94[)TLH!$:"H3H0@-(3<]#-:YF-B"]'Q$XE-WB$^!%]Y2S->$8^:=SOW8
ML*&<!$*N1P42C$L"09&[0LMN"7N100^%M(PD;.0!^9@NVWWI.F;-<I:+PAI.
M,9M9PUXE81LPP[IB/^:Q??#8FLH@Q897!@R;HO.Y_&ZY;'Z"U/(&<Z8]>_L<
M36X9O<G<LD>3#SGJD@!LPB06#'Q2\^=(\G,4GJM&,7-S0LBD$W?7E[.E9RB)
M^KG196MV\B23*=P&=3Q4.J2<>RH]G[VL"!U]=88]Y3#$?+[1GK%R;71W^S!+
MY3^/YOZ9^?3,0CZ]T)X-^P^3XO.OMVZNAX<J6:/&X"LGFD<_FL6[)MVY<((#
MS*:C(II-9[\I0=YD5#9W<&V1;.,F JH7Z>Q%3YOO=2C/W:Z:]9Z:\?TF^B8>
M8,0W!!52!MP[CA3QP_:H@=;H;(2X>ORX+O[Z?!@6K#Z(\@)%G.MT@SL.K1>L
M,EV"+S42&SEH,+!6OT3B!SEM$!]A'<8,$.KLAY<5@R_ 'QA "CJC!V32E5'$
MYB+84!6AZ46!W@IVS6,N1G/,+,FF/J1^O60;MU4QU3_L<V;7M%/ST9PS&^"<
M+Q)%C4 AV2ED&Z\ 7?V%MB3_,T3K%XJX9A=.K&NGO9.]9%F<E+)W7;LQ";[J
M@E>S!K898R[7.Q/[W5%X"NEDZ+ [G<UF:)9-^M$>ZCT]MWT!(%/S\G=1D.,9
MFU#(/(^LB$XQ,7]6)=^SNB>C.J<5Q+X5#-J (4>\6_Q&JM11F&EOS+Y;YV<^
M %>-GD5MO[D.@_6RV%9NQ5$603++<P8G.8X+JB93]W@2D^<0/O,$2*N%#\.B
M^[-P32IK7)-T,@771+R>5NMJM5.=B'NZ)NAD4NM<D_3VKHDY>L"<Q&N);K-[
M!/TQP1MZAAR2AG%"!B:H"E)1"Z>2GN^IK&'M0'I;&O@>X7!#V7K@0\^A4EJ6
MAV>>FW51X 3;CF<;)=.D?[)L 9X4OT3-\;F&:D#0X<40&K=GDUG_*EW(-Y1&
M:DZQ:2;T)CI5.B ';+1/OZ;<E'65,<,8[VI[[B<H-X7.=;*Y+,VFO)*=ILA%
MO  XXV:-O9=MDE_-&AC*6=LO;SSEZ@.F6JZ/?[)+>8-@?(;DC8 ;W25SK&43
M6>S1,JA00-(FD_4JF2 <8B.B#LU%&J"H[HDC)]3UL ;L3BJ&W8D =H>)87=B
MV)UO&G7-).=M^#M%?G]$+@[8IWXQ5R<"AN?GV[.73/EN^%)XJQYA!U-V(>(*
MH&[UYN/][T&#?>F?_8!-G\.N*6=<HX(5/$"Y&-H>P]Z!*;CU@.Q%6I3CH.P*
MW,>6,-3G@1^M"7?8C>$-DY22%&R6JH+96*WWJ?KSK8$!*U!W=V5DYJ/7=U1.
M^^2H.W$@@B]J G9/K0=C5$<F^P_ZMHGFF !TF@47J.!SJ:R83;* ;KEMAH)6
M>^@58<X,:?\F9JH)O'R'=E T-V :J3=,OI9]EV>EKT_+2(5WD=DUP+*K#%/G
MRGPB.LF"0QQY+2.@:9D)G19F:?1]^'\_N]*8,(@1>\FKYR?801\QH-V(/:1
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M5RQ8+F A1[V'8SO[D;O(9'TR"[O%8-^B<;\A,/K9CRN2W3NX.1N^)GDJ0M,
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M'[9'#606>]<7/H\45E+Z@_Z77>SL<9Q;ZUP(OIF(8T!K#3%!;@00YIQU..Y
MT[,?.=:O<'!+<=D_XINU $FVF9=]:'=TOOBEK:GZ^7D37DGRKOC?]Z(L#D8#
M,[>:OOML7J7DW[R>/<9[O!AS0YMLN_<8]&:OU4/H?[.S&;^;_0>^,D'_[YR:
MY[!(L#AWP&'<EY/#I(_+U]?![2N \)X.A[GV&)##<FMUMBW1';X<MA,5<A2
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M@<+Y\)^N#+V\&8=3M-A.Z'K=V8_+<Y>38Q#J'PJ&5OQ-%56N(W9-;P>(65>
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MI951DOQ/YB\G'D-$J(#;N9 D%X*7",8-4<LXW.'4^?A&&9>46#I+HK#XRK@
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M(#/:UQ'1V$7/^6OE100GZ8"FF".W=><^D,02>],M7[JM+WZ;;XE>+/W;<10
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M&Y6WZ&TA0L")_M\9:Q]4NI!K>P0X9[E?'])CK?4E\\PN!E"8ES#:6OU=D*\
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M2CDQ=Z@<517+;01$83< +#85 $.[1XN9)&KRU+&@E$3;FCV]35)8; ',GV5
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MZI]>Y/X4WMZCR+.34>#@6F$IE,9M:(50YJ5M@,*\6@%57LK%@O;2T_D]HK!
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M<\+"XJ"(/E,4!M@'PQIDS&2>J!M=;,,'QT87NO]8-;OO<(1]XIF-N3#9R?O
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M@]%.!>GIL*B?R/ET%D>\L&K2OK3EIIWH8B^L9>RLFQ2J]NKK\OI@%>.-V=3
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M;6<$+,;'N?9GCD4,2:,D2QLCN;0QSENO?W3>9,M(3Y$9)N9X*+5-,/NM')O
MKW%@3?C]<&!DUDG5 +>'<84F[Q_+.31?E6W%7,]/P8" IFE$>60Z09+F#;2
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M%?AZF [FV/]\$;I?):F'<H,OX%^>"0HB8G;G,O 3#7+J3X>.QVQR%9E1<AD
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M[S6<^B%WQ$+3%?XFISR@JK37XJ3MM<=V'8\@+A%2$GX._##$2/VH7';18_+
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MN=SK]D0I_]727P$<1E>KD?[N$82_\R8HX&>;,!R6!,V[XR'QXRB,3 ^S!Y\
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ME 5)<8I)8[.CSKHXG,=O(Q]\'"<,,2V*U[%91'*),YTRX*:( 8/- @=A]W-
M+<]-;AD7H![:SIG4QH>YG]N!#P&S&#Q-L1 4_F".0<R,8?A$IN#-8ZVG+\ N
MD.+<4.N_6H*>@MN0%97ZA]25X'\R3P+C W4"-DNL-5R1/.@.!B^SO?7BZ1">
MPR:=6\ZYS8YU-NU83BCIU%!TVI=[.4BX'@/"@D__08MSQ+C&O4K6S$S0DDE^
M&U;2XDK3";/]=]!?XACP/=:9/U9N<:U8J-Z<Y:Y$9\V5:"W9.BS9B0-T'J!_
M3T:.9WJ6 _]R/!#.TT1,3T#G#AD#&Y!WB0>N TX:(]_. I_PYU)QC3]@L^X(
ME30(<F0T%&:V ](N BE@1E'@#.,D@I%*Q"@G_3N<_T?P*3;1D GC&5B@_/&Y
M?( 'N(D I#)+Y\1A8L^,;6XU8GM2#I25-H0G0Q-L;PMU &, &PZT]#A9?KX#
M$BSB%A\7/8O\6,H+ZECI%DQ,V (S;YQ@S2B R$\D^GQZ@#1VH["5)#50<XZ:
MN-MD)BV5  MH;> 79!B'@)80?_L[=D(G>1:L50:J>-D@=A)KT\SU9<)WP!]8
M\1_FED3R1F?]C:!%?_6A+1[!4N81K-,E<Y.;F8G=T(:IJ@=YSAR=''-P.W'=
MMD4?;<FB1.XJ,@,WF8!H18,@]EC*^9G;F7,MNIUKU#:\PM)RY55\T/% #L O
MLS@ QS%$W>98W(+/49 9AKZ%!JU=. ,7.#:+6##E<A\^C< ?]V^QP^L!8:Z(
MV+8Z="B_K(>/)PP\0J@NQS:=I6^\W+"MI^N.SNK99#J&LGS6L6$F^66I*^_9
MTZMPS;N;@&M+%74M/?+>62HZQ2\Z69OOWX)1B[;PO@UKLJ6/1E5%I8,ZRY8^
MOOCC?,^3,G++HFSG':^I6D/?H+JJ4]DHD7W?'OW7;U@GF@P-VD05A!/0:UP#
MS@*& 7L/8_#@M?F6F1T9\E^7%2I:X<LV=NJ_I6:R33P6$5"Y8#R/'#X3:-W4
M:^LL?+5Q6J>WU:P'JUE/4KRFB!= J\I]G2KK5[.$TZE9D>JJ\S@!NRHU]"U[
M8=5W*6J^(>=>9'IC9R$M*L]PI:HD44FJ<6NV(9"+]. 4?278D'@JO,6%E;9U
ML+BTIKL>;)'GV)I+3\=<2K]T/+0\X+&NYG@51T,"9B'J;?*/N:#%,,:ZC4.6
M3NWX*2*;FHZ7M(FT,)2Y8F6EMM=RF ,-*W-9YW9XF_EU8=$EUY-\>-]9E:\+
M<XU'2,(()TA;*&-T?-$&'&=(0';-]"043!O&(_PXPPQX]H[#L9RDD)[%A?B,
M'5M1F,"497?@Z1XFW7C\6 %@"D/<CMM)DG? +<H4T@"C.S8;88B'';O.#<^-
MP+;/(?QP#./S+0S2;M"=E6[0Z3B4@.6:&_Z.<-0,&9 5YMJ Y/F>&+[QS/=X
M-(L%>):2?EU]^+=J$GXBG'B][I0L>RWKQ,[SKY"/. 6#&L&LH*M3L*"UA"HS
M?R6A[]6W,14@%Q8$AV?(,K)>L(J#0//\)GR><ZW-3QX"%!= Y<,[?L[=R=ZT
M\)C=!I"J]X&:("WQ_:+-$9I,F<L;%>1EBL33#(FK:KQ@J&)'".#';?OG"V4U
MZ;N4_96DP+]X\QYUQ;^1ZK:%I&*#/_,C]4U^Y-7IIV-96BL!5J'_J$C%_J/2
MHWJQ6R"<"YELFEJQGZ1HN!GU^DD[NI#)AN@5;XC<P(8\T)%DB:V375@K9E9:
M&#7O2,H*-8IW^$'AW%0\/P.(.WV;MN+AAX5R3S<&2 K7418/E7JM51LY3])*
M.\!E\-.,M02 (GM\]4 ?+'!\]#SIR'0R@W? (/^)?(S=R#F^A/E\FYPE'OF9
M&7C<S?\(+J-OAXO[")=G9Q^SW.0D*8%_1:;,#&/,<\"T>G_J6. F>."V@@L!
M$X/,L6)PH;,0@&6&$S+"Y(*UK#K32UP/8HX =%@ +HRG(B'$X/* N0GN;A0'
M7L@/9#"%C8_@!^"*)UY+'"X6/,^8 E=W## %"S#XTW-?/<#LOSA)CF+I!B0>
M4K+$.'+ '^8I<8L'YRM!'/R99'"$G6@"TG0\ 5NK)X%T16C />.)OFL.T")6
MP)VZ12@"_?=NE_S*[I+(!K\QA<NPW-C&Y#WE)7%]D$:(XCE0(,=O,<$01N;!
M@-[+I1U*-Q<<R&#,^%/+H0E>7#/).>.9[%G*X"CF9UY+B ,0M%Y7>LF'0< 3
MM%#"_L;X2'(VUOG]Y/24S-PX! I^B;<KX+&1RY,?>4IY^%=&Q;G!LX!+>KY6
M1-_+<,-3P& Q)FUGYWH8<TK8),SND##@T:FY83W\S@C?6YM383XL$IG?,H+.
M8$H8$!C=67C?',/W\&0;1UE=QC:+*'$;7'Y%/B=\\A.Y,,.HO1R^A\OA@QTO
MA^_[7G1RCYQ3_@J*UK@A"PQDY,HIY\>A;]^]@;\GT=1]\_]02P,$%     @
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M,'T5[K#V=%0Q4FY8VC;,AC G/5:2[#3FL'U1VBT&XS#EZO(7BOKDU"M-!E=
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MSTYF6D.5^F\481_ .I>'S8J%;B!5V*'0H"[)"1\M4NP"D5\[AO'"=_R,V-.
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M(OS7K@GSF[!TVW<I&LOHKW<R-(B6\Q5=WO39VGH6,J>'3/NDAXW<!AXCDQ"
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MC385/4X8F3%' &;2JM^3F1DD%(^MH[%O^=50$K?L=GB^N4ZQNB'WY!B%2SM
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M!7V]19,((%([C*6/ZZ:/@6AOJ10$_Q;8UGQU#WP3$MU@TIAX]@0!Q)3 5!&
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M(5#=L)M'N^Z%.CC-I4=#_H[]M6P46G455\8#UQVF[]/OAJ*J197YSSW\^A9
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MO\1UE5/81(O."+MT$'U1IZD"Z>0@&"H \3^? >=@QSE'J[%J\H3US";=7QS
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M/^"\R;TQB+D2WKQQX]U@!1'JJ23/2HBH!OM>IS@@ ,'$$T*0Z3P"&&*$=]I
MPN3W-VC^3]^?^Y;E0X0:VG>@'"+E!Z#-&&^#R+VKE(NUI2]%\/]63Z3%KUV@
MW[JRB167O?=N#*J>2K!HJ\O89[Q^.MU]18D 3K[?&$26#MW*,[3!:A(2X6S>
M%V;S6YWY=X(JLXQO@2Q/F[I%X"<B7S+V;L4?XKP(F4F/<*;,[?HG;/BG[3,H
M?B<3_G5840+SIO[_+N8T>ZHT\R)?<N9FO\>D&=&B#%B,&D284.9JR+:/*TSU
MS6YVI."Y6BK"4LS1@TTFN=6 VH"SMO7'^UP%]$Z4"M956%^L:<-G2F9P\*H-
M4..\Y!J]Q)GUW,DOZCNH><;AW C@K@9< /H* >"_#^_*>)Q&U7FLW0^B=-[9
MQW:@!5[7SG_(]E:<BCA</@]S&L)S16D%F9>,/RGF%J+4EBN>_W@,243'8+%6
MG7_+AT)5QHPR48TK+[&RP[I.<1B4S&"#NB4-H2'3-E<IWR7?;T0 058O-7BN
M#)_,Z"N(*JD8K[A7M=3R;\JU(@#R!E4'J&7;K&I0^O%JW>@>^]NOV&V/%C<\
M#+FF(N_,-TCUKZ]QW'7X)">!/N9&79'8<L":""7.<S"%@#$UQ'CZ/7H/"!P!
M_;:Y^B=K+>3'UP(=><6>AE#J;Q!<BD68AWQYD^8]BG9;K:PZ[;G*&GWAMJQL
MMH$'\SB$7>BD_"\\BE=V7^BY4T[U5>FP0#>#&J@@U0U023C]?9C&(BZN'"A/
MBSV)9*J7PS(8#KD;UJ#SFNT++5>Q7:='<^LA7CND.>#R3A'2.+E J#5.'DN_
MO7.I@O94X!HEWTK W=T75%G_)FEC&XCNRA(8^_1L-.Q")$-_G$"^T;?JX/*4
M6%[&-L1//?]V*J'FV,]E+/8D[NX)@ZEM[E>4!\%\"KCTX$@*.'\C;K;GBYCN
MY^,J91:*,!F-BLH0S3FU'H)$%S\NLR3BML/YK)*<6I*]N:I,?NK#I-%)5?\&
M<6/((<YVPL:W!XERXT49]=7V'&^LT^+I2UO75(HD"B34_LX]B/^LA-EFCNO/
MKX9X7(_IIJ3@WS"YMK5#<(/9]QOD\C7GVG-E*>TD;5^F!RPC;>L$8*&SO4^B
MVS?<.&DXB)-^2\32V?]U3NP4R\$=DY<W%3RP!-,4YOEYXT45 ;3$2", +-.N
MI5.>'00 (["<NFDM@F_!$,"/*RP$(&Q\GG$:^?O H3\,E(2SIU" AN<*$,"R
M=,;5G>J35 2@6])\LJ'K+B)USIN:<3L.?ANE_,M7;2XIG$!P#"Y0VPRT^OI>
M7?,-:H)(B27H.>X?I['Y,KVMF[AT5.5IA0#$K,$(P)>Q4,W3%+J1Z!B/!RM7
M-'V),Y-U@M\8$M63>4R^P! 22;U"(3T2K9-[33$OM5KTO.%P&=11!<M9%K#2
M,!O%@LW/+72E.$HUOKZB]!.NW/)K<L[B5TC\6"VYS?=>7%"9="KSD(PUS2P]
MY/LV)BO=[2'JDCB^2'WK/&$PQ;Q Q\'*4&B4X03'&W(_;LL=9SS!)<R12KOR
M8>EDQ577F%K6EM\VY6Q44C"']QN]']UBVR\H"%5Y:3K &+(Y,TN2$"^J/;#I
M%7MEWU*'8?+[U7Z)A0 ;_0&&E/N"#^Z%_U_M7&=45$NV;I)(!B4+C4B6'!I0
MH$F20PM(3B*2P2:(-+$)2HZ-@(+D+$FT"0*2@R3)J>DF*A*U 0E"0S^<.[/F
MWGDS[]T?;[VUWGKSX_RH4WN?;U?5/K5W5>W:.UO'A>HZ<@(]=5-=MMU7R+3:
M$^:?,,2LDF8"-IQ?6T@WE,*2=!LFD5FG'A!(H_4H9F[H;<_U?A830V468J\-
M4V? ;QLX']MVGT05NYD$J'U[5XIR;8B0GI;$W(#(V#8^_=($C*C-HPH0O-+5
M!V2?<H=^=Z_;D?XV G&T'(P6687MQ,:_20GK7%UDH#M^MFQ7ZG(2MLN+$ *1
M!67)Y=;W?4%KO7)/:+!+A+7G48?'?DU=87KVN782:M0=H&.^\=;?M('P4)+]
MW==K#SUF57/$W%P'#A<-WT5^&X=55SDI<QMU+H^K<7&F11'3H>\2_S!0 S#$
MV+U>-S6529FS==G3YZ5%5[749NQ[*FGTR37* V&@!AO>-B)?X\8IAR@K';[W
MC?X/TFDD82;^\ZDI#6<ATC5LC)OJ!)*S2Q,['L97+M\(,^(QD2)G4O *ZW69
M3B*:CVJ +0 ]QU(:(D;T;Z^U](0PNHZMW_9][4:987(2:\-M$U3EYA[6+YZG
M*!7A<IU4MG^$F4%5YY@EV([[JO1[2727CWR_:+8BVF5L3#JC8YX9]I.CUYEH
M<B<Q^W77#:7IF60NW&:6M2H6?3AR_1SD/-<]4;G#*C5 'D.>T [, ^:9QJ%Q
M5W<!=<B&=[O$)AM0+FTG6Q"/R&@?2S_I&@>7)\0S(!:U*].EIW]^U)D>8-PW
M^V-'8FS<LN%]1I W615:HLR]64Q+W6KI$KCQ.C##I]32VLH"K4.NI5 AJ<Q%
M;<^CC5"0(.-(T'B4;I$2>T)'T@^(_G97D%8RG"C8QT9-L?WL@51]XH1UMY<J
M3=;:L%=6>.TS!&.7%WT\Y;.H(;(^;;,02ECXO$Z2?I150VRG[)%PD_QFY>Q=
M.]E;=.RE*?M!?;N7 J:.)U9KF]SJZRWOD'RC/ VJ8^X7S;GMDVI2U5(:*?.T
M_%DRO<"1]FI\X(.6F7,&54CA<85^ZG9*1S4(.5Q;[)' VEL9Q9=VMDA\/]F?
M[5X(V[%&F4NK1)1)ZW3.WOB"/Z^.G=!BJ_=#0:'0>DR[9@62L#$!8A,*S'+S
MH]JV\6BI'2$3RE^]WYZLR<4U&@XN*.'FYTX&;.K!,$<=5)H:MV>W5!ARM'C2
MT2V#5P?V]#MMTQH?7N4$W&>,=YHTKCM66-'TM=3QFR+:P+Y\:#G=]+(DZO'
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M&_*-AP-E"/?B_W_V1G?:;M)!@4&-[U\/)/A?*M;8/]7?_UW"(*;Q?HD*NO!
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M]/SK3U#'H..&!W#0G3FOD^+G_@-02P,$%     @ IH!86M*O5FY*A0  6Z$
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M=I'-<GBU)U9!<MD&HU:\Y-*]6^&<=C?=8US%[8:<!GO+?\#=OT+BMR;X[]=
M ].W2@"@_'_^B.P&S-JJ/F5G*HR\:DNWGXS!O=CQ5J%8=O_]>"?8?[,)[TK
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M%GG/A.K>R9"N4#C;SEQ!)YAMRP]ZJ!S1RO?D\+-[E.OZA'QU7/?E#A+W88'
MN]\"%3 5)S?\=7'46_:W[IJN!7NYB@]1/_FPW>(P1#\%9%U1N4DQ? =Z;RRG
MO"8-S 1U:/2U2;,S-W":';71ND+YXH$1N/'F9_J;X:3NQ@=@_HWZ&X5%)H.(
MW1AIT50?"3N'1BV7U@'&QO<M#3RO-=J#<9^>?QS2.,I!:W:;6X-0;ZNVKW;E
M@.:4K7H-;X/'+HK6&9@C'BW3R.^R8N96#WTG/5]-<4Q495Q;6KTF=ZV,1##Q
M<+BN]T?D;I(#2>]^5I2BL7)X0=X2YB.BT6PPKFIR("4E4##<UNK\>I_N[ !-
MM0Z9%:@CB<[8*BH8J\>>?-J"?JH24>DX-5G52Z.[!$NJ?:E3IG%.\?(ZD>Y6
M]+%4QRI#3!6-CQ<-)-A2X%%]E*TIK-*S=:B(A!8/Y-K7JDYF8<SYE1:S,+<L
M!8=+#S-3?S(PT5<PI6M1H*PS=U-FZFI"S)3B'-2]9=Z+SHPSZ?;GW/=6TH^%
M'K<)D3ZA\\O"RE7^$T1O]J!MND<&ONN@Q#O/R045G]DT,[$CR19#\GV _)]+
MSO\5)1:G@CF6,K?$/T+Y8)00-@C*_<G)M.D3G1NMU8YF B?-H[&[1IQ;78 ;
M'OC_3Y[_%SKTG^;JYB(4@JZ*U38O#>4^+1((LLTR'5N]G/DF_?G9*@Q\U1QS
MM;J%W.OD?9300*CIV)?[\3EGOD0#Z?]>0,1^%Y!?%?S?"XC#7X@\K'T5C<8#
M:?]QA/KH_N[G][4@TFW%?N)1L,D.T:H\\3[<9OJ;K/:DD]6L./F&<Z72@;1;
MAT^?"R:9Q\39Z.NNWII\'3<$L!+9_)M(/Z"@GNCDB3%-AK:FIXXY1)EG#XK/
M95S^=BWF3>S)A'<62-6B8'%VS@(+FD*ZE7+F%;%LI=W6>]SZ*')B8:V7][E<
ML ;'7PG0OY>D_V-;<&\;IXSIO_4=UX>"6-7OB3B([GEE2&+K.'@2RSPZ:&-#
MA^7_;?C_MYS"ST+W_$6A_[5%@/\D4YUH;Z0X D:\\7A3>;HMB\5L3M\;8AU?
M'__FRZ#J1U;]8/=,BPG[:@]S&"&%4'HP7!?S$@\L&/_G._S:J?\7[ &!LL!_
M:='^''E**%:/VA>MX 5M(#Z?4AU,(9KFQ%AKM*2T.'"T2!O]HZQ[H"&U[\LC
MVOB#Y=\SMX<'YB(0!7$*AK/]"-N\]78&1D>C"A^_ Y&FK-OCBP)W:&QG;S_I
MI,\%#%F)<E:D0]3Y,)-P(5#46XYJ;HY.-8\[YE0V>@+U[EX>G'KW@C_C4)DJ
MP19-T]MU\&6,N3B:Q:"Y<12JR7IH1UZF.W:Q^$%0ZZ'_T^^D[R\_4N-B2B4U
MSH3RG^;B^*%*Y>CP, 2=T^;PW="NN7$]6C,M9'O0=/FG'XBPER@=38LCK*)W
MN_0QYRXA\*R)EA_\0:*3+;99U)OUTYUJGOH>]@@(9TGW='&*?//XG5[=:_/Z
M-4^(6<2F/>C#Z_  ':[;#Q3NB;S&8\6RE6AIM5&?GWD<UJ!%.\JS<2;)U/I\
MBY#X%>+5,H'U8E=8ASWT#!YX&W^"!ZA."6A-_$: Y1!&"P]H\AWA6(X)F!8:
MH1!W/*'QL62@=S*[VRPXN:X<5YT#<7>O9K.&/*KV-:&K)>6Y"_C)V2L\@<P4
M=(!198_0<<UE?O5A0^^.II_?GV]S)_TVS;1 &:+,F/XH0;!G0-8_2/N/( EX
MDN/# W_?B* W=!FH&%RXRBY6[$ :IY--[W_O-+I2[4:_3C!6OU#_--'[?5/J
MO&3QCI"Y_NS5"C-5E_1'-U?/(U.XVGI+4JU.WTAFK43$J9*]W830SB'7ECZ2
MK6V2FTBMU9Y<<Z,FMS$ECO6:.R]W0@@:]%UF&08'%\+VU$"HV67*EF\VS7B@
M'7:; !4_8"CT\'IY+=IE;G(WZ@#VR1#F54+X4(DJ<M9\LT8127M$N:8Z5IND
M;3);'>ZR6J63A^L.9!^O.@7?=;6ZEU$L'^D)$7XU:<FY_\.%2%A*DW/-;A43
MA.QR(JCBWQ..!_XBXW]F8H2"!<$P4__5BG;9;"-3L;%N4A35@CT3>32B12HW
MSV82L_"#,O^I;C!3^$F11Z9!@$SNQJC#L6W>,ZX]R8>Z0GWK3N]O'5.CES$N
MN\^L]O\UTBC"GO^\/?'Z-D'L1?$ O.48"<,#>=-LVYRES_& '6RN 1X1AJ/^
MINR64VJIZ4M;DS<JK_(#H/.5*QWXQ.CS<*E)$\>C N<XI?4F*+'AIA4V08-_
M-AI5.I?0Q:^ \E2GJ$,E1&>C]IR6A,M&I'*RKL=ORRY>8QF\O7VAEZCUF\>@
MZ5\$/RV'6)ZSAXM%KU?",(95BS*N0P?QXQTUL7E[U"V[$O.TM2NQ-O)$@YB"
MPY%IK)A\BCM&BL],LWC33"2LYS"^ SKWA&#/&H+Y9RPU@[F3=)8D--C2T:##
M+Y.5LU#O?(R5[NAZRZC\>DMU0V/#B\^1'5X0L@%CD@<\J<.;L9^IWV2*:Q/L
M"47;X.V)>2NH+IH-698Z?.$^QM*4D6!@U!2K@GGJP$J6CBVHFD#:UVYK!!>L
M8=MX.U461-U?[R5 7 [:QM8*T/,(!6O0$HBX#B%)830%+T=));^?<2RX:U65
MQ>CR_48&+8N%;&E2X.T706_V="ZR02Q/ZT3'#@QY>0S)]'QS?=S.<0RG8"X+
M70]9"(*G4B<<!K&ENO/(:M">5\#THWS/[$TCC".G5&6W^3E>27$"': '. %
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M9Q@M2DV=$XV6<RN&QA9=D0@TY>H3<U 8WZA?[AK4;__N? AF46>][\ (^:Y
MZ6G^@M3_!DA"^H+, G?FU/=5OIV$?"<45 =S1RK5IX\O;O-;C?K=@77*LIKY
M"WJJP"6Q:*"U"=.RFC^-=1<Y=CK6F9'R]&^2NY;9J<EZ2^V[>:7H3;"?K09O
M['.J]M.EP,+2= 5S6(Q?FRX$"T/EHV:=;K8+N3)O-*:/>#!?X,B2>"T0IKK.
M-@[[K5L($Y$C Z38)_60 <E $/J$CF&L& 3\0RIA&S3'TQ+[C_8G4MJN[MH'
M19(FN:\.^A?B@8*>4H?2!+!]',_JLWKIN!N)B%(2C=!NL[$%FF)J9/^05/J
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MC<K']Q:7PP_\%YT[JIMY)[SD/DA8+\P;2DE=8[P>HIM+]XDW@M13)8++ YY
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M$.;N$0IO+X2!8'$>R<VR-R_!]4HR0=B )</ Y#V=2!SS%DX(99&9SIZ5ZY
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M&U5.E+!\T_MT2G= -(V2C(U5T5^T/5\]:1A15-]UF4KX=[:PYK!@>K\A8;8
M\<;=R>B)[A+7!/&'!4'ATPP,[U3JK]_V+45*$O8[/P*SSXKRB\] [788&4\U
M\[6DT;R2[TW2S7CPI*B(0R"$B#Q(K:6-_\R8#<HJ8K)*7^1AP7P(73ML6.&H
MN 6CYPD[IIXA\.056)PO.+3%#O3,.)-Q9#T=7AJ6FV9.R;=8^5[/VN;^B[VI
MGM_.[XTD6.X0<-7?7'[C_8X/,Y@3A-O'/$<_4A+C<4G$N%2)@HH'7]>"NH-Q
MV@59(D*I^]J9%HQO+I=/MZUQ$3K[3U&:3KZ/Y<'X4T3AA!QK DDQ7KDFW]@5
MTY+SLW'\IM!(WNNVWZ?]=@6NZ(I7TAYE,[AC/!X2!K.(3*I1K)KS1Q-EDU:F
M-99W/\:RTO1TAXV?#,"62E)QS*Y"?_ O,X%_A5#IAUX87P0D(DVT% $)RZ0)
M-6X)14JSY4?QZI;523*>G8]T#5.B?<,[;?$;56OP!__D]L2?W"[]D]M+&0DV
M:AGCFG$%AN0Q%,.Q(>M],_U<%T_S9+H]INKQ ,8V(71Y_SI4G# ]OH)ATM -
ML-E5N._II]W*.RB")D?H61&U/95HJ;#>>]9S,_EZ^M/5IR/D?BLW*2:R?A$\
M,%QD% ]\$[?! \%4.(5U//#K1" /^UWCLV'_ D^'7PQ$UN^^8/1_%?9_2]*&
M_Q4C#Z':E0'VB.&P@Q@Z.9T)SWD>FA/G_@T%$X'$3G28"3JDZ[*E[VJ@QL52
MR4EU5DS$;12Q(Y477>9KQX\2QY;)')%PY<QT-XDYYC--C\Z%"CTIX3FR?<G[
MG'PW3IW,!V2(J8 '4&B@&()VD*53VA/RKU65> :=79@J?+Z'$VD\UX[ALLKR
M>(!.[-1$37?X53K;.*^4AJ<LSRFO+;W.QX0UG@]A8<NKZ%-Y=3U7QC''9V(7
M=+[B 5J#OPF^3&/QK3XSKM@BB];2RL>FP]WQV" Y;\Z\0W(KFT/6K4VF9&8U
MSD>5X^(Z6U @SU8@#SHU%JH)04@J=8+GZYU:D1!WB.U[W^ZU97&Y7<-%[<^%
MR3W],WO0?GA/!/8<PC!2G;UFNIG>!WQ]I.K$1N)L)G?< R;)THS#RD8)3=L.
MP<CLN3RJ2V"Y%11_W(>%%^^P4ACW#X9%/;[JKW/QP$.-%R8BQ9OFM8ES6J:F
M(Q70;M6+K8@@->]KJ*Z>L$!:J.Q(B=3^?/\R@],4!\?4<4#[Q3TCHR.>69(<
M.4")U0X@B>YH&E75 X4U^N=NU).'V7-$5AW5_?#ROS(ZJT^L)7<U[ZE$3__%
MQ=;O'GVWZ=Q1\W#U"M16Z]Q2(FJ]W< =P6<V?3T) 6'0Y$BY'EL#JA<)25S3
M#?WZ\,5S0[9AGU!X1+@ AF#$]_KA6<%9G?R\4_:550GZJ$IC*X=@P7C;.[Q)
M!8,G RH[K<#SNFSZK1XPC1 Z[]GH_&#V1O6<5<29<4])=>>9+UT=+G(_QNB7
M[LNT,H#%=?T1K[W@DDX$<*F+5.K#&$P'$7S.)T\-Y$[,P.?G^YQM^!H8&^X/
M?E'_RDEM$K#C'#K5>&Z%3W'I^% Z?)G6MNQ%&Q/FA:'WF&)AO414U<+IM]DW
MKCQW]_O6(^5!Y!@A'-=19Z#@I#H7AA_$O9'Z9*;+!@;_)FGW7;.[D'=J<[O9
ME[F$2?ALUVJ_U&H0_?<;J, \FQ(?^UL!0E?L(,S+SJGOZ,S(E#TY9/0XGL?%
M-D 1VO-!-[;M0TTL01AC?WC_1P^^$7.[*7EG W6J Q[3+V5EY9EZ<Z;"48PV
MSO+.#1X9'1[,SE%CC=)P"$8'2_=A&2N/>L"R5?QNZW#/YQKGX*?O _J'*:;F
MV^.GK<PRYU,A336)2B'[8)*ME*?&QZGMNY1F_;[O-SQ*4@D2OO8A;!QBYV\[
M>[YW;497B:^-DPTLQ0" 7'X*5RYLY.\_E/PE,6#_'Q##_U;\$OY5B?# K_>#
M?N,\H@'<)&%>\D -ZYI4B5^B1!L%=4JV\Y,70%Y,-:43SB, ^_/'H*^&<]X$
M]K?X*1E^%MWIJ*..IW?Z$*[TY$ETLL(V/)L7A$JN[-L*,RVP6-80#E^!\GE#
M2%/YGS\=D8S\PL+)B R8?AUJYRTKI,"9657BXT/)A6L5;P+:39*!D^BU7P<^
MI_"F$RFL>(1V4X 2O"#4IL7$I/7(3]6 NOFB%"NQSB>AS;,D+U'VP>N-*._V
M)I).\;<;A^H\7=T%U,M=*@:2M7A ZZH 487O=\/KODXR@_Z]:-%X\%=Q6\)A
MSN$4]D12.Q(HMM+ [:Z:!AA?U)Z!?J<S:5I\*"A\-$U7#P_HU9IZ?Z5$6&IK
MVD:7W-#RG\/U6U&\@O7)_E. L'\-\$M657=+_GT<(8-LUC&W*Y*T49.H>^;/
MA+-$:DD4:GZKL*7YR6W<$)A&5>U$"6HP43D<D<E=-B$)5?.7Y[C@F"B<>#$L
MNOS3_1 &@1$RT+/CEDYQ>33O,4-' CTF_'-_U]SN3)6K3B?X4>V5H_(HQ8+9
M++O 7;I>_H.1!4><>G/6C21(4"!1IJNR3M) 2Q1CNK?]=\Z"8X[/^AGKH*YA
M,T, *S+:+ <51NM$5&U X./#<0?I;S:F#2""CR9LQ;^77AQVVI12Y8&L6$4O
M":!C SE3<$MJS$/BCJY/7Q<TR%U+(EMHI3@_:AM/KH+6X-6):A1!@SIEG3C<
MH6RH\,1B*^7&N:Z$J!P.B=;0%$EKS2\ I<MZPF73FF8 /5'S--4OHCU %/%U
MUMKD41TFYN+<IT^>-]4_DT\*7?PF/E'%,&>H/^I::3\!54+0F,==7Y1XFF4?
MKV?<J[$N>#^T3G<^Q'=E95H&/:\SJ0HI5#4RNG,?YNS#850]9MW:V_2R]=KZ
MSL=7QX_P ,T(R2-(M#Z"!AD("6UF3]I9W]X;^([IK+365:+,!V;A%IJ)M0]6
M_K_JWCNJJ79;%P\@H%(BO8-25;HTI05$F@C8Z (* E*#% D0"!WI @(""BC2
MFW2DA!*J-.G2"8A(3Z@+".%&]S[?]VW]]OV=>\\Y=XS??VNLK#7?^<YW/L]\
MYCO66@'?+,TUQ1D/PP6\T815:MFKE5HLK()";19(: OO7M(_4]5/@>),4)47
M72B@B-+5Q3*6%D_#N&Z6#3_>%I#>Y#MDL_>)[=&3D0VQSV"XGO[R\6O*(X$6
M;Y^;8^C0H+>C)%3Z"OPC(D&!E+PT%QV.EDH:0/#Q0C@K-K$@Q[;J'(X!\RW&
MRI)BLE#6)O(&]PV+X# "3W2Z6.C.B'#%-)@6196T-D!N?!CD!CCFEH;6A,W:
M9UAP1M_6_)N,Z(2M-:E!T^D-LU([>O1$V\4%-E@N4QHJE3D9_TWY G]WEO36
M3Y/\IW-Y6<K05?G%7FBE=0/Y2[FX1QBS0/OWMH@S< 6.-\@MI$T4RW3RJ[IR
M\?*OB=:\ARG[!("U0]!RP,()Z$8F"@$8IN-5,F"K"V&0K9MP:<C&4RA>I<3F
MG9^BQG$RSA(;T#]7',@83U -A\$!W=Z+4]KSY12E,O&,GXX32D,Z5US(8'V"
MP[\:S#L!/?93;P)3!8C!5_&-/Y_P5.(4)W#E; ?7(1\G&X%46D] 6QR/5DJP
M*@]&U]RCU.=L DHJ3;B W88:K)+GV^;.B6_=/.2QWSU+,I:+!OT4G\B21QF/
M+FB?@$)\ .\]SQRF(6,P3?98T@M>JR,F@3@BQ>Q*J'M,V%C51.TTCAESX[/9
M.U1N&-PPRUKOP66M5,@K4GFR[U16$S"M5E9P>UTCS8\.,G_&?,)N(GA]M,3I
M=L3Q%2UW+1.-[JLS>I^XA.8NA*76].F_G7-40S##M9&<%/7:Y(:E(2-W*JXN
MCKOQQ^^'C/5->J.@$K2G2>F)B4 DUDL:V*EJUH2>$Q"HGGAHI4G54Q!(D#&E
M##F[M&;D=)_=R\_[_E ;5I906_98A:N;&\\:+M=:#1LP?EA&BFVI5@Q<=9]@
M[#_K.NQ!J;RJ21X"UWZ/4P1XLNWT!PU-C5B$BWD\;WVC0#V2-9:/ZA/[2M=U
MMDU-AZBP)'B&$@L)V5'P';J)R2Y CU="P9.V(H-E(N[/US<H]_O@J*UR2<TE
MRB0']H?6?@+:3.TTMBG!93@B %;%FM#2,&796GK@05? 44A@/D,;JM=T??9>
M[:OSV:^R'/"G@2O#/K$.XN3AUQ&9Q<]0;4E3;*D40_%F7 NB 6D"HVZB@C<P
M9@5OO_?16:?M+3MK;XT?N,B9)(NE.802?^?H'#CP@X^79,'OD#_'\^ NU@_"
M(0X3PO/=QZFPVI=E NFG'@JMGNI.O- I7OB>6&VA@\Q/?E=>:D%80M-;ZC@-
MSSEIB^JQ?@Z+HCUO[K0=4_K0:>*C D;"1&RED6ZG@9&*5C1@YDSE8-'U;L8T
MI.#]D//1+ \$OF#$FJ2?-B\56>NB2\Z9POD!]PQ8:K/'85::GU"JZ6!1^%36
M5X15 L,YB9#43_&?1(JBG=76#,@SX!>QG(&/2&"IJ*0E@[)MD>+*<;[MA1A5
M5LN.X_3&IR(MUPL6_92M9N-'_10D6JFPYJUK,3X8#Q3UC$\#JMY7[/(0,WO7
MV8]'G$8,T7,YD:,_WC%%L".^OX1!";3%> +Z*KN)9U+.G<!)8PIED>B\CJR)
MK#[LMF< 'U4Z?'>_^)V?O"6>KC$:LG-37H;0&8;]N$47T$%>I97 9*)4\$L_
MC>R%JTRN*G%=\.W#BP,--N^ +[;I5/40>,R"@NW2%2"WU?+5M$PR,Z%>.G[*
M.2_#TNXL.'("^@6FV?AN.P-EP#_VQX[=MX8Q?"-G0[:?O+XY&]PI32!<-VB&
M!39]LZPZ\LPISDR\_&HX]"Q0-:83W=5H$Q-ZQX@BO8*7:OYBB^?ZU@;)FN&4
MEU?*H?7:I:HD+\F(TK*\-ZV6+\1GD)>Q4!07'2P4W9[T?CF-?LSA8>G(;M[#
M@(T>G6?:(D>&/;K\MV6KF2Y4*S7-/?Y,_E$T6E&F_:T!&A+RDLB//%('1&C_
M9#W^&D6Z$U"G^ZKQ=6W.9.MRU-=;'S)@]2C^]HDK=3'"@>W>NP451%NZ[?W,
M<//:$20SAPJZ)'2=$\)DHI#?,5\N\$9F?$,L"A\N'4#!,;5#PCZ6 ^; .7?@
MXM*I$&B+65RH/N0)GX QH.*GP2E=V0=9'5UI@+ME@ EM>M#F0LPQ;0P5(9 6
MB /J&$ '?_4$-' 1,XMG%/[AU-K.;?+^-#Y$.*>$R9T2.!5&OTS8O"=P'7^1
MSE-[JGB5)SIP*Y_)V".FF.U>R,*<J-]7QT=!U7D"8<.5XRHOS(\IODWH>'[7
M]N$SOP;7P"C6(;"O5S[#GIV [M2:]%Y>O3F:\9"GM"+0VPQ5\^'RXZ\.[;S;
M3! //V(3W>=WN]\=I!/!R0:?+.#Y_.MO)I># H]*=D3C7X YFJ2H&M)C+KQ8
M.8<CQYS]4!G7OWYIWFV>K!.V[Q,1?,TA^O7K$<3S&2:L^7.<5=Y*&NV 5(2V
MR8.!&8KR F,4^S,-ARF!\8W C6C'M>>WK5P,XT!4MU%SJ[U@M$"K02EF>C\$
M+N[M\4@*&7K%XGYUE./H0>M-DX<^9:_!#0&S;9VDBZ5 ")PG#Z;3/Y<4Z"!I
M4O'X8_E0O<G7R)JC6>%7*+<+M1B%2_$3P);C]2/].H!M3JY!S=[5RCO7%);%
M:6MYF;Y#,%7^A=H5<)$<>C-XM_$T['#)C)-VA&JZPCAEE>DS_0DH;%+;*\K:
MHL=/@Y;]=95\Y8%/ ?5FDU=0;6.;8#J@ K4<D.H4?A0BD:%Z*629\T'CN/QQ
M-8RRT(:7/8'Y @PT&W$#NW/I/;=O_PRQWB![5X[_O"0!*!:383''%(M\?M<X
MFA3L]3?O Z4>GGNKZ0%(ZL1EJ^B%=5H@EXE6C9EG0]KS4\A#\,..T=KT@#$#
M NPIU^1EBIY,1*5E9BQ+)R;-J]LF&E&"*IYVO^Y<J5.QS)0FNMKKF1CU;O4$
MA'EKT/("!FFER1@I=N(O>T,L8;N<>Z8^LB(U)IF$0:__JA6O!\@3<P**Y!UL
M3R68/L)\_V+ZP*?"!$S3L=@M/;OKYQ-Q:IWW\3/%E[6AH?*>1<WYG>DD\DQ0
MZ1('AXW-0GE][K0GU"3JWX03G[UXJ]&O'#W2983CQK*NBGP&5.Y4::6NVN)X
M+EGI8:8H<NN'"E\AIIR"\KYD?*7A<C!HA)\.@=7+E91&S0]981ES^%.BLYXZ
M.+&Q*7_/PK4H/,^@/ VWQ];.\(:+$O@B6O)V?L0",;%_$\@G.OWW@N^M0$^T
MP(5Y@WM*Z*SNH!MQ0KHGH MCK_$#^"M F\<1!*X1>A^P01]17<,IP*N9Q&&%
M/5BUASX]>7MZ4TI=)#P*$N;Z8PF^(X&0<IFV.Y$GH#;QW!/0LMQG<F$TF WG
M$-'BQ:V,*4?%M52)G7H!U.=9;8V=BBEC]W4O^=T;+W-_-7DZ])S7"<CF'V\(
M?P)A71=*HGD177^BNKL[&Z>$_SSB?LF7&'9N9B7V525%$O;*9NUU94%!-M'7
MCZFI57TX49?MFS8D/=?A/E@G&)PF;V6O^M#Q_>AGTU;?KCRS%CY2O3>8*V:<
MSF1$^'60G4"TKTPPFR\]S,;I:D>D#F0G^LWO[A& ?QI':"K.+J!GPM![C_C:
M"MF*'Y]*\)Q*>EGL);+G0(TBJ7Q&3S1/R*&_1)0PDQ>KG8XX4ZP'GG7E\#O\
MZF?J2H(I29K*4!R?0/<Y'^1=WFW?[OWJQXZ3GVWDYY'M_WQSV+\#-_3SU>$?
MW^?ZUUJ1^5M1VO/Z&RGY7[ILR;M3D6^%DR^BU0!"7$^GV'!.3UL;=YNJ);CO
M,^\1XQI5;S2L:S=[-N;YQ&A(&F<]P#1GTLL_7)"=+!HV@@[:NO\<WQ8L7WUU
MP_Y[XK*Y-"#3DK(?K'A1LQ@2M&LD=5JD4KS0SOEE>P%#6P_"\K16C-B-9 MJ
M^4HUDO@ (MX!N/*1?I:G:%,ZT<&^_KO1+1NLK+66,XCFXQ'35$O))]B!>I:*
M9R;P;?5(M=@7!!"=@"K?J]7;8+D165>O75]:,Q?OYYE-:1Z&$Y6(E):83 (F
M>B/UM(<5LHD%CKF&K4G5Z<MW):NP"8B=7.(/<!DK/=(RI<%1>9;Y*#DT%-7
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M;_OQ'4GO^?WC<W*SN,L[F_C+?J((E!!, H_ $8IZL#6!#CJ^_^$L\(>S(UR
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MA[2ENQ>$]=[%T&KPOK#6>WI4\]@Y.K\I@9*H]XD=ZW[X1KU-D:DVQMLXL-7
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M5?1TJYP50;X!0_3P+#':4:^J'WKL)@ZFVO.V_IQ=D:EBY^GL%-UQI=S,AM"
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M#PX*&=_L/4>BM_RM+ZYZ$UI.+O+>>#F4-'A^H!.K5%53IKR//+B;7_K973&
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M?P&^:.@QT%VPY:+@>87/"&<9:2?,"#'T /&&!#@5UP'PY_D$6S"C70K41#-
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M^RAU8Y:P(YUW> 9TKJM"[?04TOTBZ)2WD=?Z^J$+C,WO%.[0]%0<\]W?EXG
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M1 I$?\E/VVW&<7@%0/Q4GE:_*'??"U#\ )94MX[D W-_;Q#P&@]5E8V<HX?
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M.;_D[$0J3.>H5)/5S8Z?P.J6.JM2D=1NK-:,*F2Y=M+6\?5KYZ4-: X3XFD
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M8.3]XTODB<\853F6M# =0A3-7Z]G$ $J2R* #TGX.?+:@E]5"Q"TOZ[R"W>
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M0H 0?GS.MY[SO<^]OWN?^]QS[LZL^2,SLV>OR>SW7>]:.^<SY\N R[J:.IH
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M_"H2^6<?V\:5G^ "=Q$9:!_+<T!CE$0SX2P/WGD?^Z2W]JJ/3*/E'ZW3^SK
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MCNFQ"PF'9*]>,_='[>TS2.1]TK=>KST'7,D!!7?M#6<B&E4\,LG6K:FP@N>
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M,55T9V"&Q0$BX'%*Q9VHSY%9LM_]_%3 RV)-I7'_:@E/BE7$K'^G8DCK%?\
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M&+XQ?#94S&86G6[QZ;KM&R@P/AKC4A/#<@X@XWB[PIXM&CDIXUI@YA?\;+*
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M V$$.]+3JJ2OU=,(#SDL!4745C69_2P$50TX%/VIA6<H:5^IFKR-"#S+)$D
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M@WP[!\16CW! P_9U<*HEV/V!!(U/46XR@[UF+_G8$> :+'Q;?UG.R!:]RTA
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M=/'// >8E@_]6-Y=\XRF$Z7['!B4;<B[ E/"1+MX;U@H2*Y.R'*W>U<W6U6
M3]L/A-:M1#_>G0STW"DH25[_D?$G\=MV,#L[^P)&14.*>&+B8/_\)4<O48T
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M5=1>RED!D2GP;#B/YAQ0V/ARDSA>")D%HU9QFYO,9UYU*?#T*7_M^$T9>);
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MXT/'^S5\E^%2O]MSSY39>"^2UT,_KSJ@/WLBF>LEV-$C2:+40@OJIH]^?"*
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MHQUH6\"($2Q!$X7+,FV?N=BUX!=E6\]"&/'NJMG]3E([1HRVWL%$UST10?,
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MZ9W:C)ULUZXJ-?JF_8M>D=7[?P!02P,$%     @ IH!86@:-@$;F#   G(8
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M]H_C__Y(R+?E^O.[D]DG_]<?-E^%_V5Y\K#Y_ <;K:Z_??XZ"46>26=)?(P
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M5Z2./I\=?G/1)T)#D QVLD*_UJ4[HGW4.R2'&2O4W$W6$7U2=RL)SN#1"0&
M\?LK41<N7^FC@>5*MBS;$<W+#LFF#I14Z-RX5$>T;76:S[R7IG4%!0J6>%&.
M7;'2,]Y_J+#22W+LM)5V'P%L8J$6W#IBG6S884RD(^@J%%L6E\@2_-G3,KT(
MV7[&*5ZU?02[FX^UNE.8;Q']<PHCM@9JL8U7M"IJ'U+*8[8*V;R0TF/J!>G7
M(]):E>1U=<EZ1STP.O";XHW.V<9A"NF=76A6O([]'[PF^OM5>AD38$][46:W
MU[9$2Q>+4U] P>AKXFQQ&P:+0D^)7G>,==I%].>WP+-1>#8!'O\'4$L#!!0
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M0:D\&V"RP6L@"\8RZYK3;//:LMHD5AW PK6RWCQ+=<9&WB;A-<YPF:56+V0
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M2+/4C:^.E!H&M XQ/K&H'CANO>;,'9/O5<J:JK074O\GOLJ4%;<X->M* +7
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MD=_3)BF= 7TA]1!'R _8C0B[1/YBX_WD(AA?]KF:.ON L_Z"#7C8@(<->-B
M!P@OVP8\P$!A QX0 AX]C'= S+N[B85JX@28>+A<S++92^8*UB&O\_@%.&>N
M4+WML$=K\*Q9OCXZA2J] :=<<W!#9Q!P'UO$5RX)'9+X*1K'0?'E\?.8TMR,
M7<2KEACP&-:W!ES@(7N2_)*WP>INF1]^-#V/641FF"9O8'N\=XK[Z1E+KJJ7
MH]M &'B,F]JD$7AH@U6(.T#],+T&")>YHJ+4=B&X32[15=:4+3^=N?WE(68N
M]9.\&*U6S97O4P/OJBUK:V,/75Z,QU@<#,+K9R#ON)5\=B6AZP=^=HJ(_TJ\
MG<$U"-;EL((W[",5+KQM&2?K!$W?U&SAG<8HU?&:,!4;S!<##U-16UF[?S84
MK/Y*^,+&5ST7TU C)/W^=#<DG0AP,@EPHLX;YU:T$E^V'Z8H_#$E0; </8?8
MNX^?F._YB"YOD:!NXI>43?WY51AABEF4CC V&I]/Q5DTQJ$LH%WV2GRGGS4S
M-+LPJB*LWN$GP43H#])%=R:DSJ&T^P9=[!MT#YO=@K!;$'8+PFY!V"T(,Y[,
M1S.>C D.4C0<W#9%<HT ;P6N!1,O$45+50;(;MF?"4R)]1J#\L"W*JK?F,K<
MUC*/]VWQ.L54ELC"4KQMFHFT65<VZZITW-BL*YMU95T>Z_)8E\>Z/'UW>3)2
M-4PWT<]0^*<J1EXL#/YL@DQG<)[+-Q+BY3=$_\3191QZ;!"=(TJ7?CA)[GF0
MHU)1$3Q".OI#'3<[SH@V9EK5P2.G;X64 QCR*L\W#_/>D$CK3,_[=[ON9$Z(
MDTB!LXEJG4CK1%HGTCJ1UHD$"H5U(JT3>31.Y'J&3?<1Q(7@G-,+*EB^3NQ.
MS.75@"X8>LIK$-X#I^INJRF=M59IJN7%#[Q^U&IKHF/ @=:1 P,#<C5I&[QN
M5I6]\;OE8C"E.+W!7KH"9<7+2IO:=58/$:*GMPR0C\96H^U7U5<[Y"++/NF*
MWBU?"/@?T$3A8>K+ )_)7M,4<''1;?TOD8L',W&(3Q>\38V>0;6C.#C6MZWM
MZIJ?(;=5?3RKU%A)]9Y!IK("'"-,9O(KQF+L#;G6X83/!#[QDJ!M&MH4Z_]H
MG MSWF-7V.>K3F_M)18\WOM;)V4PP/I!\DP/:[\C:,KM:T^H8YZL*S0].[MW
M5UBG$[Z(%[T4_&BG('BPRO25,E?CF8[7))R(D\"YGB/6F1L<C<9B!TIP D7>
MXWM5WJ.0[0CA6]M70KS#Y8L2JR_81$B[AV7WL.P>%JR-$[N'!08*D%%'NX=E
M][#VCV:L,ICJA9JV:X%/WZI4'G@L\'N(9H03V+^Y!Y9Q5EVD2JKV#"Z9!> &
MULJ9$>K+X<F7 H]$05F-V)XA5S*+2/(9.I_G6.8U?E!YC1LQ.YF.UC>TOJ'U
M#:UO",(AL;XA&"BL;VA]PZ/Q#?-\;\.$[O <+9-;H4?C6^J'KC]'P1T6MGKB
M\NA+3J90\ =&BG2@?24_EO4VJ%2YL8'@_- :5EV%-WQN>GC&P0)_XQ/55,%4
M]Q)[3%U!8EV?)X:K4'3GAV?2$OR9M.-"/6^4AD_=^P@A=/ JE9>2($.!#]';
M3B+9UCG_86?[7'G@\V/A&7HAO73O_!].F&Z>>V(CW=O=03=^'O2<!+QKDE2'
M =<EG"0=@ U"[X:$KN3/#_PGAEP!#=.(M+3[%4,QFLU]4_M;4Q7GZ>!;8&)%
M772YW2A39UB9B535Z*8/7/9HG#-%?=1*4MQ<S*H[Y(B.X>"89-%R5&YLU0&3
MVH+,'.E2XT+V,^E P;0>P LR#-=]%SAH@.Z:H' PH3C111FA*REYZ!#=GD.*
M5!H#=DNA7WLZG:^/C?:%VO6][;Z0W1<"L2#9?:%>[PL9BP@V2&WZ9.J"\<Z=
M\8*9;>_:2,9!Y?EFRB<(\4_EN6\AJH&D8\1SGZ8 YU<?^#* (^P.S1H!W%S=
M^&CC\4):9JG&ADY;D_;0#V+><<31::1XR;6LZ#&"HK15!HNQD\+G 6)L-/Z1
MA VB$;WS)]-H]6SZYICS.0H"[)TMLW(L*ZC:0]I/\#'VC!9;1M:/C+T@?(E\
MFER>,/#^.V:1:).UB8I>HJQVQ'V@VFX9PL:>!]YH>DGH(#VS(IOO5]%)694C
M1E9MLPQ54X\/W^$@(7V(1LN\E3II%9]VTRHR84XBS<F+@Y- (3&X@&JQ,U?7
M-)WH( /S;+GU%]U<AEKBP*0KZ (L34%HT(K@LPST;%*G'M21 6"_I0F,I+'!
MX.(E>16KKB(M*VLFFZ!!D\LQ@WM5['[@@-QZZ0[ @V[&_#_,_/!VBN@,G1,Z
M3Z@@"97;,JHJAK("%*. Z"O>]IPFV_]"\P@%/DLU<7$<^2X*V'50L1M64<W4
MX7.]MM?27AHL.F@.QM"GV.6BI&CP0MME3'EWU4U?KJK4U;:Y+@?G7C:=Q::S
MV'06F\YBTUG:VBM7>_5E9?N]@B@,:WM3M&6D;M ,5[F#\AIF/'9%,ZOP*)H*
MR3]O#Q:0ZTI;T!UT7;GEZON,$;H4%U<I5Y:RHH^?S?@DE=V>:.@MW34R]U)8
M_,3P7S$WZ6(A-LCXIRK>")-5.(K%IJ(Y .5[E&A:-;<IJAAZ1JRBM2NQ@;OR
MM D/Y+6G)0B!/B6VHV_56<#2XJ86K.KAHL1&9]5JZAA)F,$W/\ L(B&^3:\B
MD;""W6*/;PT]UU9WAUJNO*R%6Z9>XC2 'R:[ Y=8EG2_7:A7C5NF>MN;'WO/
M*;\CZ@L&<HT14_3TK'A9Z=Y@4FD#N(C+'6:8*S(=A-X0+W! YD+9RA1U9;6^
MP:5A#+CX"\BGTWJ&>PO&PO.2IH1&8EDX(Y229VZ4"NUBX=YA*#-!AHRQM[7B
MV0S1Y6B<]+I1\BKC@)NX$(\URN]$_URX$SV5(V[Z2B0YJ2AG)<OXO>CB];DS
MONYYXEE?/H.BM-NL4Y+/EILBV=HX>$;4*R!=UE_WEVTZU;72!B8S0CO]=>]/
M@$F);:\S29-F6\(#?")MJG)EM'.G&( 89UL $96=X)RFYE9O+ N]VP"%.IM
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M;$)^."UN0F;"'2'=$>*W-R-1Z#G))QSQC?4NI+/^C-V/M/N1=C_RN/<C:_1
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MXH4QC*.K<$SH+!G'=S@02^P#26Q2O*KUX8/R5:W<EYSL4T[R+2?W,2?[FO-
MTC" ^;>VK/]O_7_K_UO_W_K_,*&P_K_U_X_4_]_QKAIZF:;2J-IQ*95I4D "
M!-<^>DI>I3B/*<6J#5)UO9XA5:H^\"&UUOF&A&Y#M#95^PK8C@7@P@02M6LC
MU5=\E*B\AX'*SO4_=U@TS.J/%0^!U)74,QPU#9(!_ $DP"*R(S)0Q.,,M]QE
MK#%S5DOJ-\ R@V0 ?S04]]N*X"E/A7_<#>7M!..,GP2W83D;EK-A.1N6LV$Y
MH%#8L)P-RQU-6.X:,X;Q3IRJP.KEZ[E>?? 7)=4P0R-B9VC+>YB=SGQ +TF
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MY+\2XJ12 #UJOVV?3G!16L-0B'%;GZI 8VEI..'&"CAV@XX*V\&?"-]5OO)
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MY@Z'5<ZN99V]A$D5X>B<U 6]55&5;(ITO6P="V]PSB;O'[=R [HE^2%3=+K
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M]9,:0<,YDG=.7&\P?34D75WBH,"W\>JQO%Y^+C"#IVH*>AVGW8P-_$%/HU.
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M9MY8 RCC%#"-3"OJ<%3]:A4DX]CC/U/8UBKX9MH0N(EEM31HA@T@VK*KWO4
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MV[&:Y<#RO%#!D[M:9-T$9U^=P/ZX0I\]6>/+3'@76ROIA2\B5"EC>C&@G!$
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MQSL"MQ^=Z?EQ6B9;,,/S7?B(HRK!UTM#,V9Q>(U.7W.M.74#VRW+ \>P>:;
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M/B7ML6NW!SK1LT[]5<SMYA7I/D^'+9/VWE[]Y%=Y"APTI\ KUMXC^K#BLG^
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MD& VU2S*/ Y+'-$?R, U_(*3K,/JBQU5F%01V]2J'["FMR;/EDL<2H]FW"(
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M?UO=.W96CNBML0<R5 6Q;!G ?W5)/I&OVZ_(OQZ(+?+-_P=02P,$%     @
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M1CLQSPA>BM ID,""@9:!8I\X#9HC]OV C^$J\N?U<%:::.+Y%@+06FZ@$+U
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MANE2LA.INT*'T$\X=;2!!-]%MM>T45;J'L4T&[/"85W3'CJB?D+ARB$;] ;
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MQ&AUUI47H+?%A!U+Y":JS&-D^6L1T)4?H+/&E*5>E9KB<CS?W@W\F,I>NF(
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M-#(T8C,N:'1M4$L! A0#%     @ IH!86D>$@-E5-P  C3@  !$
M     ( !4+$# &9O<FTT,C1B,U\P,#$N:G!G4$L! A0#%     @ IH!86EQQ
M:M.:7   AW0  !$              ( !U.@# &9O<FTT,C1B,U\P,#(N:G!G
M4$L! A0#%     @ IH!86M*O5FY*A0  6Z$  !$              ( !G44$
M &9O<FTT,C1B,U\P,#,N:G!G4$L! A0#%     @ IH!86G]#4#S^9@  4W\
M !$              ( !%LL$ &9O<FTT,C1B,U\P,#0N:G!G4$L! A0#%
M  @ IH!86GUPLL +7P  ,70  !$              ( !0S(% &9O<FTT,C1B
M,U\P,#4N:G!G4$L! A0#%     @ IH!86@:-@$;F#   G(8  !$
M     ( !?9$% '-C;G@M,C R-# V,S N>'-D4$L! A0#%     @ IH!86AV$
M)><5$   K;\  !4              ( !DIX% '-C;G@M,C R-# V,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( *: 6%H'(:JV*C(  "<X!  5              "
M =JN!0!S8VYX+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4    " "F@%A:=*.(
MXT!&  !^ZP, %0              @ $WX04 <V-N>"TR,#(T,#8S,%]L86(N
M>&UL4$L! A0#%     @ IH!86E;4_\*9.   _'4$ !4              ( !
MJB<& '-C;G@M,C R-# V,S!?<')E+GAM;%!+!08     "P + ,$"  !V8 8
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>form424b3_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SCNX="http://scienture.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="scnx-20240630.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SCNX:StockholdersDeficitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SCNX:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_DirectorMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SCNX:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:KesinPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:SaptalisPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_WarrantMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214093">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:ConvertiblePreferredStockAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SCNX:LongTermConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsPushpaShankarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MsYogitaDesaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">SCNX:IssueOfConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SCNX:MrSandeepGuptaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">SCNX:ScientureIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="MBbls">
        <measure>utr:MBbls</measure>
    </unit>
    <unit id="Integer">
        <measure>SCNX:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2024-01-01to2024-06-30" id="Fact000004">424B3</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-06-30" id="Fact000005">Scienture Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-06-30" id="Fact000006">0001382574</dei:EntityCentralIndexKey>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0024"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0051"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:DevelopmentAgreementLiability
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0067"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0073"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:TerminationFee
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:IncreaseDecreaseInDevelopmentAgreementLiability
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:ConversionOfNotesAndAccruedInterestIntoPreferredStock
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="xdx2ixbrl0377"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="xdx2ixbrl0379"
      unitRef="Integer">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl0535"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl0537"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl0539"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl0541"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:OperatingLeaseInterestExpense
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:DividendIncome
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0794"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0834"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0842"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0843"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0848"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      id="xdx2ixbrl0883"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0886"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl0887"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      id="xdx2ixbrl0888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0925"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0940"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0955"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0972"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:WarrantsIssuedInConnectionWithLongtermConvertibleDebt
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl0979"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="xdx2ixbrl0993"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="xdx2ixbrl0995"
      unitRef="Integer">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1049"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1114"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl1156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl1158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="xdx2ixbrl1178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl1226"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl1228"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="xdx2ixbrl1232"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember"
      id="xdx2ixbrl1298"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember"
      id="xdx2ixbrl1302"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember"
      id="xdx2ixbrl1306"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember"
      id="xdx2ixbrl1308">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_ScientureIncMember"
      id="xdx2ixbrl1310"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1340"
      unitRef="USD"
      xsi:nil="true"/>
    <SCNX:OperatingLeaseInterestExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      id="xdx2ixbrl1376"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000021"
      unitRef="USD">114210</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000022"
      unitRef="USD">1123878</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000025"
      unitRef="USD">66414</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000027"
      unitRef="USD">485</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000028"
      unitRef="USD">485</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000030"
      unitRef="USD">114695</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000031"
      unitRef="USD">1190777</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000033"
      unitRef="USD">61579</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000034"
      unitRef="USD">64091</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000036"
      unitRef="USD">176274</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000037"
      unitRef="USD">1254868</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000045"
      unitRef="USD">884581</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000046"
      unitRef="USD">107175</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000048"
      unitRef="USD">1198822</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000049"
      unitRef="USD">332211</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000052"
      unitRef="USD">3665220</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000054"
      unitRef="USD">22567</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000055"
      unitRef="USD">21404</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000057"
      unitRef="USD">2105970</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000058"
      unitRef="USD">4126010</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000060"
      unitRef="USD">1734661</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000061"
      unitRef="USD">1625117</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000063"
      unitRef="USD">39319</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000064"
      unitRef="USD">42893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <SCNX:DevelopmentAgreementLiability
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1285000</SCNX:DevelopmentAgreementLiability>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000069"
      unitRef="USD">5164950</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000070"
      unitRef="USD">5794020</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000081"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000083"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000085"
      unitRef="Shares">3365657</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000087"
      unitRef="Shares">3365657</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">3365657</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000078"
      unitRef="USD">337</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000079"
      unitRef="USD">240</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000100"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000102"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000106"
      unitRef="Shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000108"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">500</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000098"
      unitRef="USD">500</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000116"
      unitRef="USD">10835257</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000117"
      unitRef="USD">6849064</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000119"
      unitRef="USD">-15824770</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000120"
      unitRef="USD">-11388956</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000122"
      unitRef="USD">-4988676</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000123"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000125"
      unitRef="USD">176274</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000126"
      unitRef="USD">1254868</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000129"
      unitRef="USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000134"
      unitRef="USD">1520947</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000135"
      unitRef="USD">946435</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000137"
      unitRef="USD">1413893</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000138"
      unitRef="USD">267236</us-gaap:GeneralAndAdministrativeExpense>
    <SCNX:TerminationFee
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">1285000</SCNX:TerminationFee>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000143"
      unitRef="USD">4219840</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000144"
      unitRef="USD">1213671</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000146"
      unitRef="USD">-4219840</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-413671</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000155"
      unitRef="USD">11931</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000156"
      unitRef="USD">18304</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000158"
      unitRef="USD">-227905</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000159"
      unitRef="USD">-76203</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000164"
      unitRef="USD">-215974</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-57899</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000167"
      unitRef="USD">-4435814</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000168"
      unitRef="USD">-471570</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000170"
      unitRef="USDPShares">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000176"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000186"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000194"
      unitRef="Shares">4850000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000187"
      unitRef="USD">485</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000188"
      unitRef="USD">6111783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-5439589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000190"
      unitRef="USD">672919</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000197"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000198"
      unitRef="USD">145485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000200"
      unitRef="USD">145500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000206"
      unitRef="USD">68087</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000208"
      unitRef="USD">68087</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000216"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000217"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000218"
      unitRef="USD">6325355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-9147967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-2821872</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000228"
      unitRef="USD">39724</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000230"
      unitRef="USD">39724</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-471570</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-471570</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000239"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000240"
      unitRef="USD">6365079</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-9619537</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-3253718</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000248"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000256"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000249"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000250"
      unitRef="USD">6849064</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-11388956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">965657</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-01-012024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">97</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000260"
      unitRef="USD">3941356</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000262"
      unitRef="USD">3941453</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">44837</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">44837</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-4435814</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-4435814</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000284"
      unitRef="Shares">3365657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">337</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000286"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">10835257</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-15824770</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-4988676</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">-4435814</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">-471570</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">109544</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">44837</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">39724</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-66414</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">777406</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">29729</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">1142843</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">76212</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <SCNX:IncreaseDecreaseInDevelopmentAgreementLiability
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">1285000</SCNX:IncreaseDecreaseInDevelopmentAgreementLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">102</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">-1009668</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">-625905</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">400000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-1009668</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">-225905</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">1123878</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">604813</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">114210</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">378908</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <SCNX:ConversionOfNotesAndAccruedInterestIntoPreferredStock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">3941453</SCNX:ConversionOfNotesAndAccruedInterestIntoPreferredStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000363">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zP8RcZ5GbJIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &lt;span id="xdx_827_zwSYs6RJLtDd"&gt;Organization Overview and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature
of Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scienture
Inc. (&#x201c;the Company&#x201d;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s fiscal year ends on December 31.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements for the periods ending June 30, 2024 and 2023 have been prepared in accordance with accounting principles
generally accepted in the United States (&#x201c;U.S.GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000365">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zdQz4Ku2fPp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &lt;span id="xdx_824_z3Dh44BMJeMb"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zVPOLExEFmK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zxSDaACjaeD5"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fair
    value of long-term convertible debt and warrants issued in connection with such debt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;accruals
    for estimated liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    valuation of stock-based compensation awards ; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;provisions
    for income taxes and related valuation allowances and tax uncertainties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--UnauditedInterimFinancialInformationPolicyTextBlock_zdFAodwb1E1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zQZJYwAIYHti"&gt;Unaudited
Interim Financial Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim
financial information, within the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis
consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal
recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition
as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial
statements related to the six-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for
the full fiscal year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited
financial statements and the notes thereto for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2l2P0tZC6o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zODvNvGLoWA7"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zxhgn6Q5ujW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zuJ78iJTA1a5"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholder&#x2019;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the six months ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zE1fnIck2JLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zUHFJGQLSaIh"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a &lt;span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20240630_zuRtCDhxAaY" title="Number of reportable segment::XDX::1"&gt;&lt;span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20240101__20240630_zhw6TVMnHfrl" title="Number of operating segment::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0377"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0379"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; reportable segment and operating segment structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGt2pUccSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zIC2blmEuDV8"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6LqTc1l1NQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zqhJLDK3sSA8"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240630_zRVQFAe6mlOc" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zRZgK4nRWgj5" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; as of June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z9u4ZW4nirW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z8z2xy9MUyg1"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z7hNftnCGULl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zEPGvgYRCnV1"&gt;Exclusive
License and Commercial Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#x201c;the Products&#x201d;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630_zjwFP8znkrH8" title="Revenue recognized"&gt;800,000&lt;/span&gt; for the six months
ended June 30, 2023, at the point when the development milestone events occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall pay Kesin a total gross amount of
$&lt;span id="xdx_90F_ecustom--TerminationFee_c20240301__20240331_zbrSruzSNcb4" title="Termination fee"&gt;1,285,000&lt;/span&gt; upon commercialization of product via a royalty arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--TerminationFeeDescription_c20240301__20240331_zUPQA6xR5mOb" title="Termination fee description"&gt;This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zk14AEaP86y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zn0dovk53fB1"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_ztZeoYC6DQ8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zfSzsnGkNMH9"&gt;Concentration
of Credit Risks and Major Customers&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the six months ended June 30, 2024, the Company had
one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9WtrBhyn5m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zfojqVg69RVb"&gt;Research
&amp;amp; Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjQmab8imlO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z17IT79YgzKj"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option-pricing model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based
awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest
rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company has estimated volatility
by reference to the historical volatilities of the Company and that of similar publicly traded peer companies. The risk-free interest
rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled
award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zT2pXJTCvfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_ztSYFFhT3r2e"&gt;Warrant
Valuation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zmhFfpP7PIoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zPnVd1CLtqZg"&gt;Net
Loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zQuMJxhtbJxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zlo6CuWHvH4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zrZL0Sxeovk8"&gt;Accounting
Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-07, &#x201c;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;
(&#x201c;ASU 2023-09&#x201d;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_85A_zjHDxiwRn7B1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000367">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zVPOLExEFmK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zxSDaACjaeD5"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fair
    value of long-term convertible debt and warrants issued in connection with such debt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;accruals
    for estimated liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    valuation of stock-based compensation awards ; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;provisions
    for income taxes and related valuation allowances and tax uncertainties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <SCNX:UnauditedInterimFinancialInformationPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000369">&lt;p id="xdx_846_ecustom--UnauditedInterimFinancialInformationPolicyTextBlock_zdFAodwb1E1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zQZJYwAIYHti"&gt;Unaudited
Interim Financial Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim
financial information, within the rules and regulations of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;).
Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been
condensed or omitted pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis
consistent with the audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal
recurring adjustments, necessary for the fair presentation of the results for the interim periods presented and of the financial condition
as of the date of the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial
statements related to the six-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for
the full fiscal year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited
financial statements and the notes thereto for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:UnauditedInterimFinancialInformationPolicyTextBlock>
    <SCNX:LiquidityPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000371">&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_z2l2P0tZC6o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zODvNvGLoWA7"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:LiquidityPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000373">&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zxhgn6Q5ujW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zuJ78iJTA1a5"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholder&#x2019;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the six months ended June 30, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000375">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zE1fnIck2JLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zUHFJGQLSaIh"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a &lt;span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20240101__20240630_zuRtCDhxAaY" title="Number of reportable segment::XDX::1"&gt;&lt;span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20240101__20240630_zhw6TVMnHfrl" title="Number of operating segment::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0377"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0379"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; reportable segment and operating segment structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000381">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGt2pUccSej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zIC2blmEuDV8"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000383">&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z6LqTc1l1NQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zqhJLDK3sSA8"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20240630_zRVQFAe6mlOc" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zRZgK4nRWgj5" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; as of June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000389">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z9u4ZW4nirW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z8z2xy9MUyg1"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000391">&lt;p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z7hNftnCGULl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zEPGvgYRCnV1"&gt;Exclusive
License and Commercial Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#x201c;the Products&#x201d;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630_zjwFP8znkrH8" title="Revenue recognized"&gt;800,000&lt;/span&gt; for the six months
ended June 30, 2023, at the point when the development milestone events occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall pay Kesin a total gross amount of
$&lt;span id="xdx_90F_ecustom--TerminationFee_c20240301__20240331_zbrSruzSNcb4" title="Termination fee"&gt;1,285,000&lt;/span&gt; upon commercialization of product via a royalty arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--TerminationFeeDescription_c20240301__20240331_zUPQA6xR5mOb" title="Termination fee description"&gt;This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <SCNX:TerminationFee
      contextRef="From2024-03-012024-03-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">1285000</SCNX:TerminationFee>
    <SCNX:TerminationFeeDescription
      contextRef="From2024-03-012024-03-31_custom_ScientureIncMember"
      id="Fact000397">This
agreement also requires that if the full $1,285,00 has not been repaid within two years of the early of i) commercial launch or ii) 120
from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, the Company recorded
a $1,285,000 termination fee liability. As of the date of issue of financial statements, the entire amount is outstanding.</SCNX:TerminationFeeDescription>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000399">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zk14AEaP86y7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zn0dovk53fB1"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000401">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_ztZeoYC6DQ8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zfSzsnGkNMH9"&gt;Concentration
of Credit Risks and Major Customers&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the six months ended June 30, 2024, the Company had
one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000403">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9WtrBhyn5m9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zfojqVg69RVb"&gt;Research
&amp;amp; Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000405">&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjQmab8imlO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_z17IT79YgzKj"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes
option-pricing model. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based
awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest
rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company has estimated volatility
by reference to the historical volatilities of the Company and that of similar publicly traded peer companies. The risk-free interest
rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled
award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <SCNX:WarrantValuationPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000407">&lt;p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zT2pXJTCvfo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_ztSYFFhT3r2e"&gt;Warrant
Valuation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:WarrantValuationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000409">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zmhFfpP7PIoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zPnVd1CLtqZg"&gt;Net
Loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zQuMJxhtbJxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000411">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUszOza6YcQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disclosure - Schedule of Deferred Tax Assets and Related Valuation Allowance (Details)&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000413">&lt;p id="xdx_842_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_zlo6CuWHvH4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zrZL0Sxeovk8"&gt;Accounting
Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-07, &#x201c;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;
(&#x201c;ASU 2023-09&#x201d;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;
</SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000415">&lt;p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z6nQbAnNn1mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &lt;span id="xdx_828_z9ydt3frwRMh"&gt;Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a net loss of ($&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_di_c20240101__20240630_zbwI3xn34GRc" title="Net loss"&gt;4,435,814&lt;/span&gt;) for the six months ended June 30, 2024 and stockholders&#x2019; deficit of ($&lt;span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20240630_z3BChwnobuFl" title="Stockholders deficit"&gt;4,988,676&lt;/span&gt;) as of June
30, 2024. The Company&#x2019;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">-4435814</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-4988676</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000421">&lt;p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zMWJBk7jTARa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &lt;span id="xdx_82D_zBHXdH5GoMh4"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zv1WlyVvSZec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zsVyzOBNOdca" style="display: none"&gt;Schedule
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630_z7k7JFqYVou7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zk7nJ4raPtIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zUmGu1ZyI37a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Balances with banks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;116,107&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;31,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zr2I2eQW8W4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Money market securities(Highly liquid investments)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,091,935&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zedeZ31xwa1j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cash and Cash Equivalents&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;116,106&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,123,878&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zZkuwK1tR1K2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money
market securities were considered a Level 1 financial instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000423">&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zv1WlyVvSZec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zsVyzOBNOdca" style="display: none"&gt;Schedule
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630_z7k7JFqYVou7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zk7nJ4raPtIj" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zUmGu1ZyI37a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Balances with banks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;116,107&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;31,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zr2I2eQW8W4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Money market securities(Highly liquid investments)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,091,935&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zedeZ31xwa1j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cash and Cash Equivalents&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;116,106&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,123,878&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndDueFromBanks
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">116107</us-gaap:CashAndDueFromBanks>
    <us-gaap:CashAndDueFromBanks
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">31943</us-gaap:CashAndDueFromBanks>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">1091935</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">116106</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000432"
      unitRef="USD">1123878</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000434">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_z2nIuLKOz38k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &lt;span id="xdx_829_zphOwAVXZc7f"&gt;Convertible Notes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630_zGTjHAXkOp9" title="Convertible notes issued bear interest rate percentage"&gt;8&lt;/span&gt;% per annum and certain notes issued prior to 2022 bear an interest at a rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zO3XW6PKEi3h" title="Convertible notes issued bear interest rate percentage"&gt;2&lt;/span&gt;% per annum.
As of December 31, 2023, there $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_z0f0CiwB6Lcl" title="Debt outstanding principal amount"&gt;3,665,220&lt;/span&gt; in outstanding principal. All the short-term convertible notes matured during the period of
&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20240630_zurlbo1yfv2g" title="Maturity date"&gt;December 2023&lt;/span&gt;. In March 2024, the Company had converted the outstanding principal of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331_ziHyENrEbEwi" title="Debt outstanding principal amount"&gt;3,665,220&lt;/span&gt; and the accrued interest through the
date of conversion amounting to $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zwzhG498PoP3" title="Conversion of debt, amount"&gt;276,233&lt;/span&gt; into an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU7Nm1ECNvQ2" title="Conversion of debt, shares"&gt;965,567&lt;/span&gt; shares of preferred stock of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000436"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000438"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">3665220</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000442">December 2023</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-03-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">3665220</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">276233</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-03-012024-03-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Shares">965567</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000450">&lt;p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_zW5CLpW9ZERa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &lt;span id="xdx_82A_zjNRTMqmP2Wh"&gt;Long-Term Convertible Debt, net of debt discount&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#x2018;NVK&#x201d;)
for $&lt;span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJ18I6gnzBxk" title="Long term debt"&gt;2,000,000&lt;/span&gt;. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus &lt;span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIyzq4zfEByg" title="Debt prime rate percentage"&gt;7&lt;/span&gt; percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of June 30, 2024 and December 31, 2023, the interest rate was &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z64kXxDclkgh" title="Debt interest rate percentage"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zcO3JkpuVltl" title="Debt interest rate percentage"&gt;15.50&lt;/span&gt;&lt;/span&gt;%. The debt is collateralized by all
of the Company&#x2019;s receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof.
The principal is entirely repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing
as defined in the Loan Agreement. Interest expense related to the debt amounted to $&lt;span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z8lg9PUiLBVk" title="Interest expense"&gt;95,583&lt;/span&gt; for the year ended December 31, 2023 and the
principal amount is entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common
stock of the Company at a fully-diluted Company valuation of $&lt;span id="xdx_90E_ecustom--DebtDilutedValuation_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zHBwABBsNSv4" title="Debt diluted valuation"&gt;60,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the NVK debt, the Company granted &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zIeXGRH57dA7" title="Number of warrant to purchase"&gt;509,014&lt;/span&gt; warrants to purchase common stock. The fair value of the warrants was $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZTT80t2n69l" title="Fair value adjustment of warrants"&gt;444,260&lt;/span&gt;
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the six months
ended June 30, 2024, the Company amortized $&lt;span id="xdx_906_eus-gaap--AdjustmentForAmortization_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zZ4axVI8HE5d" title="Debt discount interest expense"&gt;109,544&lt;/span&gt; of the debt discount to interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zvCGnGQmu78c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
convertible debt, net of debt discount, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zGN7ju9LgRj6" style="display: none"&gt;Schedule of Long Term Convertible
Debt Net of Discount&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240630_z00MVhXvHaE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zjI9lnujWVM6" style="font: bold 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzNfR_zA0b4lZdwnR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;Principal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDzNfR_zS986bttMv36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Unamortized debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;265,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;374,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzNfR_zADfD7WvS8Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term convertible notes, net of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,734,661&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,625,117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z84O2eGA6Jp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zycZGLgYnrFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maturities
of the outstanding notes are as follows&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zDUR8Jm0s2wh" style="display: none"&gt;Schedule of Maturities Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630_zoa1qBEoQgKd" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_z6K4ui17ZAP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zUwrVOjAZhs1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_z47ICmJNlPLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z5aaWP0cErTd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Year 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_zQ8myvEbGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z9wy2NTIIURl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">2000000</us-gaap:LongTermDebt>
    <SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000454"
      unitRef="Pure">0.07</SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000456"
      unitRef="Pure">0.1550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000458"
      unitRef="Pure">0.1550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">95583</us-gaap:InterestExpense>
    <SCNX:DebtDilutedValuation
      contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">60000000</SCNX:DebtDilutedValuation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000464"
      unitRef="Shares">509014</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">444260</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-012024-06-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000468"
      unitRef="USD">109544</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000470">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zvCGnGQmu78c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
convertible debt, net of debt discount, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zGN7ju9LgRj6" style="display: none"&gt;Schedule of Long Term Convertible
Debt Net of Discount&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240630_z00MVhXvHaE3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_zjI9lnujWVM6" style="font: bold 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDzNfR_zA0b4lZdwnR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;Principal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDzNfR_zS986bttMv36" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Unamortized debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;265,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;374,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebt_iTI_mtLTDzNfR_zADfD7WvS8Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term convertible notes, net of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,734,661&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,625,117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">265339</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">374883</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">1734661</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000479"
      unitRef="USD">1625117</us-gaap:LongTermDebt>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000481">&lt;p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zycZGLgYnrFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maturities
of the outstanding notes are as follows&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zDUR8Jm0s2wh" style="display: none"&gt;Schedule of Maturities Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630_zoa1qBEoQgKd" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_z6K4ui17ZAP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0483"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_zUwrVOjAZhs1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_z47ICmJNlPLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z5aaWP0cErTd" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Year 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_zQ8myvEbGHi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000491"
      unitRef="USD">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000493">&lt;p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zb7Cps8qYX1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify; text-indent: -0.4in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &lt;span id="xdx_82D_z2eHmy0jfRv8"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000495">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3DLDsA4GcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &lt;span id="xdx_82C_zT7enwhyHBs7"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable
in connection with the consummation Scienture&#x2019;s business combination with the Company. Scienture has disputed that the amount is
now payable, and the parties are in discussions to resolve the issue. There can be no assurance that an amicable resolution will be obtained.
If Kesin brings a legal action, Scienture will vigorously defend it.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000497">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zdWL7HZm58T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &lt;span id="xdx_82C_zkyfIw82Qx2l"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#x201c;Kesin&#x201d;), in which one of the
company&#x2019;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the six months ended June 30, 2024 and 2023 were $&lt;span id="xdx_908_ecustom--MilestonePayment_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_znSrcvphiKB3" title="Milestone structure"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--MilestonePayment_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zp6He8NwvfXj" title="Milestone structure"&gt;800,000&lt;/span&gt;, respectively.
The Company terminated the agreement with Kesin in March 2024, and recorded a termination fee and related liability of $&lt;span id="xdx_900_ecustom--TerminationFee_c20240101__20240630_z8PwfQfjD2Td" title="Termination fee"&gt;1,285,000&lt;/span&gt; as
of June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#x201c;Saptalis&#x201d;) , in which one of the Company&#x2019;s Director
is the President and CEO. Lease payments made during the six months ended June 30, 2024 and 2023 are $&lt;span id="xdx_904_eus-gaap--VariableLeasePayment_c20240101__20240630_z1I7ORLwhTYe" title="Lease payments"&gt;14,440&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--VariableLeasePayment_c20230101__20230630_zDTUEMVBCA18" title="Lease payments"&gt;0&lt;/span&gt;, respectively. The
Company has also engaged Saptalis to provide development services and conduct testing and studies for the products under development
by the Company. Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the
Statement of Comprehensive Loss for the six months ended June 30, 2024 and 2023 amounted to $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zj9dkLD2PVJ" title="Research and Development Expenses"&gt;106,539&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zqloWiXH0DPg" title="Research and Development Expenses"&gt;189,027&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, a related party to a director issued a convertible note to the Company for $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zRKYPiMMVevh" title="Convertible note"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2024, officers of the company provided a short term promissory note to the Company for $&lt;span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYxtGbxPrMO2" title="Short term"&gt;265,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ziA8hWcvFLsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Schedule of Relatives or Related Parties to Directors Purchased Securities&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A1_zblR3hLN5wsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SCNX:MilestonePayment
      contextRef="From2024-01-012024-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000499"
      unitRef="USD">0</SCNX:MilestonePayment>
    <SCNX:MilestonePayment
      contextRef="From2023-01-012023-06-30_custom_KesinPharmaCorporationMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">800000</SCNX:MilestonePayment>
    <SCNX:TerminationFee
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000503"
      unitRef="USD">1285000</SCNX:TerminationFee>
    <us-gaap:VariableLeasePayment
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000505"
      unitRef="USD">14440</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000507"
      unitRef="USD">0</us-gaap:VariableLeasePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000509"
      unitRef="USD">106539</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-06-30_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">189027</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-06-30_srt_DirectorMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-07-31_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">265000</us-gaap:ShortTermBorrowings>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000517">&lt;p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ziA8hWcvFLsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Schedule of Relatives or Related Parties to Directors Purchased Securities&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000519">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zuFJPBgZRfUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &lt;span id="xdx_82B_zw2CHRnZrIth"&gt;Scienture Inc. 2020 Stock Option and Grant Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#x201c;ISOs&#x201d;), non-statutory stock options (&#x201c;NSOs&#x201d;).
ISOs may be granted only to the Company&#x2019;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#x2019;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than &lt;span id="xdx_908_ecustom--StockOptionAndGrantPlanHaveContractualTerm_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zM5yXWy7txMk" title="Stock Option and Grant Plan have a contractual term"&gt;10&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAz4oCnTq9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity under the Plans is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zEPwYQz0q1kk" style="display: none"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding&lt;br/&gt;
    Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQYBbP7vyD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance"&gt;655,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9I1eU18C7r6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQh2YKMpR1f" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrX3A081LuFd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted"&gt;142,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSKNae7R572e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted"&gt;1.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwqwvTXzfJ0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtnTcNFkyo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cancelled and forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjIJOOjkcmuk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoB1c0zPFsQk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance as of June 20, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKAFJJWDVz9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance"&gt;797,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqolOmF3c6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.94&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYZwUH3NUFb" title="Weighted-Average Remaining Term (Years), Balance"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Vested and exercisable as of June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSOBa3eFS0O1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;499,089&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3aVjlUYnwRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;0.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35p52KHDpka" title="Weighted-Average Remaining Term (Years), Vested and exercisable"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zuL98c12J7Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average grant date fair value of options granted during the six months ended June 30, 2024 was $&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20240101__20240630_zhVrSIq0arV8" title="Weighted-average grant date fair value of options granted"&gt;0.76&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zA9mHBlMjK4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zCRFeMz4FXG9" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20240630_zgYROSuwspR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20230630_zOvAbdvSD394" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHT1rvAQ69kl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;General and Administrative Expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;44,837&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;39,724&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_z9aWAyPuREK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;44,837&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,724&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zREz9ZE30fzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Option Valuation Assumptions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zUh1LBDNNS4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zqCR334CHUbk" style="display: none"&gt;Schedule of Stock Option Valuation Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630_zVuo2lohmhxa" title="Expected volatility"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_z4LkRG3nqdt6" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zljFYYmKY537" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zFiDVeQiqpIi" title="Risk-free interest rate"&gt;4.1&lt;/span&gt;%
                                            - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z097UpEW6FX5" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zvmKUb5HnBM6" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_ztPzr0e0Phxe" title="Risk-free interest rate"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zChhopV9dZ12" title="Expected term"&gt;5.7&lt;/span&gt;
                                            - &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zdPjUDSrOtsc" title="Expected term"&gt;6.1&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zNjUHg8ibmC6" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_z3a001C74HX7" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_z4N0mxuOqB2j" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zbJfyjIxfY5" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z33Qf1WrClfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <SCNX:StockOptionAndGrantPlanHaveContractualTerm
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact000521">P10Y</SCNX:StockOptionAndGrantPlanHaveContractualTerm>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000523">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zAz4oCnTq9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity under the Plans is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zEPwYQz0q1kk" style="display: none"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding&lt;br/&gt;
    Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQYBbP7vyD4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance"&gt;655,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9I1eU18C7r6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCQh2YKMpR1f" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrX3A081LuFd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted"&gt;142,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSKNae7R572e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted"&gt;1.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwqwvTXzfJ0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFtnTcNFkyo6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cancelled and forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjIJOOjkcmuk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoB1c0zPFsQk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance as of June 20, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKAFJJWDVz9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance"&gt;797,199&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqolOmF3c6g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.94&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYZwUH3NUFb" title="Weighted-Average Remaining Term (Years), Balance"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Vested and exercisable as of June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSOBa3eFS0O1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;499,089&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3aVjlUYnwRe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;0.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35p52KHDpka" title="Weighted-Average Remaining Term (Years), Vested and exercisable"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">655000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000527"
      unitRef="USDPShares">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact000529">P7Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000531"
      unitRef="Shares">142199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000533"
      unitRef="USDPShares">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000543"
      unitRef="Shares">797199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000545"
      unitRef="USDPShares">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact000547">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">499089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000551"
      unitRef="USDPShares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact000553">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000555"
      unitRef="USDPShares">0.76</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000557">&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zA9mHBlMjK4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zCRFeMz4FXG9" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20240630_zgYROSuwspR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20230630_zOvAbdvSD394" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHT1rvAQ69kl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;General and Administrative Expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;44,837&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;39,724&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_z9aWAyPuREK4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;44,837&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,724&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000559"
      unitRef="USD">44837</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000560"
      unitRef="USD">39724</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000562"
      unitRef="USD">44837</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000563"
      unitRef="USD">39724</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000565">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zUh1LBDNNS4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zqCR334CHUbk" style="display: none"&gt;Schedule of Stock Option Valuation Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240630_zVuo2lohmhxa" title="Expected volatility"&gt;72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_z4LkRG3nqdt6" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zljFYYmKY537" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zFiDVeQiqpIi" title="Risk-free interest rate"&gt;4.1&lt;/span&gt;%
                                            - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_z097UpEW6FX5" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zvmKUb5HnBM6" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_ztPzr0e0Phxe" title="Risk-free interest rate"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MinimumMember_zChhopV9dZ12" title="Expected term"&gt;5.7&lt;/span&gt;
                                            - &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20240630__srt--RangeAxis__srt--MaximumMember_zdPjUDSrOtsc" title="Expected term"&gt;6.1&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zNjUHg8ibmC6" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_z3a001C74HX7" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240630_z4N0mxuOqB2j" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630_zbJfyjIxfY5" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000571"
      unitRef="Pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000579"
      unitRef="Pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-06-30_srt_MinimumMember_custom_ScientureIncMember"
      id="Fact000581">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-06-30_srt_MaximumMember_custom_ScientureIncMember"
      id="Fact000583">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-06-30_srt_MinimumMember_custom_ScientureIncMember"
      id="Fact000585">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-06-30_srt_MaximumMember_custom_ScientureIncMember"
      id="Fact000587">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000589"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000591"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <SCNX:WarrantsTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000593">&lt;p id="xdx_802_ecustom--WarrantsTextBlock_zs5ChSEdBwgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &lt;span id="xdx_823_zj9qcNvcwp0c"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2024, there were &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240630_za8Jnh1Id3k5" title="Warrants outstanding"&gt;509,014&lt;/span&gt; warrants outstanding and exercisable with an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240630_zjUzCCAJXFmd" title="Exercise price"&gt;0.01&lt;/span&gt; per share. The warrants were
granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_zd8wl4CRYuj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary of Assumptions Used to Estimate Fair Value of Warrants&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zjYeYk9PIra7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</SCNX:WarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">509014</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000597"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000599">&lt;p id="xdx_89B_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_zd8wl4CRYuj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary of Assumptions Used to Estimate Fair Value of Warrants&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000601">&lt;p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_zpI5X6F2TWMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12 &lt;span id="xdx_829_zPgNGc35aJh4"&gt;Net Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
options to purchase &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZlH0q9KK8Sh" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;799,199&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zTqz0Wh5OdL7" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;655,000&lt;/span&gt; shares of common stock, warrants to purchase &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAGjcOhfypW9" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;509,014&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOyDZDvZI2Ze" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;0&lt;/span&gt; common stock, convertible preferred
stock and convertible notes to purchase &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zssHV9DUz1a2" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;3,365,669&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zo1dCeTQ1pmh" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;3,195,911&lt;/span&gt; common stock and long-term convertible debt to purchase &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_z1uTG1n0rI04" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;0&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zodbNrLFPOve" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;3,350,000&lt;/span&gt;
shares common stock were outstanding at June 30, 2024 and 2023, respectively, that were not included in the computation of diluted weighted
average common shares outstanding because their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214046"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">799199</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">655000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">509014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">3365669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000613"
      unitRef="Shares">3195911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000615"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">3350000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000619">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z3FhyxedMUul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13 &lt;span id="xdx_828_zKAZ2LWlbJ5d"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#x2019;s balance sheets. The ROU assets represent the Company&#x2019;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has an operating lease for administrative office. The lease has remaining lease term around &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20240630_zJ1RuwwzGLO7" title="Operating lease remaining lease term"&gt;three years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z0rbMW6j7wO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z5eSJ5JVZeMj" style="display: none"&gt;Schedule
of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240101__20240630_zpbNLBX2MlEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230101__20230630_zB2UTW4TO4O6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zYkQ8sGbfc84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zwsE5EHfvfB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Amortization of ROU Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,152&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zR7DkI80V8C" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest on Lease Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,190&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zs9CetL5D4p2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,010&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zH2a7p6aNmIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zEctMEM8XEdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zVDztYcLInw3" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240630_zF5sHwdzuaAl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zVc7zEt5N7Be" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zz2rFE6SIsM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Right of Use Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;61,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;64,091&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzXqh_zIwSNLpUL8Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,567&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,404&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzXqh_zi45IHitPcDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,319&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzXqh_zuOQCZv5hxR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,886&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted Average Remaining Lease Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zxjGiiZRHSZj" title="Weighted Average Remaining Lease Term (in years)"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zzrwQa5zgc29" title="Weighted Average Remaining Lease Term (in years)"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_zgFK4X2ECag8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zyzWLiMzKH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="Fact000621">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000623">&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_z0rbMW6j7wO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z5eSJ5JVZeMj" style="display: none"&gt;Schedule
of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240101__20240630_zpbNLBX2MlEg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230101__20230630_zB2UTW4TO4O6" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June
    30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zYkQ8sGbfc84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zwsE5EHfvfB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Amortization of ROU Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,152&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zR7DkI80V8C" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest on Lease Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,190&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zs9CetL5D4p2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,010&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000628"
      unitRef="USD">2152</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <SCNX:OperatingLeaseInterestExpense
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000631"
      unitRef="USD">1190</SCNX:OperatingLeaseInterestExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000634"
      unitRef="USD">17010</us-gaap:ShortTermLeaseCost>
    <SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000637">&lt;p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zEctMEM8XEdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zVDztYcLInw3" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240630_zF5sHwdzuaAl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zVc7zEt5N7Be" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zz2rFE6SIsM5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Right of Use Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;61,579&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;64,091&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzXqh_zIwSNLpUL8Jj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,567&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,404&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzXqh_zi45IHitPcDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,319&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzXqh_zuOQCZv5hxR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,886&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted Average Remaining Lease Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zxjGiiZRHSZj" title="Weighted Average Remaining Lease Term (in years)"&gt;2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zzrwQa5zgc29" title="Weighted Average Remaining Lease Term (in years)"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_zgFK4X2ECag8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">61579</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">64091</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">22567</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000643"
      unitRef="USD">21404</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000645"
      unitRef="USD">39319</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">42893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">61886</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000649"
      unitRef="USD">64297</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      id="Fact000651">P2Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="Fact000653">P2Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-06-30_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Pure">0.1550</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000656"
      unitRef="Pure">0.1550</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2024-01-012024-06-30_custom_ScientureIncMember"
      id="Fact000658">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zpQgvDIgTZag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14 &lt;span id="xdx_824_zCnmZ4TY9Ny6"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2024, the executives of the Company issued a short-term loan to Company for an aggregate amount of $&lt;span id="xdx_90D_eus-gaap--ShortTermBorrowings_iI_c20240731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znTedmth05S9" title="Short term borrowings"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2024, all of the unvested options per the Company&#x2019;s Stock Option and Grant Plan became vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business
Combination&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 25, 2024, Scienture, Inc. (the &#x201c;Company&#x201d;) entered into and closed an Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#x201c;Merger Sub I&#x201d;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#x201c;Merger Sub II&#x201d;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated subsequent events through August 15, 2024, the date the financial statements were available to be issued.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-07-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">250000</us-gaap:ShortTermBorrowings>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000668"
      unitRef="USD">1123878</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000669"
      unitRef="USD">604813</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">66414</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000674"
      unitRef="USD">485</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000675"
      unitRef="USD">485</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">1190777</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000678"
      unitRef="USD">605298</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">64091</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000683"
      unitRef="USD">1254868</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000684"
      unitRef="USD">605298</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">107175</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000693"
      unitRef="USD">393676</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">332211</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">83494</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000698"
      unitRef="USD">3665220</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000699"
      unitRef="USD">2950000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000701"
      unitRef="USD">21404</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">4126010</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000705"
      unitRef="USD">3427170</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000707"
      unitRef="USD">1625117</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">42893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000713"
      unitRef="USD">5794020</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">3427170</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000725"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000739"
      unitRef="Shares">2400000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">240</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000723"
      unitRef="USD">240</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000744"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000746"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000741"
      unitRef="USD">500</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">500</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">6849064</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000761"
      unitRef="USD">6325355</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000763"
      unitRef="USD">-11388956</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000764"
      unitRef="USD">-9147967</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000766"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000767"
      unitRef="USD">-2821872</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000769"
      unitRef="USD">1254868</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">605298</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000772"
      unitRef="USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000773"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000778"
      unitRef="USD">2029812</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000779"
      unitRef="USD">3061493</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000781"
      unitRef="USD">719398</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000782"
      unitRef="USD">880110</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">2749210</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000785"
      unitRef="USD">3941603</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000787"
      unitRef="USD">-1949210</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">-3641603</us-gaap:OperatingIncomeLoss>
    <SCNX:DividendIncome
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">2401</SCNX:DividendIncome>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000796"
      unitRef="USD">-312577</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000797"
      unitRef="USD">-76351</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <SCNX:MiscellaneousIncome
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">18397</SCNX:MiscellaneousIncome>
    <SCNX:MiscellaneousIncome
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000800"
      unitRef="USD">9574</SCNX:MiscellaneousIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000802"
      unitRef="USD">-291779</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">-66777</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000808"
      unitRef="USDPShares">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000810"
      unitRef="USDPShares">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000812"
      unitRef="USDPShares">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000814"
      unitRef="USDPShares">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000830"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">4850000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">485</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">6111783</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">-5439589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">672919</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">145485</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000838"
      unitRef="USD">145500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">68087</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">68087</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000851"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000854"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000855"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">6325355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000857"
      unitRef="USD">-9147967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">-2821872</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">6325355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">-9147967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000868"
      unitRef="USD">-2821872</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">444260</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">444260</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">79449</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">79449</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000890"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">5000000.00</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">6849064</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">-11388956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">2400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000902"
      unitRef="USD">240</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">5000000.00</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">500</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">6849064</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">-11388956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_StockholdersDeficitMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000916"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">145500</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">69378</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">79449</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">68087</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">-286501</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">65394</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">248716</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">76704</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">206</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">66414</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">-2196155</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">-3352693</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">715220</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">850000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">2715220</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">850000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">519065</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">-2502693</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">604813</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">3107506</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">1123878</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">604813</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <SCNX:WarrantsIssuedInConnectionWithLongtermConvertibleDebt
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact000978"
      unitRef="USD">444260</SCNX:WarrantsIssuedInConnectionWithLongtermConvertibleDebt>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000981">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zXzEGacBJfP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_012"&gt;&lt;/span&gt;Note
1 &lt;span id="xdx_82E_zO4r7Wp0d86l"&gt;Organization Overview and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature
of Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scienture
Inc. (&#x201c;the Company&#x201d;) is a pharmaceutical research company which is engaged in the research and development of branded pharmaceutical
products. The IP application process of the company initiated in November 2019 and commenced the product development activities from
January 2020. The Company also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was incorporated in the state of Delaware in June 2019. The Company is headquartered in Hauppauge, New York, United States of
America.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s fiscal year ends on December 31.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements for the period ending December 31, 2023 and 2022 have been prepared in accordance with accounting principles
generally accepted in the United States (&#x201c;U.S.GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000983">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zhOO5ZXcJVxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &lt;span id="xdx_824_z9tbPbgJ83Fl"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zDw6Ai1JWhNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z3foTLi5y2t6"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fair
    value of long-term convertible debt and warrants issued in connection with such debt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;accruals
    for estimated liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;lease
    term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    valuation of stock-based compensation awards ; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;provisions
    for income taxes and related valuation allowances and tax uncertainties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_zOvPcfhCQI36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zy4BUgnX5aYh"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zUDtEgzcnAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zuTRUepB66i4"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholder&#x2019;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNaP59og6Bre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zDxAsKHKGC07"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_zQFvL72BwS95" title="Number of reportable segment::XDX::1"&gt;&lt;span id="xdx_907_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20230101__20231231_zzlYO99If5Lf" title="Number of operating segment::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0993"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; reportable segment and operating segment structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJ11pNKLt4j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_z2pVeuN5hIU3"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zwD0xPUmp2q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z09Lz3B2WS0k"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zjggDz3CdhM3" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zPnPWh6lbXf3" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Refer
&#x2013; Note 14&#x2013; Subsequent Events &#x2013; Termination of Exclusive License and Commercial Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z31KAvzCkY56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5zx0gMnjcI3"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z2JhbIcHdvOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zd1OqPSy1EC8"&gt;Exclusive
License and Commercial Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#x201c;the Products&#x201d;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zm95aluQBMk3" title="Revenue recognized"&gt;800,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zYelXpAhKAl7" title="Revenue recognized"&gt;300,000&lt;/span&gt;, respectively,
during the years ended December 31, 2023 and 2022 at the point when the development milestone events occurred. (Refer &#x2013; Note 14&#x2013;
Subsequent Events &#x2013; Termination of Exclusive License and Commercial Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zpBk8Rxd7OJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zXDu1rOp5G12"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Level
    3 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -58.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJrtJLxttz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z1ZC3PGQm9C2"&gt;Concentration
of Credit Risks and Major Customers&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the years ended December 31, 2023, and 2022, the company
had one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwCXj4i6zeEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zWKr6Kcp3Zc1"&gt;Research
&amp;amp; Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIdqihDN0YB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjo7F3n0srO9"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The fair values of stock-based compensations are recognized as compensation expense on a straight-line
basis over the requisite service period in which the awards are expected to vest. The Company estimates the fair value of stock option
awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes model considers several variables and assumptions
in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock,
exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the
expected term. The Company has estimated volatility by reference to the historical volatilities of the Company and that of similar publicly
traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration
to the expected term of the equity-settled award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zeToUOiWtOCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zIq0xJKLreE9"&gt;Warrant
Valuation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zCjnOUHbWpI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z3hwU0J9pJR8"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;State
Income Tax:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is incorporated in Delaware and headquartered in New York where the state tax is &lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20230101__20231231_z1dGVIh0nh06" title="State income tax rate"&gt;8.70&lt;/span&gt;% and &lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20220101__20221231_zQnpB8DJfb1" title="State income tax rate"&gt;7.25&lt;/span&gt;% respectively. However, due to
losses for the years ended December 31, 2023 and 2022, no provision on state income tax has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Federal
Income Tax:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a C Corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners. The company records
income taxes pursuant to the liability method. The Company has a loss before tax of ($&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zaXalyfNxvSa" title="Loss before tax"&gt;2,240,989&lt;/span&gt;) and ($&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zpYkYtiSAfh" title="Loss before tax"&gt;3,708,378&lt;/span&gt;) for years ended December
31, 2023 and 2022 respectively. Therefore, no provision for federal income tax has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_zqIOkbM1Gmn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zAo6Gt6RSIo1"&gt;Deferred
Tax Assets and Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are determined based on the differences between the financial statement and the tax basis of assets and liabilities.
Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company&#x2019;s
ability to generate taxable income. Management believes that, at a minimum, it is more likely than not that future taxable income may
not be sufficient to realize the recorded assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has recorded a deferred tax asset related to its net operating loss carryforwards, timing difference between written down value
of assets, and unutilized R&amp;amp;D credit, which are expected to reduce future taxable income. The company has assessed the likelihood
of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets may not be realized.
Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its expected realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
impact of the deferred tax assets and related valuation allowance on the Company&#x2019;s financial statements is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zGlZeO8SmXN4" style="display: none"&gt;Schedule
of Deferred Tax Assets and Related Valuation Allowance&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;3,173,840&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,491,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,635&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Property and equipment and operating lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,229,695&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,548,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zhfSfKJNG6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zNuN1XW7SxP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWi4i8AXB54a"&gt;Net
Loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zC30tXxD2fX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zWcF8MYTuJ24"&gt;Accounting
Pronouncements Recently Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements.
The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (ASC 326), which provides guidance on measurement
of credit losses on financial instruments. This ASU adds a current expected credit loss impairment model to U.S.GAAP that is based on
expected losses rather than incurred losses whereby a broader range of reasonable and supportable information is required to be utilized
in order to derive credit loss estimates. The effective date of the new guidance as amended by ASU No. 2019-10 is fiscal years beginning
after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023
the company determined that the update applied to trade receivables, but that there no material impact to the financial statements from
the adoption of ASU 2016-13.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No.
2016-2, Leases, to provide guidance for the accounting for leasing transactions. The standard requires the lessee to recognize a lease
liability along with a right-of-use asset for all leases with a term longer than one year. A lessee is permitted to make an accounting
policy election by class of underlying asset to not recognize the lease liability and related right-of-use asset for leases with a term
of one year or less. The provisions of this standard also apply to situations where the Company is the lessor. In March 2019, the FASB
issued ASU 2019-01, &#x201c;Lease (842): Codification improvements.&#x201d; This updated clarified that entities were exempt from disclosing
the effect of the change on income from continuing operations, net income, and related per-share amounts, if applicable, for interim
periods after the adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
standard was initially effective for annual and interim reporting periods beginning after December 15, 2019. However, in November 2019,
the FASB issued ASU 2019-10, &#x201c;Financial Instruments Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates&#x201d;, which deferred the effective date of ASU 2016-02 by an additional year. At its April 8, 2020, meeting,
the FASB voted to defer the effective date for ASC 842 another year. As such, the Company is required to adopt the new leases standard
for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company
adopted this new guidance effective January 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_z7nNPLzwrVpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zujw7gsHWdrk"&gt;Accounting
Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-07, &#x201c;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;
(&#x201c;ASU 2023-09&#x201d;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zjgDf1CgbFh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000985">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zDw6Ai1JWhNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z3foTLi5y2t6"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Company&#x2019;s financial statements in conformity with U.S.GAAP requires the Company to make estimates and assumptions
that affect the reported amounts of certain assets and liabilities; the reported amounts of revenues and expenses for the periods covered
and certain amounts disclosed in the notes to the financial statements. These estimates are based on information available through the
date of the issuance of the financial statements and actual results could differ from those estimates. To the extent there are material
differences between the Company&#x2019;s estimates and the actual results, the Company&#x2019;s future consolidated results of operation
may be affected. Areas requiring significant estimates and assumptions by the Company include, but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fair
    value of long-term convertible debt and warrants issued in connection with such debt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;accruals
    for estimated liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;lease
    term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    valuation of stock-based compensation awards ; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;provisions
    for income taxes and related valuation allowances and tax uncertainties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <SCNX:LiquidityPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000987">&lt;p id="xdx_84B_ecustom--LiquidityPolicyTextBlock_zOvPcfhCQI36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zy4BUgnX5aYh"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
entity has just commenced operations and is expected to be funded by the stockholders for liquidity purposes. The liquidity position
of the entity is also dependent on the fundings by the additional development partners.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</SCNX:LiquidityPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000989">&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zUDtEgzcnAIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zuTRUepB66i4"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss includes net loss as well as other changes in stockholder&#x2019;s equity that result from transactions and economic events other
than those with stockholders. There was no difference between net loss and comprehensive loss presented in the financial statements for
the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000991">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNaP59og6Bre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zDxAsKHKGC07"&gt;Segment
Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer, who makes resource allocation decisions and assesses performance
based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating
decision-maker, or anyone else, for any planning, strategy and key decision-making regarding operations. Accordingly, the Company has
a &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20230101__20231231_zQFvL72BwS95" title="Number of reportable segment::XDX::1"&gt;&lt;span id="xdx_907_eus-gaap--NumberOfOperatingSegments_dxL_uInteger_c20230101__20231231_zzlYO99If5Lf" title="Number of operating segment::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0993"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; reportable segment and operating segment structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000997">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zJ11pNKLt4j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_z2pVeuN5hIU3"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash
equivalents. Cash equivalents consist of amounts invested in money market funds and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact000999">&lt;p id="xdx_84A_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zwD0xPUmp2q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z09Lz3B2WS0k"&gt;Accounts
Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable consist of milestone payments due from development partners as a consideration for the rights granted for the commercialization
of the products to be developed. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability
is no longer reasonably assured based on historical experience and specific collection issues. The allowance for doubtful accounts was
$&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zjggDz3CdhM3" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zPnPWh6lbXf3" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;&lt;/span&gt; as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Refer
&#x2013; Note 14&#x2013; Subsequent Events &#x2013; Termination of Exclusive License and Commercial Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001005">&lt;p id="xdx_84C_eus-gaap--RevenueRecognitionPolicyTextBlock_z31KAvzCkY56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z5zx0gMnjcI3"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
is recognized when control of the promised services is transferred to customers, at an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASU No. 2014-09, Revenue from Contracts with Customers and the related amendments, which are codified into ASC 606,
which establishes a broad principle that requires entities to assess the products or services promised in contracts with customers at
contract inception to determine the appropriate unit at which to record revenues, which is referred to as a performance obligation. Revenue
is recognized when control of the promised products or services is transferred to customers, at an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those products or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the
following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it
is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or
services promised within each contract and determined those that were performance obligations, and assessed whether each promised good
or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
ASC 606. The Company recognizes revenue at the point of sale of service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001007">&lt;p id="xdx_84B_ecustom--ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock_z2JhbIcHdvOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zd1OqPSy1EC8"&gt;Exclusive
License and Commercial Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an exclusive license and commercial agreement with Kesin Pharma Corporation, a related party where the Company granted
the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred
to as &#x201c;the Products&#x201d;) for use in the United States of America. In consideration of the rights granted, the Company is in
receipt of milestone payments and reimbursement of costs actually incurred related to the products. Revenue has been recognized when
such development milestone events take place and the amounts are due to be received. The Company recognized $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231_zm95aluQBMk3" title="Revenue recognized"&gt;800,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231_zYelXpAhKAl7" title="Revenue recognized"&gt;300,000&lt;/span&gt;, respectively,
during the years ended December 31, 2023 and 2022 at the point when the development milestone events occurred. (Refer &#x2013; Note 14&#x2013;
Subsequent Events &#x2013; Termination of Exclusive License and Commercial Agreement).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:ExclusiveLicenseAndCommercialAgreementsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001013">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zpBk8Rxd7OJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zXDu1rOp5G12"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction
between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data
obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions of what
market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial
and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.
The hierarchy is presented down into three levels based on the reliability of the inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable
    inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets
    or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Level
    3 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -58.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term convertible notes approximate their
fair value because of the short-term nature of these instruments. The carrying amount of long-term convertible debt approximate the fair
value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001015">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zJrtJLxttz8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z1ZC3PGQm9C2"&gt;Concentration
of Credit Risks and Major Customers&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The
Company places its cash and cash equivalents with financial institutions. During the years ended December 31, 2023, and 2022, the company
had one development partner that accounted for the entire revenue recognized in the Statement of Comprehensive Loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001017">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwCXj4i6zeEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zWKr6Kcp3Zc1"&gt;Research
&amp;amp; Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed in the period incurred in accordance with ASC 730. Research and development expenses consist of independent
contractor costs , costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs
as a part of research, market research costs and other regulatory consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001019">&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIdqihDN0YB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zjo7F3n0srO9"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation expense relates to stock options. Stock-based compensation expense for its stock-based awards
is based on their grant date fair value. The fair values of stock-based compensations are recognized as compensation expense on a straight-line
basis over the requisite service period in which the awards are expected to vest. The Company estimates the fair value of stock option
awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes model considers several variables and assumptions
in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock,
exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the
expected term. The Company has estimated volatility by reference to the historical volatilities of the Company and that of similar publicly
traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration
to the expected term of the equity-settled award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <SCNX:WarrantValuationPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001021">&lt;p id="xdx_84F_ecustom--WarrantValuationPolicyTextBlock_zeToUOiWtOCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zIq0xJKLreE9"&gt;Warrant
Valuation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards is estimated
using the Black-Scholes option model with a volatility figure derived from an average of historical stock prices for comparable entities.
The Company accounts for the expected life based on the contractual life of the warrants. The risk-free interest rate is determined from
the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:WarrantValuationPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001023">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zCjnOUHbWpI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z3hwU0J9pJR8"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;State
Income Tax:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is incorporated in Delaware and headquartered in New York where the state tax is &lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20230101__20231231_z1dGVIh0nh06" title="State income tax rate"&gt;8.70&lt;/span&gt;% and &lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20220101__20221231_zQnpB8DJfb1" title="State income tax rate"&gt;7.25&lt;/span&gt;% respectively. However, due to
losses for the years ended December 31, 2023 and 2022, no provision on state income tax has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Federal
Income Tax:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a C Corporation for tax purposes, filing Form 1120 annually. Profits are not being passed through to owners. The company records
income taxes pursuant to the liability method. The Company has a loss before tax of ($&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zaXalyfNxvSa" title="Loss before tax"&gt;2,240,989&lt;/span&gt;) and ($&lt;span id="xdx_903_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zpYkYtiSAfh" title="Loss before tax"&gt;3,708,378&lt;/span&gt;) for years ended December
31, 2023 and 2022 respectively. Therefore, no provision for federal income tax has been recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Pure">0.0870</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001027"
      unitRef="Pure">0.0725</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001029"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001031"
      unitRef="USD">-3708378</us-gaap:NetIncomeLoss>
    <SCNX:DeferredTaxAssetsAndLiabilitiesPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001033">&lt;p id="xdx_847_ecustom--DeferredTaxAssetsAndLiabilitiesPolicyTextBlock_zqIOkbM1Gmn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zAo6Gt6RSIo1"&gt;Deferred
Tax Assets and Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are determined based on the differences between the financial statement and the tax basis of assets and liabilities.
Realization of the future tax benefits related to the net deferred tax assets is dependent on many factors including the Company&#x2019;s
ability to generate taxable income. Management believes that, at a minimum, it is more likely than not that future taxable income may
not be sufficient to realize the recorded assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has recorded a deferred tax asset related to its net operating loss carryforwards, timing difference between written down value
of assets, and unutilized R&amp;amp;D credit, which are expected to reduce future taxable income. The company has assessed the likelihood
of realizing the deferred tax assets and determined that it is more likely than not that a portion of the assets may not be realized.
Therefore, a valuation allowance has been created to account for 100% of the deferred tax assets to its expected realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
impact of the deferred tax assets and related valuation allowance on the Company&#x2019;s financial statements is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zGlZeO8SmXN4" style="display: none"&gt;Schedule
of Deferred Tax Assets and Related Valuation Allowance&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;3,173,840&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,491,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,635&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Property and equipment and operating lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,229,695&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,548,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zhfSfKJNG6ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:DeferredTaxAssetsAndLiabilitiesPolicyTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001035">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z9dMCRsZ6bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
impact of the deferred tax assets and related valuation allowance on the Company&#x2019;s financial statements is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zGlZeO8SmXN4" style="display: none"&gt;Schedule
of Deferred Tax Assets and Related Valuation Allowance&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zeHh9z3EU013" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zKHd2TSQzqQb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year
    Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzzIH_zEnalUKAexck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;3,173,840&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,491,667&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTANzzIH_zJ0PdC7w48Dg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,635&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTANzzIH_z2VrSDs8CPH6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Property and equipment and operating lease liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzzIH_zOqWGpZEVrzd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,229,695&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,548,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzzIH_z7jaVkY0cRXk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001037"
      unitRef="USD">3173840</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001038"
      unitRef="USD">2491667</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001040"
      unitRef="USD">6635</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">2705</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">49220</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001044"
      unitRef="USD">53960</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">3229695</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">2548331</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001052">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zNuN1XW7SxP4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWi4i8AXB54a"&gt;Net
Loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period,
adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities if any. Diluted
net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding and potential
common stock outstanding, if dilutive. For periods in which the Company reports net losses, diluted net loss per share is the same as
basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001054">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zC30tXxD2fX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zWcF8MYTuJ24"&gt;Accounting
Pronouncements Recently Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements.
The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not
believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial
position or results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (ASC 326), which provides guidance on measurement
of credit losses on financial instruments. This ASU adds a current expected credit loss impairment model to U.S.GAAP that is based on
expected losses rather than incurred losses whereby a broader range of reasonable and supportable information is required to be utilized
in order to derive credit loss estimates. The effective date of the new guidance as amended by ASU No. 2019-10 is fiscal years beginning
after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023
the company determined that the update applied to trade receivables, but that there no material impact to the financial statements from
the adoption of ASU 2016-13.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No.
2016-2, Leases, to provide guidance for the accounting for leasing transactions. The standard requires the lessee to recognize a lease
liability along with a right-of-use asset for all leases with a term longer than one year. A lessee is permitted to make an accounting
policy election by class of underlying asset to not recognize the lease liability and related right-of-use asset for leases with a term
of one year or less. The provisions of this standard also apply to situations where the Company is the lessor. In March 2019, the FASB
issued ASU 2019-01, &#x201c;Lease (842): Codification improvements.&#x201d; This updated clarified that entities were exempt from disclosing
the effect of the change on income from continuing operations, net income, and related per-share amounts, if applicable, for interim
periods after the adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
standard was initially effective for annual and interim reporting periods beginning after December 15, 2019. However, in November 2019,
the FASB issued ASU 2019-10, &#x201c;Financial Instruments Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases
(Topic 842): Effective Dates&#x201d;, which deferred the effective date of ASU 2016-02 by an additional year. At its April 8, 2020, meeting,
the FASB voted to defer the effective date for ASC 842 another year. As such, the Company is required to adopt the new leases standard
for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company
adopted this new guidance effective January 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001056">&lt;p id="xdx_846_ecustom--AccountingPronouncementsNotYetAdoptedPolicyTextBlock_z7nNPLzwrVpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zujw7gsHWdrk"&gt;Accounting
Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-07, &#x201c;Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;), which requires additional operating
segment disclosures in annual and interim consolidated financial statements. ASU 2023-07 is effective for annual periods beginning after
December 15, 2023 and for interim periods beginning after December 15, 2024 on a retrospective basis, with early adoption permitted.
The Company is evaluating the effect of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&#x201d;
(&#x201c;ASU 2023-09&#x201d;), which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components
of the effective tax rate reconciliation and modifies other income tax-related disclosures. ASU 2023-09 is effective for annual periods
beginning after December 15, 2024 on a retrospective or prospective basis. The Company is evaluating the effect of adopting ASU 2023-09.&lt;/span&gt;&lt;/p&gt;

</SCNX:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001058">&lt;p id="xdx_807_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ziEFDDx0cXUl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &lt;span id="xdx_82A_zdMta7gfnARl"&gt;Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a net loss of ($&lt;span id="xdx_905_eus-gaap--NetIncomeLoss_iN_di_c20230101__20231231_zvmxqkOfs1De" title="Net loss"&gt;2,240,989&lt;/span&gt;) for the year ended December 31,2023 and stockholders&#x2019; deficit of ($&lt;span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_di_c20231231_zXVzdrBmonR7" title="Stockholders deficit"&gt;4,539,152&lt;/span&gt;) as of December
31, 2023. The Company&#x2019;s situation raises a substantial doubt on whether the entity can continue as a going concern in the next
twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue as a going concern in the next twelve months following the date the financial statements were available
to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations
and deploy such to produce profitable operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next
twelve months, the Company intends to fund its operations through debt and/or equity financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient
amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial
condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">-2240989</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001062"
      unitRef="USD">-4539152</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001064">&lt;p id="xdx_80A_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zNCm8uqMOVk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &lt;span id="xdx_82C_zkX6sSiSPFs1"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zGt64svCsyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zBDk2rALlfoa" style="display: none"&gt;Schedule
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zncInLkOg51f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zCOb1TAClbpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zE9DcrJj5NK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Balances with banks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;31,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;604,813&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zwq44FEW84E" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Money market securities (Highly liquid investments)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,091,935&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zQQGpinOmfaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cash and Cash Equivalents&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,123,878&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;604,813&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z2yAo3N0APhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money
market securities were considered a Level 1 financial instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001066">&lt;p id="xdx_89D_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zGt64svCsyJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zBDk2rALlfoa" style="display: none"&gt;Schedule
of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zncInLkOg51f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zCOb1TAClbpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndDueFromBanks_iI_maCACEAzaE7_zE9DcrJj5NK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Balances with banks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;31,943&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;604,813&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzaE7_zwq44FEW84E" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Money market securities (Highly liquid investments)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,091,935&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzaE7_zQQGpinOmfaj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cash and Cash Equivalents&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,123,878&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;604,813&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndDueFromBanks
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">31943</us-gaap:CashAndDueFromBanks>
    <us-gaap:CashAndDueFromBanks
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001069"
      unitRef="USD">604813</us-gaap:CashAndDueFromBanks>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001071"
      unitRef="USD">1091935</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001074"
      unitRef="USD">1123878</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001075"
      unitRef="USD">604813</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001077">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zPnJODd2bSb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &lt;span id="xdx_822_zCUCyLyL3Ri4"&gt;Convertible Notes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of the convertible notes approximate their fair value because of the short-term nature of these instruments. The convertible
notes issued bear an interest at a rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231_zQNezyabIvb" title="Convertible notes issued bear interest rate percentage"&gt;8&lt;/span&gt;% per annum and certain notes issued prior to 2022 bear an interest at a rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231_zrKX2zWmVjn3" title="Convertible notes issued bear interest rate percentage"&gt;2&lt;/span&gt;% per annum.
As of December 31, 2023 and 2022, there were $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231_zcPV7uZ5UlVc" title="Debt outstanding principal amount"&gt;3,665,220&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zRqgJe6P0OG5" title="Debt outstanding principal amount"&gt;2,950,000&lt;/span&gt; in outstanding principal. All such notes have matured on &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231_zJBzvxRaRk35" title="Maturity date"&gt;December
31,2023&lt;/span&gt;. Interest expenses recognized for the years ended December 31, 2023 and 2022 amounted to $&lt;span id="xdx_905_eus-gaap--InterestExpense_c20230101__20231231_zaKb2ySq9qT4" title="Interest expenses"&gt;152,423&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20220101__20221231_zd2ER3cvcXuh" title="Interest expenses"&gt;76,705&lt;/span&gt; respectively. (Refer
&#x2013; Note 14&#x2013; Subsequent Events &#x2013; Short-Term Convertible Notes)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001081"
      unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001083"
      unitRef="USD">3665220</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001085"
      unitRef="USD">2950000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001087">December
31,2023</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001089"
      unitRef="USD">152423</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001091"
      unitRef="USD">76705</us-gaap:InterestExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001093">&lt;p id="xdx_80F_eus-gaap--LongTermDebtTextBlock_znKtDQgX6iid" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &lt;span id="xdx_826_z9iSrcK4bJe3"&gt;Long-Term Convertible Debt, net of debt discount&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2023, the Company entered into a loan agreement with NVK Finance LLC, a Nebraska Limited Liability Company (&#x2018;NVK&#x201d;)
for $&lt;span id="xdx_909_eus-gaap--LongTermDebt_iI_c20230930__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zdKdbMHZJtIi" title="Long term debt"&gt;2,000,000&lt;/span&gt;. The Board Member of the Company has significant influence in the decision making in NVK and hence considered as a related
party. The debt shall accrue interest at a per annum rate equal to Prime Rate plus &lt;span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPrimeRatePercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z63uPOWtJjd" title="Debt prime rate percentage"&gt;7&lt;/span&gt; percent and the prime rates shall be adjusted quarterly
commencing on December 2023. As of December 31, 2023, the interest rate was &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zP2DRhKI88J" title="Debt interest rate percentage"&gt;15.50&lt;/span&gt;%. The debt is collateralized by all of the Company&#x2019;s
receivables, cash and cash equivalents and the title in Intellectual Property Rights and all proceeds thereof. The principal is entirely
repayable on the maturity date i.e. September 2025 and interest shall be paid monthly upon a Qualified Financing as defined in the Loan
Agreement. Interest expense related to the debt amounted to $&lt;span id="xdx_901_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z2wvzsWEV64a" title="Interest expense"&gt;95,583&lt;/span&gt; for the year ended December 31, 2023 and the principal amount is
entirely outstanding as at December 31,2023. The outstanding balance under the NVK debt is convertible into common stock of the Company
at a fully-diluted Company valuation of $&lt;span id="xdx_90E_ecustom--DebtDilutedValuation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zYeOUkAEcixh" title="Debt diluted valuation"&gt;60,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the NVK debt, the Company granted &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zApNldlFqNb2" title="Number of warrant to purchase"&gt;509,014&lt;/span&gt; warrants to purchase common stock. The fair value of the warrants was $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zw6wBkBYrpF6" title="Fair value adjustment of warrants"&gt;444,260&lt;/span&gt;
using Black-Scholes option pricing model, which will be amortized to interest expense over the life of the notes. During the year ended
December 31, 2023, the Company amortized $&lt;span id="xdx_903_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zJGwaFucZJS" title="Debt discount interest expense"&gt;69,377&lt;/span&gt; of the debt discount to interest expense. (Refer &#x2013; Note 11&#x2013; Warrants)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zDUVQx5gzkK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
convertible debt, net of debt discount, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_z7yY1AXiToTf" style="display: none"&gt;Schedule of Long Term Convertible
Debt Net of Discount&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z1y3qGy5kTP5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_z4x8suGki5B2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDz26q_zNPBtZeAKQ3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;Principal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDz26q_zuIgG5E2buG" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Unamortized debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;374,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz26q_zq8bpEhF03c1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term convertible debt, net of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,625,117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zYJCfnsEFDG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzHcjzc6oJK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maturities
of the outstanding debt are as follows&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B1_zl1OwLZPI9l" style="display: none"&gt;Schedule of Maturities Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z7B3U38IvUe8" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zKUdTbExbrvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zsXMmWheyHy8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z1JkoUkq5Ow8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z9TcDpjMWcN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zdzeMxktg6pk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z6ORxlRme275" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-09-30_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001095"
      unitRef="USD">2000000</us-gaap:LongTermDebt>
    <SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Pure">0.07</SCNX:DebtInstrumentInterestRateStatedPrimeRatePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Pure">0.1550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">95583</us-gaap:InterestExpense>
    <SCNX:DebtDilutedValuation
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001103"
      unitRef="USD">60000000</SCNX:DebtDilutedValuation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">509014</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001107"
      unitRef="USD">444260</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2023-01-012023-12-31_custom_LoanAgreementMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001109"
      unitRef="USD">69377</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001111">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zDUVQx5gzkK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
convertible debt, net of debt discount, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_z7yY1AXiToTf" style="display: none"&gt;Schedule of Long Term Convertible
Debt Net of Discount&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z1y3qGy5kTP5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_z4x8suGki5B2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentCarryingAmount_iI_maLTDz26q_zNPBtZeAKQ3e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;Principal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_msLTDz26q_zuIgG5E2buG" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Unamortized debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;374,883&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz26q_zq8bpEhF03c1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long-term convertible debt, net of debt discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,625,117&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001113"
      unitRef="USD">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001116"
      unitRef="USD">374883</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001119"
      unitRef="USD">1625117</us-gaap:LongTermDebt>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001122">&lt;p id="xdx_893_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zzHcjzc6oJK" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Maturities
of the outstanding debt are as follows&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B1_zl1OwLZPI9l" style="display: none"&gt;Schedule of Maturities Notes&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z7B3U38IvUe8" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zKUdTbExbrvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1124"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_zsXMmWheyHy8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z1JkoUkq5Ow8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_z9TcDpjMWcN9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year 3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zdzeMxktg6pk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001128"
      unitRef="USD">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001130"
      unitRef="USD">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001132"
      unitRef="USD">2000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001134">&lt;p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_zUjeuMluJ8q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &lt;span id="xdx_829_zTJ5EdG9LLy3"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.4in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and short-term convertible notes
approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates
fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001136">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zI8SEr5Urqcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &lt;span id="xdx_820_zhB6S9qRWi07"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability
is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. The
Company does not record any anticipated gains relating to its litigation or legal claims. The gains are only recorded upon receipt of
the settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Although
the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings,
which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial
position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001138">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeKlGvgQvELb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &lt;span id="xdx_820_zNLxZlrX6as2"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had entered into an Exclusive and Commercial agreement with Kesin Pharma Corporation (&#x201c;Kesin&#x201d;), in which one of the
company&#x2019;s board member is the President and CEO, and had a significant influence in the decision making, which makes it a related
party. Sales made to Kesin as a part of milestone structure for the years ended December 31,2023 and 2022 amounted to $&lt;span id="xdx_907_ecustom--MilestonePayment_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zLN4iboufi74" title="Milestone structure"&gt;800,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--MilestonePayment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KesinPharmaCorporationMember_zV3PPzBVMOuj" title="Milestone structure"&gt;300,000&lt;/span&gt;
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has leased its office from Saptalis Pharmaceuticals LLC (&#x201c;Saptalis&#x201d;) , in which one of the Company&#x2019;s Director
is the President and CEO. Lease payments made during the year ended December 31, 2023 and 2022 are $ &lt;span id="xdx_907_eus-gaap--VariableLeasePayment_c20230101__20231231_zT34zweemnQ2" title="Lease payments"&gt;7200&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--VariableLeasePayment_c20220101__20221231_zw2WkXDhkP5c" title="Lease payments"&gt;0&lt;/span&gt; respectively. The company
has also engaged Saptalis to provide development services and conduct testing and studies for the products under development by the Company.
Expenses incurred towards such testing and studies which is included in the Research and Development Expenses in the Statement of Comprehensive
Loss for the year ended December 31, 2023 and December 31,2022 amounted to $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_z5GPAw4moWR1" title="Research and Development Expenses"&gt;355,124&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SaptalisPharmaceuticalsLlcMember_zwRq3Wd8kXG6" title="Research and Development Expenses"&gt;647,566&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zzU9Pbq43jTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relatives
or related parties to directors purchased securities from the Company on the same terms as unrelated parties as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zBoXafXs0Zrd" style="display: none"&gt;Schedule of Relatives or Related
Parties to Directors Purchased Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Name of the Related
    Party&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Transactions
                                            during the year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ended&lt;br/&gt;
                                            December 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Balances
    as at &lt;br/&gt; December 31&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left"&gt;Ms. Pushpa Shankar&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zR6kkx46ki05" title="Nature of transaction"&gt;Issue of Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zivGRnvleWEj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zV40BXwTTQU6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zNDl4oXzZesj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z1wLxfBRCFc8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Pushpa Shankar&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOhisUauXxi2" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z6W6IKkBZlE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;400,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z7OGfBKClH09" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;150,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zpYtmDMg5DM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;550,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z0Aceognm1a5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;400,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Yogita Desai&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zQyYfEK17qp3" title="Nature of transaction"&gt;Issue of Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z5BDQxCuCVt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zouchw6rWRh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_znZTxEUTqbF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;500,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zoGuiTvg30Hk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;500,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Yogita Desai&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5YiJohKvag5" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zEbZL5myDCj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOxZS5DRv444" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z2nC6z6G8Aq7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5rSYyzgbhsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Mr. Sandeep Gupta&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_ztVLCAZgv2tl" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zKoj3sCeQIcf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zGceyHaVBx3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zxgpVgY01Fx1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zJzlQC2v3Vi4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231_zQRNccPuZ8Hk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;400,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_zvvLgQw48Wm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;200,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherLiabilities_iI_c20221231_zEeA8I3C5yD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;1,950,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherLiabilities_iI_c20231231_zat80oG25oCd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;1,750,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zssJnkBScMA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SCNX:MilestonePayment
      contextRef="From2023-01-012023-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001140"
      unitRef="USD">800000</SCNX:MilestonePayment>
    <SCNX:MilestonePayment
      contextRef="From2022-01-012022-12-31_custom_KesinPharmaCorporationMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001142"
      unitRef="USD">300000</SCNX:MilestonePayment>
    <us-gaap:VariableLeasePayment
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001144"
      unitRef="USD">7200</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">0</us-gaap:VariableLeasePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001148"
      unitRef="USD">355124</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SaptalisPharmaceuticalsLlcMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">647566</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001152">&lt;p id="xdx_899_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zzU9Pbq43jTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relatives
or related parties to directors purchased securities from the Company on the same terms as unrelated parties as set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zBoXafXs0Zrd" style="display: none"&gt;Schedule of Relatives or Related
Parties to Directors Purchased Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Name of the Related
    Party&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Transactions
                                            during the year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ended&lt;br/&gt;
                                            December 31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Balances
    as at &lt;br/&gt; December 31&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left"&gt;Ms. Pushpa Shankar&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zR6kkx46ki05" title="Nature of transaction"&gt;Issue of Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zivGRnvleWEj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1156"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zV40BXwTTQU6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zNDl4oXzZesj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z1wLxfBRCFc8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Related party Balances"&gt;750,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Pushpa Shankar&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOhisUauXxi2" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z6W6IKkBZlE5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;400,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z7OGfBKClH09" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;150,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zpYtmDMg5DM9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;550,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsPushpaShankarMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z0Aceognm1a5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;400,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Yogita Desai&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zQyYfEK17qp3" title="Nature of transaction"&gt;Issue of Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_z5BDQxCuCVt2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zouchw6rWRh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_znZTxEUTqbF2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;500,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfPreferredStockMember_zoGuiTvg30Hk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;500,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Ms. Yogita Desai&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5YiJohKvag5" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zEbZL5myDCj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zOxZS5DRv444" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z2nC6z6G8Aq7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsYogitaDesaiMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_z5rSYyzgbhsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;100,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Mr. Sandeep Gupta&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_ztVLCAZgv2tl" title="Nature of transaction"&gt;Issue of Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zKoj3sCeQIcf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zGceyHaVBx3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OtherLiabilities_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zxgpVgY01Fx1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSandeepGuptaMember__us-gaap--RelatedPartyTransactionAxis__custom--IssueOfConvertibleNotesMember_zJzlQC2v3Vi4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231_zQRNccPuZ8Hk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;400,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_zvvLgQw48Wm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Transactions"&gt;200,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherLiabilities_iI_c20221231_zEeA8I3C5yD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;1,950,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherLiabilities_iI_c20231231_zat80oG25oCd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Related party Balances"&gt;1,750,000&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="Fact001154">Issue of Preferred Stock</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001160"
      unitRef="USD">750000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001162"
      unitRef="USD">750000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="Fact001164">Issue of Convertible notes</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001166"
      unitRef="USD">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">150000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001170"
      unitRef="USD">550000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_MsPushpaShankarMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001172"
      unitRef="USD">400000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      id="Fact001174">Issue of Preferred Stock</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001180"
      unitRef="USD">500000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfPreferredStockMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001182"
      unitRef="USD">500000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="Fact001184">Issue of Convertible notes</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001190"
      unitRef="USD">100000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_MsYogitaDesaiMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001192"
      unitRef="USD">100000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      id="Fact001194">Issue of Convertible notes</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001198"
      unitRef="USD">50000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_MrSandeepGuptaMember_custom_IssueOfConvertibleNotesMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001200"
      unitRef="USD">50000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001204"
      unitRef="USD">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001208"
      unitRef="USD">1950000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">1750000</us-gaap:OtherLiabilities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001212">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zoGdYyjxkLW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &lt;span id="xdx_825_zQ2GFWOXPWqh"&gt;Scienture Inc. 2020 Stock Option and Grant Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Stock Option and Grant Plan allows for the issuance of incentive stock options (&#x201c;ISOs&#x201d;), non-statutory stock options (&#x201c;NSOs&#x201d;).
ISOs may be granted only to the Company&#x2019;s employees (including officers and directors who are also considered employees) and ex-employees.
NSOs may be granted to the Company&#x2019;s employees and service providers such as advisors etc. Options under the Stock Option and Grant
Plan have a contractual term of not more than 10 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhNrbxh7Vzqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity under the Plans is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zEX7AB5731n2" style="display: none"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding&lt;br/&gt;
    Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF5x1kVqwuDa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance"&gt;560,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVHlBTf7GLX8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.83&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc7QdlZQJ6" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXqqRwitCCTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted"&gt;185,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8MvUFZFumsh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted"&gt;1.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdtQqM0Sdua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwVaLBVW3jh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cancelled and forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjNTpYy3uVW3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"&gt;(90,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNfp8fCgy9d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPe12rxIsD85" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance"&gt;655,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRNV5QtPz1g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztJhWDauLcyh" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Vested and exercisable as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRoTyGtXL94d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;410,065&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7tJg5Iv7kb6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;0.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ANPWvHvMxl" title="Weighted-Average Remaining Term (Years), Vested and exercisable"&gt;6.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zXHWXt8CfxK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 are $ &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zqIH4jxa19Jf" title="Weighted-average grant date fair value of options granted"&gt;0.55&lt;/span&gt; and $ &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zdN2S81axqQ7" title="Weighted-average grant date fair value of options granted"&gt;0.52&lt;/span&gt; per
share respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zDwNtRNdfe95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zAAjJGLK9XLc" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zvBe31OrJTE8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_z6yQW4Mm3uI1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6czHCnPZQa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;General and Administrative Expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;79,449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;68,087&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_zZhP0uofZz7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;79,449&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;68,087&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zfl0yjTjp1of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Option Valuation Assumptions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zF9ofSeWpsqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_z5INuepHptRa" style="display: none"&gt;Schedule of Stock Option Valuation Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z1JPsxux9Sj1" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zmwIbdNDKs3h" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPozpEI5Z7Yj" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zeCWA87rWms2" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zN85UrRSbLZd" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zZ4Iv5ykoTv9" title="Risk-free interest rate"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdrIPv15VaOj" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zOhAEVGf5Nl3" title="Risk-free interest rate"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zM2ArlvlHfid" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zk2fRZ1t86M2" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z6qQAQxuPRTb" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zxf2kfBPSH67" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zPdrvXR87tSe" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6TxcaUKyVrb" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z3TAfS65KS5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001214">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhNrbxh7Vzqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s stock option activity under the Plans is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zEX7AB5731n2" style="display: none"&gt;Summary of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding&lt;br/&gt;
    Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted-&lt;br/&gt;
    Average&lt;br/&gt; Remaining&lt;br/&gt; Term&lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF5x1kVqwuDa" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Outstanding Options, Balance"&gt;560,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVHlBTf7GLX8" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.83&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc7QdlZQJ6" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXqqRwitCCTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Granted"&gt;185,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8MvUFZFumsh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Granted"&gt;1.13&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOdtQqM0Sdua" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkwVaLBVW3jh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cancelled and forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjNTpYy3uVW3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Cancelled and forfeited"&gt;(90,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhNfp8fCgy9d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Cancelled and forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPe12rxIsD85" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Balance"&gt;655,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRNV5QtPz1g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted- Average Exercise Price, Balance"&gt;0.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztJhWDauLcyh" title="Weighted-Average Remaining Term (Years), Balance"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Vested and exercisable as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRoTyGtXL94d" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;410,065&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7tJg5Iv7kb6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding Options, Vested and exercisable"&gt;0.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5ANPWvHvMxl" title="Weighted-Average Remaining Term (Years), Vested and exercisable"&gt;6.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001216"
      unitRef="Shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001218"
      unitRef="USDPShares">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact001220">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">655000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001236"
      unitRef="USDPShares">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact001238">P7Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Shares">410065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember"
      id="Fact001244">P6Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001246"
      unitRef="USDPShares">0.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001248"
      unitRef="USDPShares">0.52</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001250">&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zDwNtRNdfe95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the Statement of Operations and Comprehensive Loss for the periods presented as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zAAjJGLK9XLc" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zvBe31OrJTE8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_z6yQW4Mm3uI1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6czHCnPZQa9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;General and Administrative Expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;79,449&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;68,087&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_zZhP0uofZz7a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;79,449&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;68,087&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001252"
      unitRef="USD">79449</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001253"
      unitRef="USD">68087</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001255"
      unitRef="USD">79449</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001256"
      unitRef="USD">68087</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001258">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zF9ofSeWpsqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following
assumptions for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_z5INuepHptRa" style="display: none"&gt;Schedule of Stock Option Valuation Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z1JPsxux9Sj1" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zmwIbdNDKs3h" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPozpEI5Z7Yj" title="Expected volatility"&gt;65&lt;/span&gt;%
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zeCWA87rWms2" title="Expected volatility"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zN85UrRSbLZd" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zZ4Iv5ykoTv9" title="Risk-free interest rate"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zdrIPv15VaOj" title="Risk-free interest rate"&gt;0.5&lt;/span&gt;%
                                            - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zOhAEVGf5Nl3" title="Risk-free interest rate"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zM2ArlvlHfid" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zk2fRZ1t86M2" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z6qQAQxuPRTb" title="Expected term"&gt;5.9&lt;/span&gt;
                                            - &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zxf2kfBPSH67" title="Expected term"&gt;6.0&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zPdrvXR87tSe" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6TxcaUKyVrb" title="Expected dividend"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001262"
      unitRef="Pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001268"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001270"
      unitRef="Pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001272"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001274"
      unitRef="Pure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_custom_ScientureIncMember"
      id="Fact001276">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_custom_ScientureIncMember"
      id="Fact001278">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_custom_ScientureIncMember"
      id="Fact001280">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_custom_ScientureIncMember"
      id="Fact001282">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001284"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001286"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <SCNX:WarrantsTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001288">&lt;p id="xdx_80B_ecustom--WarrantsTextBlock_z2uBaeldUZQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &lt;span id="xdx_828_zjJYoJPv7vef"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, there were &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zvrlfNWC7sVe" title="Warrants outstanding"&gt;509,014&lt;/span&gt; warrants outstanding and exercisable with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231_zt1f26zAynAe" title="Exercise price"&gt;0.01&lt;/span&gt; per share. The warrants
were granted in connection with the NVK debt (Refer - Note 6 - Long-Term Convertible Debt, net of debt discount).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_z8D6GkXzwMMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the assumptions used to estimate the fair value of the outstanding warrants during the years ended December
31, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zVf7q0TpTnJk"&gt;Summary
of Assumptions Used to Estimate Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVLmQ77K6JZ" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdsZmmyblyr8" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPewogR85Im6" title="Weighted average expected volatility"&gt;70.52&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY5NOV8FZNWj" title="Weighted average expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSwwDS58AMN8" title="Measurement Input, warrant"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1enIGVpaRie" title="Measurement Input, warrant"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1306"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected life of warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2zkRQoUspJi" title="Expected life of warrants::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1308"&gt;5&lt;/span&gt;&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUByi9mQWN1l" title="Expected life of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zNIrjYAglo44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SCNX:WarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Shares">509014</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001292"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001294">&lt;p id="xdx_896_ecustom--SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock_z8D6GkXzwMMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the assumptions used to estimate the fair value of the outstanding warrants during the years ended December
31, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zVf7q0TpTnJk"&gt;Summary
of Assumptions Used to Estimate Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVLmQ77K6JZ" title="Expected dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zdsZmmyblyr8" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPewogR85Im6" title="Weighted average expected volatility"&gt;70.52&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zY5NOV8FZNWj" title="Weighted average expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted-average risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zSwwDS58AMN8" title="Measurement Input, warrant"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1enIGVpaRie" title="Measurement Input, warrant"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1306"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected life of warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2zkRQoUspJi" title="Expected life of warrants::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1308"&gt;5&lt;/span&gt;&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUByi9mQWN1l" title="Expected life of warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SCNX:SummaryOfAssumptionsUsedToEstimateFairValueOfWarrantsGrantedTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001296"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001300"
      unitRef="Pure">0.7052</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Pure">0.0450</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001312">&lt;p id="xdx_800_eus-gaap--EarningsPerShareTextBlock_zKG8iYccpH9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12 &lt;span id="xdx_828_zWrTvHXZAjZc"&gt;Net Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
options to purchase &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdcN6ie87LY9" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;655,000&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zyUmj8r75sQ2" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;560,000&lt;/span&gt; common stock, warrants to purchase &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2tUia3qffhb" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;509,014&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zF43kSNamNv8" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;0&lt;/span&gt; common stock, convertible preferred stock and
convertible notes to purchase &lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zcC7Yl3prK5i" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;3,365,669&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAndConvertibleNotesMember_zzZf2q1YOI3c" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;3,195,911&lt;/span&gt; common stock and long-term convertible debt to purchase &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zKA0AO7PqBo7" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;9,529,683&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--LongTermConvertibleDebtMember_zBhuCFgfuxv7" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;0&lt;/span&gt; common
stock were outstanding at December 31, 2023 and 2022, respectively, that were not included in the computation of diluted weighted average
common shares outstanding because their effect would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214078"
      decimals="INF"
      id="Fact001314"
      unitRef="Shares">655000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember_custom_ScientureIncMember10214093"
      decimals="INF"
      id="Fact001316"
      unitRef="Shares">560000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001318"
      unitRef="Shares">509014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001322"
      unitRef="Shares">3365669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_ConvertiblePreferredStockAndConvertibleNotesMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">3195911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">9529683</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_LongTermConvertibleDebtMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001330">&lt;p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zsFEWLecBRa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13 &lt;span id="xdx_82B_z0rhTWXvyYeg"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease, Right of Use asset, Operating
Lease Liability (Current and Non-Current) in the Company&#x2019;s balance sheets. The ROU assets represent the Company&#x2019;s right to
use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most of the leases do not provide an implicit rate, the Company generally uses its incremental borrowing rate
at commencement date. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain
that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As a practical expedient, the Company elected, for all office and facility leases, not to separate non-lease components from lease components
and instead to account for each separate lease component and its associated non-lease components as a single lease component. The Company
made an accounting policy election by class of underlying asset not to recognize the lease liability and related right-of-use asset for
leases with a term of one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has an operating lease for administrative office. The lease has remaining lease term around &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20231231_zaj2Rk7nhTv9" title="Operating lease remaining lease term"&gt;three years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zToErlEKqkZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPaeAyH1ayQb" style="display: none"&gt;Schedule
of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20230101__20231231_z2MQND7Kh3e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220101__20221231_zh88lqTPybte" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zai3HCkJQOXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zQtTHkBhxP81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Amortization of ROU Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zXZf6aH4AZFl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest on Lease Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,380&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zN8A8EDYU3o2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34,021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,677&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zmkUbHMUpZF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zBbIItIxlkge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zWFwA36huf6h" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230101__20231231_zfYsSYsmUmIj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220101__20221231_zHgs7DhqDWyd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwWHbpwCpoif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for accounts included in the measurements of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_zmn9GUTze486" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Operating cash flows for Operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zjPhnh0I6vf6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Right of Use Assets obtained in exchange for new Lease
    Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zj1Jbx3tg6Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zh5jqRu4f5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zJ8qcezPhf3a" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_zC7qbWjklbBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221231_zDvlWpkIDcTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zpGFtCgLs6fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Right of Use Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;64,091&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz1rv_zdnfwdzZem13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,404&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz1rv_zYQpA1BfkORc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz1rv_zNVHShUkQBj5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Lease Liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted Average Remaining Lease Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zg4JFaGrPaUj" title="Weighted Average Remaining Lease Term (in years)"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_znoFu0feokYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zshZMNbRKP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI93dHWMlht4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of lease liabilities were as follows at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zNjlhPOh32xc" style="display: none"&gt;Schedule
of Maturities Of Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zC57GLbl5BQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzwiu_zn2eppBoQPoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 82%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzwiu_zzKDdFoEHi0d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,887&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzwiu_zs02qORnNKo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,823&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzwiu_zuCDIapBPvOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zuEJwBYqRJCk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,430&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z4BMHHSpcT69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zQwb8xjZk8W" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="Fact001332">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001334">&lt;p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zToErlEKqkZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zPaeAyH1ayQb" style="display: none"&gt;Schedule
of Lease Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20230101__20231231_z2MQND7Kh3e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220101__20221231_zh88lqTPybte" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maSTLCzKLS_zai3HCkJQOXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_maSTLCzKLS_zQtTHkBhxP81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Amortization of ROU Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;5,025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--OperatingLeaseInterestExpense_maSTLCzKLS_zXZf6aH4AZFl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Interest on Lease Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,380&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermLeaseCost_iT_mtSTLCzKLS_zN8A8EDYU3o2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term lease costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34,021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,677&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001339"
      unitRef="USD">5025</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <SCNX:OperatingLeaseInterestExpense
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001342"
      unitRef="USD">2380</SCNX:OperatingLeaseInterestExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">34021</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-01-012022-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">32677</us-gaap:ShortTermLeaseCost>
    <SCNX:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001348">&lt;p id="xdx_890_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zBbIItIxlkge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zWFwA36huf6h" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20230101__20231231_zfYsSYsmUmIj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220101__20221231_zHgs7DhqDWyd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwWHbpwCpoif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for accounts included in the measurements of lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_zmn9GUTze486" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Operating cash flows for Operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;7,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zjPhnh0I6vf6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Right of Use Assets obtained in exchange for new Lease
    Liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;205&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SCNX:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001353"
      unitRef="USD">7200</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001356"
      unitRef="USD">205</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001359">&lt;p id="xdx_892_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zh5jqRu4f5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zJ8qcezPhf3a" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related To Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_zC7qbWjklbBl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221231_zDvlWpkIDcTb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December
    31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"&gt;Operating Leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zpGFtCgLs6fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;Right of Use Assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;64,091&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1362"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz1rv_zdnfwdzZem13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Short term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21,404&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz1rv_zYQpA1BfkORc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Long term Lease liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,893&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz1rv_zNVHShUkQBj5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Lease Liabilities&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Weighted Average Remaining Lease Term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zg4JFaGrPaUj" title="Weighted Average Remaining Lease Term (in years)"&gt;2.83&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_znoFu0feokYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Discount Rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SCNX:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">64091</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">21404</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">42893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001370"
      unitRef="USD">64297</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      id="Fact001373">P2Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Pure">0.1550</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001378">&lt;p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zI93dHWMlht4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of lease liabilities were as follows at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zNjlhPOh32xc" style="display: none"&gt;Schedule
of Maturities Of Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zC57GLbl5BQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzwiu_zn2eppBoQPoj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 82%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;29,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzwiu_zzKDdFoEHi0d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,887&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzwiu_zs02qORnNKo4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,823&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzwiu_zuCDIapBPvOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;76,727&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zuEJwBYqRJCk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,430&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z4BMHHSpcT69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,297&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001380"
      unitRef="USD">29017</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001382"
      unitRef="USD">29887</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">17823</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">76727</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">12430</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31_custom_ScientureIncMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">64297</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="From2023-01-012023-12-31_custom_ScientureIncMember"
      id="Fact001392">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zp5idgqWE7n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14 &lt;span&gt;&lt;span&gt;&lt;span id="xdx_826_z5viaF1ESI81"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Short-Term
Convertible Notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
the short-term convertible notes matured during the period of December 2023. The Company has not paid the amounts due including the principal
and the accrued interest. However, in March 2024, the Company had converted the outstanding principal of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLFnovpPvqEi" title="Stock issued during period value conversion of convertible securities"&gt;3,665,220&lt;/span&gt; and the accrued interest
till the date of conversion amounting to $&lt;span id="xdx_90E_eus-gaap--InterestReceivable_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmimkFfdZ56f" title="Interest receivable"&gt;276,233&lt;/span&gt; into an aggregate of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8kl19zbfXIl" title="Stock issued during period shares conversion of convertible securities"&gt;965,568&lt;/span&gt; preferred stock of the company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business
Combination&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 25, 2024, Scienture, Inc. (the &#x201c;Company&#x201d;) entered into and closed an Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) with MEDS, MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of MEDS (&#x201c;Merger Sub I&#x201d;)
and MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#x201c;Merger Sub II&#x201d;).
Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into the Company, with the Company continuing as the surviving entity
and a wholly owned subsidiary of MEDS, and (ii) the Company merged with and into Merger Sub II, with Merger Sub II continuing as the
surviving entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Termination
of Exclusive License and Commercial Agreement&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scienture
Inc. (Scienture) and Kesin had entered into two exclusive license commercial agreements where Scienture had granted Kesin the rights
to commercialize the products. In March 2024, the parties have terminated the agreement, and the parties agreed that, Scienture shall
pay Kesin a total gross amount of $&lt;span id="xdx_906_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfVQpz2Lc7J5" title="Royalty expense"&gt;1,285,000&lt;/span&gt; upon commercialization of product via a royalty arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
agreement also requires that if the full $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfph3xQ4yVKl" title="Royalty expense"&gt;1,285,000&lt;/span&gt; has not been repaid within two years of the early of i) commercial launch or ii)
120 days from FDA approval, then interest will accrue prospectively at a rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUcEYMBSshb3" title="Debt instrument interest rate stated percentage"&gt;8&lt;/span&gt;% annually on unpaid balance. As of the date of issue
of financial statements, the entire amount is outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated subsequent events through July 31, 2024, the date the financial statements were available to be issued.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">3665220</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:InterestReceivable
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">276233</us-gaap:InterestReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001398"
      unitRef="Shares">965568</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001400"
      unitRef="USD">1285000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="0"
      id="Fact001402"
      unitRef="USD">1285000</us-gaap:RoyaltyExpense>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_ScientureIncMember"
      decimals="INF"
      id="Fact001404"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
